

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 06:53:49 ; Search time 1010.34 Seconds  
(without alignments)  
8030.908 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_3800\_4300

Perfect score: 501  
Sequence: 1 caattgtgtgaagcttgcgg.....ttgtgtcttaacaagaagtgt 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database : EST:\*

1: em\_estba:\*  
2: em\_esthum:\*  
3: em\_estlin:\*  
4: em\_estlmu:\*  
5: em\_estlov:\*  
6: em\_estlpl:\*  
7: em\_estro:\*  
8: em\_hlc:\*  
9: gb\_est1:\*  
10: gb\_est2:\*  
11: gb\_hlc:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pln:\*  
21: em\_gss\_vrt:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rod:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
c 1	489	97.6	835	9 AF188523	AF188523 AF188523
2	483	96.4	695	9 AL133724	AL133724 DKFZP761J
3	483	96.4	777	13 BI602169	BI602169 603246290
4	479.8	95.8	644	10 AW162535	AW162535 au77b01.x
5	479	95.6	920	12 BG676871	BG676871 602623473
6	437.2	87.3	801	13 BI603180	BI603180 603249824

c 7	427.2	85.3	546	12 BF748808	BF748808 MRO-BN011
8	410.8	82.0	679	10 AW953240	AW953240 EST365310
9	385.2	76.9	574	12 BF667219	BF667219 602121018
10	369	73.7	521	13 BM353207	BM353207 1g44a10.y
11	368	73.5	539	13 BM353362	BM353362 1g46a10.y
12	359	71.7	359	9 AA484945	AA484945 aa41b06.r
c 13	311.4	62.2	609	13 BG992490	BG992490 MR3-HT103
14	301	60.1	870	12 BG425739	BG425739 602492044
15	299	59.7	354	9 AI372818	AI372818 EST175362
16	293.8	58.6	657	10 BB309170	BB309170 BB309170
17	282.8	56.4	359	9 AA705585	AA705585 ab42b01.s
18	272.6	54.4	371	9 AA151055	AA151055 2145c03.r
19	271	54.1	310	9 AI372817	AI372817 EST175361
20	269.8	53.9	483	12 BG384511	BG384511 303736 MA
21	263.8	52.7	523	10 BE372746	BE372746 601224258
22	254	50.7	896	12 BG468527	BG468527 602510307
23	251	50.1	501	12 BF044659	BF044659 BP250020A
24	250	49.9	658	13 BI153873	BI153873 602870875
25	239.6	47.8	374	10 AW484613	AW484613 61734 MAR
c 26	237.8	47.5	371	9 AU083157	AU083157 AU083157
27	233	46.5	388	13 BI050739	BI050739 RC6-GN007
28	225.6	45.0	377	12 BF042085	BF042085 BP250013A
29	217	43.3	491	14 BQ694790	BQ694790 1000933 H
30	216.4	43.2	594	10 AV720937	AV720937 AV720937
31	207.6	41.4	765	9 AL553184	AL553184 AL553184
32	207.2	41.4	328	9 AA879884	AA879884 vw01c06.r
33	206.8	41.3	394	13 BI337284	BI337284 AR08C04L
34	205	40.9	749	12 BF695548	BF695548 601851957
35	203.8	40.7	450	12 BE703924	BE703924 MRO-N112
c 36	202.2	40.4	352	14 T03019	T03019 FB20D6 Feta
37	192.2	38.4	334	12 BF041935	BF041935 BP250006A
c 38	188	37.5	1039	9 AL570666	AL570666 AL570666
39	158.4	31.6	333	10 AW463757	AW463757 BP230013B
40	156.2	31.2	370	12 BE930535	BE930535 RC6-GN007
41	149.2	29.8	321	10 AW227478	AW227478 up10h03.y
42	146.4	29.2	535	12 BF963798	BF963798 OV2-NN004
43	145.4	29.0	184	12 BE699344	BE699344 RC3-NN006
c 44	143	28.5	512	12 BF090072	BF090072 OV2-NN004
45	141.6	28.3	705	13 BG922853	BG922853 602817405

ALIGNMENTS

RESULT 1  
AF188523/c  
LOCUS AF188523 835 bp mRNA linear EST 02-MAR-2000  
DEFINITION AF188523 Homo sapiens ATCC HTB-12; SW1088 Homo sapiens cDNA clone  
ACCESSION AF188523  
VERSION AF188523.1 GI:7144569  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
REFERENCE 1 (bases 1 to 835)  
AUTHORS Ye, Z. and Connor, J. R.  
TITLE Identification of Iron Regulated Genes by Rescreening cDNA  
Libraries from SSH with Antisense Probe from Three Iron Conditions  
JOURNAL Unpublished (2000)  
COMMENT Contact: Ye Z  
Neuroscience and Anatomy  
Pennsylvania State University College of Medicine  
500 University Drive, Hershey, PA 17033, USA  
library screened by SSH and reverse Northern blot; increased  
expression in iron loading was confirmed by Northern blot.

FEATURES  
source

1. 835  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="ISC 4"  
/clone\_lib="Homo sapiens ATCC HTB-12; SW1088"

/tissue\_type="astrocytoma"  
/cell\_line="ATCC HTB-12; SW1088"  
/note="Organ: liver"  
BASE COUNT 225 a 209 c 156 g 245 t  
ORIGIN

Query Match 97.6%; Score 489; DB 9; Length 835;  
Best Local Similarity 99.8%; Pred. No. 3.4e-117;  
Matches 500; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 CAATTGTGGAAGCTTGCCTCAAGCCTTAGCGGTAAACGAACGCTGTGATTAAGAAGAC 60  
|||||  
Db 769 CAATTGTGGAAGCTTGCCTCAAGCCTTAGCGGTAAACGAACGCTGTGATTAAGAAGAC 710  
QY 61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 120  
|||||  
Db 709 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 650  
QY 121 GAAATCATGCATGACAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 180  
|||||  
Db 649 GAAATCATGCATGACAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 590  
QY 181 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGGTTACGGGATGACC 240  
|||||  
Db 589 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGGTTACCGGATGACC 530  
QY 241 AGCTCGTCTTGGTGTGATTACATCTCATGCCCCGTGTGTGGGACTTGTCTTGTCA 300  
|||||  
Db 529 AGCTCGTCTTGGTGTGATTACATCTCATGCCCCGTGTGTGGGACTTGTCTTGTCA 470  
QY 301 TTGCAAACTCAGATGCTTTCCAAAGCCAATCACTGGGAGACCGACACAGGAGAGAC 360  
|||||  
Db 469 TTGCAAACTCAGATGCTTTCCAAAGCCAATCACTGGGAGACCGACACAGGAGAGAC 410  
QY 361 CAAGGGGAAGGGAGAGAAAGAAATAAGACAACGTTATTCTTAACAGACTTCTAT 420  
|||||  
Db 409 CAAGGGGAAGGGAGAGAAAGAAATAAGACAACGTTATTCTTAACAGACTTCTAT 350  
QY 421 AGGAGTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATCAAGTTTTC 480  
|||||  
Db 349 AGGAGTGTAGAAGGTGCACATA-TTTTAAATCTCACTGGCAATATCAAGTTTTC 291  
QY 481 ATTGTGCTTAAACAAGGTGT 501  
|||||  
Db 290 ATTGTGCTTAAACAAGGTGT 270

RESULT 2  
AL133724 695 bp mRNA linear EST 25-FEB-2000  
LOCUS  
DEFINITION DKFZP761J19121\_r1 761 (synonym: hamy2) Homo sapiens cDNA clone  
          DKFZP761J19121 5', mRNA sequence.  
ACCESSION AL133724  
VERSION AL133724  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 695)  
AUTHORS Poustka,A., Klein,M., Mewes,H.W., Gassenhuber,J. and Wiemann,S.  
TITLE EST (Poustka, et al.)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Poustka A.J.  
          Department Lehrach  
          Max-Planck-Institute for Molecular Genetics  
          Inhestrasse 73, 14195 Berlin, Germany  
          Tel: +49-30-84131623  
          Fax: +49-30-84131128  
          Email: poustka@mpimg-berlin-dahlem.mpg.de  
          This is the 5' sequence of the clone insert  
          Clone from S. Wiemann, Molecular Genome Analysis, German Cancer  
          Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de;

sequenced by DKFZ (German Cancer Research Center,  
Heidelberg/Germany) within the cDNA sequencing consortium of the  
German Genome Project.  
No si sequence available.  
This clone (DKFZp761J19121) is available at the RZPD in Berlin.  
Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059  
Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.  
FEATURES  
source  
location/Qualifiers  
1..695  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="DKFZp761J19121"  
/clone\_lib="761 (synonym: hamy2)"  
/tissue\_type="amygdala"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/note="Vector: pSport1; Site\_1: NotI; Site\_2: SalI"

BASE COUNT 202 a 134 c 185 g 174 t  
ORIGIN

Query Match 96.4%; Score 483; DB 9; Length 695;  
Best Local Similarity 98.4%; Pred. No. 1.2e-115;  
Matches 501; Conservative 0; Mismatches 0; Indels 8; Gaps 1;

QY 1 CAATTGTGGAAGCTTGCCTCAAGCCTTAGCGGTAAACGAACGCTGTGATTAAGAAGAC 60  
|||||  
Db 13 CAATTGTGGAAGCTTGCCTCAAGCCTTAGCGGTAAACGAACGCTGTGATTAAGAAGAC 72  
QY 61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGACTTCT 120  
|||||  
Db 73 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGACTTCT 132  
QY 121 GAAATCATGCATGAGCA-----GATCGCCCCCTGGAGAGAAGACGAGCTTTAC 172  
|||||  
Db 133 GAAATCATGCATGAGCAGCTGGATGATCGCCCCCTGGAGAGAAGACGAGCTTTAC 192  
QY 173 CGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGTTACAG 232  
|||||  
Db 193 CGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGTTACAG 252  
QY 233 GGATGACCAGCTCGTCTTGGTGTGATTACATCTCATGGCCGTTGTGGGACTTG 292  
|||||  
Db 253 GGATGACCAGCTCGTCTTGGTGTGATTACATCTCATGGCCGTTGTGGGACTTG 312  
QY 293 CTTTGTCAATTTGCAAACTCAGGATGCTTCCAAAGCCAATCACTGGGAGACCGACACA 352  
|||||  
Db 313 CTTTGTCAATTTGCAAACTCAGGATGCTTCCAAAGCCAATCACTGGGAGACCGACACA 372  
QY 353 GGGAGGACCAAGGGGGAAGGGAGAGAAAGGAATAAGACAACGTTATTCTTAACAGA 412  
|||||  
Db 373 GGGAGGACCAAGGGGGAAGGGGAGAGAAAGGAATAAGACAACGTTATTCTTAACAGA 432  
QY 413 CTTTCTATAGAGATTGTAAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTC 472  
|||||  
Db 433 CTTTCTATAGAGATTGTAAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTC 492  
QY 473 AAGTTTCAATTTGTCTTAAACAAGGTGT 501  
|||||  
Db 493 AAGTTTCAATTTGTCTTAAACAAGGTGT 521

RESULT 3  
BI602169 777 bp mRNA linear EST 07-SEP-2001  
LOCUS  
DEFINITION 603246290F1 NIH\_MGC\_96 Homo sapiens cDNA clone IMAGE:5288423 5',  
          mRNA sequence.  
ACCESSION BI602169  
VERSION BI602169  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```
REFERENCE      1 (bases 1 to 777)
AUTHORS        NIH-MGC http://mgc.nci.nih.gov/.
TITLE          National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL        Unpublished (1999)
COMMENT        Contact: Robert Strausberg, Ph.D.
                Email: cgabbs-remail.nih.gov
                Tissue Procurement: Miklos Palkovits, M.D., Ph.D.
                cDNA Library Preparation: Michael J. Brownstein (NHGRI), Shiraki
                Toshiyuki and Piero Carninci (RIKEN)
                cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
                DNA Sequencing by: Incyte Genomics, Inc.
                Clone distribution: MGC clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                http://image.llnl.gov
                Plate: LLAM11729 row: d column: 24
                High quality sequence stop: 777.
FEATURES
  source
    1..777
      /organism="Homo sapiens"
      /db_xref="taxon:9606"
      /clone="IMAGE:5288423"
      /clone_1lb="NIH_MGC_96"
      /tissue_type="hypothalamus"
      /lab_host="DH10B"
      /note="Organ: brain; Vector: pBluescriptR (modified
      pBluescript KS+); Site_1: BamHI; Site_2: SalI-XhoI (gtcgag
      ); Oligo-dT primed using primer 5'-TTTTTTT TTTT TTVN-3',
      size-selected for average insert size 2.3 kb and
      normalized to R0T 5. This is a primary library enriched
      for full-length clones and constructed using the
      Cap-trapper method (Carninci, in preparation). Library
      constructed by M. Brownstein (NIH/NHGRI, National
      Institutes of Health). Note: this is a NIH_MGC Library."
BASE COUNT      223 a      159 c      207 g      188 t
ORIGIN
Query Match      96.4%; Score 483; DB 13; Length 777;
Best Local Similarity 98.4%; Pred. No. 1.2e-115;
Matches 501; Conservative 0; Mismatches 0; Indels 8; Gaps 1;
QY      1 CAATTGTGGAAGCTTGCGGTCAAGCCCTTACGGGTAACGAACGTCGATTAAAGAAGAC 60
      |||||||
Db      208 CAATTGTGGAAGCTTGCGGTCAAGCCCTTACGGGTAACGAACGTCGATTAAAGAAGAC 267
QY      61 CAGCTCGAGTATCAGAGAAGAAATGAAGGCCAACTACAGAGGAATGGCGAAGAGCTTCT 120
      |||||||
Db      268 CAGCTCGAGTATCAGAGAAGAAATGAAGGCCAACTACAGAGGAATGGCGAAGAGCTTCT 327
QY      121 GAAATCATGATGAGCA-----GATTCGCCCCCTGGAGGAGAGAGAGCGTCTTAC 172
      |||||||
Db      328 GAAATCATGATGAGCAAGCTGGAGTATCTGCCCTTGAGAGAGAGAGAGCGTCTTAC 387
QY      173 CGAATTCCTTCACATCTTCAACGCCATCAGTGGAGCTCCAACAAAGCACAATGCTTCACG 232
      |||||||
Db      388 CGAATTCCTTCACATCTTCAACGCCATCAGTGGAGCTCCAACAAAGCACAATGCTTCACG 447
QY      233 GGATGACCAGCTCGTCTTCGGTCTGTGATTAATCATCTCATGGCCCGTGTGGGACTTG 292
      |||||||
Db      448 GGATGACCAGCTCGTCTTCGGTCTGTGATTAATCATCTCATGGCCCGTGTGGGACTTG 507
QY      293 CTTTGTCATTTGCAACTCAGATGCTTTCGAAGCCCAATCCTGGGAGACCGAGACACA 352
      |||||||
Db      508 CTTTGTCATTTGCAACTCAGATGCTTTCGAAGCCCAATCCTGGGAGACCGAGACACA 567
QY      353 GGGAGGACCAAGGGGAGAGAGAAAGGAATTAAGAACAACGTTATTCTTAACAGA 412
      |||||||
Db      568 GGGAGGACCAAGGGGAGAGAGAAAGGAATTAAGAACAACGTTATTCTTAACAGA 627
QY      413 CTTTCTATAGAGTTGTAAGAAGGTGCACATATTTTAAATCTCAGTCGCAATATTCA 472
      |||||||
Db      628 CTTTCTATAGAGTTGTAAGAAGGTGCACATATTTTAAATCTCAGTCGCAATATTCA 687
QY      473 AAGTTTTCATTTGTGCTTAACAAGGTGT 501
```

```
Db      688 AAGTTTTCATTTGTGCTTAACAAGGTGT 716
|||||
RESULT 4
AW162535/c
LOCUS
DEFINITION  AW162535 644 bp mRNA linear EST 09-NOV-1999
             au77b01.x1 Schneider fetal brain 00004 Homo sapiens cDNA clone
             IMAGE:2782249 3' similar to TR:Q63603 Q63603 TRG MRNA ;, mRNA
             sequence.
ACCESSION  AW162535
VERSION    AW162535.1 GI:6301568
KEYWORDS   EST.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE  1 (bases 1 to 644)
AUTHORS    Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisel,G., Jost,S.,
            Krizman,D., Kucaba,T., Lacy,M., Le,N., Lennon,G., Marra,M., Martin
            ,J., Moore,B., Schellenberg,K., Steptoe,M., Tan,F., Theising,B.,
            White,Y., Wylie,T., Waterston,R. and Wilson,R.
            Washu-NCI human EST Project
            Unpublished (1997)
            Other_ESTs: au77b01.y1
            Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Possible reversed clone: polyT not found
            Seq primer: -40UP from Gibco
            High quality sequence stop: 455.
FEATURES
  source
    1..644
      /organism="Homo sapiens"
      /db_xref="taxon:9606"
      /clone="IMAGE:2782249"
      /clone_1lb="Schneider fetal brain 00004"
      /sex="male"
      /tissue_type="frontal lobe"
      /dev_stage="5 months post-conception"
      /lab_host="DH10B"
      /note="Organ: brain; Vector: pBluescript SK (Stratagene);
      Site_1: SclI; Site_2: XhoI; Double-stranded cDNA was
      prepared from human fetal brain tissue. 5' and 3'
      adaptors were used in cloning as follows: 5' adaptor
      sequence:
      5'-GAGAGAGAGAGAGAGCTCAAGATCCTTAATTAATTAATTCCTCCCTCCCTCC-3'
      and 3' adaptor sequence:
      5'-GAGAGAGAGAGAGCTCGAGTTT TTT TTT TTT TTT-3'. The library was
      size-selected for >0.5 kb inserts and has an average
      insert size estimated at 1.2 kb. This library was
      constructed using the CAP-trapper method for full-length
      enrichment and has not undergone amplification. Library
      was constructed by Dr. Claudio Schneider (LNCIB-Area
      Science Park, Trieste, Italy)."
BASE COUNT      162 a      168 c      128 g      186 t
ORIGIN
Query Match      95.8%; Score 479.8; DB 10; Length 644;
Best Local Similarity 98.0%; Pred. No. 8.3e-115;
Matches 499; Conservative 0; Mismatches 2; Indels 8; Gaps 1;
QY      1 CAATTGTGGAAGCTTGCGGTCAAGCCTTAGCGTAAACGAACGTCGATTAAAGAAGAC 60
      |||||||
Db      638 CAATTGTGCAAGCTTGCGGTCAAGCCTTAGCGTAAACGAACGTCGATTAAAGAAGAC 579
QY      61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 120
      |||||||
```

Db 578 CAGCTCGAGTATCAGAGAAATGATAGCCCACTACAGGAAATGGCGAAGAGCCTTCT 519

QY 121 GAAATCATGCATGAGCA-----GATCTGCCCCCTGGAGAGAGAGAGCGCTCTTAC 172

Db 518 GAAATCATGCATGAGCAGCTGGGATGATCTGCCCTTGAGAGAGAGAGAGCGCTCTTAC 459

QY 173 CGAATTCCCTTCACATCTTCAACGCCCATCAGTGGGACTCCAAACAGCAATGGTTCACG 232

Db 458 CGAATTCCTTCACATCTTCAACGCCCATCAGTGGGACTCCAAACAGCAATGGTTCACG 399

QY 233 GGATGACCAGCTCGTCTTCGGTCTGTGATACATCTCATGGCCCCGTGTGGGACTTG 292

Db 398 GGATGACCAGCTCGTCTTCGGTCTGTGATACATCTCATGGCCCCGTGTGGGACTTG 339

QY 293 CTTTGTCAATTTGCAAACTCAGGATGCTTTCGAAAGCCCAATCAGTGGGAGACCGAGCACA 352

Db 338 CTTTGTCAATTTGCAAACTCAGGATGCTTTCGAAAGCCCAATCAGTGGGAGACCGAGCACA 279

QY 353 GGGAGAGCCAAAGGGGAGGAGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGA 412

Db 278 GGGAGAGCCAAAGGGGAGGAGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGA 219

QY 413 CTTTCTATAGAGTTGTAGAAGGTGCACATATTTTAAATCTCAGCTGGCAATATTCA 472

Db 218 CTTTCTATAGAGTTGTAGAAGGTGCACATATTTTAAATCTCAGCTGGCAATATTCA 159

QY 473 AAGTTTCATGTGTCTTAAACAAGGTGT 501

Db 158 AAGTTTCATGTGTCTTAAACAAGGTGT 130

RESULT 5

LOCUS BG676871 920 bp mRNA linear EST 01-MAY-2001

DEFINITION 602623473f1 NCI\_CGAP\_Skn4 Homo sapiens cDNA clone IMAGE:4748442 5', mRNA sequence.

ACCESSION BG676871

VERSION BG676871.1 GI:13908268

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 920)

AUTHORS NIH-MGC http://mgc.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgapbs-r@mail.nih.gov

Tissue Procurement: James Cleaver, M.D.

CDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LAM10600 row: a column: 19

High quality sequence stop: 849.

location/Qualifiers

1. 920

/organism="Homo sapiens"

/db\_xref="taxon:9606"

/clone="IMAGE:4748442"

/clone\_lib="NCI\_CGAP\_Skn4"

/tissue\_type="squamous cell carcinoma"

/lab\_host="DH10B (T1 phage-resistant)"

/note="Organ: skin; Vector: PCMV-SPORT6; Site\_1: NotI;

Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dT.

Average insert size 1.5kb. Library constructed by Life

Technologies. Note: this is a NCI\_CGAP Library."

BASE COUNT 274 a 164 c 230 g 251 t 1 others

, ORIGIN

Query Match 95.6%; Score 479; DB 12; Length 920;

Best Local Similarity 98.6%; Pred. No. 1.4e-114;

Matches 494; Conservative 0; Mismatches 5; Indels 2; Gaps 1;

QY 1 CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTGTGATTAAGAAGAC 60

Db 19 CAATTTGTGGAAGCT--GCCGTACAGCCTTAGCGGTAACGAACGCTGTGATTAAGAAGAC 76

QY 61 CAGCTCGAGTATCAGAGAAATGAAGCCCACTACAGGAAATGGCGAAGAGCCTTCT 120

Db 77 CAGCTCGAGTATCAGAGAAATGAAGCCCACTACAGGAAATGGCGAAGAGCCTTCT 136

QY 121 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGAGAGAGAGCGCTTTACCGAATTCC 180

Db 137 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGAGAGAGAGCGCTTTACCGAATTCC 196

QY 181 CTTACATCTTCAACGCCCATCAGTGGGACTCCAACAGCACCAATGTTTCAGGGGATGACC 240

Db 197 CTTACATCTTCAACGCCCATCAGTGGGACTCCAACAGCACCAATGTTTCAGGGGATGACC 256

QY 241 AGCTCGTCTTGGTCTGCTGATTTACATCTCATGCCCCGTGTGGGAGACTTGTGTCA 300

Db 257 AGCTCGTCTTGGTCTGCTGATTTACATCTCATGCCCCGTGTGGGAGACTTGTGTCA 316

QY 301 TTGCAAACTCAGATGCTTTCCAAAGCCCAATCAGTGGGAGACCGAGACAGGAGAGAC 360

Db 317 TTGCAAACTCAGATGCTTTCCAAAGCCCAATCAGTGGGAGACCGAGACAGGAGAGAC 376

QY 361 CAAGGGGAAGGGGAGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGACTTCTAT 420

Db 377 CAAGGGGAAGGGGAGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGACTTCTAT 436

QY 421 AGGAGTTGTAAGAAGGTGCACATATTTTAAATCTCAGTGGCAATATTCAAGTTTTC 480

Db 437 AGGAGTTGTAAGAAGGTGCACATATTTTAAATCTCAGTGGCAATATTCAAGTTTTC 496

QY 481 ATTGTGCTTAAACAAGGTGT 501

Db 497 ATTGTGCTTAAACAAGGTGT 517

RESULT 6

LOCUS BI603180 801 bp mRNA linear EST 07-SEP-2001

DEFINITION 603249824f1 NIH\_MGC\_96 Homo sapiens cDNA clone IMAGE:5301749 5', mRNA sequence.

ACCESSION BI603180

VERSION BI603180

KEYWORDS EST.

SOURCE BI603180.1 GI:15496119

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 801)

AUTHORS NIH-MGC http://mgc.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgapbs-r@mail.nih.gov

Tissue Procurement: Miklos Palkovits, M.D., Ph.D.

CDNA Library Preparation: Michael J. Brownstein (NHGRI), Shiraki

Toshiyuki and Piero Carninci (RIKEN)

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LAM11763 row: p column: 06

High quality sequence stop: 710.

location/Qualifiers

1. 801

/organism="Homo sapiens"

/db\_xref="taxon:9606"

source



```

/clone="IMAGE:5301749"
/clone_lib="NIH_MGC_96"
/tissue_type="hypothalamus"
/lab_host="DH10B"
/note="Organ: brain; Vector: pBluescriptR (modified
pBluescript KS+); Site_1: BamHI; Site_2: SalI-XhoI (gtcgag
); Oligo-dT primed using primer 5'-TTTTTTTTTTTTTTTTVN-3',
size-selected for average insert size 2.3 kb and
normalized to ROT 5. This is a primary library enriched
for full-length clones and constructed using the
Cap-trapper method (Carninci, in preparation). Library
constructed by M. Brownstein (NIMH/NHGRI, National
Institutes of Health). Note: this is a NIH_MGC Library."

```

Query Match	87.38;	Score 437.2;	DB 13;	Length 801;
Best Local Similarity	96.38;	Pred. No. 1.1e-103;		
Matches 493; Conservative	0;	Mismatches 8;	Indels 11;	Gaps 4;

OY		1	CATTGTGGAGACTTGCCTGTCACGCCCTTAGCCGGTTAAACGAACGCTCTGATTTAAGAAGAC	60
Db		208	CAATTTGTGGAGCCTTGCGGTCAAGCCTTAGCCGGTTAAACGAACGCTCTGATTTAAGAAGAC	267
OY		61	CAGCTCAGATATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCCTTCT	120
Db		268	CAGCTCAGATATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCCTTCT	327
OY		121	GAAATCATGCATGAGCA-----GATCTGCCCCCTGGAGGAGAGAAGACGACGCTTAC	172
Db		328	GAAATCATGCATGAGCACAGCTGGGATGATCTGCCCCCTGGAGGAGAGAAGACGACGCTTAC	387
OY		173	CGAATTCCTTCACATCTTCCAAGCCATCAGTGGGACTCCAACAAAGCACAAATGGTTCACG	232
Db		388	CGAATTCCTTCACATCTTCCAAGCCATCAGTGGGACTCCAACAAAGCACAAATGGTTCACG	447
OY		233	GGATGACCAGCTCGTCTTCGCTGCTGTGATTACATCTCATATGCCCCGTGTGTGSGGAC-TT	291
Db		448	GGATGACCAGCTCGTCTTCGCTGCTGTGATTACATCTCATATGCCCCGTGTGTGSGGACCTT	507
OY		292	GCTTTGTCATTTGGCAAACCTCAGGATGCTTTCCAAAGCCAATCCTGGGGAGACCGAGCAC	351
Db		508	GCTTTGTCATTTGGCAAACCTCAGGATGCTTTCCAAAGCCAATCCTGGGGAGACCGAGCAC	567
OY		352	AGGAGAGACCAAGGGGGAAGGGGAGAAAAGAAATAAGACAACAACGTTATTCTTTAACAG	411
Db		568	AGGAGAGACCAAGGGGGAAGGGGAGAAAAGAAATAAGACAACAACGTTATTCTTTAACAG	627
OY		412	ACTTTCATAGGAGTTGTGAAGAAGGTGCA-CATATTTTTTTTAATCTCA-CTGGCAATAT	469
Db		628	ACTTTCATAGGAGTTGTGAAGAAGGTGCAACCATATTTTTTTTAAATCTCACCTGGCAATAT	687
OY		470	TCAAAGTTTCATTTGTGTCTTAACAAAGGTGT	501
Db		688	TCAAAGTTTCATGTGTCTTAACCAAAAGGTGT	719

RESULT 7  
BF748808/c  
LOCUS BF748808 546 bp mRNA linear EST 10-JAN-2001  
DEFINITION MR0-BN0115-041000-013-e10 BN0115 Homo sapiens CDNA, mRNA sequence.  
ACCESSION BF748808  
VERSION BF748808.1 GI:12075471  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 546)  
Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,  
Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F.,  
Goldman, G.H., Carvalho, A.F., Matsukuma, A., Baia, G.S., Simpson, D.H.,  
Brunstein, A., deoliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare

TITLE	M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and Simpson, A.J.J.
JOURNAL	Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
MEDLINE	Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
COMMENT	20202663 Contact: Simpson A.J.G.

Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: [asimpson@ludwig.org.br](mailto:asimpson@ludwig.org.br)  
This sequence was derived from the FAPESP/LICR Human Cancer Genome project. This entry can be seen in the following URL (<http://www.ludwig.org.br/scripts/gethtml2.pl?tl=MR0&t2=MR0-BN0115-041000-013-e10&t3=2000-10-04&t4=1>)  
Seq primer: puc 18 forward  
High quality sequence start: 16  
High quality sequence stop: 545.

FEATURES	Location/Qualifiers
source	1. .546

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="BN0115"
/dev_stage="Adult"
/note="Organ: breast_normal; Vector: puc18; Site_1: SmaI;
Site_2: SmaI; A mini-library was made by cloning products
derived from ORESTES PCR (U.S. Letters Patent application
No. 196,716 - Ludwig Institute for Cancer Research)
profiles into the pUC 18 vector. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."
140 a 135 c 115 g 156 t
BASE COUNT
ORIGIN

```

Query Match	85.3%;	Score 427.2;	DB 12;	Length 546;
Best Local Similarity	99.1%;	Pred. No. 4.5e-101;		
Matches 440;	Conservative 0;	Mismatches 3;	Indels 1;	Gaps 1;

QY	59	ACCAGCTCGAGTATTCAGGAGAAGAAATGAAGCCCAACTACAGGGAAATGGCGAAGGAGCTTT       	118
Dp	546	ACCAGCTCGAGTATCAGGAGAACAATAAGGCCCACTACAGGGAAATGGCGAAGGAGCTTT       	487
QY	119	CTGAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAAGCAGCGCTTTACCGAATT       	178
Dp	486	CTGAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAAGCAGCGCTTTACCGAATT       	427
QY	179	CCCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACATGTGTTCACGGGATGA       	238
Dp	426	CCCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACATGTGTTCACGGGATGA       	367
QY	239	CCAGCTCGTCTTGCGTGTGTGATTACATCTCATGCCCCGTGTGTGGGACTTGCTTTGT       	298
Dp	366	CCAGCTCGTCTTGCGTGTGTGATTACATCTCATGCCCCGTGTGTGGGACTTGCTTTGT       	307
QY	299	CATTTGCAAACTCAGGATGCTTTCCAAAGCCAAATCACTGGGGAGACGACACAGGAGG       	358
Dp	306	CATTTGCAAACTCAGGATGCTTTCCAAAGCCCACTCAGTGGGAGACGACACAGGAGG       	247
QY	359	ACCAAGGGGAAGGGGAGAGAAAAGAAATAAGAACAACGTTATT--CTTAACGAGCTTTC       	417
Dp	246	ACCAAGGGGAAGGGGAGAGAAAAGAAATAAGAACAACGTTATTCTTAACGAGCTTTC       	187
QY	418	TATAGAGTTGTAAGAAGGTGCACATATTTTTTAAATCTCACGTGGCAATATTTCAAAGTT       	477
Dp	186	TATAGAGTTGTAAGAAGGTGCACATATTTTTTAAATCTCACGTGGCAATATTTCAAAGTT       	127
QY	478	TTCATTTGTCTTTAACAAAGGTGT 501       	
Dp	126	TTCATTTGTCTTTAACCAAGGTGT 103       	

```
RESULT 8
AM953240                                679 bp      mRNA      linear      EST 01-JUN-2000
LOCUS                                     EST365310 MAGE resequences, MAGB Homo sapiens cDNA, mRNA sequence.
DEFINITION
ACCESSION AM953240
VERSION    AM953240.1  GI:8142923
KEYWORDS   EST.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 679)
AUTHORS   Hegde,P., Qi,R., Abernathy,K., Dharap,S., Gaspard,R., Gay,C., Holt
            ,I.E., Saeed,A.I., Sharov,V., Lee,N.H., Yeatman,T.J. and
            Quackenbush,J.
TITLE      Assessment of gene expression patterns in a model of colon tumor
            metastasis using a 19,200 element cDNA microarray
JOURNAL    Unpublished (2000)
COMMENT    Contact: John Quackenbush
            The Institute for Genomic Research
            9712 Medical Center Dr., Rockville, MD 20850, USA
            Tel: 301 838 3528
            Fax: 301 838 0208
            Email: johnq@tigr.org
            Plate: 48
            Seq primer: Reverse.
FEATURES   Location/Qualifiers
            source                1..679
                                   /organism="Homo sapiens"
                                   /db_xref="taxon:9606"
                                   /clone_lib="MAGE resequences, MAGB"
                                   /note="Vector: pBluescriptSkm"
BASE COUNT 194 a      146 c      191 g      147 t      1 others
ORIGIN
Query Match      82.0%; Score 410.8; DB 10; Length 679;
Best Local Similarity 97.5%; Pred. No. 8.8e-97;
Matches 430; Conservative 0; Mismatches 3; Indels 8; Gaps 1;

QY      1 CAATTGTGGAAGCTTGGGTCAAGCCTTAGCGGTAACGAAGCTCTGATTAAGAAGAC 60
         |||||||
Db       239 CAATTGTGGAAGCTTGGGTCAAGCCTTAGCGGTAACGAAGCTCTGATTAAGAAGAC 298

QY      61 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGGAGCTTCT 120
         |||||||
Db       299 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGGAGCTTCT 358

QY      121 GAAATCATGATGAGCA-----GATCTGCCCCCTGGAGAGAGACGAGCGTCTTAC 172
         |||||||
Db       359 GAAATCATGATGAGCAGCTGGATGATCTGCCCTGGAGAGAGACGAGCGTCTTAC 418

QY      173 CGAATTCCCTTCACATCTTCAACGCCATCAGTGGAGCTCCAACAAGCACAATGTTACG 232
         |||||||
Db       419 CGAATTCCCTTCACATCTTCAACGCCATCAGTGGAGCTCCAACAAGCACAATGTTACG 478

QY      233 GGATGACCAGCTCTCTTGGTCTGCTGATTAACATCTCATGGCCCGTGTGGGACTTG 292
         |||||||
Db       479 GGATGACCAGCTCTCTTGGTCTGCTGATTAACATCTCATGGCCCGTGTGGGACTTG 538

QY      293 CTTTGTCAATTTGCAAACTCAGGATGCTTCCAAGCCAATCAGTGGGAGACCGAGCACA 352
         |||||||
Db       539 CTTTGTCAATTTGCAAACTCAGGATGCTTCCAAGCCAATCAGTGGGAGACCGAGCACA 598

QY      353 GGGAGGACCAAGGGGAGAGAGAAATTAAGAACACGTTATTCTTAACAGA 412
         |||||||
Db       599 GGGAGGACCAAGGGGAGAGAGAAATTAAGAACACGTTATTCTTAACAGA 658

QY      413 CTTTCTATAGAGTTGTAAGA 433
         |||||||
Db       659 CTTTCTTATAGAGTTGTAAGA 679
```

```
RESULT 9
BF667219                                574 bp      mRNA      linear      EST 21-DEC-2000
LOCUS                                     602121018F1 NIH_MGC_56 Homo sapiens cDNA clone IMAGE:4278077 5',
DEFINITION mRNA sequence.
ACCESSION BF667219
VERSION    BF667219.1  GI:11941114
KEYWORDS   EST.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 574)
AUTHORS   NIH-MGC http://mgc.nci.nih.gov/.
            National Institutes of Health, Mammalian Gene Collection (MGC)
            Unpublished (1999)
JOURNAL    Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-remail.nih.gov
            Tissue Procurement: ATCC
            CDNA Library Preparation: CLONTECH Laboratories, Inc.
            CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
            DNA Sequencing by: Incyte Genomics, Inc.
            Clone distribution: MGC clone distribution information can be
            found through the I.M.A.G.E. Consortium/LNL at:
            http://image.lnl.gov
            Plate: LNCMI101 row: c column: 06
            High quality sequence stop: 544.
FEATURES   Location/Qualifiers
            source                1..574
                                   /organism="Homo sapiens"
                                   /db_xref="taxon:9606"
                                   /clone="IMAGE:4278077"
                                   /clone_lib="NIH_MGC_56"
                                   /issue_type="primitive neuroectoderm"
                                   /lab_host="DH10B (T1 phage-resistant)"
                                   /note="Organ: brain; Vector: pDNR-LIB (Clontech); Site_1:
                                   SfiI (ggccattatggcc); Site_2: SfiI (ggccattatggcc);
                                   SfiI (ggccgcctcgcc); Double-stranded cDNA was prepared from cell line RNA. 5'
                                   and 3' adaptors were used in cloning as follows: 5'
                                   adaptor sequence: 5'-CACGGCCATTAAGGCC-3' and 3' adaptor
                                   sequence: 5'-ATTCTAGAGGCGGAGCGGCCGCACATG-dT(30)BN-3'
                                   (where B = A, C, or G and N = A, C, G, or T). Average
                                   insert size 1.65 kb (range 0.9-4.0 kb). 15/15 colonies
                                   contained inserts by PCR. This library was enriched for
                                   full-length clones and was constructed by Clontech
                                   Laboratories (Palo Alto, CA)."
```

```
BASE COUNT 165 a      133 c      158 g      118 t
ORIGIN
Query Match      76.9%; Score 385.2; DB 12; Length 574;
Best Local Similarity 99.2%; Pred. No. 4.2e-90;
Matches 387; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      3 ATTTGTGAAGCTTGGGTCAAGCCTTAGCGGTAACGAAGCTCTGATTAAGAAGACCA 62
         |||||||
Db       185 AATTGTGAAGCTTGGGTCAAGCCTTAGCGGTAACGAAGCTCTGATTAAGAAGACCA 244

QY      63 GCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTCTGA 122
         |||||||
Db       245 GCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTCTGA 304

QY      123 AATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCCT 182
         |||||||
Db       305 AATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCCT 364

QY      183 TCACATCTTCAACGCCATCAGTGGGACTCCAACAACACCAATGTTACAGGGATGACCAG 242
         |||||||
Db       365 TCACATCTTCAACGCCATCAGTGGGACTCCAACAACACCAATGTTACAGGGATGACCAG 424

QY      243 CTCGCTCTGGTCTGTGATTAACATCTCATGGCCCGTGTGGGACTTGTTCATT 302
         |||||||
Db       425 CTCGCTCTGGTCTGTGATTAACATCTCATGGCCCGTGTGTGGGACTTGTTCATT 484
```

QY	303	TGCAAACTCAGGATGCTTTCCAAAGCCCAATCACTGGGGAGAGACCGAGCACAGGAGACCA	362
Db	485	TGCAAACTCAGGATGCTTTCCAAAGCCCAATCACTGGGGAGAGACCGAGCACAGGAGACCA	544
QY	363	AGGGGAAGGGGAGAGAAAGGAATTAAGAA	392
Db	545	AGGGGAAGGGGAGAGAGACAGGAATACAGAA	574
RESULT 10			
BM353207			
LOCUS			
DEFINITION	BM353207	521 bp	MRNA
	ig44a10.y1	HR85	1slet Homo sapiens cDNA 5' similar to TR:063603
ACCESSION	063603 TRG	PROTEIN	;
VERSION	BM353207		MRNA sequence.
KEYWORDS	BM353207.1	GI:18085565	
SOURCE	EST.		
ORGANISM	human.		
	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
	1 (bases 1 to 521)		
	Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,		
	Lemshka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,		
	Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A.,		
	Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J., Cardenas		
	,M., Gibbons,M., McCann,R., Cole,R., Tsagareishvili,R., Williams,T.		
	, Jackson,Y. and Bowers,Y.		
	Endocrine Pancreas Consortium		
	Unpublished (2000)		
	Other_ESTs: ig44a10.x1		
	Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue		
	Endocrine Pancreas Consortium		
	Harvard University, Howard Hughes Medical Institute		
	Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,		
	MA 02138		
	Tel: 617-495-1812		
	Fax: 617-495-8557		
	Email: dmelton@biohp.harvard.edu		
	Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:		
	Washington University Genome Sequencing Center For information on		
	obtaining a clone please contact: Dr. Hiroshi Inoue		
	(hinoue@im.wustl.edu)		
	Seq primer: -40RP from Gibco		
	High quality sequence stop: 462.		
FEATURES			
source			
	1..521		
	Location/Qualifiers		
	/organism="Homo sapiens"		
	/db_xref="taxon:9606"		
	/clone_lib="HR85 islet"		
	/tissue_type="Purified pancreatic islet"		
	/lab_host="DH10B"		
	/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1:		
	NotI; Site_2: XhoI; cDNA made by oligo-dT priming.		
	Size-selected on agarose gel. Average insert size ~1kb. 5'		
	XhoI site was destroyed after directional cloning.		
	Amplified once. Contact information: Hiroshi Inoue, MD,		
	Metabolism Div. (Alan Permutt Lab), Washington University		
	School of Medicine, Box 8127, 660 South Euclid Ave., St.		
	Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:		
	314-362-1916, Fax: 314-747-2692."		
BASE COUNT	151 a	120 c	137 g
ORIGIN			113 t
Query Match	73.7%;	Score 369;	DB 13;
Best Local Similarity	100.0%;	Pred. NO. 7.1e-86;	Length 521;
Matches 369;	Conservative	0;	Mismatches 0;
		Indels	0;
		Gaps	0;
QY	1	CAATTGTGGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAACGTCGTGATTAAGAAGAC	60
Db	153	CAATTGTGGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAACGTCGTGATTAAGAAGAC	212
QY	61	CAGCTCAGTATCAGGAAGAAATGAAGCCCACTACAGGGGAATGGCGAAGAGCTTCT	120

Db	213	CAGCTCGAGTATCAGGAGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGACTTTCT	272
QY	121	GAAATCAGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTC	180
Db	273	GAAATCAGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTC	332
QY	181	CTTCACATCTTCAACGCCATCAGTGGGACTCCACACAGCACAATGTTTCACGGATGACC	240
Db	333	CTTCACATCTTCAACGCCATCAGTGGGACTCCACACAGCACAATGTTTCACGGATGACC	392
QY	241	AGCTCGTCTTCGGTCGTGTGATACATCTCATGGCCCCGTGTGGGAGACTTGCCTTGTCA	300
Db	393	AGCTCGTCTTCGGTCGTGTGATACATCTCATGGCCCCGTGTGGGAGACTTGCCTTGTCA	452
QY	301	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCATTGGGGAGACCGCAGACAGGAGGAC	360
Db	453	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCATTGGGGAGACCGCAGACAGGAGGAC	512
QY	361	CAAGGGGAA 369	
Db	513	CAAGGGGAA 521	
RESULT	11		
LOCUS	BM353362	539 bp	MRNA
DEFINITION	ig46a10.y1 HR85 islet Homo sapiens cDNA 5' similar to TR:Q63603		
ACCESSION	Q63603	TRG	PROTEIN ; mRNA sequence.
VERSION	BM353362		
KEYWORDS	BM353362.1	GI:18085720	
SOURCE	EST.		
ORGANISM	human.		
	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.		
REFERENCE	1 (bases 1 to 539)		
AUTHORS	Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K., Lemishka,I., Scarce,M., Brestelli,J., Gradwohl,G., Clifton,S., Hillier,L., Marra,M., Pape,D., Wylie,T., Martin,J., Blistain,A., Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J., Cardenas ,M., Gibbons,M., McCann,R., Cole,R., Tsagareishvili,R., Williams,T., Jackson,Y. and Bowers,Y.		
	Endocrine Pancreas Consortium		
	Unpublished (2000)		
	Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue		
	Harvard University, Howard Hughes Medical Institute		
	Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge, MA 02138		
	Tel: 617-495-1812		
	Fax: 617-495-8557		
	Email: dmelton@biohp.harvard.edu		
	Library was constructed by Dr. Hiroshi Inoue DNA sequencing by: Washington University Genome Sequencing Center For information on obtaining a clone please contact: Dr. Hiroshi Inoue (hinoue@im.wustl.edu)		
	Seq primer: -40RP from Gibco		
	High quality sequence stop: 478.		
FEATURES	Location/Qualifiers		
source	1..539		
	/organism="Homo sapiens"		
	/db_xref="taxon:9606"		
	/clone_lib="HR85 islet"		
	/tissue_type="Purified pancreatic islet"		
	/lab_host="DH10B"		
	/note="Organ: Pancreas; Vector: pBluescript SK(-); Site_1: NotI; Site_2: XhoI; cDNA made by oligo-dT priming. Size-selected on agarose gel. Average insert size ~1kb. 5' XhoI site was destroyed after directional cloning. Amplified once. Contact information: Hiroshi Inoue, MD, Metabolism Div. (Alan Permutt lab), Washington University School of Medicine, Box 8127, 660 South Euclid Ave., St.		

Louis, MO 63110, E-mail: [hinoue@imgate.wustl.edu](mailto:hinoue@imgate.wustl.edu), Tel.: 314-362-1916, Fax: 314-747-2692."

BASE COUNT	153 a	127 c	144 g	114 t	1 others
ORIGIN					

Query Match	73.58;	Score 368;	DB 13;	Length 539;
Best Local Similarity	99.78;	Pred. No. 1.3e-85;		
Matches 368;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

QY	1	C AATTTGTGGAAGCCTTGCGGTCACAGCCCTTAGCGGTAACAACGCACGCTCTGATTAAAGAGAC	60
Dd	171	C AATTTGTGGAAGCCTTGCGGTCACAGCCCTTAGCGGTAACAACGCACGCTCTGATTAAAGAGAC	230
QY	61	C AGCTCGAGTATCAGAAGAGAATAAGCAACCACACTACAGGGAAATGGCGAAGAGAGCTTTCT	120
Dd	231	C AGCTCGAGTATCAGAAGAGAATAAGCAACCACACTACAGGGAAATGGCGAAGAGAGCTTTCT	290
QY	121	G AAATCATGCATGAGCAGATCTGCCGCCCTGGAGGAGAGAAGACGAGCGTTCTTACCGAAATTC	180
Dd	291	G AAATCATGCATGAGCAGATCTGCCGCCCTGGAGGAGAGAAGACGAGCGTTCTTACCGAAATTC	350
QY	181	C TTCACATCTTCAACGCCCATCAGTGSAGACTCCAACAAGCACAAATGTTCAACGGGATGACC	240
Dd	351	C TTCACATCTTCAACGCCCATCAGTGSAGACTCCAACAAGCACAAATGTTCAACGGGATGACC	410
QY	241	A GCTCGTCTTCGGGTCTGTGATTACAATCTCATGGCCCCGTGTGGGGACTTGTCTTTGTCA	300
Dd	411	A GCTCGTCTTCGGGTCTGTGATTACAATCTCATGGCCCCGTGTGGGGACTTGTCTTTGTCA	470
QY	301	T TTGCAAACTCAGGATGCTTTTCCAAGCCAAATCACA CTGGGGAGACCGAGCACAGGGAGGAC	360
Dd	471	T TTGCAAACTCAGGATGCTTTTCCAAGCCAAATCACA CTGGGGAGACCGAGCACAGGGAGGAC	530
QY	361	C AAGGGGAA 369	
Dd	531	C AAGGGGAA 539	

RESULT 12	AA484945	LOCUS	AA484945	359 bp	mRNA	linear	EST 15-AUG-1997
DEFINITION	aa41b06.r1	NCI CGAP GCBI Homo sapiens CDNA clone IMAGE:815795 5'					
	similar to TR:G550420	G550420 TRG mRNA ; , mRNA sequence.					

ACCESSION	AA484945	GI:2214164
VERSION	AA484945.1	
KEYWORDS	EST.	
SOURCE	human.	

ORGANISM Homo sapiens

REFERENCE  
1 (bases 1 to 359)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE	1 (bases 1 to 359)
AUTHORS	NCI-CGAP <a href="http://www.ncbi.nlm.nih.gov/ncicgap">http://www.ncbi.nlm.nih.gov/ncicgap</a> .
TITLE	National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

JOURNAL Unpublished (1997)

COMMENT Contact: Robert Strausberg, Ph.D.

Tissue Procurement: Louis M. Staudt, M.D., Ph.D., David Allman, Ph.D., Gerald Marti, M.D.

CDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima Bonaldo, Ph.D.

cdna library Arrayed by: Greg Lennon, Ph.D.  
DNA sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
[www-bio.llnl.gov/bbrp/image/image.html](http://www-bio.llnl.gov/bbrp/image/image.html)

Seq primer: -28m13 rev1 ET from Amersham.

## FEATURES

### Location/Qualifiers

source

```
/organism="Homo sapiens"  
/db_xref="GDB:6035413"  
/db_xref="taxon:9606"  
/clone="IMAGE:815795"
```

```

/clone_lib="NCI_CGAP_GCB1"
/tissue_type="germinal center B cell"
/lab_host="DH10B"
/notes="Vector: pT7T3D-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
was prepared from human tonsillar cells enriched for
germinal center B cells by flow sorting (CD20+, IgD-),
provided by Dr. Louis M. Staudt (NCI), Dr. David Altman
(NCI) and Dr. Gerald Marti (CBER). cDNA synthesis was
primed with a Not I - oligo(dT) primer
[5'-TGTACCAATCTGAGTGGAGCGCGCCCTCATTTTTTTTTTTT-3'
]. Double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT7T3 vector. Library
went through one round of normalization, and was
constructed by Bento Soares and M. Fatima Donaldso."

```

Query Match	71.7%;	Score 359;	DB 9;	Length 359;
Best Local Similarity	100.0%;	Pred. No. 2.8e-83;		
Matches 359; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	47	TGATTAAAGAGACCAAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGGAATGG	106
Db	1	TGATTAAAGAAAGACCAAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGGAATGG	60
QY	107	CGAAGGAGCTTTCTGAAATCATGTCATGAGCAGATCTGCCCCCTGGAGGAGAAGCAGCGC	166
Db	61	CGAAGGAGCTTTCTGAAATCATGTCATGAGCAGATCTGCCCCCTGGAGGAGAAGCAGCGC	120
QY	167	TCTTACCGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGG	226
Db	121	TCTTACCGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGG	180
QY	227	TTCAAGGGATGACCAAGCTCGTCTTGGGTCGTGTGATTACATCTCATGGCCGTGTGTGG	286
Db	181	TTCAAGGGATGACCAAGCTCGTCTTGGGTCGTGTGATTACATCTCATGGCCGTGTGTGG	240
QY	287	GACTTCCTTTGTCAATTTGCCAACTCAGATGCTTTCCAAGCCAACTCACTGGGGAGACCG	346
Db	241	GACTTCCTTTGTCAATTTGCCAACTCAGATGCTTTCCAAGCCAACTCACTGGGGAGACCG	300
QY	347	AGCACAAGGAGGAGCAAGGGGGAAGGGGAGAGAAAGGAATTAAGAACAACAGTTATTTCT	405
Db	301	AGCACAAGGAGGAGCAAGGGGGAAGGGGAGAGAAAGGAATTAAGAACAACAGTTATTTCT	359

RESULT 13  
BG992A90/c

LOCUS	609 bp	mRNA	linear	EST 13-JUN-200
DEFINITION	MR3-HT1039-020201-002-b09	HT1039	Homo sapiens	CDNA, mRNA sequence.
ACCESSION	BG992490			

**KEYWORDS** EST,

SOURCE human.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 609)  
AUTHORS Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,

Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F., Goldman, G.H., Carvalho, A.F., Matsukuma, A., Bala, G.S., Simpson, D.H., Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and Simpson, A.J.

TITLE Shotgun sequencing of the human transcriptome with ORF expressed

sequence tags

JOURNAL Proc. Na

MEDLINE

COMMENT      Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research





ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 354)  
AUTHORS Adams,M.D., Kerlavage,A.R., Fleischmann,R.D., Fuldner,R.A., Bult

TITLE Initial assessment of human gene diversity and expression patterns  
based upon 83 million nucleotides of cDNA sequence  
JOURNAL Nature 377 (6547 Suppl), 3-174 (1995)  
MEDLINE 96026280

COMMENT Other ESTs: EST175328 EST175329 EST175330 EST175331 EST175332  
EST175333 EST175334 EST175335 EST175336 EST175337 EST175338  
EST175339 EST17534  
Contact: HGI (Human Gene Index)  
The Institute for Genomic Research  
9712, Medical Center Drive, Rockville, MD 20850, USA  
Tel: (301)-838-0200  
Fax: (301)-838-0208  
Email: hg1etlgr.org.

FEATURES  
Source  
1. 354  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="FUIHBU1"  
/lab\_host="E. coli DH5-alpha"  
/note="Vector: BA, M13-derived; Site\_1: HindIII; Site\_2:  
NotI: The infant brain library, constructed by Bento  
Soares, Columbia University, was oligo-(dT) primed and  
directionally cloned into an M13-derived plasmid using  
total brain mRNA from a 72-day old human female afflicted  
with spinal muscular atrophy."  
BASE COUNT 97 a 77 c 100 g 79 t 1 others  
ORIGIN

Query Match 59.7%; Score 299; DB 9; Length 354;  
Best Local Similarity 94.4%; Pred. No. 1.3e-67;  
Matches 334; Conservative 0; Mismatches 11; Indels 9; Gaps 2;

OY 100 GAAATGGCGAAGAGCTTCTGAATCATGATGAGCA-----GATCTGCCCCCTGG 151  
Db 1 GAAATGGCGAAGAGCTTCTGAATCATGATGAGCACTGGATGATCTGCCCCCTGG 60  
OY 152 AGGAGAAGACGAGCGTCTTACCGAATTCCTTACATCTTCAACGCCATCAGTGGACTC 211  
Db 61 AGGAGAAGACGAGCGTCTTACCGAATTCCTTACATCTTCAACGCCATCAGTGGACTC 120  
OY 212 CAACAAGCACATGTTCAAGGGATGACCAAGCTGCTTCGGTGGTGAATTACATCTCA 271  
Db 121 CAACAAGCACATGTTCAAGGGATGACCAAGCTGCTTCGGTGGTGAATTACATCTCA 180  
OY 272 TGGCCCGTGTGGGGACTGCTTGTTCATTTGCAAACTCAGGATGCTTTCCAAAGCCAA 331  
Db 181 TGGCCCGTGTGGGGACTGCTTGTTCATTTGCAAACTCAGGATGCTTTCCAAAGCCAA 240  
OY 332 TCACTGGGGAGACCGACACAGGAGGACCAAGGGGAAGGAGAGAGAAATAAAGA 391  
Db 241 TCACTGGGGAGACCGACACAGGAGGACCAAGGGGAAGGAGAGAGAAATAAAGA 300

OY 392 ACAACGTTATTCTTAAACA-GACTTCTATAGAGCTTGTAGAAGGTGCACATA 444  
Db 301 ACAACGTTATTCTTAAACAGGACCTTCTTTAGGAGTTGGTNAGAAGGTCACACA 354

Search completed: February 7, 2003, 08:49:46  
Job time : 1017.34 secs

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 05:39:15 ; Search time 994.674 Seconds  
(without alignments)  
14629.322 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_1\_500

Perfect score: 500

Sequence: 1 agtttacaccatcaccacaa.....aggccacgtgatgcgcct 500

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_cm:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_cm:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vi:\*  
30: em\_htg\_hum:\*  
31: em\_htg\_inv:\*  
32: em\_htg\_other:\*  
33: em\_htg\_mus:\*  
34: em\_htg\_pln:\*  
35: em\_htg\_rod:\*  
36: em\_htg\_mam:\*  
37: em\_htg\_vrt:\*  
38: em\_sy:\*  
39: em\_htgo\_hum:\*  
40: em\_htgo\_mus:\*  
41: em\_htgo\_other:\*

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	498.4	99.7	7506	6	AX255048	AX255048 Sequence
2	498.4	99.7	7522	9	AF527605	AF527605 Homo sapi
3	498.4	99.7	7545	9	AB028981	AB028981 Homo sapi
4	204.4	40.9	6454	6	AX173022	AX173022 Sequence
5	194.8	39.0	139887	9	CNS01RGX	AL160233 Human chr
6	126.8	25.4	163316	9	AL161420	AL161420 Human DNA
7	90.4	18.1	175281	2	AC109966	AC109966 Rattus no
8	85	17.0	4391	6	AX173028	AX173028 Sequence
9	85	17.0	4393	6	AX173118	AX173118 Sequence
10	75.8	15.2	175281	2	AC109966	AC109966 Rattus no
11	75.8	15.2	192825	2	AC119357	AC119357 Rattus no
12	71.4	14.3	5564	9	AK074081	AK074081 Homo sapi
13	71.4	14.3	6422	9	AK090429	AK090429 Homo sapi
14	71.4	14.3	7215	6	AX174569	AX174569 Sequence
15	71.4	14.3	9298	9	HSMB03577	AL832270 Homo sapi
16	69.8	14.0	665	6	AX371133	AX371133 Sequence
17	60.8	12.2	181127	10	AL672038	AL672038 Mouse DNA
18	60.2	12.0	58723	9	AL391237	AL391237 Human DNA
19	59	11.8	162378	2	AC105541	AC105541 Rattus no
20	59	11.8	174007	2	AC118998	AC118998 Rattus no
21	58.2	11.6	82603	2	AC111850	AC111850 Rattus no
22	52.8	10.6	171811	9	AC011739	AC011739 Homo sapi
23	52	10.4	181179	9	AL161725	AL161725 Human DNA
24	48.4	9.7	167215	5	AY016023	AY016023 Spherooid
25	48	9.6	281	11	G47605	G47605 Z25470_1 Ze
26	46	9.2	4886	9	AB037816	AB037816 Homo sapi
27	46	9.2	6372	6	AX173175	AX173175 Sequence
28	43.4	8.7	82603	2	AC111850	AC111850 Rattus no
29	42.6	8.5	147556	2	AC110359	AC110359 Rattus no
30	42.4	8.5	73515	2	AC017375	AC017375 Drosophila
31	42.4	8.5	166626	3	AC008318	AC008318 Drosophila
32	42.4	8.5	261475	2	AC096357	AC096357 Rattus no
33	42.4	8.5	301639	3	AE003590	AE003590 Drosophila
34	41	8.2	6828	6	AX172874	AX172874 Sequence
35	40.4	8.1	211	6	AX173251	AX173251 Sequence
36	40.4	8.1	3023	9	AK022412	AK022412 Homo sapi
37	40.4	8.1	122321	9	AC011472	AC011472 Homo sapi
38	38.6	7.7	159108	2	AC026031	AC026031 Homo sapi
39	38.6	7.7	156222	9	AC087224	AC087224 Homo sapi
40	38.6	7.7	159108	2	AC026031	AC026031 Homo sapi
41	38.6	7.7	159350	3	AC008354	AC008354 Drosophila
42	38.6	7.7	257224	3	AE003617	AE003617 Drosophila
43	37.8	7.6	181994	2	AC116703	AC116703 Mus muscu
44	37.6	7.5	154846	2	AP001374	AP001374 Homo sapi
45	37.6	7.5	156211	9	AC091551	AC091551 Homo sapi

ALIGNMENTS

RESULT 1  
AX255048  
LOCUS AX255048 7506 bp DNA linear PAT 10-OCT-2001  
DEFINITION Sequence 7 from Patent WO01170808.  
ACCESSION AX255048  
VERSION AX255048.1 GI:16074541  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 7506)  
AUTHORS Rastelli,L.K. and Gerlitsen,M.  
TITLE Angiogenesis-associated proteins, and nucleic acids encoding the same

Pred. No. is the number of results predicted by chance to have a

JOURNAL	Patent: WO 0170808-A 7 27-SEP-2001;									
FEATURES	Curagen Corporation (US) ; GENENTECH, INC. (US)									
source	Location/Qualifiers									
	1..7506									
	/organism="Homo sapiens"									
	/db_xref="taxon:9606"									
BASE COUNT	2147	a	1689	c	1764	g	1906	t		
ORIGIN										
Query Match	99.7%; Score 498.4; DB 6; Length 7506;									
Best Local Similarity	99.8%; Pred. No. 3.7e-146;									
Matches 499; Conservative	0; Mismatches 1; Indels 0; Gaps 0;									
QY	1	AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC	60							
Db	2142	AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC	2201							
QY	61	TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATTTCTTCATGTGCTGTGACAACTC	120							
Db	2202	TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATTTCTTCATGTGCTGTGACAACTC	2261							
QY	121	AAGTAAAGGAAGCAGGAAGAAGAGGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT	180							
Db	2262	AAGTAAAGGAAGCAGGAAGAAGAGGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT	2321							
QY	181	TCCCCTCTGAAAGACGGAAGGGTGTGACAAAGCAGCAGCACATCCCGGTCTCGCGAA	240							
Db	2322	TCCCCTCTGAAAGACGGAAGGGTGTGACAAAGCAGCAGCACATCCCGGTCTCGCGAA	2381							
QY	241	CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGATGGCGCAGCATTATGTCGCGA	300							
Db	2382	CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGATGGCGCAGCATTATGTCGCGA	2441							
QY	301	AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTTCTAC	360							
Db	2442	AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTTCTAC	2501							
QY	361	AGTGTATCTCAGGATCAGCATTTACATAATTTTTTCCAGTACTGTCAGAAAACCGAATC	420							
Db	2502	AGTGTATCTCAGGATCAGCATTTACATAATTTTTTCCAGTACTGTCAGAAAACCGAATC	2561							
QY	421	TGGAGCCCCAAGCCTTAGGAAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGA	480							
Db	2562	TGGAGCCCCAAGCCTTAGGAAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGA	2621							
QY	481	AGGCCACGTGATGATCGCCT 500								
Db	2622	AGGCCACGTGATGATCGCCT 2641								
RESULT 2										
AF527605										
LOCUS	AF527605	7522	bp	mRNA	linear	PRI	01-AUG-2002			
DEFINITION	Homo sapiens zizimin1 mRNA, complete cds.									
ACCESSION	AF527605									
VERSION	AF527605.1	GI:22038158								
KEYWORDS										
SOURCE	human.									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo. 1 (bases 1 to 7522)									
AUTHORS	Meller, N., Irani-Tehrani, M., Kiosses, W.B., Del Pozo, M.A. and Schwartz, M.A.									
TITLE	zizimin1, a novel Cdc42 activator, reveals new guanine nucleotide exchange-exchange factor domain for rho proteins									
JOURNAL	Nat. Cell Biol. (2002) In press									
REFERENCE	2 (bases 1 to 7522)									
AUTHORS	Meller, N. and Schwartz, M.A.									
TITLE	Direct Submission									
JOURNAL	Submitted (05-JUL-2002) Cell Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA									
FEATURES	Location/Qualifiers									

source	1. .7522	/organism="Homo sapiens"
		/db_xref="taxon:9606"
		/chromosome="13"
CDS	56. .6265	
		/note="guanine nucleotide exchange factor; Cdc42 activator"
		/codon_start=1
		/product="zizimin1"
		/protein_id="AAM90306.1"
		/db_xref="GI:22038159"
		/translation="MSQPLLPASAEFRKFTLRALSKPGTAELROSVEVVRGSVLLAKPLIEPLDIENVIVQKTIQLNDCLREMLLEPYDDEFQTAILRRQGRYICSTVPKAE EEAQSLFVTECIKTYNSDMLVNYKYEDYSGEFRQLPNKYVKLDPVHVEYDEEVD KDEDASLGSQKGITKHGWLKGNMNSAISVTMRSEKRRFFHLIQLGDGSYNLNFYK DEKISKEPKGSIFLDSQMGVQNNKVRREAFELKMDKSSYLLAADSEVEEMEETIL NKILQNLNEAAMQEKRNQDSHEDDEQSKLESGSGLDSTLPELAKSAREAEIKLSES RVKLFYLDPAOKLDESSAEPEVKSFEKGRILVKCNDLSFNLOCCVAENESEPTT NVEPEFVTLSEFDIKYNRKISADFHVDLNFESVRQMLATSPALMNGSGOSPVLKGI LHEAAMOYPRKOGIFSVTCPHPDIFLVARIEKVLQGSITHCAPYMKSSDSSKVAQV LKNAQACQRLGQYRMPFAMARTLFKASGNLDKNARPSAIYRQDSNKLSDNMLKL ADFRKPEKMAKLPVILGNLDITIDNVSSDFPNVNSSIIPTKQETCSKPTTFVEE EVPCIPKHQPYTIYTNHLVYPRYLYKLYDSQSKFAKARNIAICIEFKDSDEEDSOP LK CIYGRPGGPVETRSAAFAVLHHQNPFEYDEIKIELPQLHEKHLLLTFFHYSCDNS SKGSTKRDRVETQVGSWLP.LPLKDGVRVTSQHIIPVSNLPSGLYQELGMRHYG PEIKWVDGKPLIKISTHLVSTVYTDQOHLNFEQYQCKTESGAQALGNELVKYLSL HAMEGHVIAFLPTILNQLFRVLRATQEEVAVNTRVLIHVAQCHEGLESHLSRY VKIAYKAEPYVASEYKTVHEELTKSMTTILKPSADFLTSNKLKYSWFFFDVLIKSMA OHLIENSKVKLLRNQREFPASYHNAVETVNMMLPHITQKFRDNPEASKNANSLAVFI KRCFTFMDRGFVFKQINNYISCFAPGDPKTLFEYKFEFLRVNCNHEHYIPLNLPMEG KGRIORYDLOLDYSLTDEFGRNHFVLGILLREVGTAILOEFREVRLIAISVLKNLLIK HSFDRIAASRSHQARIATLYLPFLGLIENVQRIENVDSPEPVNAGMTVKDESLALP AVNPLVTPQKGSTLDNSLHKDLGASIGIASPYTTSPTNINSVRNADSRGSLISTDSG NSLPERNSEKNSLDKHQOOSTLGNSSVVRCDKLDQSEIKSLMCFYLILKSSMDALF TYNNKASTSELMDDEFTISEVCLHQFOYMGKRYIARTGMHARLQQLGSLDNLSTFNHS YGSHDADVLHQSLLEANIATEVCILALDTLSLFTLAFKNQLADHGNPLMKRYEDVY LCFLOKHQSETALKNVFTALRSLLYKFPSTFEYEGRADMCAALCYEILKCNLSLSIR TEASQLLYFLMRNFDYTGKRSFVRTHLOVLIISVQLADVIGIGTRFQOSLIINN CANSDBLIKHTSFSSDVKDLTKRIRTVLMATAQMKHEHDEPMLVLDLOYSLAKSYAST PELRKTWLDMSARIHVKNQDSEAAACVHVHTALVAEYLTREKVAQWPEPLPHSHA CLRSRGGVFRQGTAFRYITPNIIDEASMMEDVGMQDVHFNEDVLMELLEQCADGLW KAERYELLADIYKLIIPYIEKRDRERLAHLYDTLHRAYSKYTEVMHSGRLLIGTYFR VAFEGQAAQOYFTDSEDEVEGEFEDEDEGEYIYKEKLPLEISEQRLKLYSDKES ENYKMIQDSQKVNPKDLDSKYAIQVTHVIPFEDEKELQERKTEFEERSHNIRMFEM PFTQYTGKRQGGVEQCKRRTILTAIHCFPYVKRRIPLVMYOHNTDLPLEVAIDEMSK VAEIROLCSSAEVDMIKLOLKLQGSVSVQVNAGPLAYARAFLDNTNTRYPDNKVKLL KEVERQVEACGOALAVNERLIKEDQLEYQEMKANYREMAKELSEIMHEQLG"
BASE COUNT	2146 a 1694 c 1774 g 1908 t	
ORIGIN		
Query Match	99.7%;	Score 498.4; DB 9; Length 7522;
Best Local Similarity	99.8%;	Pred. No. 3.7e-146;
Matches 499;	Conservative 0;	Mismatches 1; Indels 0; Gaps 0;
QY	1	AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60
Db	2155	AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 2214
QY	61	TCAGCTGCATGAAAGACCAACCACCTGTGCTCACAATCTCTCCATGTCAGCTGTGACAATC 120
Db	2215	TCAGCTGCATGAAAGACCAACCACCTGTGCTCACAATCTCTCCATGTCAGCTGTGACAATC 2274
QY	121	AAGTAAAGGAAGCAGCAGAGAGGATGCTGTTGAACCCCAAGTTGGCTACTCCTGGCT 180
Db	2275	AAGTAAAGGAAGCAGCAGAGAGGATGCTGTTGAACCCCAAGTTGGCTACTCCTGGCT 2334
QY	181	TCCCCTCTGAAAGACGGAAGGGTGTGACAAGCAGCAGACATCCCGGTCTCGGCGAA 240
Db	2335	TCCCCTCTGAAAGACGGAAGGGTGTGACAAGCAGCAGACATCCCGGTCTCGGCGAA 2394
QY	241	CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCAAGCATTATGTCGGA 300
Db	2395	CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCAAGCATTATGTCGGA 2454



QY 301 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAAATTCCACTCATCTGTTTCTAC 360  
|||||  
Db 2455 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAAATTCCACTCATCTGTTTCTAC 2514  
QY 361 AGTGTATACTCAGGATCAGCATTTACATAATTTTTCACAGTACTGTCAGAAAACCGAATC 420  
|||||  
Db 2515 AGTGTATACTCAGGATCAGCATTTACATAATTTTTCACAGTACTGTCAGAAAACCGAATC 2574  
QY 421 TGGAGCCCAAGCCTTAGGAAACGAAGTTGTAAGTACCTTAAGAGCTCTGCATGCGATGGA 480  
|||||  
Db 2575 TGGAGCCCAAGCCTTAGGAAACGAAGTTGTAAGTACCTTAAGAGCTCTGCATGCGATGGA 2634  
QY 481 AGGCCACGTGATGCCT 500  
|||||  
Db 2635 AGGCCACGTGATGCCT 2654  
RESULT 3  
AB028981 7545 bp mRNA linear PRI 10-MAY-2002  
LOCUS AB028981 Homo sapiens mRNA for KIAA1058 protein, partial cds.  
ACCESSION AB028981  
VERSION AB028981.2 GI:20521745  
KEYWORDS  
SOURCE Homo sapiens brain cDNA to mRNA, clone\_lib:pBluescriptII SK plus  
clone:hh12146s1.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kikuno,R., Nagase,T., Ishikawa,K., Hiroseawa,M., Miyajima,N.,  
Tanaka,A., Kotani,H., Nomura,N. and Ohara,O.  
TITLE Prediction of the coding sequences of unidentified human genes.  
XIV. The complete sequences of 100 new cDNA clones from brain which  
code for large proteins in vitro  
JOURNAL DNA Res. 6 (3), 197-205 (1999)  
MEDLINE 99397452  
PUBMED 10470851  
REFERENCE 2 (bases 1 to 7545)  
AUTHORS Ohara,O., Nagase,T. and Kikuno,R.  
TITLE Direct Submission  
JOURNAL Submitted (17-JUN-1999) Osamu Ohara, Kazusa DNA Research Institute,  
Laboratory of DNA Technology; Yana 1532-3, Kisarazu, Chiba  
292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp, Tel:+81-438-52-3913,  
Fax:+81-438-52-3914)  
COMMENT On May 9, 2002 this sequence version replaced gi:5689452.  
FEATURES  
source  
1..7545  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
/clone="hh12146s1"  
/tissue\_type="brain"  
/clone\_lib="pBluescriptII SK plus"  
/note="This sequence was obtained by subcloning of the DNA  
fragments derived from two cDNA clones (1 - 1846 was  
derived from ef00877 and 1847 - 7545 was derived from  
hh12146)."  
1..7545  
/gene="KIAA1058"  
<1..6288  
/gene="KIAA1058"  
/codon\_start=1  
/product="KIAA1058 protein"  
/protein\_id="BAAB3010.2"  
/db\_xref="GI:20521746"  
/translation="LACIARPDGTRSCSSCRSLDIRFQPRMADKCRTSRSVKKL  
VIESPLQYKDAOGVEAEBSBPVPAKPKLIEPIIDYENVIVOKTQIILNCLREMLLF  
PYDFQTAILRQGRYICSTVPAKAEBAQSLFTECIKTYNSDWHLVNYKYEDYSGE  
FRQLPNKVVKLDKLPVHYEVEVDKDEDASLSQKGIKTHGWLKGNNSAISV  
TMRSPKRRFHLIQLGDSYNLNFYKDEKISKEPKGSIFLDSMGVQNNKYRFAFE  
LKMQDKSSYLLAADSEVEMEWITILNKILQINFEAAMQEKRNNGSDHEDDEQSKLEGS

GSGLDSYLP ELAKSAREAEIKLKSES RVKLFYLD PDAQKLD FSSAEPEVKS FEEKFG  
RILYKCNDSLSEFNLOCCVANEENEGPTNVEPFVTLSDIEDIKYNRKISADPHLVARLNEFS  
VRQMLATTS PALMNGSGQSDSVLKGITLHEAAMOY PKQGISVTC PHPIJFLVARIKYS  
LOGSITHCAEIPYMKSSSDSKRYAQVKLVKLNAKQACORLGQYRMPFAMARJLFEK DASNL  
DKNAFSAIYRQDSNKLSDNDMLKLADFRKPEKMAKLPVILGNLDITIDNVSSDFPN  
YVNSYIPTKQEFETCSKPTITEVEEEFVPCIPKHTQPYTIYTNHLVYPKYLYKDSQK  
SFAKARNIAICIEFKDSDEDSQPLKCIYGRPGVEYTRSAFAAVLHHQNEPEYDEI  
KIEPTQLHEKHHLLITFEHVSCDNSSKSGTKRDVETOVQYSWLPLKDG RVVTS  
OHIPVSA NLP S YGLGYQELGMGRHYGEIKWVDGKPLKISTHLVSTVYTDQHLHN  
EFQYCKTESGAQALGNELVYKLSLHAMEGHVIAFLPTILNQLFRVLTATQEEVA  
VNTTRVLIHVVAQCHEEGLESHLSRYVKYAYKAEPYVASEKTVHEELKSMTTILKP  
SADFLTSNKLKYSWFEFDVLIKSMAQHLIENSKVLLRNQREPASVYHAEVTVNML  
EYKFEFLRVVCNHEHYIPLNDPMPFGKGIQRYODLQLDYSLTDEFCRHFVLGLLR  
EVGTALQEFREVRLLAISVLKNLLIKHSFDDRYASRSHQARIATLYPLRGLLIENVQ  
RINVRDVSPEPVNAGMTVKDESIALPAVNPIVTPQKGSTLDNSLHKDLGAI SIGIASP  
YTTSTPNINSVRNADSRGSLISTDSGNSLPERNSEKSNSLDKHQSSITLGN SVYRCDK  
LDQSEIKSLIMCFLYIILKSMSDDALFTYWNKASTSELMDFETISEVCLHOFQYMGKRY  
IARTGMHARLQQLGSLDNSLTENHSYGHSDADVYLHOSLLEANIATEVCLTALDTLSL  
FTLAEKNQLLADHGHNPLMKKVFEDVYLCFLQKHQSEYALKNVFTALRSIYKFPSTFY  
EGRADCAALCYEILKCCNSKLSIRTEASQDLTYFLMRNNEVDYTGKKSFEVRTHLVITI  
SVSQILDADVIGIGTRFQGSIIINNCANS DRLIKHTSFSSDYKDLTKRIRVLMATA  
QMKHENDPEMLVDLOYSLAKSYASTPELRKTDWDSMARIVHKNGDLSEAMCYVHT  
ALVAEYLTRKEAVQWEPPLPHSHSACLRSRGVYRQGTAFRVITPNIDEASME  
DVGMQDVHFNEDLMELLEOCADGLMKAERYELIADLYKLIPIYEKRDFEERIALY  
DTLHRAYSKVTSEVMHSGRLIGTYFRVAFFGQAOYOTDSETDVEGFEDEDEKEYI  
YKEPKLTPLSVEISQRLIKLYSDKFGSENVKMIODSGYKNPKDLSKYAYIOVTHVYFE  
FDEKELQERKTEFEERSHNIRRMFEMPOTQTKRQGVYEQCKRRTILTAIHCFPYVK  
KRIPWYQHTDNLNPIEVAIDEMSKVAELROLCSAEVDMIKLQKLQGSVSYQVNA  
GPLAYARAFI.DDNTKRYPDNKVYKLLKEVFQFVEAGQALAVNERLIKEDQLEYOEE  
MKANYREMAKELSEIMHEQLG"  
BASE COUNT 2175 a 1687 c 1753 g 1930 t  
ORIGIN  
Query Match 99.7%; Score 498.4; DB 9; Length 7545;  
Best Local Similarity 99.8%; Pred. No. 3.7e-146;  
Matches 499; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60  
|||||  
Db 2178 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 2237  
QY 61 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATCTCTCATGTGACGCTGACAACATC 120  
|||||  
Db 2238 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATCTCTCATGTGACGCTGACAACATC 2297  
QY 121 AAGTAAAGGAAGCAGAGAAGAGGATGTGCTGA AACCACAAGTTGGCTACTCCTGGCT 180  
|||||  
Db 2298 AAGTAAAGGAAGCAGAGAAGAGGATGTGCTGA AACCACAAGTTGGCTACTCCTGGCT 2357  
QY 181 TCCCCTCCTGAAAAGCAGGAAGGTTGTGACAACGAGCAGACACATCCCGGCTCGGGCAA 240  
|||||  
Db 2358 TCCCCTCCTGAAAAGCAGGAAGGTTGTGACAACGAGCAGACACATCCCGGCTCGGGCAA 2417  
QY 241 CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGACAGGCAATTATGTCGGA 300  
|||||  
Db 2418 CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGACAGGCAATTATGTCGGA 2477  
QY 301 AATTAATGGGTAGATGAGGCAAGCCACTGCTGA A AATTTCACACTCATCTGTTCTAC 360  
|||||  
Db 2478 AATTAATGGGTAGATGAGGCAAGCCACTGCTGA A AATTTCACACTCATCTGTTCTAC 2537  
QY 361 AGTGTATACTCAGGATCAGCATTTACATAATTTTTCACAGTACTGTCA GAAAACCGAATC 420  
|||||  
Db 2538 AGTGTATACTCAGGATCAGCATTTACATAATTTTTCACAGTACTGTCA GAAAACCGAATC 2597  
QY 421 TGGAGCCCAAGCCTTAGGAAACGAAGCTTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA 480  
|||||  
Db 2598 TGGAGCCCAAGCCTTAGGAAACGAAGCTTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA 2657  
QY 481 AGGCCACGTGATGCCT 500  
|||||  
Db 2658 AGGCCACGTGATGCCT 2677

```

RESULT 4
AX173022
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
        CDS

```

BASE COUNT	2119 a	1234 c	1303 g	1798 t
ORIGIN				

Query Match	40.98;	Score 204.4;	DB 6;	Length 6454;
Best Local Similarity	63.48;	Pred. No. 4.3e-53;		
Matches 313; Conservative	0;	Mismatches 181;	Indels 0;	Gaps 0;

```

      2 GTTTACACCATCACCAAAACCCAGAAATTTATGATGAGATTAAAAATAGAGTTGCCACT 61
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 2000 GTCTGCATCACAAACCAAAATCCAGAGTTCTATGATGAGATTAAAAATTGAGCTTCCCAT 2059

```

[illegible]

RESULT 5	
CNS01RGX	
LOCUS	
DEFINITION	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
COMMENT	
CNS01RGX	139887 bp DNA linear PRI 26-APR-2001
Human chromosome 14	DNA sequence BAC C-2373J19 of library Caltech-D
from chromosome 14 of Homo sapiens (Human),	complete sequence.
AL160233	
AL160233.3	GI:13016589
HTG.	
human.	
Homo sapiens	
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
1 (bases 1 to 139887)	
Heilig, R., Petit, J.L., Vico, V., Dasilva, C., Robert, C., Wincker, P.,	
Brottier, P., Catolico, L., Barbe, V., Pelletier, E., Artiguenave, F.,	
Levy, M., Eckenberg, R., Bruls, T., deBerardinis, V., Cruaud, C.,	
Gyapay, G., Saurin, W. and Weissbach, J.	
Sequencing of the human chromosome 14	
unpublished	
2 (bases 1 to 139887)	
Genoscope.	
Direct Submission	
Submitted (26-APR-2001) Genoscope - Centre National de Sequencage ;	
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr	
- web : www.genoscope.cns.fr)	
On Feb 20, 2001 this sequence version replaced gi:7799784.	
----- Genome Center	
Center: Genoscope / Centre National de Sequencage	
Center code: GS	
Web site: http://www.genoscope.cns.fr/	
Contact: SeqRef@genoscope.cns.fr	

The following BAC sequence is oriented from the T7 to the SP6 end.  
Upstream BAC (overlapping the T7 end) : R-857B24 (AC=AL049870)  
Downstream BAC (overlapping the SP6 end) : R-398E10 -----  
Summary Statistics  
Assembly program: Phrap; version 2.0  
Quality coverage: 8.87x in Q20 bases; sum-of-contigs

```

Overall quality chart :
Range      :      bases
0          :
1 - 9      :      2
10 - 19    :      2
20 - 29    :      3
30 - 39    :      28
40 - 49    :      816
50 - 59    :      1974
60 - 69    :      2026
70 - 79    :      6616
80 - 89    :      31804
90 - 99    :      96616
-----
Percentage of bases with a quality value >= 40 : 99 %.
FEATURES
source
1. 139887
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="14"
/clone="C-2373J19"
/clone_lib="CalTech-D"
BASE COUNT      41045 a 25978 c 27103 g 45761 t
ORIGIN
Query Match      39.0%; Score 194.8; DB 9; Length 139887;
Best Local Similarity 62.1%; Pred. No. 8.4e-50;
Matches 307; Conservative 0; Mismatches 187; Indels 0; Gaps 0;
QY      2 GTTTTACACCATCACCACCAAAACCAGAAATTTATGATGAGATTAAATAGATTGCCACT 61
Db      421 GTCTCACAATCACAATCAAAACCAGAGTTCTATGATGAGATTAAATAGACTTCCCTTT 480
QY      62 CAGCTGCATGAAAGACACCACTGTGCTCACAATTCCTCCATGTCAGCTGTGACAACCTCA 121
Db      481 CACTTGCAATCAAAAACATCATTTGCTTTTCACTTTTGTGCAATTAAGTTGGAATTAAAC 540
QY      122 AGTAAAGGAAGCAGCAAGAAAGAGGATGTGCTGAACCCCAAGTTGGCTACTCGCTT 181
Db      541 ACAAAAGGAACAACCAAAAAGCAAGACACAGTTGAACCTCCAGTTGAGTTTGGCTGGTA 600
QY      182 CCCCCTCTGAAGACGGAAGGCTGTGACAAGCGACGACATCCCGGTCTCGCGGAAC 241
Db      601 CCATTGCTGAAGATGCTAGAAATCATCACAATTTGGGACAGCTGCCAGTTCCACCAAT 660
QY      242 CTTCCTTGGGCTATCTTGCTACCAAGAGCTTGGATGGGCAAGGCAATTATGTCGGA 301
Db      661 CTTCCTCCAGGCTACTTAAATCTGAATGATGATTAATCAAGAGCAATGTAATGTGAT 720
QY      302 ATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTACA 361
Db      721 ATTAATGGGTAGATGCTGAAGCCCTTTGTGAAGATTAAGAAGCCACTTAGAATCTACC 780
QY      362 GTGTACTACTCAGATCAGCATTTTACATAATTTTTCACAGTACTGTCCAGAAACCAATCT 421
Db      781 ATTACACTTAAGATCTGCATTTGCACAAATTTCTCCATCATTTGCCAGCTGAATCAGTCA 840
QY      422 GGAGCCCAAGCCTTAGCAAAAGCAACTTGTAAAGTACCTTAAGAGTCTGCATGCCATGAA 481
Db      841 GACTCGAAAGAGATTCCAGGGGAGGAGCTCATTAATATTTAAAGTCTTTGCATGCCATGGAG 900
QY      482 GGCCACGTGATGAT 495
Db      901 ATCCAAGTCATGAT 914
RESULT 6
LOCUS      AL161420/c
DEFINITION Human DNA sequence from clone Rp11-155N3 on chromosome 13 contains ESTs, STSs and GSSs. Contains the 3' part of a novel gene similar to KIAA00694, the KIAA1058 gene and a putative novel gene, complete

```

ACCESSION	sequence. AL161420
VERSION	AL161420.10
KEYWORDS	GI:10443397 HTG; KIAA0694; KIAA1058.
SOURCE	human.
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 163316)
AUTHORS	Smith, M.
TITLE	Direct Submission
JOURNAL	Submitted (31-JAN-2001) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk requests: clonerequest@sanger.ac.uk On Oct 1, 2000 this sequence version replaced gi:10039689.
COMMENT	During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above. The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Em:, EMBL; Sw:, SWISSPROT; Tr:, TREMBL; Wp:, WORMPEP; Information on the WORMPEP database can be found at http://www.sanger.ac.uk/Projects/C-elegans/wormpep This sequence was generated from part of bacterial clone contigs of human chromosome 13, constructed by the Sanger Centre Chromosome 13 Mapping Group. Further information can be found at http://www.sanger.ac.uk/HGP/Chr13 This sequence is the entire insert of clone RP11-155N3 The true left end of clone RP11-318G1 is at 114983 in this sequence. The true right end of clone RP11-56D6 is at 42341 in this sequence. The true right end of clone RP11-551M18 is at 43464 in this sequence. This sequence has been finished according to sequence map criteria as follows. An attempt is made to resolve all sequencing problems, such as compressions and repeats, but not necessarily within known annotated repeat sequence elements. Where the sequence is ambiguous, there is an annotation using the 'unsure' feature key. RP11-155N3 is from the library RPCI-11.1 constructed by the group of Pieter de Jong. For further details see http://www.chori.org/bacpac/home.htm VECTOR: pBACE3.6.
FEATURES	Location/Qualifiers 1..163316 /organism="Homo sapiens" /db_xref="taxon:9606" /chromosome="13" /clone="RP11-155N3" /clone_lib="RPCI-11.1" 6..510 /note="match: GSS: Em:AQ372034" 75..372 /note="Aluub repeat: matches 1..298 of consensus" 447..742 /note="AluSp repeat: matches 1..296 of consensus" 745..1025 /note="L1MC1 repeat: matches 6019..6327 of consensus" 1250..1566 /note="AluSx repeat: matches 2..311 of consensus" 1631..2325 /note="L1MC5 repeat: matches 6683..7400 of consensus" 2326..2619 /note="AluSx repeat: matches 1..295 of consensus" 2620..2890 /note="L1MC5 repeat: matches 7400..7665 of consensus" complement(3019..3311) /note="match: STS: Em:HSA273ZH1" 3060..3191 /note="match: GSS: Em:B17811" complement(3065..3246) /note="match: STS: Em:AF009212" 3067..3190



repeat\_region /note="match: GSS: Em:AQ114323"  
3087. .3122  
/note="18 copies 2 mer tg 97% conserved"  
repeat\_region 3089. .3124  
/note="6 copies 6 mer tgtgtg 97% conserved"  
misc\_feature 3123. .3280  
/note="match: GSS: Em:AQ459714"  
3191. .3475  
/note="Alusx repeat: matches 1. .288 of consensus"  
repeat\_region 3692. .3773  
/note="MIR repeat: matches 3. .94 of consensus"  
3887. .4074  
/note="L2 repeat: matches 1607. .1787 of consensus"  
repeat\_region 4082. .4144  
/note="3 copies 21 mer 88% conserved"  
4418. .4630  
/note="L2 repeat: matches 1354. .1587 of consensus"  
repeat\_region 7208. .7609  
/note="MLT1B repeat: matches 8. .390 of consensus"  
9220. .9344  
/note="MIR repeat: matches 71. .196 of consensus"  
9586. .9667  
/note="L1ME repeat: matches 5569. .5651 of consensus"  
9714. .9813  
/note="L2 repeat: matches 771. .874 of consensus"  
9869. .10202  
/note="L2 repeat: matches 971. .1261 of consensus"  
10203. .10581  
/note="MSTA repeat: matches 1. .426 of consensus"  
10582. .11267  
/note="L2 repeat: matches 1261. .2121 of consensus"  
11460. .11570  
/note="L2 repeat: matches 2377. .2497 of consensus"  
11603. .11778  
/note="L1MB3 repeat: matches 5996. .6166 of consensus"  
11779. .12160  
/note="MER51A repeat: matches 1. .371 of consensus"  
12161. .12729  
/note="L1MB3 repeat: matches 5403. .5996 of consensus"  
12682. .12950  
/note="L1MD repeat: matches -1. .274 of consensus"  
12945. .13209  
/note="L1MC5 repeat: matches 7249. .7517 of consensus"  
13323. .13413  
/note="AluJ/FRAM repeat: matches 221. .311 of consensus"  
13711. .13846  
/note="Alusq/x repeat: matches 1. .136 of consensus"  
13955. .14417  
/note="match: GSS: Em:AQ475161"  
complement(14122. .14590)  
/note="match: GSS: Em:AQ349540"  
14334. .14400  
/note="L1MA10 repeat: matches 6204. .6272 of consensus"  
14407. .14693  
/note="Alusx repeat: matches 1. .288 of consensus"  
14584. .15413  
/note="match: GSS: Em:AQ739876"  
14719. .14793  
/note="L1MC/D repeat: matches 5744. .5818 of consensus"  
15013. .15193  
/note="L1MB3 repeat: matches 5993. .6184 of consensus"  
complement(join(16480. .17741,19199. .19206,20108. .20246,  
20382. .20482,23281. .23471,27992. .28202,30654. .30800,  
31633. .31668,32116. .32121,32345. .32458,33162. .33284,  
47391. .47497,48865. .48933,49823. .49880,52300. .52515,  
52636. .52749,54341. .54523,54642. .54779,60487. .60602,  
68322. .68365,68917. .69053,71585. .71632,73040. .73106,  
76401. .76515,78891. .79024,83174. .83515,86012. .86125,  
86363. .86541,90418. .90529,90921. .91004,91224. .91370,  
102891. .102962,103540. .103665,104551. .104620,  
104885. .105000,106035. .106124,106806. .106892,  
107964. .108085,108701. .108824,109525. .109617,  
111151. .111216,111353. .111540,111625. .111704,

mRNA 120481. .120603))  
/gene="bA155N3.2"  
complement(join(16480. .17741,19199. .19206,20108. .20246,  
20382. .20482,23281. .23471,27992. .28202,30654. .30800,  
31633. .31668,32116. .32121,32345. .32458,33162. .33284,  
47391. .47497,48865. .48933,49823. .49880,52300. .52515,  
52636. .52749,54341. .54523,54642. .54779,60487. .60602,  
68917. .68984,71585. .71632,73040. .73106,76401. .76515,  
78891. .79024,83398. .83515,86012. .86125,86363. .86541,  
90418. .90529,90921. .91004,91224. .91370,102891. .102962,  
103540. .103665,104551. .104620,104885. .105000,  
106035. .106124,106806. .106892,107964. .108085,  
108701. .108824,109525. .109617,111151. .111216,  
111353. .111540,111625. .111704,120481. .>120603))  
/gene="bA155N3.2"  
/product="bA155N3.2.1 (K1AA1058)"  
/note="match: cDNAs: Em:AB028981 Em:U79289  
match: ESTs: Em:W27872 Em:H29845 Em:H29936 Em:AW160928  
Em:AW457794 Em:T62004 Em:R64450 Em:D58813 Em:H10596  
Em:AW380042 Em:AW344638 Em:AW450751 Em:AF188523  
Em:AA151055 Em:T33377 Em:AW466130 Em:AI014329 Em:Z42960  
Em:AI372817 Em:AI372818 Em:AW389763 Em:AW230012  
Em:AI133724 Em:AW162535 Em:AW607903 Em:AA484945 Em:H28862  
Em:Z39079 Em:AI767696 Em:AW576807 Em:AI078244 Em:R78583  
Em:AA705585 Em:AI271453 Em:AW512964 Em:W88550 Em:AI870702  
Em:AI079478 Em:AI693777 Em:AW576805 Em:AI467994  
Em:AI372819 Em:AI732576 Em:AI277278 Em:AI969485  
Em:AI768094 Em:AA779769 Em:AA502043 Em:R27124 Em:AW576813  
Em:AW576816 Em:AW168032 Em:AI365152 Em:AA165512  
Em:AI120344 Em:AI888868 Em:AA165554 Em:R73986 Em:AA523853  
Em:AI041815 Em:AI134605 Em:AW009821 Em:D62808 Em:AI769357  
Em:AW363093 Em:AI733873 Em:W88496 Em:T03019 Em:AW071481  
Em:AI034000"  
/evidence=not\_experimental  
complement(16480)  
/gene="bA155N3.2"  
complement(16482)  
/gene="bA155N3.2"  
complement(16483)  
/gene="bA155N3.2"  
complement(16498. .16503)  
/gene="bA155N3.2"  
16511. .16637  
/note="match: STS: Em:G42960"  
complement(16523. .16528)  
/gene="bA155N3.2"  
complement(16570. .16575)  
/gene="bA155N3.2"  
complement(join(17741,19199. .19206,20108. .20246,  
20382. .20482,23281. .23471,27992. .28202,30654. .30800,

Query Match 25.4% Score 126.8; DB 9; Length 163316;  
Best Local Similarity 98.5% Pred. NO. 2.9e-28;  
Matches 128; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 AGATTAAATAGAGTGGCCCACTCAGCTGCATGAAGAACACACCTGTTGCTCACAATTCT 98  
|||||  
Db 108826 AGATTAAATAGAGTGGCCCACTCAGCTGCATGAAGAACACACCTGTTGCTCACAATTCT 108767  
|||||

QY 99 TCCATGTCAGCTGTGACAACTCAAGTAAGGAAGCAGAAAGAAGAGGATGCTTGAAA 158  
|||||  
Db 108766 TCCATGTCAGCTGTGACAACTCAAGTAAGGAAGCAGAAAGAAGAGGATGCTTGAAA 108707  
|||||

QY 159 CCCAAGTTGG 168  
|||||  
Db 108706 CCCAAGTTGG 108697  
|||||

RESULT 7  
AC109966/c 175281 bp DNA linear HTG 13-JUL-2002  
LOCUS Rattus norvegicus clone CH230-32315, \*\*\* SEQUENCING IN PROGRESS  
DEFINITION \*\*\* 75 unordered pieces.



ACCESSION AC109966  
VERSION AC109966.3 GI:21738210  
KEYWORDS HTG; HTGS\_PHASE1.  
SOURCE Norway rat.  
ORGANISM Rattus norvegicus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
REFERENCE 1 (bases 1 to 175281)  
AUTHORS Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,  
Alsbrooks,S.L., Amaratunge,H.C., Are,J.R., Ayele,M., Banks,T.,  
Barbaria,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D.,  
Bouck,J., Bowie,S., Brieva,M., Brown,E., Brown,M., Bryant,N.P.,  
Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C.,  
Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D.,  
Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C.,  
Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R.,  
Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A.,  
Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H.,  
Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J.,  
Earnhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M.,  
Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P.,  
Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R.,  
Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K.,  
Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J.,  
Hernandez,O., Hodgson,A., Hognes,M., Holloway,C., Hollins,B.,  
HomsI,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Jackson,L.E.,  
Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S.,  
Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C.,  
Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L.,  
Li,J., Li,Z., Lichtarge,O., Llieu,C., Liu,J., Liu,W., Loulseged,H.,  
Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J.,  
Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E.,  
Massey,E., Mawhiney,E., Mcleod,M.P., Meador,M., Mei,G., Metzker,M.,  
Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S.,  
Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N.,  
Nguyen,N., Nickerson,E., Nwokenkwo,S., Oguh,M., Okwuonu,G.,  
Oragunye,N., Oyiedo,R., Pace,A., Payton,B., Peery,J., Perez,L.,  
Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y.,  
Rives,M., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savery,G.,  
Scherer,S., Scott,G., Shen,H., Shoostari,N., Sisson,I.,  
Sodergren,E., Sonaiké,T., Sparks,A., Stanley,H., Stone,H.,  
Sutton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H.,  
Tansey,J., Taylor,C., Taylor,T., Telfrod,B., Thomas,N., Thomas,S.,  
Usmani,K., Vasquez,L., Vera,V., Villalon,D., Vinson,R., Wang,Q.,  
Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S.,  
Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K.,  
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D.,  
Weinstock,G. and Gibbs,R.  
TITLE Direct Submission  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 175281)  
AUTHORS Worley,K.C.  
TITLE Direct Submission  
JOURNAL Submitted (09-FEB-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
REFERENCE 3 (bases 1 to 175281)  
AUTHORS Worley,K.C.  
TITLE Direct Submission  
JOURNAL Submitted (13-JUL-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
COMMENT On Jul 12, 2002 this sequence version replaced gi:18847026.  
----- Genome Center  
Center: Baylor College of Medicine  
Center code: BCM  
Web site: http://www.hgsc.bcm.tmc.edu/  
Contact: hgsc-help@bcm.tmc.edu  
----- Project Information  
Center project name: GOLDP  
Center clone name: CH230-32315  
----- Summary Statistics

Sequencing vector: Plasmid;  
Chemistry: Dye-terminator Big Dye; 100% of reads  
Assembly program: Phrap; version 0.990329  
Consensus quality: 105442 bases at least Q40  
Consensus quality: 111492 bases at least Q30  
Consensus quality: 116270 bases at least Q20  
-----  
\* NOTE: Estimated insert size may differ from sequence length  
\* (see http://www.hgsc.bcm.tmc.edu/docs/Genbank\_draft\_data.html).  
\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 75 contigs. The true order of the pieces  
\* is not known and their order in this sequence record is  
\* arbitrary. Gaps between the contigs are represented as  
\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.  
1  
1290: contig of 1290 bp in length  
1390: gap of unknown length  
2414: contig of 1024 bp in length  
2514: gap of unknown length  
3639: contig of 1125 bp in length  
3739: gap of unknown length  
5063: contig of 1324 bp in length  
5163: gap of unknown length  
6243: contig of 1080 bp in length  
6343: gap of unknown length  
7536: contig of 1193 bp in length  
7636: gap of unknown length  
9071: contig of 1435 bp in length  
9171: gap of unknown length  
10200: contig of 1029 bp in length  
10300: gap of unknown length  
11505: contig of 1205 bp in length  
11605: gap of unknown length  
12680: contig of 1075 bp in length  
12780: gap of unknown length  
14056: contig of 1276 bp in length  
14156: gap of unknown length  
15413: contig of 1257 bp in length  
15513: gap of unknown length  
16580: contig of 1067 bp in length  
16680: gap of unknown length  
17692: contig of 1012 bp in length  
17792: gap of unknown length  
19013: contig of 1221 bp in length  
19113: gap of unknown length  
20418: contig of 1305 bp in length  
20518: gap of unknown length  
21880: contig of 1362 bp in length  
21980: gap of unknown length  
22985: contig of 1005 bp in length  
23085: gap of unknown length  
24156: contig of 1071 bp in length  
24256: gap of unknown length  
25732: contig of 1476 bp in length  
25832: gap of unknown length  
27196: contig of 1364 bp in length  
27296: gap of unknown length  
28615: contig of 1319 bp in length  
28715: gap of unknown length  
30145: contig of 1430 bp in length  
30245: gap of unknown length  
31418: contig of 1173 bp in length  
31518: gap of unknown length  
32896: contig of 1378 bp in length  
32996: gap of unknown length  
34142: contig of 1146 bp in length  
34242: gap of unknown length  
35262: contig of 1020 bp in length  
35362: gap of unknown length  
36924: contig of 1562 bp in length  
37024: gap of unknown length

*	37025	*	38670:	contig of 1646 bp in length
*	38671	*	38770:	gap of unknown length
*	38771	*	40612:	contig of 1842 bp in length
*	40613	*	40712:	gap of unknown length
*	40713	*	42724:	contig of 2012 bp in length
*	42725	*	42824:	gap of unknown length
*	42825	*	43829:	contig of 1005 bp in length
*	43830	*	43929:	gap of unknown length
*	43930	*	45818:	contig of 1889 bp in length
*	45819	*	45918:	gap of unknown length
*	45919	*	48183:	contig of 2265 bp in length
*	48184	*	48283:	gap of unknown length
*	48284	*	49887:	contig of 1604 bp in length
*	49888	*	49987:	gap of unknown length
*	49988	*	51568:	contig of 1581 bp in length
*	51569	*	51668:	gap of unknown length
*	51669	*	53251:	contig of 1583 bp in length
*	53252	*	53351:	gap of unknown length
*	53352	*	55636:	contig of 2285 bp in length
*	55637	*	55736:	gap of unknown length
*	55737	*	57159:	contig of 1423 bp in length
*	57160	*	57259:	gap of unknown length
*	57260	*	59519:	contig of 2260 bp in length
*	59520	*	59619:	gap of unknown length
*	59620	*	63392:	contig of 3773 bp in length
*	63393	*	63492:	gap of unknown length
*	63493	*	65130:	contig of 1638 bp in length
*	65131	*	65230:	gap of unknown length
*	65231	*	68145:	contig of 2915 bp in length
*	68146	*	68245:	gap of unknown length
*	68246	*	70070:	contig of 1825 bp in length
*	70071	*	70170:	gap of unknown length
*	70171	*	73494:	contig of 3324 bp in length
*	73495	*	73594:	gap of unknown length
*	73595	*	75991:	contig of 2397 bp in length
*	75992	*	76091:	gap of unknown length
*	76092	*	77867:	contig of 1776 bp in length
*	77868	*	77967:	gap of unknown length
*	77968	*	80318:	contig of 2351 bp in length
*	80319	*	80418:	gap of unknown length
*	80419	*	82211:	contig of 1793 bp in length
*	82212	*	82311:	gap of unknown length
*	82312	*	84412:	contig of 2101 bp in length
*	84413	*	84512:	gap of unknown length
*	84513	*	85982:	contig of 1470 bp in length
*	85983	*	86082:	gap of unknown length
*	86083	*	88348:	contig of 2266 bp in length
*	88349	*	88448:	gap of unknown length
*	88449	*	90746:	contig of 2298 bp in length
*	90747	*	90846:	gap of unknown length
*	90847	*	92600:	contig of 1754 bp in length

Query Match 18.1%; Score 90.4; DB 2; Length 175281;  
Best Local Similarity 83.1%; Pred. No. 9.8e-17;  
Matches 103; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 163 AGTTGGCTACTCTGCTTCCCTCCTGAAGACGGAAGGCTGTGACACGACGACA 222  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 84981 AGTTGGCTTCTCTGCTTCCCTCTGAAAGACGCGACAGAGTGTGACGAATGAACAGCA 84922  
QY 223 CATCCCGGTCTCGGGAACCTTCTTGGGCTATCTTGCTACCAAGAGCTTGGATGGG 282  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 84921 TATCCCTGTCTCGGCCAACCTGCGGCTGTGGCTACCTTGGCTACCAAGAGCTCAGCATGGG 84862  
QY 283 CAGG 286  
|||||  
Db 84861 CAGG 84858

RESULT 8  
LOCUS AX173028 4391 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 7 from Patent WO0142294.

ACCESSION AX173028  
VERSION AX173028.1 GI:14597978  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE 1 (bases 1 to 4391)  
AUTHORS Lu, P., Garman, J.D. and Candia, A.F.  
TITLE Clasp-4 transmembrane protein  
JOURNAL Patent: WO 0142294-A 7 14-JUN-2001;  
Arbor Vita Corporation (US)  
FEATURES  
source Location/Qualifiers  
1. .4391  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/note="human CLASP-4 cDNA"  
414. .4058  
/note="human CLASP-4"  
/codon\_start=1  
/protein\_id="CAC43730.1"  
/db\_xref="GI:14597978"  
/translation="MEIQVLIRFLSVILMQLFWLPMIHEDDVPISCPMVLFIYSK  
CHEEGLDSYLSSEFIKYSFPGKPSAPQAPLIHETLATMTALLKQADFLAINKLIKY  
SWFFETIAKSMATYLLLEENKIKLHGQREFPKAYHHAHLFLAITIVESQVAEIPKE  
SRNVNYSLASFLKCLTLMDRGFENVLINDYISFSKDPYLAIEYKEFLQYICNHE  
HYPLNLPMAFPAKPKLQVRQDSNLEYSLSDEYCKHFLVGLLRETSIALQDNYEIRY  
TAISVIKNLILKHAFTDRYQHKNOQAKIAQLYLPFVGLLENQIRLAGRDLYSCAM  
PNSASRDEFPCCGFTSPANRGSLSITDKDTAGSFQNGHGIRKEDSRGSLIPEGATGPD  
QNGTGENTRQSRSSVSQYRNDQYRSLMCLYIYKMSIEDTLTYWNKVSPOE  
LINILILEYCLFHFYRMGKRNIARYHDAMLSKHFGIDRSQTMPALRNRSGVQARL  
QHLSSLESFTLNHSTTEADIFHQALLEGNTATEVSLVLDITISFTQCFTHELN  
NDGHNPLMKRVEDIHIAFLKNGQSEVSLKHVPASLRAFISFPSAFKGRVNMCARFC  
YEVLKCCSTKISSTRNEASALYILMRNNEYTKRKTFLRHLQIILAVSOLIADVAL  
SGGSRFQESLFIINNFANSRDRPMLARFPAEVKDLTKRIRIYLMATAQMEHEKDEPM  
LIDLYSLAKSYASTPELRKTWPLABAFPAEVKDLTKRIRIYLMATAQMEHEKDEPM  
LFPNGCSAFKRTIPNIDEEGAMKEDGAMDVHYSEVLLLELQCVNGLMKAEYEIIL  
SEISKLIGPIYENRREFENLTQYRRLHGAYTKILEVMHTKRLGLTFERRVAFYGQSF  
FEEDGKEYIYKEPKLTGLSEISLRVLKLYGEKFGTENVKLIQDSKVNAKELDPKYA  
HIQVTYVKPYFDKDELTERKTEFEERNHNISRFEAPYTLISGKKQGCIEQCKRRITL  
TTSNSFPYVKRIPINCEQOINLPIDGATDEIKDTAELOKCSSTDVDMIOLOKLK  
QGWVSQVNAGPLAYARAFNLDSQASKYPPKKVSELKDMFRFIQACSIALELNERLI  
KEDQVEYHEGLKSNFRDMVKELSDIIEHQILQEDTMHSPMWSNTLHVCAISGTSDDR  
GYGSPRYAEV"

BASE COUNT 1359 a 851 c 908 g 1273 t  
ORIGIN

Query Match 17.0%; Score 85; DB 6; Length 4391;  
Best Local Similarity 52.4%; Pred. No. 2.5e-15;  
Matches 187; Conservative 0; Mismatches 170; Indels 0; Gaps 0;

QY 140 AAGAGGATGTCGTTGAACCCAGTTGGCTACTCTGCTTCCCTCCTGAAGACGGA 199  
||| || ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 78 AAGCGGCCCCCGTTGACCTCCGGTTGGGTTGCCCTGGGTCCTTGTGAAGTTGGT 137  
QY 200 AGGCTGTGACAAAGCGAGACACATCCCGGTCTCGGCGAACCTTCTCGGGCTATCTT 259  
||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 138 AGATTCTTCCCTTTTGGCGCGGCTGCCGTTTCCCAATCTTCCCCCGGCTCTTGA 197  
QY 260 GGCTACCAAGAGCTTGGGATGGGCGAGCATTATGCTCCGGAATTAATGGGTAGATGA 319  
||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 198 ATTCTGATTGATGATATATCAAGGGGGCAATGTAATGTGATTTTAATGGGTGGT 257  
QY 320 GGCAAGCAGCTGCTGAAAATTCCACTCATCTGCTGTTTACAGTGATATCTACAGATCAG 379  
| ||||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 258 GTAAAGCCTTTGTGAGGTTTAAAGGCCCTTGGGTTCTCCCATTTCCCTTAGGTTCTG 317  
QY 380 CATTTACATAATTTTTCAGTACTGTGAGAAAACCGAATCTGAGGCCCAAGCCTTAGGA 439  
||||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 318 CATTTGCCCAATTTCTTCATCATTTGCCGCTGATTCGGTCAGACTCGAAAGAGGTTCCA 377  
QY 440 AACGACTTGTAAAGTACCTTAAGAGTCTGCATGCGATGGAAGGCCACGTGATGATC 496  
| ||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Dn	378	GGGGGCTCATTAATTTTAAAGGTCTTTGCATGCCATGGAGATCCCAAGTCTTGATC	434
RESULT 9			
LOCUS	AXI73118	4393 bp	DNA linear PAT 03-JUL-2001
DEFINITION	Sequence 97 from Patent WO0142294.		
ACCESSION	AXI73118		
VERSION	AXI73118.1	GI:14598012	
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS	Lu,P., Garman,J.D. and Candia,A.F.		
TITLE	Clasp-4 transmembrane protein		
JOURNAL	Patent: WO 0142294-A 97 14-JUN-2001;		
FEATURES	Arbor Vita Corporation (US)		
source	Location/Qualifiers		
	1..4393		
	/organism="synthetic construct"		
	/db_xref="taxon:32630"		
	/note="polynucleotide fragment"		
BASE COUNT	1359 a 852 c 910 g 1272 t		
ORIGIN			
Query Match	17.0%; Score 85; DB 6; Length 4393;		
Best Local Similarity	52.4%; Pred. No. 2.5e-15;		
Matches	187; Conservative 0; Mismatches 170; Indels 0; Gaps 0;		
OY	140 AAGAGGATGTCGTGAACCACAAGTTGGCTACTCCTGGCTTCCCCCTCGAAGACGGA	199	
Db	78 AAGCGGGCCCCGGTGAACCTCCGGTTGGTTGGCTTGGCTTCCCTTGCTGAAGTTGGT	137	
OY	200 AGGGTGTGACAAAGCGACGACACATCCC GGTCCTCGCGCAACCTTCTCGGGCTATCTT	259	
Db	138 AGATTCTTCCCTTTTGGCGCGCGGCTGCCGGTTTCCCAATCTTCCCCCGGGCTCCTTA	197	
OY	260 GGCTACCAAGAGCTTGGGATGGGCGACGCAATTATGTCGCGAAATTAAATGGTAGATGGA	319	
Db	198 ATCTGATGATGATAATCAAGGGGCAATGTAATGTGGAATTTTAAATGGGTGGTGGT	257	
OY	320 GGCAAGCCACGTGCTGAAAATTTCCACTCATCTGTTTTCTACAGTGTATCTCAGATCAG	379	
Db	258 GTAAAGCCTTTGTGGAGGTTTAAAGGCCCTTGGGTTTCCCATTTCCCTTAGGTTCTG	317	
OY	380 CATTTACATAATTTTTTCCAGTACTGTGCAGAAAAACCGAATCTGGAGCCCCAAGCCTTAGGA	439	
Db	318 CATTGGCCAATCTTCCATCATTTGCCGGCTGATTCCGTTACAGACTCGAAAGAGTTCCA	377	
OY	440 AACGAAGTGTAAAGTACCTTAAGAGTCTGCATGCCATGGAGGCCACGATGATC	496	
Db	378 GGGGGGCTCATTAATTTTAAAGGCTCTTTGCATGCCATGGAGATCCCAAGTCTTGATC	434	
RESULT 10			
LOCUS	AC109966	175281 bp	DNA linear HTG 13-JUL-2002
DEFINITION	Rattus norvegicus clone CH230-32315, *** SEQUENCING IN PROGRESS		
ACCESSION	AC109966		
VERSION	AC109966.3	GI:21738210	
KEYWORDS	HTG; HTGS_PHASE1.		
SOURCE	Norway rat.		
ORGANISM	Rattus norvegicus		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;		
	Rattus.		
REFERENCE	1 (bases 1 to 175281)		
AUTHORS	Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,		
	Alsbrooks,S.L., Amaratunge,H.C., Are,J.R., Ayele,M., Banks,T.,		
	Barbaria,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D.,		
	Bouck,J., Bowie,S., Brieva,M., Brown,E., Brown,M., Bryant,N.P.,		

	Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C., Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C., Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R., Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A., Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H., Eouthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J., Earhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M., Falls,T., Ferraguto,D., Flaggs,N., Ford,J., Foster,P., Frantz,P., Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R., Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K., Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J., Hernandez,O., Hodgson,A., Hogues,M., Holloway,C., Hollins,B., Homsí,F., Howard,S., Huber,J., Hulik,S., Hume,J., Jackson,L.E., Jacobson,B., Jia,Y., Johnson,R., Jolivét,S., Joudah,S., Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C., Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L., Li,J., Li,Z., Lichtarge,O., Lieu,C., Liu,J., Liu,W., Loulseged,H., Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J., Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E., Massey,E., Mawhney,E., McLeod,M.P., Meador,M., Mel,G., Metzker,M., Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S., Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N., Nguyen,N., Nickerson,E., Nwokenkwo,S., Oguh,M., Okwuonu,G., Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L., Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y., Rives,M., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savary,G., Scherer,S., Scott,G., Shen,H., Shooshitari,N., Sisson,I., Sodergren,E., Sonaike,T., Sparks,A., Stanley,H., Stone,H., Sutton,A., Svatek,A., Tabore,P., Tamerisa,A., Tamerisa,K., Tang,H., Tansey,J., Taylor,C., Taylor,T., Telford,B., Thomas,N., Thomas,S., Usmani,K., Vasquez,L., Vera,V., Villalon,D., Vinson,R., Wang,Q., Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S., Williams,G., Williamson,A., Wleczek,R., Wooden,S., Worley,K., Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D., Weinstein,G. and Gibbs,R.
TITLE	Direct Submission
JOURNAL	Unpublished
AUTHORS	2 (bases 1 to 175281)
TITLE	Worley,K.C.
JOURNAL	Direct Submission
AUTHORS	Submitted (09-FEB-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
TITLE	3 (bases 1 to 175281)
JOURNAL	Worley,K.C.
AUTHORS	Direct Submission
TITLE	Submitted (13-JUL-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
JOURNAL	On Jul 12, 2002 this sequence version replaced gi:18847026.
COMMENT	----- Genome Center Center: Baylor College of Medicine Center code: BCM Web site: http://www.hgsc.bcm.tmc.edu/ Contact: hgsc-help@bcm.tmc.edu ----- Project Information Center project name: QOLP Center clone name: CH230-32315 ----- Summary Statistics Sequencing vector: Plasmid; Chemistry: Dye-Terminator Big Dye; 100% of reads Assembly program: Phrap; version 0.990329 Consensus quality: 105442 bases at least Q40 Consensus quality: 111492 bases at least Q30 Consensus quality: 116270 bases at least Q20 ----- * NOTE: Estimated insert size may differ from sequence length * (see http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html), * NOTE: This is a 'working draft' sequence. It currently * consists of 75 contigs. The true order of the pieces * is not known and their order in this sequence record is * arbitrary. Gaps between the contigs are represented as

\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.  
1 1290: contig of 1290 bp in length  
\* 1291 1390: gap of unknown length  
\* 1391 2414: contig of 1024 bp in length  
\* 2415 2514: gap of unknown length  
\* 2515 3639: contig of 1125 bp in length  
\* 3640 3739: gap of unknown length  
\* 3740 5063: contig of 1324 bp in length  
\* 5064 5163: gap of unknown length  
\* 5164 6243: contig of 1080 bp in length  
\* 6244 6343: gap of unknown length  
\* 6344 7536: contig of 1193 bp in length  
\* 7537 7636: gap of unknown length  
\* 7637 9071: contig of 1435 bp in length  
\* 9072 9171: gap of unknown length  
\* 9172 10200: contig of 1029 bp in length  
\* 10201 10300: gap of unknown length  
\* 10301 11505: contig of 1205 bp in length  
\* 11506 11605: gap of unknown length  
\* 11606 12680: contig of 1075 bp in length  
\* 12681 12780: gap of unknown length  
\* 12781 14056: contig of 1276 bp in length  
\* 14057 14156: gap of unknown length  
\* 14157 15413: contig of 1257 bp in length  
\* 15414 15513: gap of unknown length  
\* 15514 16580: contig of 1067 bp in length  
\* 16581 16680: gap of unknown length  
\* 16681 17692: contig of 1012 bp in length  
\* 17693 17792: gap of unknown length  
\* 17793 19013: contig of 1221 bp in length  
\* 19014 19113: gap of unknown length  
\* 19114 20418: contig of 1305 bp in length  
\* 20419 20518: gap of unknown length  
\* 20519 21880: contig of 1362 bp in length  
\* 21881 21980: gap of unknown length  
\* 21981 22985: contig of 1005 bp in length  
\* 22986 23085: gap of unknown length  
\* 23086 24156: contig of 1071 bp in length  
\* 24157 24256: gap of unknown length  
\* 24257 25732: contig of 1476 bp in length  
\* 25733 25832: gap of unknown length  
\* 25833 27196: contig of 1364 bp in length  
\* 27197 27296: gap of unknown length  
\* 27297 28615: contig of 1319 bp in length  
\* 28616 28715: gap of unknown length  
\* 28716 30145: contig of 1430 bp in length  
\* 30146 30245: gap of unknown length  
\* 30246 31418: contig of 1173 bp in length  
\* 31419 31518: gap of unknown length  
\* 31519 32896: contig of 1378 bp in length  
\* 32897 32996: gap of unknown length  
\* 32997 34142: contig of 1146 bp in length  
\* 34143 34242: gap of unknown length  
\* 34243 35262: contig of 1020 bp in length  
\* 35263 35362: gap of unknown length  
\* 35363 36924: contig of 1562 bp in length  
\* 36925 37024: gap of unknown length  
\* 37025 38670: contig of 1646 bp in length  
\* 38671 38770: gap of unknown length  
\* 38771 40612: contig of 1842 bp in length  
\* 40613 40712: gap of unknown length  
\* 40713 42724: contig of 2012 bp in length  
\* 42725 42824: gap of unknown length  
\* 42825 43829: contig of 1005 bp in length  
\* 43830 43929: gap of unknown length  
\* 43930 45818: contig of 1889 bp in length  
\* 45819 45918: gap of unknown length  
\* 45919 48183: contig of 2265 bp in length  
\* 48184 48283: gap of unknown length  
\* 48284 49887: contig of 1604 bp in length

\* 49888 49987: gap of unknown length  
\* 49988 51568: contig of 1581 bp in length  
\* 51569 51668: gap of unknown length  
\* 51669 53251: contig of 1583 bp in length  
\* 53252 53351: gap of unknown length  
\* 53352 55636: contig of 2285 bp in length  
\* 55637 55736: gap of unknown length  
\* 55737 57159: contig of 1423 bp in length  
\* 57160 57259: gap of unknown length  
\* 57260 59519: contig of 2260 bp in length  
\* 59520 59619: gap of unknown length  
\* 59620 63392: contig of 3773 bp in length  
\* 63393 63492: gap of unknown length  
\* 63493 65130: contig of 1638 bp in length  
\* 65131 65230: gap of unknown length  
\* 65231 68145: contig of 2915 bp in length  
\* 68146 68245: gap of unknown length  
\* 68246 70070: contig of 1825 bp in length  
\* 70071 70170: gap of unknown length  
\* 70171 73494: contig of 3324 bp in length  
\* 73495 73594: gap of unknown length  
\* 73595 75991: contig of 2397 bp in length  
\* 75992 76091: gap of unknown length  
\* 76092 77867: contig of 1776 bp in length  
\* 77868 77967: gap of unknown length  
\* 77968 80318: contig of 2351 bp in length  
\* 80319 80418: gap of unknown length  
\* 80419 82211: contig of 1793 bp in length  
\* 82212 82311: gap of unknown length  
\* 82312 84412: contig of 2101 bp in length  
\* 84413 84512: gap of unknown length  
\* 84513 85982: contig of 1470 bp in length  
\* 85983 86082: gap of unknown length  
\* 86083 88348: contig of 2266 bp in length  
\* 88349 88448: gap of unknown length  
\* 88449 90746: contig of 2298 bp in length  
\* 90747 90846: gap of unknown length  
\* 90847 92600: contig of 1754 bp in length

Query Match 15.2%; Score 75.8; DB 2; Length 175281;  
Best Local Similarity 68.9%; Pred. No. 4.1e-12;  
Matches 104; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 323 AAGCCACTGCTGAATAATTTCCACTCATCTGGTTTCTACAGTGATATCAGATCAGCAT 382  
Db 83560 AAGCACACACTTAACAGATTTTCTTCCTTCCTCCCTGCCCTCAACCTAGATCAGCAC 83619  
QY 383 TTACATTAATTTTTCAGTACTGTGAGAAAACCGAATCTGAGGCCCAAGCCTTAGAAMAC 442  
Db 83620 TTACACAATTTTTCATATCTGTGAGAAAACGGAATCTGAGGCCCAAGCCTCAGGAGT 83679  
QY 443 GAACCTGTAAAGTACCTTAAGAGTCTGCATG 473  
Db 83680 GAACCTAGTAATACCTTAAGGTACCAATG 83710

RESULT 11  
AC119357/c 192825 bp DNA linear HTG 18-JUL-2002  
LOCUS Rattus norvegicus clone CH230-473M19, \*\*\* SEQUENCING IN PROGRESS  
DEFINITION \*\*\* 89 unordered pieces.

ACCESSION AC119357  
VERSION AC119357.3 GI:21746916  
KEYWORDS HTG; HTGS\_PHASE1.  
SOURCE Norway rat.  
ORGANISM Rattus norvegicus

REFERENCE 1 (bases 1 to 192825)  
AUTHORS Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,  
Alsbrooks,S.L., Amaratunge,H.C., Are,J.R., Ayele,M., Banks,T.,  
Barbaria,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D.,



Bouck,J., Bowie,S., Brieva,M., Brown,E., Brown,M., Bryant,N.P.,  
Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C.,  
Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D.,  
Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C.,  
Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R.,  
Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A.,  
Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H.,  
Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J.,  
Earnhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M.,  
Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P.,  
Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R.,  
Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K.,  
Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J.,  
Hernandez,O., Hodgson,A., Hognes,M., Holloway,C., Hollins,B.,  
HomsI,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Jackson,L.E.,  
Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S.,  
Karlssoen,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C.,  
Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L.,  
Li,J., Li,Z., Lichtarge,O., Lieu,C., Liu,J., Liu,W., Loulseged,H.,  
Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J.,  
Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E.,  
Massey,E., Mawhney,E., Mcleod,M.P., Meador,M., Mei,G., Metzker,M.,  
Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S.,  
Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N.,  
Nguyen,N., Nickerson,E., Nwokenkwo,S., Oguh,M., Okwuonu,G.,  
Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L.,  
Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y.,  
Rives,M., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savery,G.,  
Scherer,S., Scott,G., Shen,H., Shooshtari,N., Sisson,I.,  
Sodergren,E., Sonaik,T., Sparks,A., Stanley,H., Stone,H.,  
Sulton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H.,  
Tansey,J., Taylor,C., Taylor,T., Telfrod,B., Thomas,N., Thomas,S.,  
Usmani,K., Vasquez,L., Vera,Y., Villalon,D., Vinson,R., Wang,Q.,  
Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S.,  
Williams,G., Williamson,A., Wlaczek,R., Wooden,S., Worley,K.,  
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D.,  
Weinstock,G. and Gibbs,R.

TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
JOURNAL

Unpublished  
2 (bases 1 to 192825)  
Worley,K.C.  
Direct Submission  
Submitted (26-APR-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
3 (bases 1 to 192825)  
Worley,K.C.  
Direct Submission  
Submitted (18-JUL-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
On Jul 14, 2002 this sequence version replaced gi:20429771.

COMMENT

Center: Baylor College of Medicine  
Center code: BCM  
Web site: <http://www.hgsc.bcm.tmc.edu/>  
Contact: [hgsc-help@bcm.tmc.edu](mailto:hgsc-help@bcm.tmc.edu)  
Project Information  
Center project name: GYFP  
Center clone name: CH230-473M19  
Summary Statistics  
Sequencing vector: Plasmid;  
Chemistry: Dye-terminator Big Dye: 100% of reads  
Assembly program: Phrap; version 0.990329  
Consensus quality: 117932 bases at least Q40  
Consensus quality: 124308 bases at least Q30  
Consensus quality: 129203 bases at least Q20

\* NOTE: Estimated insert size may differ from sequence length  
\* (see [http://www.hgsc.bcm.tmc.edu/docs/Genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/docs/Genbank_draft_data.html)).  
\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 89 contigs. The true order of the pieces  
\* is not known and their order in this sequence record is

\* arbitrary. Gaps between the contigs are represented as  
\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.

1  
1130 1129: contig of 1129 bp in length  
1230 1229: gap of unknown length  
2850 2849: contig of 1620 bp in length  
2950 2949: gap of unknown length  
4126 4125: contig of 1176 bp in length  
4226 4225: gap of unknown length  
5645 5644: contig of 1419 bp in length  
5745 5744: gap of unknown length  
6998 6997: contig of 1253 bp in length  
7098 7097: gap of unknown length  
8758 8757: contig of 1660 bp in length  
8858 8857: gap of unknown length  
9861 9860: contig of 1003 bp in length  
9961 9960: gap of unknown length  
11606 11605: contig of 1645 bp in length  
11706 11705: gap of unknown length  
12752 12751: contig of 1046 bp in length  
12852 12851: gap of unknown length  
14491 14490: contig of 1639 bp in length  
14591 14590: gap of unknown length  
16102 16101: contig of 1511 bp in length  
16202 16201: gap of unknown length  
17629 17628: contig of 1427 bp in length  
17729 17728: gap of unknown length  
18884 18883: contig of 1155 bp in length  
18984 18983: gap of unknown length  
20212 20211: contig of 1228 bp in length  
20312 20311: gap of unknown length  
21354 21353: contig of 1042 bp in length  
21454 21453: gap of unknown length  
22519 22518: contig of 1065 bp in length  
22619 22618: gap of unknown length  
24108 24107: contig of 1489 bp in length  
24208 24207: gap of unknown length  
25604 25603: contig of 1396 bp in length  
25704 25703: gap of unknown length  
27172 27171: contig of 1468 bp in length  
27272 27271: gap of unknown length  
28994 28993: contig of 1722 bp in length  
29094 29093: gap of unknown length  
30123 30122: contig of 1029 bp in length  
30223 30222: gap of unknown length  
31318 31317: contig of 1095 bp in length  
31418 31417: gap of unknown length  
33145 33144: contig of 1727 bp in length  
33245 33244: gap of unknown length  
34432 34431: contig of 1187 bp in length  
34532 34531: gap of unknown length  
35744 35743: contig of 1212 bp in length  
35844 35843: gap of unknown length  
37181 37180: contig of 1337 bp in length  
37281 37280: gap of unknown length  
38597 38596: contig of 1316 bp in length  
38697 38696: gap of unknown length  
40032 40031: contig of 1335 bp in length  
40132 40131: gap of unknown length  
41486 41485: contig of 1354 bp in length  
41586 41585: gap of unknown length  
42745 42744: contig of 1159 bp in length  
42845 42844: gap of unknown length  
45159 45158: contig of 2314 bp in length  
45259 45258: gap of unknown length  
46753 46752: contig of 1494 bp in length  
46853 46852: gap of unknown length  
48030 48029: contig of 1177 bp in length  
48130 48129: gap of unknown length  
49683 49682: contig of 1553 bp in length  
49782: gap of unknown length

*	49783		51724:	contig of 1942 bp in length
*	51725		51824:	gap of unknown length
*	51825		5137:	contig of 1313 bp in length
*	53138		53237:	gap of unknown length
*	53238		55287:	contig of 2050 bp in length
*	55288		55387:	gap of unknown length
*	55388		57026:	contig of 1639 bp in length
*	57027		57126:	gap of unknown length
*	57127		58750:	contig of 1624 bp in length
*	58751		58850:	gap of unknown length
*	58851		60180:	contig of 1330 bp in length
*	60181		60280:	gap of unknown length
*	60281		61971:	contig of 1691 bp in length
*	61972		62071:	gap of unknown length
*	62072		63893:	contig of 1822 bp in length
*	63894		63993:	gap of unknown length
*	63994		65782:	contig of 1789 bp in length
*	65783		65882:	gap of unknown length
*	65883		67125:	contig of 1243 bp in length
*	67126		67225:	gap of unknown length
*	67226		69485:	contig of 2260 bp in length
*	69486		69585:	gap of unknown length
*	69586		71428:	contig of 1843 bp in length
*	71429		71528:	gap of unknown length
*	71529		73230:	contig of 1702 bp in length
*	73231		73330:	gap of unknown length
*	73331		75374:	contig of 2044 bp in length
*	75375		75474:	gap of unknown length
*	75475		77927:	contig of 2453 bp in length
*	77928		78027:	gap of unknown length
*	78028		79268:	contig of 1241 bp in length
*	79269		79368:	gap of unknown length
*	79369		81963:	contig of 2595 bp in length
*	81964		82063:	gap of unknown length
*	82064		83940:	contig of 1877 bp in length
*	83941		84040:	gap of unknown length
*	84041		85690:	contig of 1650 bp in length
*	85691		85790:	gap of unknown length
*	85791		88775:	contig of 2985 bp in length

Query Match 15.2%; Score 75.8; DB 2; Length 192825;  
Best Local Similarity 68.9%; Pred. No. 4.2e-12;  
Matches 104; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

Qy	323	AAGCCACTGCTGAATAATTCCACTCATCTGTTTCTACAGTGTATCTCAGGATCAGCAT	382
Db	33590	AAGCACACACTAACAAGATTTTCTTCCTCTCTCCCTGCGCTCAACCTAGGATCAGCAC	33531
Qy	383	TTACATAATTTTTCACAGTACTGTACAGAAACCGAATCTGGAGCCCAAGCCTTAGGAAC	442
Db	33530	TTACACAATTTTTCACATACTGTACAGAAACGGAATCTGAGCCCAAGCCTCAGGAGT	33471
Qy	443	GAACCTGTAAGTACCTTAAGAGTCTGCATG	473
Db	33470	GAACTAGTGAATACTCTTAAGTACCAATG	33440

RESULT 12  
AK074081 5564 bp mRNA linear PRI 15-FEB-2002  
LOCUS Homo sapiens mRNA for FLJ00152 protein.  
ACCESSION AK074081  
VERSION AK074081.1 GI:18676509  
KEYWORDS fts (full insert sequence).  
SOURCE Homo sapiens adult spleen cDNA to mRNA, clone:FLJ00152.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Jikuya,H., Takano,J., Nomura,N., Kikuno,R., Nagase,T. and Ohara,O.  
TITLE The nucleotide sequence of a long cDNA clone isolated from human spleen  
JOURNAL Published Only in Database (2002)

REFERENCE 2 (bases 1 to 5564)  
AUTHORS Jikuya,H., Takano,J., Nomura,N., Kikuno,R., Nagase,T. and Ohara,O.  
TITLE Direct Submission  
JOURNAL Submitted (21-JAN-2002) Takahiro Nagase, Kazusa DNA Research Institute, Department of Human Gene Research, 1532-3, Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:cdna1info@kazusa.or.jp, URL:http://www.kazusa.or.jp/NEDO, Tel:81-438-52-3913, Fax:81-438-52-3914)

COMMENT NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert and 5'- & 3'-end one pass sequencing; Research Association for Biotechnology; cDNA library construction and clone selection; Kazusa DNA Research Institute.

FEATURES  
source Location/Qualifiers  
1..5564

gene /organism="Homo sapiens"  
CDS /db\_xref="taxon:9606"  
/clone="FLJ00152"  
/tissue\_type="spleen"  
/dev\_stage="adult"  
/note="vector:pbluescriptII SK plus"  
1..5564  
/gene="FLJ00152"  
<1..4122  
/gene="FLJ00152"  
/note="Start codon is not identified."  
/codon\_start=1  
/evidence=not\_experimental  
/product="FLJ00152 protein"  
/protein\_id="BAB84907.1"  
/db\_xref="GI:18676510"

/translation="GEDASNAMPVIFGKSSGPEFLOEYVTAITYHNKSPDEYEEKIK  
LPAKLTVNHLLFTFYHISCOOKOGASVETLLGYSWLPILNLERLOTGSGYLPVALEK  
LPPANSMSHSAEKVPLNPPTKMAEGHKGVFNIQVAVSSVHTQDNHLEKFTLCHSLE  
SCVTFPIRVLDOKISEMALEHKLIIICLNSSRLEPLVFLHLVLDKLFQLSVQPMV  
IAGGTANFSQFAFESVVAIANSLSKSLDQHGRCNCLASVHYVFRLEPQORDVP  
KSGAPALIDPRSHTYGRTSAAVSSKILQARVSSNPDLAGTSHSADEYKNIMS  
SKTADRNCRSMSYCGSSSDAPSSPAAPRPASKKHHELAQMVSTGMYRETVKY  
AMFEFELLVKMSAOHVHNMKDRSEFRTRFSDFRMDITTVNVVTSIALALLVKKPK  
ENQAEKMNISLAFFLYDLISLMDRGFVFNLRHYCSOLSAKLSNLPILISMLEFLR  
ILCSHEHYLNILNLFEMNADTAPTSPCPSISSONSSSCSFODOKIASMFDTLSEYRQ  
HFLTGLFTLELAALDAEGEGISKVQRKAVSAIHSLSSHDLDPRCVKPEYVKIAAL  
YLPVGIILDALPOLQCDFTVADTRRYRTSGSDEDEQAGAINONVALAAGNENFLKT  
SGIVLSSLPYKQYNMLNADTTRNLMICFLWIMKNADQSLIRKWIADLPSTQLNRILD  
LEIVCLCFEYKQKQSSDKVSTQVLOKSRDVKARLEALRGEARGEMRRRAPGNDR  
FPGLENLRLWKEQTHWRQANEKLDKTKAELDQALISGNLATEAHLIILDMQENIIQ  
ASSALDCKDSLGLGVRLVANSNCQSTYTLTHCFATLRALIAKFGDLFEEVEOC  
FDLCHQVLRHCCSSMDVTRSOACATLYLLMRFSFGATSNFARVKMQVTMSLAVGRA  
PDFNEHLRLSLRTILAYSEEDTAMQTPPTQVEELICNLNSILYDTVKMREQEDP  
EMLMIDMYRIAKSYOASPDRLRWLQNMAREKHTKKCYTEAMCLVHAALVAEYLSM  
LEDHSYLPVGSVSFQNISSNVEESVSEDTLSPEDEGVCAGQYFTESGLVGLLEQAA  
ELFSTGGLYETVNEFYKLFIPILAHREFRKLTLTHSREKORAFDSIVNKHDKRMGT  
FRVGFSGSKFGDLDEQEFVYKEPAITKLPEISHRLAEAYGOCFGAEFVEVIRKSTPVD  
KTLEDPNKAYIQITFEVPEYFEDEYEMKDRVTYFEKNENLRREMYTPTLTLEGRGELH  
EQYRRNTVLTTHMAFPYIKTRISYIQKEEFVLTPIEVAIEDMKKKPAVSSCH"

BASE COUNT 1533 a 1332 c 1314 g 1385 t  
ORIGIN

Query Match 14.3%; Score 71.4; DB 9; Length 5564;  
Best Local Similarity 51.1%; Pred. No. 5.3e-11;  
Matches 208; Conservative 0; Mismatches 181; Indels 18; Gaps 1;

Qy	2	GTTTACACCATCACCAAAACCCAGAAATTTATGATGAGATTAAATAGAGTTGCCACT	61
Db	82	GTTACATACCATATAAGTCTCGACTTTTATGAGAAGTGAATAATTAGCTCCCGCT	141
Qy	62	CAGCTGCATGAAGAAGCACCACTGTGCTACATTTCTCCATGTACAGCTGACCACTCA	121
Db	142	AAGCTCACAGTAATAATCACCACTCCTGTTACACCTTCTACCATATACAGCTGCACGA	197
Qy	122	AGTAAAGGAAGCAGCAGAGGATGCTGTTGAAACCCAAAGTTGGCTACTCCTGGCTT	181
Db	198	-----GAAGCAAGGAGCCTCGGTGGAAACTCTCCTGGGATATTATGCTG	243





TITLE Clasp-5 transmembrane protein  
JOURNAL Patent: WO 0142296-A 1 14-JUN-2001;  
Arbor Vita Corporation (US)  
FEATURES Location/Qualifiers  
source 1..7215

/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/note="full length human CLASP-5 cDNA"  
112..6159  
/note="human CLASP-5"  
/codon\_start=1  
/protein\_id="CAC43733.1"  
/db\_xref="GI:14598201"  
/translation="MTHLNSLDVLAOLGDFDDELDLVFETPKCEFTLPQSLPEEGV  
ELDPHVRDCVQTYIREMLIVNRKNQSGPEICGFKKTSRKDFHKTLPKQTFESETLEC  
SEPAQAQGRHLNVLCDVSGKGPVTACDFLRSIQPKRLLENLQQVSAEDFEKONEE  
ARRTNROAELFALYPSVDEDAVEIRPVPECPKELGNRLVKLTLTKEIEIEPLFA  
SIALYDKERKKISENHCDLNSDQKGFRAHTPSVAASSQARSAYSVTPSSDIY  
LVVKTIEKVLQOGDIGCAEPTVVIKESDGSKEKTEKLQAESFCORLGKYMPPFA  
WAPISLSFFNVSTLEREYTDVDSVGRSPVGERRTLAQSRLSERALSLENGVGSN  
FKSTLSVSSFKEQGRLEDDELFKFLADYKRSSSLQRVKSIPLRLLEISTAPEI  
INCCLTPEMLPVKPPENNTRPHEKILEEPREYVPHVYRNLLYYPQRLNFVNKL  
ASARNITIKIQFMCGEDASNAMPVIFGSSGPEFLQEVYLTAVTYHNKSPDEYEVKIK  
LPAKLTNVNHLLETFYHISCQOKOGASVETLLGYSWLPILNERLQTSYCLPALEK  
LPNYSMSHSAEKVPLONPPIKWAEGHKGVNIEQAVSVHTQDNHLEKFEFTLCHSLE  
SQVTEPIRVLDOKISEMALEHLEKLSIICLNSRLPLEVLFLHLVDLKLQLSVQPMV  
IAGQTANFSQAFESVVAIANSLHNSKDLSDQHGRCNLASVHYVFRLPREVQRPV  
KSGAPTALIDPRSYHTYGRTSAAAVSSKLLQARWSSSNPDLAGTHSADAEVKNIMS  
SKIADRNCRMSYICGSSSDAPSSPAAPRPASKKHFEELALQMVSTGMVKSMAQH  
HNMDKDSERTRTREFRMDITITIVNVTSIALLVYPKOKENEOAEKMNISLAFLL  
YDLISLMDRGEFVNLRHYCSQSLAKLSNLPILISMRLFLRLTCSHEHYLNLFEM  
NADTAPTSPPSISQSSSSQSLAKLSNLPILISMRLFLRLTCSHEHYLNLFEM  
AEGEISKVQRKAVSAIHSLSHDLDPKVCPEYKVIKIALYLPVLTGTTIDALPOLC  
DETVAADTRRYRTSGSDEQEGAGAINQNALAIAGNNENLKTSGIVLSLPIKYQYML  
NADTTRNLMLICFLWIMKNADQSLIRKWIADLPSTQLNRILDLFLICYLCEYKKGQSS  
DKVSTQVLQKSRDVKARLEEAALRGEGARGMRRRANGDRFPLNENLNRMKKEQTH  
WROANEKLDKTKAELDOEALISGLATEAHLILDMQENITQASSALDKDSLGGVL  
RVIVNSLNCDSQSTYTLTHCFATRLALIAKFGDLFEVEEQCFDLCHQVLAHCCSSMD  
VTRSOACATLYILMRFSGATSNFARVKMQVTMSLASLVGRAPDFNEEHLRSLRTIL  
AYSEEDTAMQMTPEPTQVEELLNLSNLTIDYVAMREFQEDPEMLMDLMRIASKYQA  
SPDLRLTWLQNMAREKHKKCYTEAMCLVHAALVAEYLSLMDHSDYSPVGSVSFQNS  
ISSNVLEESVSEDTLSDEDEVCAGQYFTESGLVGLLEQAAELFSTGLIETVNEY  
KVIPILEAHREFRKLTLTHSKLRAFDSIVNKHKRMETGYFRVGFSGKFGDLDEQ  
EYVYKEPAITKLPEISHRLAEFYGCQFGAEFVEYIKDSTPVDKTKLDPNKAYIQITVE  
EYFEDEYEMKDRVTYFEKNLNRFMYTTPFTLEGRPRGELHEQYRRNTVLTMAHAF  
YIKTRISVIQKEEFVLTPIEVAIEDMKKTLQLAVALINQEPDPAKMLQMYLQGSVAT  
VNOGRPLEVAQVFLAEIPRADPKLIRHNNKLRICEKEFIMRCGEAVEKNNRLITADOREY  
QOEELKKNYNKLKENLRPMLEKKIPELYKPIFRVESQKRDSFHRSSFRCETQLSQGS"

BASE COUNT 2005 a 1734 c 1721 g 1755 t  
ORIGIN

Query Match 14.3%; Score 71.4; DB 6; Length 7215;  
Best Local Similarity 51.1%; Pred. No. 5.6e-11;  
Matches 208; Conservative 0; Mismatches 181; Indels 18; Gaps 1;

QY 2 GTTTTACACCATCAACCAAGCAATTTATGATGAGATTAAATAGAGTTGCCACT 61  
||| | ||||| | | | | ||||| || | ||||| || | ||||| ||  
Db 1759 GTTACATACCATATAAGTCTCTGACTTTATGAAGAAGTGAATAATTAGCTCCCCGCT 1818  
QY 62 CAGCTGCATGAAGAAGCAACCACTGTTGCTGCATCTCTCCATGTCAGCTGTGACAACCTCA 121  
||| | | ||| ||||| | | ||| ||||| ||| ||||| ||| |  
Db 1819 AAGCTCACAGTAATACCACTCTCTGTTCACTTCTACCATATACAGCTGTCAACA---- 1874  
QY 122 AGTAAAGGAAGCAGAGAGGATGCGTTGAACCAAGTTGGCTACTCTCGGCTT 181  
||| | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 1875 -----GAAGCAAGAGAGCCTCCGCGGAAACTCTCTCTGGGATATTTCATGGCTG 1920  
QY 182 CCCCTCCTGAAGAAGCAAGGCTGTGACAAGCAGACACATCCGGGCTCTCGGGAAC 241  
|| | || | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 1921 CCAATTCCTCTTAATGAACGCTCTTCAAACTGGATCCTACTGTCTCCAGTTGCCCTTGAA 1980  
QY 242 CTTCCTTCGGGCTATCTTGCTACCAAGAGCTTTGGGATGGGACGCAATTATGGTCCGGA 301  
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

Db 1981 AAATTGCCACCCCAACTACTCCATGCAATTCTGCTGAGAAAGTCCCATTTACAGAATCCCTCC 2040  
QY 302 ATTAATAGGGTAGATGGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTCTTACA 361  
||||| ||| | | ||| ||| | | | | ||| | | | ||||| |  
Db 2041 ATTAAGTGGCTGAAGGACATTAAGGAGATTTAATATTGAAGTGCAGAGCTGTTCTTCT 2100  
QY 362 GTGTATACTCAGGATCAGCAATTTACATAATTTTTCAGTACTGTCA 408  
|| | | | ||||| | | | | | | | | | | | | | | | |  
Db 2101 GTACACACCCAGGACAAACCACTGAGAGAGTTCTTACCCCTCTGCCA 2147

RESULT 15  
HSM803577  
LOCUS HSM803577 9298 bp mRNA linear PRI 12-JUL-2002  
DEFINITION Homo sapiens mRNA; cDNA DKFZp66701117 (from clone DKFZp66701117).  
ACCESSION AL832270  
VERSION AL832270.1 GI:21732817  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1 (bases 1 to 9298)  
AUTHORS Wambutt,R., Heubner,D., Mewes,H.W., Weil,B. and Wiemann,S.  
TITLE Direct Submission  
JOURNAL Submitted (09-JUL-2002) 1, D-85764 Neuberberg, GERMANY  
COMMENT Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de; sequenced by AGOWA (Berlin/Germany) within the cDNA sequencing consortium of the German Genome Project.  
This clone (DKFZp66701117) is available at the RZPD in Berlin. please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzd.de Further information about the clone and the sequencing project is available at http://mips.gsf.de/proj/cDNA/.

FEATURES  
source 1..9298  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="DKFZp66701117"  
/tissue\_type="lymph node"  
/clone\_lib="667 (synonym: hln02). Vector pSport1; host DH10B; sites NotI + SalI"  
/dev\_stage="adult"  
9259..9264  
polyA\_signal  
polyA\_site 9281  
BASE COUNT 2546 a 2239 c 2161 g 2352 t  
ORIGIN

Query Match 14.3%; Score 71.4; DB 9; Length 9298;  
Best Local Similarity 51.1%; Pred. No. 5.9e-11;  
Matches 208; Conservative 0; Mismatches 181; Indels 18; Gaps 1;

QY 2 GTTTTACACCATCAACCAAGCAATTTATGATGAGATTAAATAGAGTTGCCACT 61  
||| | ||||| | | | | ||||| || | ||||| || | ||||| ||  
Db 3805 GTTACATACCATATAAGTCTCTGACTTTTATGAAGAAGTGAATAATTAGCTCCCCGCT 3864  
QY 62 CAGCTGCATGAAGAAGCAACCACTGTTGCTCACATCTCTCATGTCAGCTGTGACAACCTCA 121  
||| | | ||| ||||| | | ||| ||||| ||| ||||| ||| |  
Db 3865 AAGCTCACAGTAATACCACTCTGTTCACTTCTACCATATACAGCTGTCAACA---- 3920  
QY 122 AGTAAAGGAAGCAGAGAGGATGTCGTTGAACCAAGTTGGCTACTCTGGCTT 181  
||| | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 3921 -----GAAGCAAGAGAGCCTCCGCGGAAACTCTCTCTGGGATATTTCATGGCTG 3966  
QY 182 CCCCTCCTGAAGAAGCAAGGCTGTGACAAGCAGACACATCCCGGCTCTCGGGAAC 241  
|| | || | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 3967 CCAATTCCTCTTAATGAACGCTCTTCAAACTGGATCCTACTGTCTCCAGTTGCCCTTGAA 4026  
QY 242 CTTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGGACGCAATTATGGTCCGGA 301  
| | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Db 4027 AAATTGCCACCCCACTACTCCATGCAATTCTGCTGAGAAAGTCCCATTTACAGAATCCCTCC 4086



QY 302 ATTAATGGGTAGATGGAGCAAGCCACTGCTGAAATTTCCACTCATCTGGTTCTACA 361  
|||||  
Db 4087 ATTAAGTGGGCTGAAGACATTAAGGAGTATTATATATGAAGTGCAAGCTGTTCTTCT 4146  
|||||  
QY 362 GTGTACTCTCAGATCAGCATTTTACATTAATTTTCCAGTACTGTCA 408  
|||||  
Db 4147 GTACACACCCAGGACACAACCACTGGAGAAGTCTTCAACCCTCTGCCA 4193  
|||||

Search completed: February 7, 2003, 08:03:14  
Job time : 1332.67 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 05:36:04 ; Search time 127.83 Seconds  
(without alignments)  
8808.598 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_1\_500  
Perfect score: 500  
Sequence: 1 agtttaacacatcaccaaa.....aggcacagtgatgcgcct 500

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2185239 segs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N\_Geneseq\_101002:\*  
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:\*  
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:\*  
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:\*  
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:\*  
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:\*  
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:\*  
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:\*  
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:\*  
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:\*  
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:\*  
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:\*  
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:\*  
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:\*  
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:\*  
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:\*  
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:\*  
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:\*  
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:\*  
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:\*  
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:\*  
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:\*  
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:\*  
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:\*  
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	500	100.0	4807	21	AAC87972	Human CLASP-2 nucl
2	500	100.0	4807	21	AAC87973	Human CLASP-2A nuc
3	500	100.0	4807	24	ABK84966	DNA encoding cadhe
4	500	100.0	4807	24	ABK84973	DNA encoding cadhe
5	499	99.8	4806	24	ABK84964	DNA encoding cadhe
6	499	99.8	5048	24	ABK84965	DNA encoding cadhe
7	498.4	99.7	5862	24	ABK84970	DNA encoding cadhe
8	498.4	99.7	6816	21	AAC74524	Human ORFX ORF79 p
9	498.4	99.7	7506	22	AAD19118	Angiogenesis assoc

10	496.8	99.4	6791	24	ABK85003	DNA encoding cadhe
11	486.4	97.3	4898	21	AAC87974	Preliminary CLASP-
12	486.4	97.3	4898	21	AAC87975	Preliminary CLASP-
13	486.4	97.3	4898	21	AAC87976	Preliminary CLASP-
14	486.4	97.3	4898	21	AAC87977	Preliminary CLASP-
15	486.4	97.3	4898	21	AAC87978	Preliminary CLASP-
16	486.4	97.3	4898	21	AAC87979	Preliminary CLASP-
17	486.4	97.3	4898	21	AAC87980	Preliminary CLASP-
18	486.4	97.3	4898	21	AAC87981	Preliminary CLASP-
19	486.4	97.3	4898	24	ABK84992	DNA encoding cadhe
20	486.4	97.3	4898	24	ABK84993	DNA encoding cadhe
21	486.4	97.3	4898	24	ABK84994	DNA encoding cadhe
22	486.4	97.3	4898	24	ABK84995	DNA encoding cadhe
23	486.4	97.3	4898	24	ABK84996	DNA encoding cadhe
24	486.4	97.3	4898	24	ABK84997	DNA encoding cadhe
25	486.4	97.3	4898	24	ABK84998	DNA encoding cadhe
26	486.4	97.3	4898	24	ABK84999	DNA encoding cadhe
27	204.4	40.9	6454	22	AAS08334	Human cDNA encodin
28	173.8	34.8	5688	21	AAC87969	Human CLASP relate
29	173.8	34.8	5688	21	AAA14825	DNA encoding a hum
30	173.8	34.8	7277	24	AAS18951	Human cDNA encodin
31	117.2	23.4	5214	21	AAC87968	Mouse CLASP-1 nucl
32	117.2	23.4	5214	21	AAA14824	DNA encoding a mur
33	85	17.0	4393	22	AAS08357	Human cDNA encodin
34	71.4	14.3	7215	22	AAS07373	Human cDNA encodin
35	69.8	14.0	665	24	ABK53548	Human eosinophil-m
36	54.2	10.8	5955	23	ABL11149	Drosophila melanog
37	46	9.2	6372	22	AAH43851	Human CLASP-7 enco
38	42.4	8.5	5589	23	ABL17737	Drosophila melanog
39	42.4	8.5	9389	23	ABL17736	Drosophila melanog
40	41	8.2	6828	22	AAH41934	Human CLASP-3 cDNA
41	40.4	8.1	211	22	AAH43868	Human CLASP-7 intr
42	40.4	8.1	3023	22	AAH17551	Human cDNA sequenc
43	38.6	7.7	4842	23	ABL11148	Drosophila melanog
44	34.6	6.9	6691	20	AAH13025	Enterococcus faeca
45	34	6.8	1851	21	AAA52623	Eosinophil activat

ALIGNMENTS

RESULT 1	
AAC87972	
ID AAC87972 standard; cDNA; 4807 BP.	
AC AAC87972;	
XX	
DT 07-MAR-2001 (first entry)	
XX	
DE Human CLASP-2 nucleotide sequence.	
XX	
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;	
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;	
KW immunomodulatory; antiinflammatory; antiarthritic; cytosstatic;	
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;	
KW hypersensitivity; transplantation rejection response; immunodeficiency;	
KW proliferation; differentiation; inflammatory response; arthritis;	
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;	
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;	
KW endometriosis; pregnancy induced hypertension; ss.	
XX	
OS Homo sapiens.	
XX	
PN WO200061747-A2.	
XX	
PD 19-OCT-2000.	
XX	
PF 13-APR-2000; 2000WO-US10158.	
XX	
PR 14-APR-1999; 99US-0129171.	
PR 14-MAY-1999; 99US-0134114.	
PR 14-MAY-1999; 99US-0134117.	
PR 14-MAY-1999; 99US-0134118.	

```
PR 21-OCT-1999; 99US-0160860.
PR 29-OCT-1999; 99US-0162498.
PR 13-DEC-1999; 99US-0170453.
PR 14-JAN-2000; 2000US-0176195.
PR 14-FEB-2000; 2000US-0182296.
XX
PA (ARBO-) ARBOR VITA CORP.
XX
XX Lu PS;
PI
DR WPI; 2000-619230/59.
DR P-PSDB; AAB36527.
XX
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and
PT inflammatory responses -
XX
XX Example 1; Fig 1; 286pp; English.
PS
XX
CC The present invention describes cadherin-like asymmetry protein-2
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be
CC used to inhibit an immune response in a subject by interfering with the
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An
CC immune response in a subject may also be inhibited by administering an
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,
CC proteins and antibodies can be used to prevent or treat a CLASP-2
CC mediated disease, such as an autoimmune disease caused or exacerbated
CC by increased activity of TH1 cells. They can also be used to treat
CC hypersensitivities, prevent transplantation rejection responses and
CC augment immune responsiveness in immunodeficiency states, inhibit
CC proliferation and differentiation of cells involved in an inflammatory
CC response e.g, arthritis, inflammatory bowel disease and increase
CC differentiation and proliferation of haematopoietic cells e.g. to treat
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders
CC treated by disrupting CLASP-2 function include multiple sclerosis,
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.
CC The present sequence encodes human CLASP-2, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 500; DB 21; Length 4807;
Best Local Similarity 100.0%; Pred. No. 3.1e-157;
Matches 500; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60
Db 1 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60
QY 61 TCAGCTGCATGAAAAAGCACACCCTGTTGCTGCACATTTCTTCATGTCAGCTGTGACAACTC 120
Db 61 TCAGCTGCATGAAAAAGCACACCCTGTTGCTGCACATTTCTTCATGTCAGCTGTGACAACTC 120
QY 121 AAGTAAAGGAGCAGCAAGAGAGGATGCTGTTGAAACCCCAAGTTGGCTACTCCTGGCT 180
Db 121 AAGTAAAGGAGCAGCAAGAGAGGATGCTGTTGAAACCCCAAGTTGGCTACTCCTGGCT 180
QY 181 TCCCTCTCTGAAGACGGAAGGGTGGTGACAAGCGAGCAGACATCCCGGCTCTGGCGAA 240
Db 181 TCCCTCTCTGAAGACGGAAGGGTGGTGACAAGCGAGCAGACATCCCGGCTCTGGCGAA 240
QY 241 CCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGCGGCAATTATGTCGCGA 300
Db 241 CCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGCGGCAATTATGTCGCGA 300
QY 301 AATTAAATGGGTAGATGAGGCAAGCACTGCTGAAAATTTCCACTCATCTGTTTCTAC 360
Db 301 AATTAAATGGGTAGATGAGGCAAGCACTGCTGAAAATTTCCACTCATCTGTTTCTAC 360
QY 361 AGGTATACTCAGGATCAGCATTTTACATTAATTTTTCAGTACTGTCAGAAACCGAATC 420
Db 361 AGGTATACTCAGGATCAGCATTTTACATTAATTTTTCAGTACTGTCAGAAACCGAATC 420
```

```
Db 361 AGGTATACTCAGGATCAGCATTTTACATTAATTTTTCAGTACTGTCAGAAACCGAATC 420
QY 421 TGGAGCCCCAAGCCTTAGGAACGAACCTTGTAAAGTACTTAAAGTCTGCATGCGATGA 480
Db 421 TGGAGCCCCAAGCCTTAGGAACGAACCTTGTAAAGTACTTAAAGTCTGCATGCGATGA 480
QY 481 AGGCCACGTGATGATCGCCT 500
Db 481 AGGCCACGTGATGATCGCCT 500

RESULT 2
AAC87973
ID AAC87973 standard; cDNA; 4807 BP.
XX
AC AAC87973;
XX
DT 07-MAR-2001 (first entry)
XX
DE Human CLASP-2A nucleotide sequence.
XX
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;
KW hypersensitivity; transplantation rejection response; immunodeficiency;
KW proliferation; differentiation; inflammatory response; arthritis;
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;
KW endometriosis; pregnancy induced hypertension; ss.
XX
OS Homo sapiens.
XX
PN WO200061747-A2.
XX
PD 19-OCT-2000.
XX
PF 13-APR-2000; 2000WO-US10158.
XX
PR 14-APR-1999; 99US-0129171.
PR 14-MAY-1999; 99US-0134114.
PR 14-MAY-1999; 99US-0134117.
PR 14-MAY-1999; 99US-0134118.
PR 21-OCT-1999; 99US-0160860.
PR 29-OCT-1999; 99US-0162498.
PR 13-DEC-1999; 99US-0170453.
PR 14-JAN-2000; 2000US-0176195.
PR 14-FEB-2000; 2000US-0182296.
XX
PA (ARBO-) ARBOR VITA CORP.
XX
PI Lu PS;
PT
DR WPI; 2000-619230/59.
DR P-PSDB; AAB36528.
XX
XX Isolated cadherin-like asymmetry protein-2 polynucleotide and
XX polypeptide used to diagnose, treat and prevent autoimmune diseases and
XX inflammatory responses -
XX
XX Example 1; Fig 2B; 286pp; English.
PS
XX
CC The present invention describes cadherin-like asymmetry protein-2
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be
CC used to inhibit an immune response in a subject by interfering with the
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An
CC immune response in a subject may also be inhibited by administering an
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,
CC proteins and antibodies can be used to prevent or treat a CLASP-2
CC mediated disease, such as an autoimmune disease caused or exacerbated
CC by increased activity of TH1 cells. They can also be used to treat
```



CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence encodes human CLASP-2A, which is used in the  
CC exemplification of the present invention.

XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 500; DB 21; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.1e-157;  
Matches 500; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTGGCCAC 60  
|||||  
Db 1 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTGGCCAC 60  
QY 61 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTCTCCATGTCAGCTGTGACAAC 120  
|||||  
Db 61 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTCTCCATGTCAGCTGTGACAAC 120  
QY 121 AAGTAAAGAGACGACGAAAGAGAGGAGTGTGTAAGAACCCAGTTGGCTACTCTGGCT 180  
|||||  
Db 121 AAGTAAAGAGACGACGAAAGAGAGGAGTGTGTAAGAACCCAGTTGGCTACTCTGGCT 180  
QY 181 TCCCTCTCTGAAAGACGGAGGGGTGTGACAAGCGAGCAGACACATCCCGTCTCGCGAA 240  
|||||  
Db 181 TCCCTCTCTGAAAGACGGAGGGGTGTGACAAGCGAGCAGACACATCCCGTCTCGCGAA 240  
QY 241 CCTTCCTTCGGGCTATCTTGGCTACCAAGACCTTGGATGGCGACATTATGTCGCGA 300  
|||||  
Db 241 CCTTCCTTCGGGCTATCTTGGCTACCAAGACCTTGGATGGCGACATTATGTCGCGA 300  
QY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAAATTTCCACTCATCTGTTCTAC 360  
|||||  
Db 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAAATTTCCACTCATCTGTTCTAC 360  
QY 361 AGTGATACTCAGGATCAGCATTTACATAATTTTTCAGTACTGTCAGAAAACCGAATC 420  
|||||  
Db 361 AGTGATACTCAGGATCAGCATTTACATAATTTTTCAGTACTGTCAGAAAACCGAATC 420  
QY 421 TGGAGCCCAAGCCTTAGGAAACGAACCTTTAAAGTACCTTAAGAGTCTGCATGCGATGA 480  
|||||  
Db 421 TGGAGCCCAAGCCTTAGGAAACGAACCTTTAAAGTACCTTAAGAGTCTGCATGCGATGA 480  
QY 481 AGGCCACGTTGATGTCGCCT 500  
|||||  
Db 481 AGGCCACGTTGATGTCGCCT 500

RESULT 3  
ABK84966  
ID ABK84966 standard; cDNA; 4807 BP.  
XX  
AC ABK84966;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #1.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX

OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI; 2002-416861/44.  
DR P-PSDB; ABG61672.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Disclosure; Figure 3A; 245pp; English.

XX The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.

SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;  
Query Match 100.0%; Score 500; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.1e-157;  
Matches 500; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
Db 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
QY 61 TCAGCTGCATGAAAAAGCACCACCTGTTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120  
Db 61 TCAGCTGCATGAAAAAGCACCACCTGTGTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120  
QY 121 AAGTAAAGGAAGCAGCAGAAGAGGGATGTCGTTGAAAACCCAAAGTTGGCTACTCTGGCT 180  
Db 121 AAGTAAAGGAAGCAGCAGAAGAGGGATGTCGTTGAAAACCCAAAGTTGGCTACTCTGGCT 180  
QY 181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGACGACACATCCCGTCTCGCGAA 240  
Db 181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGACGACACATCCCGTCTCGCGAA 240  
QY 241 CCTTCCTTGGGCTATCTGGCTACCAAGAGCTTGGGATGGCGAGGCATTAATGTCGCGA 300  
Db 241 CCTTCCTTGGGCTATCTGGCTACCAAGAGCTTGGGATGGCGAGGCATTAATGTCGCGA 300  
QY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTTCTAC 360  
Db 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTTCTAC 360  
QY 361 AGTGTATACTCAGATCAGCATTTACATAATTTTCCAGTACTGTGAGAAAACCGAATC 420  
Db 361 AGTGTATACTCAGATCAGCATTTACATAATTTTCCAGTACTGTGAGAAAACCGAATC 420  
QY 421 TGGAGCCCCAAGCCTTAGAAGACGAACCTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
Db 421 TGGAGCCCCAAGCCTTAGAAGACGAACCTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
QY 481 AGGCCACGTGATGATCGCCT 500  
Db 481 AGGCCACGTGATGATCGCCT 500

RESULT 4  
ABK84973  
ID ABK84973 standard; DNA; 4807 BP.  
XX  
AC ABK84973;  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI; 2002-416861/44.

QY 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Example 4; Figure 6A; 245pp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences  
CC and PCR primers of the invention.  
XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 500; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.1e-157;  
Matches 500; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Example 4; Figure 6A; 245pp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences  
CC and PCR primers of the invention.  
XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;  
Query Match 100.0%; Score 500; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.1e-157;  
Matches 500; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Db 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
QY 61 TCAGCTGCATGAAAAAGCACCACCTGTTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120  
Db 61 TCAGCTGCATGAAAAAGCACCACCTGTTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120  
QY 121 AAGTAAAGGAAGCAGCAGAAGAGGGATGTCGTTGAAAACCCAAAGTTGGCTACTCTGGCT 180  
Db 121 AAGTAAAGGAAGCAGCAGAAGAGGGATGTCGTTGAAAACCCAAAGTTGGCTACTCTGGCT 180  
QY 181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGACGACACATCCCGTCTCGCGAA 240  
Db 181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGACGACACATCCCGTCTCGCGAA 240  
QY 241 CCTTCCTTGGGCTATCTTGGCTACCAAGAGCTTGGGATGGCGAGGCATTAATGTCGCGA 300

Db	241	CCCTCCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCAGGCATTATGGTCCGGA	300
QY	301	AATTAATGGGTAGATGGAGGCAAGCCACTGCTGAAAAATTTCCACTCATCTGGTTTCTAC	360
Db	301	AATTAATGGGTAGATGGAGGCAAGCCACTGCTGAAAAATTTCCACTCATCTGGTTTCTAC	360
QY	361	AGTGTACTCAGGATCAGCATTTACATAATTTTTTCCAGTACTGTGAGAAACCAGATC	420
Db	361	AGTGTACTCAGGATCAGCATTTACATAATTTTTTCCAGTACTGTGAGAAACCAGATC	420
QY	421	TGGAGGCCCAAGCCTTAGGAACCAACTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA	480
Db	421	TGGAGGCCCAAGCCTTAGGAACCAACTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA	480
QY	481	AGGCCACGTGATGTCGCT	500
Db	481	AGGCCACGTGATGTCGCT	500

RESULT 5	
ABK84964	
ID	ABK84964 standard; cDNA; 4806 BP.
XX	
AC	ABK84964;
XX	
DT	13-AUG-2002 (first entry)
XX	
DE	DNA encoding cadherin-like asymmetry protein (CLASP).
XX	
KW	Human; autoimmune disease; haematopoietic disorder; Digorge syndrome;
KW	blood protein disorder; agammaglobulinaemia; dysagammaglobulinaemia;
KW	ataxia telangiectasia; common variable immunodeficiency; lymphopenia;
KW	thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;
KW	haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;
KW	endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;
KW	autoimmune pulmonary inflammation; organ rejection; inflammation;
KW	CLASP; gene; ss.
XX	
OS	Homo sapiens.
XX	
-PN	WO200231117-A2.
XX	
PD	18-APR-2002.
XX	
PF	15-OCT-2001; 2001WO-US32202.
XX	
PR	13-OCT-2000; 2000US-0687837.
XX	
PA	(ARBO-) ARBOR VITA CORP.
PA	(GARM/) GARMAN J D.
PA	(CAND/) CANDIA A F.
XX	
PI	Lu PS;
XX	
DR	WPI; 2002-416861/44.
DR	P-PSDB; ABG61670.
XX	
PT	New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating
PT	an immune response, and for treating multiple sclerosis, rheumatoid
PT	arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,
PT	and sepsis
XX	
PS	Disclosure; Figure 1; 245pp; English.
XX	
CC	The invention relates to an isolated polypeptide (I) comprising an amino
CC	acid sequence that has 90 % sequence identity to one of the human
CC	cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)
CC	sequences (PS). (I) is useful for identifying a compound or agent that
CC	binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for
CC	detecting a CLASP-2 polypeptide in a sample. (II) is useful for
CC	inhibiting an immune response in a subject. A pharmaceutical composition
CC	comprising a nucleic acid encoding (I), or (II) is useful for preventing

or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where the autoimmune disease is caused or exacerbated by increased activity of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for detection or inhibition of CLASP-2 expression (e.g., antisense or ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2 polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-2 antibodies or are used as therapeutic polypeptides. The CLASP-2 polynucleotide or fragments can be used in diagnostics (e.g., as probes for CLASP-2 expression), as a lymphocyte marker and for therapeutic purposes. CLASP-2 polynucleotides can construct transgenic and knockout animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2 polynucleotides are for screening for CLASP-2 agonists and antagonists. CLASP-2 polypeptides or polynucleotides can treat deficiencies or disorders of the immune system, by activating or inhibiting the activation, differentiation of immune cells and can treat or detect deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides or polynucleotides can increase differentiation and proliferation of haematopoietic cells, including the pluripotent stem cells to treat those disorders associated with a decrease in certain (or many) types of haematopoietic cells e.g., immunologic deficiency syndromes including blood protein disorders (e.g., agammaglobulinaemia, dysgammaglobulinaemia, ataxia telangiectasia, common variable immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia, Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus, endometriosis, autoimmune thyroiditis, and autoimmune pulmonary inflammation. CLASP-2 can be used to treat anaphylaxis or hypersensitivity to an antigenic molecules, organ rejection or graft-versus-host disease (GVHD) and inflammation. ABK84922-ABK85018 represent cadherin-like asymmetry protein (CLASP) coding sequences and PCR primers of the invention.

Query Match	99.8%;	Score 499;	DB 24;	Length 4806;
Best Local Similarity	100.0%;	Pred. No. 6.7e-157;		
Matches 499;	Conservative	0;	Mismatches 0;	Indels 0;
				Gaps 0;
QY 2	GTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTTGCCACT	61		
Db 1	GTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTTGCCACT	60		
QY 62	CAGCTGCATGAAAAAGCAACCACCTGTGCTCACATTCCTTCATGTCAAGCTGTGACAACTCA	121		
Db 61	CAGCTGCATGAAAAAGCAACCACCTGTGCTCACATTCCTTCATGTCAAGCTGTGACAACTCA	120		
QY 122	AGTAAAGGAGCACGACGAGAAGAGGATGTGCTGTTGAACCCAAAGTTGGCTACTCCGTGGCTT	181		
Db 121	AGTAAAGGAGCACGACGAGAAGAGGATGTGCTGTTGAACCCAAAGTTGGCTACTCCGTGGCTT	180		
QY 182	CCCCCTCTGAAAGAGCGAAGGGGTGTGACAAGCGAGCAGCACATCCCGGTCTCGGGCAAC	241		
Db 181	CCCCCTCTGAAAGAGCGAAGGGGTGTGACAAGCGAGCAGCACATCCCGGTCTCGGGCAAC	240		
QY 242	CTTCCTTCGGGCTATCTTGGCTACCAAGAGCCTGGGATGGGCGAGGCATTATGTCGGGA	301		
Db 241	CTTCCTTCGGGCTATCTTGGCTACCAAGAGCCTGGGATGGGCGAGGCATTATGTCGGGA	300		
QY 302	ATTAATGGGTAGATGAGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTGTTCTACA	361		
Db 301	ATTAATGGGTAGATGAGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTGTTCTACA	360		
QY 362	GTGTATACTCAGGATCAGCAATTTACATAATTTTCCAGTACTGTCAAGAAAACCGAATCT	421		
Db 361	GTGTATACTCAGGATCAGCAATTTACATAATTTTCCAGTACTGTCAAGAAAACCGAATCT	420		
QY 422	GGAGCCCAAGCCTTAGGAAACGAACCTGTAAGTACCTTAAGAGTCTGCATGCGATGGA	481		
Db 421	GGAGCCCAAGCCTTAGGAAACGAACCTGTAAGTACCTTAAGAGTCTGCATGCGATGGA	480		
QY 482	GGCCACGTGATGATCGCCT	500		



DB 481 GGGCAGCTGATCGCCT 499

RESULT 6  
ABK84965  
XX ABK84965 standard; cDNA; 5048 BP.  
XX  
AC ABK84965;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI: 2002-416861/44.  
DR P-PSDB; ABG61671.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Disclosure: Figure 2; 245pp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of

CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.  
XX  
SQ Sequence 5048 BP; 1403 A; 1187 C; 1215 G; 1243 T; 0 other;

Query Match 99.8%; Score 499; DB 24; Length 5048;  
Best Local Similarity 100.0%; Pred. No. 6.9e-157;  
Matches 499; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 GTTTACACCATCACCAAAACCCAGAAATTTATGATGAGATTAAATAGAGTTGCCACT 61  
DB 1 GTTTTACACCATCACCAAAACCCAGAAATTTATGATGAGATTAAATAGAGTTGCCACT 60

QY 62 CAGCTGCATGAAAAGCACCACTGTGCTCACATTCCTCCATGTCCAGCTGTGACAACTCA 121  
DB 61 CAGCTGCATGAAAAGCACCACTGTGCTCACATTCCTCCATGTCCAGCTGTGACAACTCA 120

QY 122 AGTAAAGGAAGCAGCAGAGAGGGATGTCGTTGAACCCCAAGTTGGCTTACTCGGCTT 181  
DB 121 AGTAAAGGAAGCAGCAGAGAGGGATGTCGTTGAACCCCAAGTTGGCTTACTCGGCTT 180

QY 182 CCCCTCTGAAGAGCAGAGGGTGTGACAAGCGACGACACATCCCGGTCTCGCGAAC 241  
DB 181 CCCCTCTGAAGAGCAGAGGGTGTGACAAGCGACGACACATCCCGGTCTCGCGAAC 240

QY 242 CTTCTTCGGGCTATCTTGCTACCAGAAGCTTGGATGGGAGGCACTTATGTCGGAA 301  
DB 241 CTTCTTCGGGCTATCTTGCTACCAGAAGCTTGGATGGGAGGCACTTATGTCGGAA 300

QY 302 ATTAAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTCCACTCATCTGTTCTACA 361  
DB 301 ATTAAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTCCACTCATCTGTTCTACA 360

QY 362 GTGTACTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTCCAGAAACCGAATCT 421  
DB 361 GTGTACTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTCCAGAAACCGAATCT 420

QY 422 GGAGCCCAAGCCTTAGGAACGAACCTGTAAGTACTTTAAGAGTCTGCATGGCATGGAA 481  
DB 421 GGAGCCCAAGCCTTAGGAACGAACCTGTAAGTACTTTAAGAGTCTGCATGGCATGGAA 480

QY 482 GGGCAGCTGATGATCGCCT 500  
DB 481 GGGCAGCTGATGATCGCCT 499

RESULT 7  
ABK84970  
ID ABK84970 standard; cDNA; 5862 BP.  
XX  
AC ABK84970;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #5.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;



KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
OS Homo sapiens.  
XX WO200231117-A2.  
PN 18-APR-2002.  
XX 15-OCT-2001; 2001WO-US32202.  
PR 13-OCT-2000; 2000US-0687837.  
XX (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX Lu PS;  
PI WPI; 2002-416861/44.  
DR P-PSDB; ABG61676.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Disclosure; Figure 3A; 245bp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.  
XX  
SQ Sequence 5862 BP; 1670 A; 1327 C; 1341 G; 1524 T; 0 other;

Query Match 99.7%; Score 498.4; DB 24; Length 5862;  
Best Local Similarity 99.8%; Pred. No. 1.2e-156;  
Matches 499; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1 AGTTTACACCATCACCAAAACCAGAAATTTTATGATGAGATTAAATAGATTGCCAC 60  
Db 495 AGTTTACACCATCACCAAAACCAGAAATTTTATGATGAGATTAAATAGATTGCCAC 554  
OY 61 TCAGCTGCATGAAAGACACCACTGTTGCTCACATCTTCCATGTCAGCTGTGACAACTC 120  
Db 555 TCAGCTGCATGAAAGACACCACTGTTGCTCACATCTTCCATGTCAGCTGTGACAACTC 614  
OY 121 AAGTAAAGGAAGCAGCAAGAGAGGATGTCGTTGAAACCAGTTGGCTACTCGGCT 180  
Db 615 AAGTAAAGGAAGCAGCAAGAGAGGATGTCGTTGAAACCAGTTGGCTACTCGGCT 674  
OY 181 TCCCTCCTGAAAGACGGAAGGTGGTGACAAACGAGACACATCCCGTCTCGCGAA 240  
Db 675 TCCCTCCTGAAAGACGGAAGGTGGTGACAAACGAGACACATCCCGTCTCGCGAA 734  
OY 241 CCTTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGCAGGCAATTATGTCGCGA 300  
Db 735 CCTTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGCAGGCAATTATGTCGCGA 794  
OY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTAC 360  
Db 795 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTAC 854  
OY 361 AGTGTATACATCAGATCAGCATTTACATATTTTCCAGTACTGTGAGAAACCGAATC 420  
Db 855 AGTGTATACATCAGATCAGCATTTACATATTTTCCAGTACTGTGAGAAACCGAATC 914  
OY 421 TGGAGCCCAAGCCTTAGGAACGAACCTTGAAGTACCTTAAGAGTCTGCATGCGATGA 480  
Db 915 TGGAGCCCAAGCCTTAGGAACGAACCTTGAAGTACCTTAAGAGTCTGCATGCGATGA 974  
OY 481 AGGCCACGTGATGTCGCT 500  
Db 975 AGGCCACGTGATGTCGCT 994  
RESULT 8  
AAC74524  
ID AAC74524 standard; cDNA; 6816 BP.  
XX  
AC AAC74524;  
XX  
DT 08-FEB-2001 (first entry)  
XX  
DE Human ORFX ORF79 polynucleotide sequence SEQ ID NO:157.  
XX  
KW Human; open reading frame; ORFX; detection; cytosstatic; hepatotropic;  
KW vulnerable; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;  
KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;  
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;  
KW hypotensive; dermatological; immunosuppressive; antiinflammatory;  
KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;  
KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;  
KW neurodegenerative disorder; osteoarthritis; graft vs host disease;  
KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;  
KW cholesterol ester storage; systemic lupus erythematosus; infection;  
KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;  
KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;  
KW bone damage; cartilage damage; antiinflammatory disease; coagulation;  
KW thrombosis; contraceptive; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200058473-A2.  
XX  
PD 05-OCT-2000.  
XX

PF 31-MAR-2000; 2000WO-US08621.  
XX  
PR 31-MAR-1999; 99US-0127607.  
PR 02-APR-1999; 99US-0127636.  
PR 05-APR-1999; 99US-0127728.  
PR 30-MAR-2000; 2000US-0540763.  
XX  
PA (CURA-) CURAGEN CORP.  
XX  
PI Shimkets RA, Leach M;  
XX  
DR MPI: 2000-602362/57.  
DR P-PSDB; AAB40315.  
XX  
PT Novel nucleic acids and peptides derived from open reading frame X,  
PT useful for treating e.g. cancers, proliferative disorders,  
PT neurodegenerative disorders and cardiovascular disease -  
XX  
PS Claim 5; Page 502-506; 5507pp; English.  
XX  
CC AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,  
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX  
CC sequences have activities such as: cytostatic; hepatotropic; vulnery;  
CC antipsoriatic; antiparkinsonian; nootropic; neuroprotective;  
CC osteopathic; anticonvulsant; antiarthritic; immunosuppressant;  
CC immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;  
CC antidiabetic; hypotensive; dermatological; immunosuppressive;  
CC antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;  
CC antithyroid; and antinaemic. The sequences can be used for determining  
CC the presence of or predisposition to, or preventing or treating  
CC pathological conditions associated with an ORFX-associated disorder. The  
CC nucleic acids can be used to express ORFX proteins in gene therapy  
CC vectors. The proteins and nucleic acids may be used to treat cancers,  
CC proliferative disorders, neurodegenerative disorders, osteoarthritis,  
CC graft vs host disease, cardiovascular disease, diabetes mellitus,  
CC hypertension, hypothyroidism, cholesterol ester storage, systemic lupus  
CC erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,  
CC bacterial or fungal infection, malaria, autoimmune disorders, asthma,  
CC allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,  
CC nocturnal haemoglobinuria, antiinflammatory disease; to enhance  
CC coagulation; to inhibit thrombosis; and as a contraceptive.  
XX  
SQ Sequence 6816 BP; 1977 A; 1523 C; 1557 G; 1757 T; 2 other;  
  
Query Match 99.7%; Score 498.4; DB 21; Length 6816;  
Best Local Similarity 99.8%; Pred. No. 1.3e-156;  
Matches 499; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 AGTTTACACCATCACCAAAACCAGATTTTATGATGAGATTAAATAGAGTGGCCAC 60  
DB 1443 AGTTTACACCATCACCAAAACCAGATTTTATGATGAGATTAAATAGAGTGGCCAC 1502  
QY 61 TCAGCTGCATGAAAAGCACCACCTGTTGCTCAGATTCTTCATGTCAGCTGTGACAAC 120  
DB 1503 TCAGCTGCATGAAAAGCACCACCTGTTGCTCAGATTCTTCATGTCAGCTGTGACAAC 1562  
QY 121 AAGTAAAGGAAGCAGAAAGAGGGATGCTGTAAGAACCCAAAGTTGGCTACTCCTGGCT 180  
DB 1563 AAGTAAAGGAAGCAGAAAGAGGGATGCTGTAAGAACCCAAAGTTGGCTACTCCTGGCT 1622  
QY 181 TCCCTCTCCTGAAGAAGGAGGGTGTGACAAAGCAGACACATCCCGGTCTCGGCGAA 240  
DB 1623 TCCCTCTCCTGAAGAAGGAGGGTGTGACAAAGCAGACACATCCCGGTCTCGGCGAA 1682  
QY 241 CCTTCCTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGGACAGCATTAATGTCGGA 300  
DB 1683 CCTTCCTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGGACAGCATTAATGTCGGA 1742  
QY 301 AATTAAATGGGTAGATGGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTCTAC 360  
DB 1743 AATTAAATGGGTAGATGGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTCTAC 1802  
QY 361 AGTGTATACTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTGAGAAAACCGAATC 420

DB 1803 AGTGTATACTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTGAGAAAACCGAATC 1862  
QY 421 TGGAGCCCAAGCCTTAGGAAGAACTTGTAAAGTACCTTAAGAGCTGTCATGCGATGGA 480  
DB 1863 TGGAGCCCAAGCCTTAGGAAGAACTTGTAAAGTACCTTAAGAGCTGTCATGCGATGGA 1922  
QY 481 AGGCCACGTGATGATCGCCT 500  
DB 1923 AGGCCACGTGATGATCGCCT 1942  
  
RESULT 9  
AAD19118  
ID AAD19118 standard; cDNA; 7506 BP.  
XX  
AC AAD19118;  
XX  
DT 18-DEC-2001 (first entry)  
XX  
DE Angiogenesis associated human thyroid regulated transcript (hTRG) cDNA.  
XX  
KW Angiogenesis associated protein; AAP; cytostatic; cardiant; gene therapy;  
KW ophthalmological; vulnery; myocardial infarction; macular degeneration;  
KW diabetic retinopathy; angiogenesis; wound healing; prophylactic; vaccine;  
KW rheumatoid arthritis; psoriasis; drug screening; tumour; transplantation;  
KW cancer; therapeutic; diagnostic; human; thyroid regulated transcript;  
KW TRG; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 43..6366  
FT /\*tag= a  
FT /product= "human thyroid regulated transcript (hTRG)"  
XX  
WO200170808-A2.  
XX  
PD 27-SEP-2001.  
XX  
PF 22-MAR-2001; 2001WO-US09609.  
XX  
PR 22-MAR-2000; 2000US-191134P.  
XX  
PA (CURA-) CURAGEN CORP.  
PA (GETH ) GENENTECH INC.  
XX  
PI Rastelli LK, Gerritsen M;  
XX  
DR MPI: 2001-602775/68.  
DR P-PSDB; AAE11889.  
XX  
PT Novel angiogenesis associated polypeptides and polynucleotides encoding  
PT the polypeptides, useful for modulating angiogenesis and for treating  
PT tumors and cancers -  
XX  
PS Claim 6; Page 18-21; 159pp; English.  
XX  
CC The invention relates to angiogenesis associated proteins (AAP) and their  
CC corresponding cDNA molecules, which are useful for modulating  
CC angiogenesis. AAP proteins and nucleic acids are useful for promoting  
CC wound healing, for example after organ transplantation, and in the  
CC treatment of tumours, myocardial infarction, cancers, diabetic  
CC retinopathy, macular degeneration, psoriasis and rheumatoid arthritis.  
CC AAP proteins and DNA's are useful in potential prophylactic and  
CC therapeutic applications implicated in a variety of disorders including  
CC those related to angiogenesis, and also in diagnostic applications.  
CC AAP cDNA is also useful in gene therapy. The invention also relates to  
CC a method for screening a tissue sample for tumourigenic potential. AAP  
CC proteins are used to screen drugs or compounds that modulate AAP activity  
CC or expression as well as treating disorders characterised by insufficient  
CC or excessive production of AAP or production of AAP forms that have  
CC decreased or aberrant activity compared to the wild type protein, or

CC modulate biological function that involve AAP. The present cDNA sequence  
CC encodes human thyroid regulated transcript (hTRG) protein which is an  
CC angiogenesis associated protein (AAP) of the invention. Human TRG is  
CC upregulated in the in vitro model of angiogenesis and is likely to be  
CC involved in signal transduction between receptors and kinases. Modulation  
CC of hTRG is useful to treat diseases related to thyroid stimulating  
CC hormone (TSH) imbalance.

XX Sequence 7506 BP; 2147 A; 1689 C; 1764 G; 1906 T; 0 other;

Query Match 99.7%; Score 498.4; DB 22; Length 7506;  
Best Local Similarity 99.8%; Pred. No. 1.4e-156;  
Matches 499; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 AGTTTACACCATCACCAAAACCAGATTATTGATGAGATTAAATAGAGTTGCCAC 60  
DB 2142 AGTTTACACCATCACCAAAACCAGATTATTGATGAGATTAAATAGAGTTGCCAC 2201  
QY 61 TCAGCTGATGAAAAAGCACCACTGTTGCTCAGATTCTTCATGTCAGCTGACAACTC 120  
DB 2202 TCAGCTGATGAAAAAGCACCACTGTTGCTCAGATTCTTCATGTCAGCTGACAACTC 2261  
QY 121 AAGTAAAGAACACGAAAGAGGATGCTGTAACCCAGTTGGCTACTCTGGCT 180  
DB 2262 AAGTAAAGAACACGAAAGAGGATGCTGTAACCCAGTTGGCTACTCTGGCT 2321  
QY 181 TCCCTCTCTGAAGACGGAAGGTTGTGACAAAGCAGCAGACATCCCGTCTCGCGAA 240  
DB 2322 TCCCTCTCTGAAGACGGAAGGTTGTGACAAAGCAGCAGACATCCCGTCTCGCGAA 2381  
QY 241 CCTTCCTCGGGCTATCTTGCTACCAAGAGCTTGGATGGGACGCAATTATGTCGCGA 300  
DB 2382 CCTTCCTCGGGCTATCTTGCTACCAAGAGCTTGGATGGGACGCAATTATGTCGCGA 2441  
QY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCACATCATCTGTTCTAC 360  
DB 2442 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCACATCATCTGTTCTAC 2501  
QY 361 AGTGATACTCAGGATCAGCATTTACATAATTTTCCAGTACTGTCAGAAAACCGAATC 420  
DB 2502 AGTGATACTCAGGATCAGCATTTACATAATTTTCCAGTACTGTCAGAAAACCGAATC 2561  
QY 421 TGGAGCCCAAGCCTTAGGAAACGAACCTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
DB 2562 TGGAGCCCAAGCCTTAGGAAACGAACCTGTAAGTACCTTAAGAGTCTGCATGCGATGA 2621  
QY 481 AGGCCACGTGATGATCGCCT 500  
DB 2622 AGGCCACGTGATGATCGCCT 2641

RESULT 10  
ABK85003  
ID ABK85003 standard; DNA; 6791 BP.  
XX  
AC ABK85003;

XX 13-AUG-2002 (first entry)

DE DNA encoding cadherin-like asymmetry protein (CLASP) from exon 2.

XX Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ds.

OS Homo sapiens.  
XX  
PN WO200231117-A2.

XX 18-APR-2002.  
PD  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX

PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX

PI Lu PS;

DR WPI: 2002-416861/44.  
DR P-PSDB; ABG61702.  
XX

PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis

PS Example 1; Figure 11; 245bp; English.

CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences  
CC and PCR primers of the invention.

SO Sequence 6791 BP; 1968 A; 1545 C; 1574 G; 1704 T; 0 other;

Query Match 99.4%; Score 496.8; DB 24; Length 6791;  
Best Local Similarity 99.6%; Pred. No. 4.4e-156;  
Matches 498; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGTTTACACCATCACCAAAACCAGAAATTGATGAGATTAAATAGAGTTGCCAC 60  
DB 1985 AGTTTACACCATCACCAAAACCAGAAATTGATGAGATTAAATAGAGTTGCCAC 2044



QY 61 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTTCCATGTGTCAGCTGTGACAACTC 120  
|||||  
Db 2045 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTTCCATGTGTCAGCTGTGACAACTC 2104  
QY 121 AAGTAAAGGAAGCAGCAGAGAAGAGGATGTCGTTGAAACCCCAAGTTGGCTACTCCTGGCT 180  
|||||  
Db 2105 AAGTAAAGGAAGCAGCAGAGAAGAGGATGTCGTTGAAACCCCAAGTTGGCTACTCCTGGCT 2164  
QY 181 TCCCTCTCTGAAAGACGGAAGGGGTGTGACAAAGCAGACACATCCCGGTCTCGGCGAA 240  
|||||  
Db 2165 TCCCTCTCTGAAAGACGGAAGGGGTGTGACAAAGCAGACACATCCCGGTCTCGGCGTA 2224  
QY 241 CCTTCCTTCGGGCTATCTTGCTTACCAAGAGCTTGGGATGGGACGCAATTATGCTCCGGA 300  
|||||  
Db 2225 CCTTCCTTCGGGCTATCTTGCTTACCAAGAGCTTGGGATGGGACGCAATTATGCTCCGGA 2284  
QY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTTCTAC 360  
|||||  
Db 2285 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTTCTAC 2344  
QY 361 AGTGTACTCAGATCAGCATTTACATAATTTTCCAGTACTGTCAAGAAACCGAATC 420  
|||||  
Db 2345 AGTGTACTCAGATCAGCATTTACATAATTTTCCAGTACTGTCAAGAAACCGAATC 2404  
QY 421 TGGAGCCCCAAGCCTTAGGAAGCAACTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
|||||  
Db 2405 TGGAGCCCCAAGCCTTAGGAAGCAACTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 2464  
QY 481 AGGCCACGTGATGATCGCCT 500  
|||||  
Db 2465 AGGCCACGTGATGATCGCCT 2484

RESULT 11  
AAC87974  
ID AAC87974 standard; cDNA; 4898 BP.  
XX AAC87974;  
XX 07-MAR-2001 (first entry)  
DT Preliminary CLASP-2 nucleotide sequence #1.  
XX

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
Kw cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
Kw immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
Kw hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
Kw hypersensitivity; transplantation rejection response; immunodeficiency;  
Kw proliferation; differentiation; inflammatory response; arthritis;  
Kw inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
Kw anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
Kw endometriosis; pregnancy induced hypertension; ss.

OS Homo sapiens.  
XX  
PN WO200061747-A2.  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.

XX  
P1 Lu PS;  
XX  
DR WPI; 2000-619230/59.  
DR P-PSDB; AAB36529.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses  
PS  
XX  
XX Disclosure; Fig 10A; 286pp; English.

CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 97.3%; Score 486.4; DB 21; Length 4898;  
Best Local Similarity 99.6%; Pred. No. 1.2e-152;  
Matches 498; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTTGCCAC 60  
|||||  
Db 93 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAATAGAGTTGCCAC 152  
QY 61 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTTCCATGTGAGCTGTGACAACTC 120  
|||||  
Db 153 TCAGCTGCATGAAAAAGCACCACTGTGTGCTCACATCTTCCATGTGAGCTGTGACAACTC 212  
QY 121 AAGTAAAGGAAGCAGCAGAGAAGAGGATGTCGTTGAAACCCCAAGTTGGCTACTCCTGGCT 180  
|||||  
Db 213 AAGTAAAGGAAGCAGCAGAGAAGAGGATGTCGTTGAAACCCCAAGTTGGCTACTCCTGGCT 272  
QY 181 TCCCTCTCTGAAAGACGGAAGGGGTGTGACAAGCCAGACACATCCCGGTCTCGGCGAA 240  
|||||  
Db 273 TCCCTCTCTGAAAGACGGAAGGGGTGTGACAAGCCAGACACATCCCGGTCTCGGCGAA 332  
QY 241 CCTTCCTTCGGGCTATCTTGCTTACCAAGAGCTTGGGATGGGACGCAATTATGCTCCGGA 300  
|||||  
Db 333 CCTTCCTTCGGGCTATCTTGCTTACCAAGAGCTTGGGATGGGACGCAATTATGCTCCGGA 392  
QY 301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTTCTAC 360  
|||||  
Db 393 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTTCTAC 452  
QY 361 AGTGTACTCAGATCAGCATTTACATAATTTTCCAGTACTGTCAAGAAACCGAATC 420  
|||||  
Db 453 AG-GGATACTCAGATCAGCATTTACATAATTTTCCAGTACTGTCAAGAAACCGAATC 511  
QY 421 TGGAGCCCCAAGCCTTAGGAAGCAACTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
|||||  
Db 512 TGGAGCCCCAAGCCTTAGGAAGCAACTGTGTAAGTACCTTAAGAGTCTGCATGCGATGA 571  
QY 481 AGGCCACGTGATGATCGCCT 500



Db 572 AGGCCACGTGATGATCGCCT 591

|||||  
RESULT 12  
AAC87975  
ID AAC87975 standard; cDNA; 4898 BP.  
XX  
AC AAC87975;  
XX  
DT 07-MAR-2001 (first entry)  
DE Preliminary CLASP-2 nucleotide sequence #2.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
XX  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX  
DR WPI; 2000-619230/59.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10B; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.

CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 97.3%; Score 486.4; DB 21; Length 4898;  
Best Local Similarity 99.6%; Pred. No. 1.2e-152;  
Matches 498; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGACATTAAATAGAGTTGCCAC 60  
DB 93 AGTTTACACCATCACCAAAACCCAGAATTTTATGATGACATTAAATAGAGTTGCCAC 152  
QY 61 TCAGCTGCATGAAGAACACACCCTGTGCTCACATTCTTCCATGTCAGCTGTGACAACTC 120  
DB 153 TCAGCTGCATGAAGAACACACCCTGTGCTCACATTCTTCCATGTCAGCTGTGACAACTC 212  
QY 121 AAGTAAAGGAAGCAGCAGGAAGGATGTCGTTGAAACCCAAAGTTGGCTACTCTGGCT 180  
DB 213 AAGTAAAGGAAGCAGCAGGAAGGATGTCGTTGAAACCCAAAGTTGGCTACTCTGGCT 272  
QY 181 TCCCTCTCTGAAGAGACGGAAGGTGTGACAAAGCAGCAGCACATCCCGTCTGCGGAA 240  
DB 273 TCCCTCTCTGAAGAGACGGAAGGTGTGACAAAGCAGCAGCACATCCCGTCTGCGGAA 332  
QY 241 CCTTCCTTCGGGCTATCTTGGCTACCAAGACTTGGGATGGGACGACATTAATGTTCCGGA 300  
DB 333 CCTTCCTTCGGGCTATCTTGGCTACCAAGACTTGGGATGGGACGACATTAATGTTCCGGA 392  
QY 301 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTCCACTCATCTGTTCTAC 360  
DB 393 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTCCACTCATCTGTTCTAC 452  
QY 361 AGTGTAACCTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTCAGAAACCGAATC 420  
DB 453 AG-GGATFACTCAGGATCAGCATTTTACATAATTTTCCAGTACTGTCAGAAACCGAATC 511  
QY 421 TGGAGCCCAAGCCTTAGGAACGAACCTGTTAAGTACCTTAAGAGTCTGCATGCGATGGA 480  
DB 512 TGGAGCCCAAGCCTTAGGAACGAACCTGTTAAGTACCTTAAGAGTCTGCATGCGATGGA 571  
QY 481 AGGCCACGTGATGATCGCCT 500  
DB 572 AGGCCACGTGATGATCGCCT 591

RESULT 13  
AAC87976  
ID AAC87976 standard; cDNA; 4898 BP.  
XX  
AC AAC87976;  
XX  
DT 07-MAR-2001 (first entry)  
DE Preliminary CLASP-2 nucleotide sequence #3.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.

XX 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI; 2000-619230/59.  
DR  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Inflammatory responses -  
XX  
PS Disclosure; Fig 10C; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 97.3%; Score 486.4; DB 21; Length 4898;  
Best Local Similarity 99.6%; Pred. No. 1.2e-152;  
Matches 498; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60  
Db 93 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 152  
QY 61 TCAGCTGCATGAAAAGCACCACTGTTGCTCACAATTCTTCATGTCAGCTGTGACAACTC 120  
Db 153 TCAGCTGCATGAAAAGCACCACTGTTGCTCACAATTCTTCATGTCAGCTGTGACAACTC 212  
QY 121 AAGTAAAGGAAGCAGAGAAGAGGATGCTTGAACCCTAAGTGGCTACTCCTGGCT 180  
Db 213 AAGTAAAGGAAGCAGAGAAGAGGATGCTTGAACCCTAAGTGGCTACTCCTGGCT 272  
QY 181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAGCGAGACACATCCGGGTCTCGGCGAA 240  
Db 273 TCCCTCTCTGAAAGACGGAAGGGTGTGACAGCGAGACACATCCGGGTCTCGGCGAA 332  
QY 241 CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGACAGCAATTATGTCGGA 300  
Db 333 CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGACAGCAATTATGTCGGA 392  
QY 301 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGGTTTCTAC 360  
|||||

Db 393 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGGTTCTAC 452  
QY 361 AGTGTAFACTCAGATTCAGCATTTTACATAATTTTTCCAGTACTGTGAAAACCGAATC 420  
Db 453 AG-GGATACTCAGATTCAGCATTTTACATAATTTTTCCAGTACTGTGAAAACCGAATC 511  
QY 421 TGGAGCCCCAAGCCTTAGCAAAACGAACCTTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
Db 512 TGGAGCCCCAAGCCTTAGCAAAACGAACCTTGTAAGTACCTTAAGAGTCTGCATGCGATGA 571  
QY 481 AGGCCACGTGATGATCGCCT 500  
Db 572 AGGCCACGTGATGATCGCCT 591  
RESULT 14  
AAC87977  
ID AAC87977 standard; cDNA; 4898 BP.  
XX  
AC AAC87977;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #4.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI; 2000-619230/59.  
DR  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10D; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,

CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC anaemia, thrombocytopenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 97.3%; Score 486.4; DB 21; Length 4898;  
Best Local Similarity 99.6%; Pred. No. 1.2e-152;  
Matches 498; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 AGTTTACACCATCACCAAAACCCAGAATTTATGATGAGATTAAATAGAGTTGCCAC 60  
Db 93 AGTTTACACCATCACCAAAACCCAGAATTTATGATGAGATTAAATAGAGTTGCCAC 152  
QY 61 TCAGCTGCATGAAAAGCACCACTGTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120  
Db 153 TCAGCTGCATGAAAAGCACCACTGTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 212  
QY 121 AAGTAAAGGAAGCAGCAGAGAGGCGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT 180  
Db 213 AAGTAAAGGAAGCAGCAGAGAGGCGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT 272  
QY 181 TCCCTCTCTGAAAAGACGAGGGGTGTGACAAGCGACGACATCCCGTCTCGGCGAA 240  
Db 273 TCCCTCTCTGAAAAGACGAGGGGTGTGACAAGCGACGACATCCCGTCTCGGCGAA 332  
QY 241 CCTTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGGCAGGCATTTATGTCGCGA 300  
Db 333 CCTTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGGCAGGCATTTATGTCGCGA 392  
QY 301 AATTAAATGGTAGATGAGGCGAACGCCACTGCTGAAAAATTTCCACTCATCTGTTCTAC 360  
Db 393 AATTAAATGGTAGATGAGGCGAACGCCACTGCTGAAAAATTTCCACTCATCTGTTCTAC 452  
QY 361 AGTGATACTCAGGATGACGATTTACATAATTTTTCCAGTACTGTCAAGAAACCGAATC 420  
Db 453 AG-GGATACTCAGGATGACGATTTACATAATTTTTCCAGTACTGTCAAGAAACCGAATC 511  
QY 421 TCGAGCCCAAGCCTTAGGAAACGAACCTTGTAAGTACCTTAAGAGTCTGCATGCGATGA 480  
Db 512 TCGAGCCCAAGCCTTAGGAAACGAACCTTGTAAGTACCTTAAGAGTCTGCATGCGATGA 571  
QY 481 AGGCCACGTGATGTCGCT 500  
Db 572 AGGCCACGTGATGTCGCT 591

RESULT 15  
AAC87978  
ID AAC87978 standard; cDNA; 4898 BP.  
XX  
AC AAC87978;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #5.  
XX

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antineumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;

KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

OS Homo sapiens.

PN WO200061747-A2.

PD 19-OCT-2000.

PF 13-APR-2000; 2000WO-US10158.

PR 14-APR-1999; 99US-0129171.

PR 14-MAY-1999; 99US-0134114.

PR 14-MAY-1999; 99US-0134117.

PR 14-MAY-1999; 99US-0134118.

PR 21-OCT-1999; 99US-0160860.

PR 29-OCT-1999; 99US-0162498.

PR 13-DEC-1999; 99US-0170453.

PR 14-JAN-2000; 2000US-0176195.

PR 14-FEB-2000; 2000US-0182296.

PA (ARBO-) ARBOR VITA CORP.

PI Lu PS;

DR WPI; 2000-619230/59.

XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -

PS Disclosure; Fig 10E; 286pp; English.

XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 97.3%; Score 486.4; DB 21; Length 4898;  
Best Local Similarity 99.6%; Pred. No. 1.2e-152;  
Matches 498; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 AGTTTACACCATCACCAAAACCCAGAATTTATGATGAGATTAAATAGAGTTGCCAC 60

Db 93 AGTTTACACCATCACCAAAACCCAGAATTTATGATGAGATTAAATAGAGTTGCCAC 152

QY 61 TCAGCTGCATGAAAAGCACCACTGTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 120

Db 153 TCAGCTGCATGAAAAGCACCACTGTGCTCACATCTTCCATGTGCAGCTGTGACAACTC 212

QY 121 AAGTAAAGGAAGCAGCAGAGAGGCGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT 180

Db 213 AAGTAAAGGAAGCAGCAGAGAGGCGATGTCGTTGAACCCAAAGTTGGCTACTCCTGGCT 272

QY181TCCCCCTCCGTAAGAGCGAAGGGTGGTGACAAGCGAGCAGCACATCCCGGTCTCGCGGAA240

|||||

Db273TCCCCCTCCGTAAGAGCGAAGGGTGGTGACAAGCGAGCAGCACATCCCGGTCTCGCGGAA332

QY241CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCAAGGCATTTATGGTCCGGA300

|||||

Db333CCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCAAGGCATTTATGGTCCGGA392

QY301AATTAAATGGGTAGATGGAGGCCAAGCCACTGCTGAAAATTTCACATCTGGTTCTTAC360

|||||

Db393AATTAAATGGGTAGATGGAGGCCAAGCCACTGCTGAAAATTTCACATCTGGTTCTTAC452

QY361AGTGTATCTCAGGATCAGCATTTACATTAATTTTTCAGTACTGTCAGAAAAACCGAATC420

|||

Db453AG-GGATACTCAGGATCAGCATTTACATTAATTTTTCAGTACTGTCAGAAAAACCGAATC511

QY421TGGAGCCCAAGCCTTAGGAAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGA480

|||||

Db512TGGAGCCCAAGCCTTAGGAAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGA571

QY481AGGCCACGTGATGATCGCCT500

|||||

Db572AGGCCACGTGATGATCGCCT591

Search completed: February 7, 2003, 07:07:37  
-Job time : 137.83 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:00:34 ; Search time 28.6285 Seconds  
(without alignments)  
5356.145 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_1\_500

Perfect score: 500

Sequence: 1 agtttacaccatcaccacaa.....aggccacgtgatgcgcct 500

Scoring table:

IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_NA:\*  
1: /cgn2\_6/ptodata/1/ina/5A\_COMB.seq:\*  
2: /cgn2\_6/ptodata/1/ina/5B\_COMB.seq:\*  
3: /cgn2\_6/ptodata/1/ina/6A\_COMB.seq:\*  
4: /cgn2\_6/ptodata/1/ina/6B\_COMB.seq:\*  
5: /cgn2\_6/ptodata/1/ina/PCTUS\_COMB.seq:\*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	30.4	6.1	1005	4	US-08-936-165A-228
C 2	30.4	6.1	1920	4	US-09-160-496-4
C 3	30.2	6.0	1972	3	US-08-961-083-203
C 4	30.2	6.0	14231	4	US-08-961-527-81
C 5	30	6.0	2520	1	US-08-405-254-9
C 6	29.4	5.9	442	4	US-09-071-035-443
C 7	29.4	5.9	606	4	US-09-071-035-441
C 8	29.4	5.9	1006	3	US-08-924-747-15
C 9	29.4	5.9	1006	4	US-09-247-373B-15
C 10	29.4	5.9	1006	4	US-09-296-715-15
C 11	29.2	5.8	726	3	US-08-660-645A-11
C 12	29.2	5.8	726	3	US-09-298-718-11
C 13	29.2	5.8	726	4	US-09-546-969-11
C 14	29.2	5.8	726	4	US-08-980-832-28
C 15	29.2	5.8	4403765	4	US-09-103-840A-2
C 16	29.2	5.8	4411529	4	US-09-103-840A-1
C 17	29	5.8	856	1	US-08-117-373-10
C 18	29	5.8	1542	4	US-09-008-271A-13
C 19	29	5.8	4084	2	US-08-568-459A-1
C 20	29	5.8	4084	2	US-08-487-826B-1
C 21	29	5.8	4084	4	US-09-210-288-1
C 22	29	5.8	4084	6	5198347-5
C 23	29	5.8	4156	4	US-08-961-527-211
C 24	28.8	5.8	1747	1	US-07-808-455A-2
C 25	28.6	5.7	1643	1	US-08-383-750-3
C 26	28.6	5.7	1643	3	US-08-352-678-3
C 27	28.6	5.7	1643	5	PCT-US93-09636-3

28	28.4	5.7	1072	1	US-07-971-096-1	Sequence 1, Appli
29	28.4	5.7	1072	1	US-08-175-096-1	Sequence 1, Appli
30	28.2	5.6	608	4	US-09-385-982-236	Sequence 236, App
C 31	28.2	5.6	18609	4	US-08-943-731-1	Sequence 1, Appli
C 32	28	5.6	488	4	US-09-385-982-368	Sequence 368, App
C 33	28	5.6	111282	4	US-09-754-250-3	Sequence 3, Appli
C 34	27.8	5.6	2970	4	US-09-110-517-3	Sequence 3, Appli
C 35	27.8	5.6	3826	4	US-09-302-620B-90	Sequence 90, Appli
C 36	27.8	5.6	9412	2	US-08-955-138-1	Sequence 1, Appli
C 37	27.6	5.5	1463	4	US-09-399-913-1	Sequence 1, Appli
C 38	27.6	5.5	1463	4	US-09-298-731-1	Sequence 1, Appli
C 39	27.6	5.5	1540	4	US-09-399-913-9	Sequence 9, Appli
C 40	27.6	5.5	1540	4	US-09-298-731-9	Sequence 5, Appli
C 41	27.6	5.5	1907	4	US-09-399-913-5	Sequence 5, Appli
C 42	27.6	5.5	1907	4	US-09-298-731-5	Sequence 5, Appli
C 43	27.6	5.5	2624	1	US-08-032-382B-1	Sequence 87, Appli
C 44	27.4	5.5	518	4	US-09-123-912-87	Sequence 87, Appli
C 45	27.4	5.5	518	4	US-09-643-597-87	Sequence 87, Appli

ALIGNMENTS

RESULT 1  
US-08-936-165A-228/C  
; Sequence 228, Application US/08936165A  
; Patent No. 6348582  
; GENERAL INFORMATION:  
; APPLICANT: Black, Michael  
; APPLICANT: Burnham, Martin  
; APPLICANT: Hodgson, John  
; APPLICANT: Knowles, David  
; APPLICANT: Lonetto, Michael  
; APPLICANT: Nicholas, Richard  
; APPLICANT: Pratt, Julie  
; APPLICANT: Reichard, Richard  
; APPLICANT: Rosenberg, Martin  
; APPLICANT: Ward, Judith  
; TITLE OF INVENTION: No. 6348582e1 Prokaryotic Polynucleotides,  
; TITLE OF INVENTION: Polypeptides and Their Uses  
; NUMBER OF SEQUENCES: 534  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: SmithKline Beecham Corporation  
; STREET: 709 Swedeland Road  
; CITY: King of Prussia  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19406-0939  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/936,165A  
; FILING DATE: 24-SEP-1997  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/027,032  
; FILING DATE: 24-SEP-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Gimm, Edward R  
; REGISTRATION NUMBER: 38,891  
; REFERENCE/DOCKET NUMBER: P50549  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 610-270-4478  
; TELEFAX: 610-270-5090  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 228:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1005 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single

; TOPOLOGY: linear  
; MOLECULE TYPE: Genomic DNA  
US-08-936-165A-228

Query Match 6.1%; Score 30.4; DB 4; Length 1005;  
Best Local Similarity 62.5%; Pred. No. 2.2;  
Matches 65; Conservative 0; Mismatches 36; Indels 3; Gaps 1;

OY 2 GTTTTACACCATCACCAAAACCCAGATTTTATGA---TGAGATTAATAATAGAGTTGCC 58  
||| | |||| | | |||| | |||| | ||| | ||| | ||| |  
Db 439 GTGTCCACCACGACCAATATACCTATATTTCATGAGGGTCAGTATTGATGTAGGTACAC 380

OY 59 ACTCAGCTGCATGAAAGCACACCCTGTGCTCACAATTCTTCCA 102  
|||| ||||| | | |||| | || | | | | | |  
Db 379 ACTCCGCTGCATCTAAGACACCCAATCTTCCACTTGTACCTGCA 336

RESULT 2

US-09-160-496-4/c  
; Sequence 4, Application US/09160496

; Patent No. 6346613

; GENERAL INFORMATION:

; APPLICANT: O'Mahony, Daniel J

; APPLICANT: Cagney, Gerard

; TITLE OF INVENTION: Composition and Method for Enhancing Paracellular

; TITLE OF INVENTION: Transport across Cell Layers

; FILE REFERENCE: Docket No. 6346613: 98.1070.US

; CURRENT APPLICATION NUMBER: US/09/160,496

; EARLIER APPLICATION NUMBER: US 60/059,644

; EARLIER FILING DATE: 1997-09-24

; NUMBER OF SEQ ID NOS: 6

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 4

; LENGTH: 1920

; TYPE: DNA

; ORGANISM: Gallus gallus

; PUBLICATION INFORMATION:

; TITLE: Occludin: A novel integral membrane protein localizing

; TITLE: at tight junctions

; JOURNAL: J. Cell Biol.

; VOLUME: 123

; ISSUE: 6

; PAGES: 1777-1788

; DATE: Dec 1993

; DATABASE ACCESSION NUMBER: D21837

US-09-160-496-4

Query Match 6.1%; Score 30.4; DB 4; Length 1920;  
Best Local Similarity 53.3%; Pred. No. 3.1;  
Matches 64; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

OY 182 CCCCTCTGAAGAGCGAAGGGTGTGACACAGCAGCACATCCCGTCTCGCGGAAC 241  
||||| | | | | | | | | | | | | | | | | | | | | |

Db 842 CCCCTCTGCACACGCGCGCGGTCCAGTAGATGTTGGCTTGGCCGTAGCCGAGAT 783

OY 242 CTCCTTCGGGCTATCTTGCTACCAAGAGCTTGGGATGGCAGGCAATTATGTCGGAA 301  
||| | | | | | | | | | | | | | | | | | | | | |

Db 782 CTTACTGCGGCTCTTCTGGGCGAAGAAGACAGATGAGCAGACAGATCAGATGAGGAA 723

RESULT 3

US-08-961-083-203

; Sequence 203, Application US/08961083

; Patent No. 6159469

; GENERAL INFORMATION:

; APPLICANT: Choi et. al.

; TITLE OF INVENTION: Streptococcus pneumoniae Antigens and Vaccines

; NUMBER OF SEQUENCES: 452

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Human Genome Sciences, Inc.

; STREET: 9410 Key West Avenue

; CITY: Rockville

; STATE: Maryland  
; COUNTRY: USA  
; ZIP: 20850

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.50 inch, 1.4mb storage

; COMPUTER: HP Vectra 486/33

; OPERATING SYSTEM: MSDOS version 6.2

; SOFTWARE: ASCII text

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/961,083

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Brookes, A. Anders

; REGISTRATION NUMBER: 36,373

; REFERENCE/DOCKET NUMBER: PB340P2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (301) 309-8504

; TELEFAX: (301) 309-8512

; INFORMATION FOR SEQ ID NO: 203:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 1972 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

US-08-961-083-203

Query Match 6.0%; Score 30.2; DB 3; Length 1972;  
Best Local Similarity 53.9%; Pred. No. 3.7;  
Matches 62; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

OY 238 GAACCTTCCTTCGGCTATCTTGCTACCAAGAGCTTGGATGGCAGGCAATTATGCTCC 297  
||| | | | | | | | | | | | | | | | | | | | | |

Db 44 GAATGCCCATTTGTTGCTTCTCCGTTGTATGGCAATGATATGTAACGGATTATGCTGG 103

OY 298 GGAATTAAATGGTAGATGAGGCAAGCCACTGCTGAATAATTCCACTCATCTG 352  
|| | | | | | | | | | | | | | | | | | | | | |

Db 104 GGAACACATTTAAGGAGCATGGGAAGCTATTCTGTAAGATGTAAGCCATATG 158

RESULT 4

US-08-961-527-81

; Sequence 81, Application US/08961527

; Patent No. 6420135

; GENERAL INFORMATION:

; APPLICANT: Charles Kunsch

; TITLE OF INVENTION: Streptococcus pneumoniae Polynucleotides and Sequences

; NUMBER OF SEQUENCES: 391

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Human Genome Sciences, Inc.

; STREET: 9410 Key West Avenue

; CITY: Rockville

; STATE: Maryland

; COUNTRY: USA

; ZIP: 20850

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.50 inch, 1.4mb storage

; COMPUTER: HP Vectra 486/33

; OPERATING SYSTEM: MSDOS version 6.2

; SOFTWARE: ASCII text

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/961,527

; FILING DATE:

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Brookes, A. Anders

; REGISTRATION NUMBER: 36,373



Db 360 CGCAGACACGAGTGTACTTTGGCTAAGGTGAAGACAATAAAATT 406

RESULT 7

US-09-071-035-441  
; Sequence 441, Application US/09071035  
; Patent No. 6448043  
; GENERAL INFORMATION:  
; APPLICANT: Gil H. Choi  
; TITLE OF INVENTION: Enterococcus faecalis Polynucleotides and Polypeptides  
; NUMBER OF SEQUENCES: 496  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Human Genome Sciences, Inc.  
; STREET: 9410 Key West Avenue  
; CITY: Rockville  
; STATE: Maryland  
; COUNTRY: USA  
; ZIP: 20850  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage  
; COMPUTER: HP Vectra 486/33  
; OPERATING SYSTEM: MSDOS version 6.2  
; SOFTWARE: ASCII Text  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/071,035  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: A. Anders Brookes  
; REGISTRATION NUMBER: 36,373  
; REFERENCE/DOCKET NUMBER: PB369P2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (301) 309-8504  
; TELEFAX: (301) 309-8512  
; INFORMATION FOR SEQ ID NO: 441:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 606 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
US-09-071-035-441

Query Match 5.9%; Score 29.4; DB 4; Length 606;  
Best Local Similarity 48.5%; Pred. No. 3.6;  
Matches 81; Conservative 0; Mismatches 86; Indels 0; Gaps 0;

QY 300 AAATTAAATGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGGTTCTA 359  
||| || | | ||| | | | | ||| ||| ||| |||  
Db 401 AAAAAAATGGAATTGATGTTAAAACTGAGTAGCGTTAGTTCCGTAGAAAGGTTACAA 460  
QY 360 CAGTGTATCTCAGATCAGCATTTACATAATTTTCCAGTACTGTCAAAAACCGAAT 419  
| | ||| | | ||| ||| | | ||| | | ||| | |  
Db 461 CGATTTATAAAAATGATCACAATGATATGCTTTACTTTTGATTTGTGAACAATAAGAA 520  
QY 420 CTGAGCCCCAAGCCTTAGCAACGAAGTGTAAAGTACCTTAAGAGT 466  
| | | | | | | | | | | | | | | | | | | |  
Db 521 CGCAGACACGAGTGTACTTTTGGCTAAGGTGAAGACAATAAAATT 567

RESULT 8

US-08-924-747-15/c  
; Sequence 15, Application US/08924747  
; Patent No. 6063570  
; GENERAL INFORMATION:  
; APPLICANT: MCGONIGLE, BRIAN  
; APPLICANT: O'KEEFE, DANIEL  
; TITLE OF INVENTION: SOYBEAN GLUTATHIONE-S-TRANSFERASE  
; ENZYMES  
; NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:  
; ADDRESSEE: E.I. DU PONT DE NEMOURS AND COMPANY  
; STREET: 1007 MARKET STREET  
; CITY: WILMINGTON  
; STATE: DELAWARE  
; COUNTRY: UNITED STATES OF AMERICA  
; ZIP: 19898

COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.50 INCH  
; COMPUTER: IBM PC COMPATIBLE  
; OPERATING SYSTEM: MICROSOFT WORD FOR WINDOWS 95  
; SOFTWARE: MICROSOFT WORD VERSION 7.0A  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/924,747  
; FILING DATE:  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: FLOYD, LINDA AXAMETHY  
; REGISTRATION NUMBER: 33,692  
; REFERENCE/DOCKET NUMBER: CL-1108  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 302-773-0164  
; TELEFAX: 302-773-0164  
; INFORMATION FOR SEQ ID NO: 15:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1006 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; TISSUE TYPE: SOYBEAN  
; IMMEDIATE SOURCE:  
; CLONE: SRI.PK0011.D6  
US-08-924-747-15

Query Match 5.9%; Score 29.4; DB 3; Length 1006;  
Best Local Similarity 60.8%; Pred. No. 4.8;  
Matches 48; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 63 AGCTGCATGAANAAGCACCACCTGTGCTCACAATCTTCCATGTCAGCTGTGACACTCAA 122  
||| | | | | | | | | | | | | | | | | |  
Db 412 AGCTCAATGCTCTCCTCAACATCTTCTCAGCGCTCTTCTCATCAGCTGTGAACGGAT 353

QY 123 GTAAAGGAAGCAGCAGAA 141  
| | | | | | | | | | | | | | | | | |  
Db 352 TTCCATGCAGCACCAAAAA 334

RESULT 9

US-09-247-373B-15/c  
; Sequence 15, Application US/09247373B  
; Patent No. 6168954  
; GENERAL INFORMATION:  
; APPLICANT: MCGONIGLE, BRIAN  
; APPLICANT: O'KEEFE, DANIEL  
; TITLE OF INVENTION: SOYBEAN GLUTATHIONE-S-TRANSFERASE ENZYMES  
; FILE REFERENCE: CL-1108-A  
; CURRENT APPLICATION NUMBER: US/09/247,373B  
; CURRENT FILING DATE: 1999-02-10  
; PRIOR APPLICATION NUMBER: 08/924,747  
; PRIOR FILING DATE: 1997-09-05  
; NUMBER OF SEQ ID NOS: 56  
; SOFTWARE: Microsoft Office 97  
; SEQ ID NO 15  
; LENGTH: 1006  
; TYPE: DNA  
; ORGANISM: SOYBEAN  
US-09-247-373B-15

Query Match 5.9%; Score 29.4; DB 4; Length 1006;





```

; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: NJ
; COUNTRY: USA
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/298,718
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/660,645
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Pokras, Bruce A.
; REGISTRATION NUMBER: 32,748
; REFERENCE/DOCKET NUMBER: RAN 6002/170
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 235-5801
; TELEFAX: (201) 235-2363
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 726 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-298-718-11
Query Match          5.8%; Score 29.2; DB 3; Length 726;
Best Local Similarity 48.2%; Pred. No. 4.6;
Matches 82; Conservative 0; Mismatches 88; Indels 0; Gaps 0;
```

```

QY 276 GGATGGCGAGCATTAATGTCGGAATTAATGGGTAGATGAGGCCAAGCCACTGCTGA 335
    ||| || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 557 GGACGGTGGCGCAGCCAGTACCGAAACGAGATCTGGATGGAAGCCAGACGCCGA 498

QY 336 AAATTCCACTCATCTGTTCTACAGTGTACTCAGATCAGCATTTACATAATTTT 395
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 497 ACCGGCCAGAAGATACGTACATCCAACGGTCAACCCAGGATCAGAGCGGTAGGTAA 438

QY 396 TCCAGTACTGTCAGAAACCGAATCTGGAGCCCAAGCCTTAGGAACGAA 445
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 437 ATAACGGCAGCAGACGACCTTCACGCCCAACCGAAGTAGGTGGAACGAA 388
```

```

RESULT 13
US-09-546-969-11/c
; Sequence 11, Application US/09546969
; Patent No. 6207409
; GENERAL INFORMATION:
; APPLICANT: Hohmann, Hans-Peter
; APPLICANT: Pasamontes, Luis
; APPLICANT: Tessier, Michel
; APPLICANT: van Loon, Adolphus
; TITLE OF INVENTION: FERMENTATIVE CAROTENOID PRODUCTION
; NUMBER OF SEQUENCES: 47
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: NJ
; COUNTRY: USA
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
```

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentln Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/546,969
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/660,645
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Pokras, Bruce A.
; REGISTRATION NUMBER: 32,748
; REFERENCE/DOCKET NUMBER: RAN 6002/170
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 235-5801
; TELEFAX: (201) 235-2363
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 726 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-546-969-11
Query Match          5.8%; Score 29.2; DB 4; Length 726;
Best Local Similarity 48.2%; Pred. No. 4.6;
Matches 82; Conservative 0; Mismatches 88; Indels 0; Gaps 0;
```

```

QY 276 GGATGGCGAGCATTAATGTCGGAATTAATGGGTAGATGAGGCCAAGCCACTGCTGA 335
    ||| || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 557 GGACGGTGGCGCAGCCAGTACCGAAACGAGATCTGGATGGAAGCCAGACGCCGA 498

QY 336 AAATTCCACTCATCTGTTCTACAGTGTACTCAGATCAGCATTTACATAATTTT 395
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 497 ACCGGCCAGAAGATACGTACATCCAACGGTCAACCCAGGATCAGAGCGGTAGGTAA 438

QY 396 TCCAGTACTGTCAGAAACCGAATCTGGAGCCCAAGCCTTAGGAACGAA 445
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 437 ATAACGGCAGCAGACGACCTTCACGCCCAACCGAAGTAGGTGGAACGAA 388
```

```

RESULT 14
US-08-980-832-28/c
; Sequence 28, Application US/08980832B
; Patent No. 6291204
; GENERAL INFORMATION:
; APPLICANT: Pasamontes, Luis
; APPLICANT: Tsygankov, Yuri
; TITLE OF INVENTION: Improved Fermentative Carotenoid Production
; FILE REFERENCE: Improved Fermentative Carotenoid
; CURRENT APPLICATION NUMBER: US/08/980,832B
; CURRENT FILING DATE: 1997-12-01
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 28
; LENGTH: 726
; TYPE: DNA
; ORGANISM: Alcaligenes PC-1
US-08-980-832-28
```

```

Query Match          5.8%; Score 29.2; DB 4; Length 726;
Best Local Similarity 48.2%; Pred. No. 4.6;
Matches 82; Conservative 0; Mismatches 88; Indels 0; Gaps 0;

QY 276 GGATGGCGAGCATTAATGTCGGAATTAATGGGTAGATGAGGCCAAGCCACTGCTGA 335
    ||| || ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 557 GGACGGTGGCGCAGCCAGTACCGAAACGAGATCTGGATGGAAGCCAGACGCCGA 498

QY 336 AAATTCCACTCATCTGTTCTACAGTGTATACAGATCAGCATTTACATAATTTT 395
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 497 ACCGGCCAGAAGATACGTACATCCAACGGTCAACCCAGGATCAGAGCGGTAGGTAA 438
```







GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:01:14 ; Search time 32.2903 Seconds  
(Without alignments)  
7339.716 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_1\_500  
Perfect score: 500  
Sequence: 1 agtttaccaccatcaccaaa.....agggccacgtgatgcgcct 500

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 408267 seqs, 237001491 residues

Total number of hits satisfying chosen parameters: 816534

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : published\_Applications\_NA:\*

1: /cgn2\_6/ptodata/2/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/2/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/2/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/2/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/2/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/2/pubpna/PCTUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/2/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/2/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/2/pubpna/US09\_NEW\_PUB.seq:\*  
10: /cgn2\_6/ptodata/2/pubpna/US09\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/2/pubpna/US10\_NEW\_PUB.seq:\*  
12: /cgn2\_6/ptodata/2/pubpna/US10\_PUBCOMB.seq:\*  
13: /cgn2\_6/ptodata/2/pubpna/US60\_NEW\_PUB.seq:\*  
14: /cgn2\_6/ptodata/2/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	204.4	40.9	6454	10 US-09-736-969A-1	Sequence 1, Appli
2	85	17.0	4391	10 US-09-736-969A-7	Sequence 7, Appli
3	71.4	14.3	7215	10 US-09-736-960-1	Sequence 1, Appli
4	46	9.2	6372	9 US-09-736-968A-1	Sequence 1, Appli
5	40.4	8.1	211	9 US-09-736-968A-77	Sequence 77, Appli
6	34.6	6.9	6691	10 US-09-070-927A-88	Sequence 88, Appli
7	32.4	6.5	1314	9 US-09-738-626-795	Sequence 795, App
8	32.4	6.5	3309400	9 US-09-738-626-1	Sequence 1, Appli
9	31.8	6.4	659158	9 US-09-771-208-20	Sequence 20, Appli
10	31.6	6.3	14141	10 US-09-070-927A-394	Sequence 394, App
11	31.4	6.3	4915	10 US-09-070-927A-125	Sequence 125, App
12	31.2	6.2	2000	9 US-09-938-842A-3143	Sequence 3143, Ap
13	30.8	6.2	417	10 US-09-960-352-12649	Sequence 12649, A
14	30.6	6.1	32191	10 US-09-764-864-1678	Sequence 1678, Ap
15	30.4	6.1	1005	10 US-09-939-980-228	Sequence 228, App
16	30.4	6.1	326014	10 US-09-731-231A-3	Sequence 3, Appli
17	30.2	6.0	477	10 US-09-764-877-623	Sequence 623, App
18	30.2	6.0	1972	10 US-09-765-272-203	Sequence 203, App
19	29.6	5.9	405	10 US-09-960-352-2213	Sequence 2213, Ap

C	20	29.4	5.9	251	9	US-09-796-692-9270	Sequence 9270, Ap
C	21	29.4	5.9	371	10	US-09-864-761-32600	Sequence 32600, A
C	22	29.4	5.9	528	9	US-09-796-692-3999	Sequence 3999, Ap
C	23	29.4	5.9	1686	9	US-10-114-893-37	Sequence 37, Appli
C	24	29.4	5.9	2707	10	US-09-917-800A-1420	Sequence 1420, Ap
C	25	29.4	5.9	7925	10	US-09-070-927A-311	Sequence 311, App
C	26	29.4	5.9	9450	9	US-10-126-912-2	Sequence 2, Appli
C	27	29.4	5.9	9757	9	US-10-126-912-7	Sequence 7, Appli
C	28	29.4	5.9	9828	9	US-10-126-912-1	Sequence 1, Appli
C	29	29.2	5.8	726	9	US-09-920-923-28	Sequence 28, Appli
C	30	29.2	5.8	726	10	US-09-547-267-11	Sequence 11, Appli
C	31	29.2	5.8	1685	10	US-09-827-998-19	Sequence 19, Appli
C	32	29.2	5.8	1944	10	US-09-864-761-2825	Sequence 2825, Ap
C	33	29.2	5.8	4158	10	US-09-827-998-15	Sequence 15, Appli
C	34	29.2	5.8	5313	10	US-09-827-998-9	Sequence 9, Appli
C	35	29.2	5.8	5376	10	US-09-827-998-2	Sequence 2, Appli
C	36	29.2	5.8	5461	10	US-09-827-998-8	Sequence 8, Appli
C	37	29.2	5.8	6719	10	US-09-827-998-1	Sequence 1, Appli
C	38	29	5.8	416	9	US-09-736-457-469	Sequence 469, App
C	39	29	5.8	416	9	US-09-902-941-469	Sequence 469, App
C	40	29	5.8	416	9	US-09-849-626-469	Sequence 469, App
C	41	29	5.8	494	10	US-09-920-300A-446	Sequence 446, App
C	42	29	5.8	494	12	US-10-033-528-446	Sequence 446, App
C	43	29	5.8	590	10	US-09-864-761-9899	Sequence 9899, Ap
C	44	29	5.8	954	10	US-09-947-971-3	Sequence 3, Appli
C	45	29	5.8	2586	10	US-09-804-551B-19	Sequence 19, Appli

ALIGNMENTS

RESULT 1  
US-09-736-969A-1  
; Sequence 1, Application US/09736969A  
; Patent No. US20020068302A1  
; GENERAL INFORMATION:  
; APPLICANT: Lu, Peter  
; APPLICANT: Garman, Jonathan David  
; APPLICANT: Candia III, Albert Frederick  
; APPLICANT: Arbor Vita Corporation  
; TITLE OF INVENTION: CLASP-4 Transmembrane Protein  
; FILE REFERENCE: 020054-000411US  
; CURRENT APPLICATION NUMBER: US/09/736, 969A  
; CURRENT FILING DATE: 2000-12-13  
; PRIOR APPLICATION NUMBER: US 60/160, 860  
; PRIOR FILING DATE: 1999-10-21  
; PRIOR APPLICATION NUMBER: US 60/162, 498  
; PRIOR FILING DATE: 1999-10-29  
; PRIOR APPLICATION NUMBER: US 60/170, 453  
; PRIOR FILING DATE: 1999-12-13  
; PRIOR APPLICATION NUMBER: US 60/176, 195  
; PRIOR FILING DATE: 2000-01-14  
; PRIOR APPLICATION NUMBER: US 60/182, 296  
; PRIOR FILING DATE: 2000-02-14  
; PRIOR APPLICATION NUMBER: US 09/547, 276  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 267  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 460  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 527  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 528  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 09/687, 837  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 503  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 508  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 539  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 543

```

; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 6454
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-4 cDNA
; NAME/KEY: CDS
; LOCATION: (95)..(6121)
; OTHER INFORMATION: human CLASP-4
US-09-736-969A-1
```

```

Query Match          40.9%; Score 204.4; DB 10; Length 6454;
Best Local Similarity 63.4%; Pred. No. 8.1e-57;
Matches 313; Conservative 0; Mismatches 181; Indels 0; Gaps 0;
```

```

QY      2 GTTTTACACCATCAACCAAAACCAGATTTTATGATGAGATTAAATAGAGTTGCCCACT 61
      || || || || || || || || || || || || || || || || || || || || ||
Db     2000 GTCTCGCATCAACCAAAATCCAGAGTTCTATGATGAGATTAAATTTGAGCTTCCCAAT 2059

QY      62 CAGCTGCATGAAAAGCACCCAGCTGTGGCTCAGATCTTCCATGTCAGCTGTGACAACTCA 121
      || || || || || || || || || || || || || || || || || || || || ||
Db     2060 CACCTACATCAAAAACATCATTTGCTTTTCACCTTTTATCATGTGTAAGTTGTGAATTAA 2119

QY      122 AGTAAAGGAAGCAGGAAGAGAGGATGTCTGTAACCCCAAGTTGGCTACTCCTGGCTT 181
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db     2120 ACAAAAGGAACAACCAAAAAGCAAGACACAGTGAACCTCAGTTGGGTTTGCCCTGGGTA 2179

QY      182 CCCCCTCCTGAAGAGGAGGAGGTGTGACAGCAGCAGCACATCCCGGTCTCGCGAAC 241
      || || || || || || || || || || || || || || || || || || || || ||
Db     2180 CCTTGCTGAAGATGGTAGATCATCATCTGATGAGCAGCAGCTGCCAGTTTCCGCCAAT 2239

QY      242 CTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGCAGGCATTATGTCGGGAA 301
      || || || || || || || || || || || || || || || || || || || || ||
Db     2240 CTTCCTCGGGCTACTTGAATCTGATGATGACAGAAATCAAGAGGCAATGTAACGTGGAT 2299

QY      302 ATTAATGGGTAGATGGAGGCAAGCCACCTGCTGAAAAATTTCCACTCATCTGTTCTACA 361
      || || || || || || || || || || || || || || || || || || || || ||
Db     2300 ATTAATGGGTAGATGGTGCAAAAGCCTTTGTTGAAGTTTAAAGCCACTTAGAATCTACC 2359

QY      362 GTGTATACTCAGATCAGCATTATACATAATTTTTCCAGTACTGTCAGAAAAACCGAATCT 421
      || || || || || || || || || || || || || || || || || || || || ||
Db     2360 ATTTACACTCAAGATCTGCATGTGCACAAATTTCTCCATCATGTGCAGCTGATTCAGTCA 2419

QY      422 GGAGCCCAAGCCTTAGGAAGAAAGAACTTGTAAAGTACCTTAAGAGTCTGCATGCGATGAA 481
      || || || || || || || || || || || || || || || || || || || || ||
Db     2420 GGCTCGAAAGAGTTCCAGGGGAGCTCATTTAAATATTTAAAGTGTTCATGCCATGGAG 2479

QY      482 GGCCACGTGATGAT 495
      || || || || || || || || || || || || || || || || || || || || ||
Db     2480 ATCCAAGTCATGAT 2493
```

```

RESULT 2
US-09-736-969A-7
; Sequence 7, Application US/09736969A
; Patent No. US20020068302A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-4 Transmembrane Protein
; FILE REFERENCE: 020054-000411US
; CURRENT APPLICATION NUMBER: US/09/736,969A
; CURRENT FILING DATE: 2000-12-13
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
```

```

; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 4391
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: human CLASP-4 cDNA
; NAME/KEY: CDS
; LOCATION: (414)..(4058)
; OTHER INFORMATION: human CLASP-4
US-09-736-969A-7
```

```

Query Match          17.0%; Score 85; DB 10; Length 4391;
Best Local Similarity 52.4%; Pred. No. 1.5e-17;
Matches 187; Conservative 0; Mismatches 170; Indels 0; Gaps 0;
```

```

QY      140 AAGAGGATGTGCTGAACCAAGTTGGCTACTCTGGCTTCCCTCCCTGAAGACGA 199
      || || || || || || || || || || || || || || || || || || || || ||
Db     78 AAGCGGGGGCCCCGGTGAACCTCCGGTTGGGTTGGCTGGGTCCCTTGCAGAAAGTTGGT 137

QY      200 AGGCTGTGACAAGCAGACACATCCCGGTCTGGCGGAACCTTCCTTCGGGCTATCTT 259
      || || || || || || || || || || || || || || || || || || || || ||
Db     138 AGATTCTTCCCTTTTGGGGGGGGGCTGCCGGTTTCCCCATTCTTCCCGGGGCTCCTTA 197

QY      260 GCGTACCAAGAGCTTGGATGGGCGAGGCATTATGCTCCGAAATTAATGGGTAGATGA 319
      || || || || || || || || || || || || || || || || || || || || ||
Db     198 ATTCTGATTGATGATAATCAAGGGGCAATGTATGTGATTTTAAATGGGTGTTGTT 257

QY      320 GCGAAGCCACTGCTGAATAATTCCACTCATCTGTTCTACAGTGTATACTCAGATCAG 379
      || || || || || || || || || || || || || || || || || || || || ||
Db     258 GTAAGCCTTTGTGAGGTTTAAAGGCCCTTGGGTTCTCCCATTTCCCTTAGGTTCTG 317

QY      380 CATTTACATAATTTTTTCCAGTACTGTGAGAAAACCGAATCTGAGGCCAAGCCTTAGGA 439
      || || || || || || || || || || || || || || || || || || || || ||
Db     318 CATTTGCCCAATTTCTTCATCATTTGCCGGCTGATTCGGTTCAGACTCGAAGAGGTTCCA 377

QY      440 AACGACTTGTAAAGTACCTTAAAGAGTCTGCATGCGATGGAAGGCCACAGTATGATC 496
      || || || || || || || || || || || || || || || || || || || || ||
Db     378 GGGGGCTCATTTAAATTTTAAAGGCTTTTGCATGCCATGGAGATCCCAAGATCTTGATC 434
```

```

RESULT 3
US-09-736-960-1
; Sequence 1, Application US/09736960
; Patent No. US20020102267A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-000511US
; CURRENT APPLICATION NUMBER: US/09/736,960
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 7215
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-5 cDNA
; NAME/KEY: CDS
; LOCATION: (112)..(6159)
; OTHER INFORMATION: human CLASP-5
US-09-736-960-1

Query Match          14.3%; Score 71.4; DB 10; Length 7215;
Best Local Similarity 51.1%; Pred. No. 6e-13;
Matches 208; Conservative 0; Mismatches 181; Indels 18; Gaps 1;

QY      2  GTTTACACCATCACCAAAACCAGAATTTTATGATGAGATTAAATAGAGTTGCCACT 61
      ||| | |||| | | ||| ||||| || | |||| | | ||| ||
Db      1759 GTTACATACCATATAATAGTCTCCTGACTTTTATGAAGAAGTGAATAATTAAGCTCCCGCT 1818

QY      62  CAGCTGCATGAAAAGCACCACCTGTGCTCACATTTCTTCCATGTCAGCTGTGACAACACTCA 121
      |||| | ||| ||||| || ||||| || | |||| | | ||| ||
Db      1819 AAGCTCACAGTAATCACCACTCCTGTTCCACTTCTTACCATATCAGCTGTCAAGCA----- 1874

QY      122 AGTAAGAAGCAGCAGACAAGAGGATGTCGTTGAACCCCAAGTTGGCTACTCCTGGCTT 181
      |||| | | | ||||| | ||||| | | ||| ||| |||||
Db      1875 -----GAAGCAAGGAGCCCTCCGTTGGAACACTCTCCTGGATATTTCATGGCTG 1920

QY      182 CCCCTCCTGAAGAGCGAAGGGTGTGACAAAGCGAGCAGACATCCCGTCTCGCGGAAC 241
      || | || | | | | | | | | | | | | |||| | | |
Db      1921 CCAATTCTCTTAATGAAACGCTCTTCAAACTGGAATCCTACTGTCCTCCAGTTGCCCTTGAA 1980

QY      242 CTTCTTGGGCTATCTTGCTACCAAGAGCTTGGGATGGGAGGCAATATATGTCGCGAA 301
```

```

      | | | | | | | | | | | | | | | | | | | |
Db      1981 AAATGGCACCACACTACTCCATGCAATTCGTGCTGAGAAAGTCCCATTTACAGAATCCCTCC 2040

QY      302 ATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTCTTACA 361
      ||||| |||| | | || | || | | | | | | | | | |
Db      2041 ATTAAGTGGGTGAAGGACATTAAGGAGTATTTAATATTGAAGTGCAAGCTGTTCTTCT 2100

QY      362 GTGTATACTGAGATCAGCATTTTACATTAATTTTTCAGTACTGTCA 408
      || | | | |||| | | | | | | | | | | | | | |
Db      2101 GTACACACCAGGACAACCACCTGGAGAAGTTCTTCAACCCCTCTGCCA 2147

RESULT 4
US-09-736-968A-1
; Sequence 1, Application US/09736968A
; Patent No. US20020169283A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-7 Transmembrane Protein
; FILE REFERENCE: 020054-000611US
; CURRENT APPLICATION NUMBER: US/09/736,968A
; CURRENT FILING DATE: 2000-12-13
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 6372
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-7 cDNA
; NAME/KEY: CDS
; LOCATION: (13)..(6156)
; OTHER INFORMATION: human CLASP-7
US-09-736-968A-1

Query Match          9.2%; Score 46; DB 9; Length 6372;
Best Local Similarity 63.6%; Pred. No. 0.00013;
Matches 70; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY      2  GTTTACACCATCACCAAAACCAGAATTTTATGATGAGATTAAATAGACTTGCCCACT 61
```

Db 1828 GTGCTACCAATACAGTCCCCGAGTCTACGAGAGTTCAGCTGCATCTTCCAGCC 1887  
QY 62 CAGCTGCATGAAGACACCACCTGTGCTCACAATTCTTCCATGTCAGCTG 111  
Db 1888 TGGCTGACAGAGAACCATCACCTGCTGTCACCTTCTACCATGTCAGCTG 1937

RESULT 5  
US-09-736-968A-77

; Sequence 77, Application US/09736968A  
; Patent No. US20020169283A1  
; GENERAL INFORMATION:  
; APPLICANT: Lu, Peter  
; APPLICANT: Garman, Jonathan David  
; APPLICANT: Candia III, Albert Frederick  
; APPLICANT: Arbor Vita Corporation  
; TITLE OF INVENTION: CLASP-7 Transmembrane Protein  
; FILE REFERENCE: 020054-000611US  
; CURRENT APPLICATION NUMBER: US/09/736, 968A  
; CURRENT FILING DATE: 2000-12-13  
; PRIOR APPLICATION NUMBER: US 60/160, 860  
; PRIOR FILING DATE: 1999-10-21  
; PRIOR APPLICATION NUMBER: US 60/162, 498  
; PRIOR FILING DATE: 1999-10-29  
; PRIOR APPLICATION NUMBER: US 60/170, 453  
; PRIOR FILING DATE: 1999-12-13  
; PRIOR APPLICATION NUMBER: US 60/176, 195  
; PRIOR FILING DATE: 2000-01-14  
; PRIOR APPLICATION NUMBER: US 60/182, 296  
; PRIOR FILING DATE: 2000-02-14  
; PRIOR APPLICATION NUMBER: US 09/547, 276  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 267  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 460  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196, 527  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 09/687, 837  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 503  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 508  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 539  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240, 543  
; PRIOR FILING DATE: 2000-10-13  
; NUMBER OF SEQ ID NOS: 115  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 77  
; LENGTH: 211  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: exon 88470-88680  
US-09-736-968A-77

Query Match 8.1%; Score 40.4; DB 9; Length 211;  
Best Local Similarity 65.6%; Pred. No. 0.0013;  
Matches 59; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

QY 22 CCCAGAAATTTATGATGAGATTAAATAGATGCCCACTCAGCTGCATGAAAAACACCA 81  
Db 38 CCCGAGTTCTACGAGAGTTCAAGCTGCATCTTCCAGCCTGCGTGACAGAGAACAACATCA 97  
QY 82 CCGTTGCTCACATCTTCCATGTCAGCTG 111  
Db 98 CCGCTGCTCACCTTCTACCATGTCAGCTG 127

RESULT 6  
US-09-070-927A-88  
; Sequence 88, Application US/09070927A  
; Patent No. US20020120116A1  
; GENERAL INFORMATION:  
; APPLICANT: Charles A. Kunsch  
; APPLICANT: Patrick J. Dillon  
; APPLICANT: Steven Barash

; TITLE OF INVENTION: Enterococcus faecialis Polynucleotides and Polypeptides  
; NUMBER OF SEQUENCES: 982  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Human Genome Sciences, Inc.  
; STREET: 9410 Key West Avenue  
; CITY: Rockville  
; STATE: Maryland  
; COUNTRY: USA  
; ZIP: 20850  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage  
; COMPUTER: HP Vectra 486/33  
; OPERATING SYSTEM: MSDOS version 6.2  
; SOFTWARE: ASCII Text  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/070, 927A  
; FILING DATE: 04-May-2000  
; CLASSIFICATION: <unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/046, 655  
; FILING DATE: 1997-05-16  
; APPLICATION NUMBER: 60/044, 031  
; FILING DATE: 1997-05-06  
; APPLICATION NUMBER: 60/066, 009  
; FILING DATE: 1997-11-14  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kenley K. Hoover  
; REGISTRATION NUMBER: 40,302  
; REFERENCE/DOCKET NUMBER: PB369  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (301) 309-8504  
; TELEFAX: (301) 309-8512  
; INFORMATION FOR SEQ ID NO: 88:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 6691 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; SEQUENCE DESCRIPTION: SEQ ID NO: 88:  
US-09-070-927A-88

Query Match 6.9%; Score 34.6; DB 10; Length 6691;  
Best Local Similarity 54.3%; Pred. No. 0.78;  
Matches 70; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY 12 ATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCCACTCAGCTCATG 71  
Db 1656 AACACCAAAAGAAATAGTCAAGAAGACTAGATCAATATATTGTTGGACAGCAAGCTGCCAA 1715  
QY 72 AAAAGCACCACTGTTGCTCACAATTCTTCCATGTAGCTGTGACAACCTCAAGTAAAGGAA 131  
Db 1716 AAAATCAGTGCGGTAGCTTTACGTAAACCGCTATCGTGGCTTGCAATTAGAGAAAAATAT 1775  
QY 132 GCACGAAGA 140  
Db 1776 GCAACAAGA 1784

RESULT 7  
US-09-738-626-795/c  
; Sequence 795, Application US/09738626  
; Publication No. US20020197605A1  
; GENERAL INFORMATION:  
; APPLICANT: NAKAGAWA, SATOSHI



```
; APPLICANT: MIZOGUCHI, HIROSHI
; APPLICANT: ANDO, SEIKO
; APPLICANT: HAYASHI, MIKIRO
; APPLICANT: OCHIAI, KEIKO
; APPLICANT: YOKOI, HARUHIKO
; APPLICANT: TATEISHI, NAKO
; APPLICANT: SENOH, AKIHIRO
; APPLICANT: IKEDA, MASATO
; APPLICANT: OZAKI, AKIO
; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
; FILE REFERENCE: 249-125
; CURRENT APPLICATION NUMBER: US/09/738,626
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: JP 99/377484
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: JP 00/159162
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: JP 00/280988
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 7059
; SOFTWARE: PatentIn ver. 3.0
; SEQ ID NO 795
; LENGTH: 1314
; TYPE: DNA
; ORGANISM: Corynebacterium glutamicum
US-09-738-626-795
```

```
Query Match          6.5%; Score 32.4; DB 9; Length 1314;
Best Local Similarity 54.1%; Pred. No. 1.6;
Matches 66; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
```

```
QY 40 GATTAAATAGAGTGTGCCCACTCAGCTGCATGAAAGCACCACCTGTTGCTCACAATTCTT 99
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 892 GATTTAGTAGTCTTTGACCGGCAGCAACGCATTAAAGAGCCCTGCTGTTTGCACGCGCTT 833

QY 100 CCATGTCAGCTGTGACAACTCAAGTAAAGGAGCAGGAGGAGGATGCTGTTGAAAC 159
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 832 CTTCCACGGTGTGCCAACAAGTCAACCAACGAGGAGCAGGAGGAGGATGCTGCGGAC 773

QY 160 CC 161
      ||
Db 772 CC 771
```

```
RESULT 8
US-09-738-626-1
; Sequence 1, Application US/09738626
; Publication No. US20020197605A1
; GENERAL INFORMATION:
; APPLICANT: NAKAGAWA, SATOSHI
; APPLICANT: MIZOGUCHI, HIROSHI
; APPLICANT: ANDO, SEIKO
; APPLICANT: HAYASHI, MIKIRO
; APPLICANT: OCHIAI, KEIKO
; APPLICANT: YOKOI, HARUHIKO
; APPLICANT: TATEISHI, NAKO
; APPLICANT: SENOH, AKIHIRO
; APPLICANT: IKEDA, MASATO
; APPLICANT: OZAKI, AKIO
; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
; FILE REFERENCE: 249-125
; CURRENT APPLICATION NUMBER: US/09/738,626
; CURRENT FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: JP 99/377484
; PRIOR FILING DATE: 1999-12-16
; PRIOR APPLICATION NUMBER: JP 00/159162
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: JP 00/280988
; PRIOR FILING DATE: 2000-08-03
; NUMBER OF SEQ ID NOS: 7059
; SOFTWARE: PatentIn ver. 3.0
; SEQ ID NO 1
; LENGTH: 3309400
```

```
; TYPE: DNA
; ORGANISM: Corynebacterium glutamicum
US-09-738-626-1
```

```
Query Match          6.5%; Score 32.4; DB 9; Length 3309400;
Best Local Similarity 54.1%; Pred. No. 91;
Matches 66; Conservative 0; Mismatches 56; Indels 0; Gaps 0;
```

```
QY 40 GATTAAATAGAGTGTGCCCACTCAGCTGCATGAAAGCACCACCTGTTGCTCACAATTCTT 99
      ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 737638 GATTTAGTAGTCTTTGACCGGCAGCAACGCATTAAAGAGCCCTGCTGTTTGCACGCGCTT 737697

QY 100 CCATGTCAGCTGTGACAACTCAAGTAAAGGAGCAGGAGGAGGATGCTGTTGAAAC 159
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 737698 CTTCCACGGTGTGCCAACAAGTCAACCAACGAGGAGGAGGATGCTGCGGAC 737757

QY 160 CC 161
      ||
Db 737758 CC 737759
```

```
RESULT 9
US-09-771-208-20
; Sequence 20, Application US/09771208
; Patent No. US20020155564A1
; GENERAL INFORMATION:
```

```
; APPLICANT: MEDRANO, JUAN
; APPLICANT: BRADFORD, ERIC
; APPLICANT: HORVAT, SIMON
; TITLE OF INVENTION: CLONING OF A HIGH-GROWTH GENE
; FILE REFERENCE: 407T-923710US
; CURRENT APPLICATION NUMBER: US/09/771,208
; CURRENT FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: US 08/999,477
; PRIOR FILING DATE: 1997-12-29
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 659158
; TYPE: DNA
; ORGANISM: Mus musculus
```

```
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (123459)..(123478)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (602466)..(602485)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (546998)..(547017)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (494715)..(494814)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (390986)..(391005)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (346860)..(346883)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (317174)..(317193)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (280353)..(280373)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (271829)..(271848)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
; LOCATION: (183872)..(183891)
; OTHER INFORMATION: n is unidentified a, c, g, or t
; NAME/KEY: misc_feature
```

LOCATION: (170625)..(170645)  
; OTHER INFORMATION: n is unidentified a, c, g, or t  
; NAME/KEY: misc\_feature  
; LOCATION: (132680)..(132700)  
; OTHER INFORMATION: n is unidentified a, c, g, or t  
; NAME/KEY: misc\_feature  
; OTHER INFORMATION: n is a, c, g, or t  
US-09-771-208-20

Query Match 6.4%; Score 31.8; DB 9; Length 659158;  
Best Local Similarity 67.2%; Pred. No. 86;  
Matches 45; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 53 TTGCCACTCAGTCGATGAAAGCACCACCTGTTCATTCATTCATGTCAGCTGT 112  
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11  
Db 138799 TTGACATCTCTTCTACTGAGAAGTAGACCTGTTCTCTCTCCTTGATCTGGGCTGT 138858

QY 113 GACAACT 119  
11111111  
Db 138859 GACAACT 138865

RESULT 10  
US-09-070-927A-394/c  
; Sequence 394, Application US/09070927A  
; Patent No. US20020120116A1  
; GENERAL INFORMATION:

APPLICANT: Charles A. Kunsch  
Patrick J. Dillon  
Steven Barash  
TITLE OF INVENTION: Enterococcus faecialis Polynucleotides and Polypeptides  
NUMBER OF SEQUENCES: 982  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Human Genome Sciences, Inc.  
STREET: 9410 Key West Avenue  
CITY: Rockville  
STATE: Maryland  
COUNTRY: USA  
ZIP: 20850

COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage  
COMPUTER: HP Vectra 486/33  
OPERATING SYSTEM: MSDOS version 6.2  
SOFTWARE: ASCII Text  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/070, 927A  
FILING DATE: 04-May-2000  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/046,655  
FILING DATE: 1997-05-16  
APPLICATION NUMBER: 60/044,031  
FILING DATE: 1997-05-06  
APPLICATION NUMBER: 60/066,009  
FILING DATE: 1997-11-14

ATTORNEY/AGENT INFORMATION:  
NAME: Kenley K. Hoover  
REGISTRATION NUMBER: 40,302  
REFERENCE/DOCKET NUMBER: PB369  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (301) 309-8504  
TELEFAX: (301) 309-8512  
INFORMATION FOR SEQ ID NO: 394:

SEQUENCE CHARACTERISTICS:  
LENGTH: 14141 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 394:  
US-09-070-927A-394

Query Match 6.3%; Score 31.6; DB 10; Length 14141;  
Best Local Similarity 56.9%; Pred. No. 12;

Matches 58; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 66 TGCATGAAAGCACCACCTGTGCTCACATTCCTCCATGTCAGCTGTGACAACTCAAGTA 125  
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11  
Db 7335 TGCCTAAACGGCCACACTGTGTTCATCTCTTCAAGACCGCTTTCCTCAAAATA 7276

QY 126 AAGGAAGCAGCAGAGAAGGATGTCGTTGAACCCCAAGTTG 167  
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11  
Db 7275 TAGGTTCTCGAGCAACATCTTCTTCCCGAAATCAATG 7234

RESULT 11  
US-09-070-927A-125  
; Sequence 125, Application US/09070927A  
; Patent No. US20020120116A1  
; GENERAL INFORMATION:

APPLICANT: Charles A. Kunsch  
Patrick J. Dillon  
Steven Barash  
TITLE OF INVENTION: Enterococcus faecialis Polynucleotides and Polypeptides  
NUMBER OF SEQUENCES: 982  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Human Genome Sciences, Inc.  
STREET: 9410 Key West Avenue  
CITY: Rockville  
STATE: Maryland  
COUNTRY: USA  
ZIP: 20850

COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage  
COMPUTER: HP Vectra 486/33  
OPERATING SYSTEM: MSDOS version 6.2  
SOFTWARE: ASCII Text  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/070, 927A  
FILING DATE: 04-May-2000  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/046,655  
FILING DATE: 1997-05-16  
APPLICATION NUMBER: 60/044,031  
FILING DATE: 1997-05-06  
APPLICATION NUMBER: 60/066,009  
FILING DATE: 1997-11-14

ATTORNEY/AGENT INFORMATION:  
NAME: Kenley K. Hoover  
REGISTRATION NUMBER: 40,302  
REFERENCE/DOCKET NUMBER: PB369  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (301) 309-8504  
TELEFAX: (301) 309-8512  
INFORMATION FOR SEQ ID NO: 125:

SEQUENCE CHARACTERISTICS:  
LENGTH: 4915 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 125:  
US-09-070-927A-125

Query Match 6.3%; Score 31.4; DB 10; Length 4915;  
Best Local Similarity 57.7%; Pred. No. 7.4;  
Matches 56; Conservative 0; Mismatches 41; Indels 0; Gaps 0;

QY 299 GAAATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTCACACTCATGCTTCT 358  
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11  
Db 235 GAAACAACTCACTTTTCTACTGAAATTTACATCTTGATAATAATCATTTGTTTCA 294

QY 359 ACAGTGTATCTCAGGATCAGCATTTACATAATTTT 395  
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11  
Db 295 TAACTACATCTCTGATATCATATAGATAATCTTT 331



APPLICATION NUMBER: US/09/939,980  
FILING DATE: 27-Aug-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/936,165  
FILING DATE: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Gimmil, Edward R  
REGISTRATION NUMBER: 38,891  
REFERENCE/DOCKET NUMBER: P50549  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 610-270-4478  
TELEFAX: 610-270-5090  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 228:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1005 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
SEQUENCE DESCRIPTION: SEQ ID NO: 228:  
US-09-939-980-228

Query Match 6.1%; Score 30.4; DB 10; Length 1005;  
Best Local Similarity 62.5%; Pred. No. 6.3;  
Matches 65; Conservative 0; Mismatches 36; Indels 3; Gaps 1;  
QY 2 GTTTTACACCATCACCAGAAACCCAGATTATTGA---TGAGATTAAATAGAGTTGCC 58  
DB 439 GTGTCCACCAAGCAATATACCTATATTTTCATGAGGGTCAGTATTGAATGTAGGTACAC 380  
QY 59 ACTCAGCTGCATGAAAGCACCACCTGTGCTCACATTTCTCCA 102  
DB 379 ACTCCGCTGCATCTAAGACACCCCAATCTTCACCTGTACCTGCA 336

Search completed: February 7, 2003, 09:14:04  
Job time : 1286.29 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 06:53:49 ; Search time 1008.32 Seconds  
(without alignments)  
8030.908 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_1\_500  
Perfect score: 500  
Sequence: 1 agtttaccatcaccaaaa.....aggccacgtgatgatcgccct 500

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues  
Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
EST:\*  
1: em\_estba:\*  
2: em\_esthum:\*  
3: em\_estin:\*  
4: em\_estmu:\*  
5: em\_estov:\*  
6: em\_estpl:\*  
7: em\_estro:\*  
8: em\_htc:\*  
9: gb\_est1:\*  
10: gb\_est2:\*  
11: gb\_htc:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pln:\*  
21: em\_gss\_vrt:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rod:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES				
Result No.	Score	Query Match	Length DB ID	Description
1	457.6	91.5	800 12	BE783911 601470964
2	359.8	72.0	465 12	BE938152 MR3-TN004
3	347.2	69.4	465 12	BE938144 MR3-TN004
4	308	61.6	891 14	BQ919716 AGENCOURT
5	166	33.2	412 10	BB672508 BB672508
6	166	33.2	441 10	BB819621 BB819621

7	148.2	29.6	245	12	BF948041	BF948041 MR3-NN021
8	144.4	28.9	538	12	BF472403	BF472403 UI-M-BH3-
9	134.8	27.0	543	10	BB763030	BB763030 BB763030
10	117	23.4	345	10	BB222768	BB222768 BB222768
11	106	21.2	330	10	BB207661	BB207661 BB207661
12	100.2	20.0	285	10	BB225426	BB225426 BB225426
13	94.4	18.9	274	10	BB177025	BB177025 BB177025
14	90.4	18.1	314	10	BB219663	BB219663 BB219663
15	89.8	18.0	249	10	BB538596	BB538596 BB538596
16	83.6	16.7	212	10	AV344231	AV344231 AV344231
17	80.6	16.1	255	10	BB200610	BB200610 BB200610
18	78.2	15.6	259	10	BB241632	BB241632 BB241632
19	77.4	15.5	219	10	BB184661	BB184661 BB184661
20	76.6	15.3	917	17	CNS03GUC	AL243453 Tetraodon
21	74	14.8	447	12	BG019353	BG019353 daa78906.
22	73.2	14.6	239	10	BB256604	BB256604 BB256604
23	57	11.4	669	13	BI961883	BI961883 MONO1_7_H
24	55.6	11.1	749	13	BI828723	BI828723 603074748
25	53.4	10.7	147	14	BQ339280	BQ339280 MR3-NN021
26	51.6	10.3	271	13	BM029853	BM029853 488237 MA
27	49.2	9.8	534	12	BE945462	BE945462 UI-M-BH3-
28	49.2	9.8	656	13	BJ395781	BJ395781 BJ395781
29	46	9.2	909	14	BQ730710	BQ730710 AGENCOURT
30	45.6	9.1	695	14	C88441	C88441 C88441 Carp
31	42.4	8.5	506	9	AA391952	AA391952 LD10883.5
32	40.8	8.2	254	17	AZ632934	AZ632934 1M0487B21
33	39	7.8	657	13	BG914864	BG914864 602813690
34	39	7.8	1507	11	AK010755	AK010755 Mus muscu
35	38	7.6	522	10	BE667330	BE667330 151645 MA
36	37.6	7.5	631	13	BI507332	BI507332 BB170003A
37	37	7.4	635	9	AA892774	AA892774 EST196577
38	37	7.4	642	14	BQ206156	BQ206156 UI-R-EP0-
39	37	7.4	753	14	BQ201592	BQ201592 UI-R-D21-
40	37	7.4	836	17	CNS0090K	AL053937 Drosophila
41	36.6	7.3	802	17	CNS01781	AL107724 Drosophila
42	36.2	7.2	350	10	AW784142	AW784142 NXNV_103_
43	36	7.2	595	9	AA695066	AA695066 GM02069.5
44	36	7.2	864	13	BI558960	BI558960 603241321
45	35.4	7.1	995	17	CNS02IU2	AL199379 Tetraodon

ALIGNMENTS

RESULT 1  
BE783911  
LOCUS BE783911 800 bp mRNA linear EST 20-OCT-2000  
DEFINITION 601470964F1 NIH\_MGC\_67 Homo sapiens cDNA clone IMAGE:3874046 5',  
mRNA sequence.  
ACCESSION BE783911 GI:10205109  
VERSION BE783911.1  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.  
REFERENCE 1 (bases 1 to 800)  
AUTHORS NIH-MGC <http://mgc.ncl.nih.gov/>.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: [cgapbs-remail.nih.gov](mailto:cgapbs-remail.nih.gov)  
Tissue Procurement: ATCC  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
Plate: L1AM9630 row: p column: 15  
High quality sequence stop: 629.  
Location/Qualifiers  
1..800

FEATURES

source

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:3874046"
/tissue_lib="NH_MGC_67"
/tissue_type="retinoblastoma"
/lab_host="DH10B (phage-resistant)"
/note="Organ: eye; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.75 kb. Library constructed by Life
Technologies."

BASE COUNT      227 a      198 c      185 g      190 t
ORIGIN

Query Match      91.5%; Score 457.6; DB 12; Length 800;
Best Local Similarity 98.6%; Pred. No. 6.9e-133;
Matches 493; Conservative 0; Mismatches 4; Indels 3; Gaps 3;

QY      4 TTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAA-TAGAGTGGCCACTC 62
      |||
Db      20 TTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAAGCTAGAGTTGCCCACTC 79

QY      63 AGCTGCATGAAAAGCACCACCTGTTGCTCACAATTCCTCCATGTCAGCTGTGACAAC-TCA 121
      |||
Db      80 AGCTGCATGAAAAGCACCACCTGTTAGCTCACAATTCCTCCATGTCAGCTGTGACAACGTTCA 139

QY      122 AGTAAAGGAAGCAGAAAGAGGGATGCTGTGAAACCCAAAGTTGGCTACTCCTGGCTT 181
      |||
Db      140 AGTAAAGGAAGCAGAAAGAGGGATGCTGTGAAACCCAAAGTTGGCTACTCCTGGCTT 199

QY      182 CCCCTCTGAAGACGGAAGGGTGTGACAAGCAGCAGACACATCCCAGTCTCGGCGAAC 241
      |||
Db      200 CCCCTCTGAAGACGGAAGGGTGTGACAAGCAGCAGACACATCCCAGTCTCGGCGAAC 259

QY      242 CTTCTCTCGGCTATCTTGGCTACCAAGAGCTTGGATGGGAGCAATTATGTTCCGGAA 301
      |||
Db      260 CTTCTCTCGGCTATCTTGGCTACCAAGAGCTTGGATGGGAGCAATTATGTTCCGGAA 319

QY      302 ATTAATGGGTAGATGGAGGCAAGCCACTGCTGAA-AATTTCCACTCATCTGTTTCTAC 360
      |||
Db      320 ATTAATGGGTAGATGGAGGCAAGCCACTGCTGAACAATTTCCACTCATCTGTTTCTAC 379

QY      361 AGTGTATACTCAGATCAGCATTTTACATAATTTTCCAGTACTGTCAGAAACCGAATC 420
      |||
Db      380 AGTGTATACTCAGATCAGCATTTTACATAATTTTCTCCAGTACTGTCAGAAACCGAATC 439

QY      421 TGGAGCCCCAAGCCTTAGGAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA 480
      |||
Db      440 TGGAGCCCCAAGCCTTAGGAACGAACCTGTAAAGTACCTTAAGAGTCTGCATGCGATGGA 499

QY      481 AGGCCACGTGATGATCGCCT 500
      |||
Db      500 AGGCCACGTGATGATCGCCT 519

RESULT 2
BE938152      465 bp      mRNA      linear      EST 02-OCT-2000
LOCUS      MR3-TN0048-280800-001-g08 TN0048 Homo sapiens cDNA, mRNA sequence.
ACCESSION      BE938152
VERSION      BE938152.1 GI:10465154
KEYWORDS      EST.
SOURCE      human.
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 465)
AUTHORS      Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare
,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
TITLE      Shotgun sequencing of the human transcriptome with ORF expressed
```

```

sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE      20202663
COMMENT      Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=et2-MR3-TN0048-280
800-001-g08&ts=2000-08-28&tl=1)
Seq primer: puc 18 forward
High quality sequence stop: 465.

FEATURES
      source
      Location/Qualifiers
          1..465
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /clone_lib="TN0048"
              /dev_stage="Adult"
              /note="Organ: testis-normal; Vector: puc18; Site_1: SmaI;
Site_2: SmaI; A mini-library was made by cloning products
derived from ORESTES PCR (U.S. Letters Patent application
No. 196,716 - Ludwig Institute for Cancer Research)
profiles into the puc 18 vector. Reverse transcription of
tissue mRNA and cDNA amplification were performed under
low stringency conditions."

BASE COUNT      127 a      114 c      115 g      109 t
ORIGIN

Query Match      72.0%; Score 359.8; DB 12; Length 465;
Best Local Similarity 99.4%; Pred. No. 3.5e-102;
Matches 361; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAAATAGAGTTGCCAC 60
      |||
Db      103 AGTTTACACCATCACCAAAACCCAGAAATTTTATGATGAGATTAAAATAGAGTTGCCAC 162

QY      61 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATTCCTCCATGTCAGCTGTGACAACCTC 120
      |||
Db      163 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATTCCTCCATGTCAGCTGTGACAACCTC 222

QY      121 AAGTAAAGGAAGCAGAGAAGAGGATGTCCTTGAACCCAAAGTTGGCTACTCCTGGCT 180
      |||
Db      223 AAGTAAAGGAAGCAGAGAAGAGGATGTCCTTGAACCCAAAGTTGGCTACTCCTGGCT 282

QY      181 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGAGCAGACATCCCGGCTCTGGCGAA 240
      |||
Db      283 TCCCTCTCTGAAAGACGGAAGGGTGTGACAAGCGAGCAGACATCCCGGCTCTGGCGAA 342

QY      241 CCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGAGGCATTTATGTCGGGA 300
      |||
Db      343 CCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGAGGCATTTATGTCGGGA 402

QY      301 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTCTAC 360
      |||
Db      403 AATTAAATGGGTAGATGAGGCAAGCCACTGCTGAAATTTCCACTCATCTGTTCTAC 462

QY      361 AGT 363
      |||
Db      463 AGT 465

RESULT 3
BE938144      465 bp      mRNA      linear      EST 02-OCT-2000
LOCUS      MR3-TN0048-280800-001-e05 TN0048 Homo sapiens cDNA, mRNA sequence.
ACCESSION      BE938144
VERSION      BE938144.1 GI:10465135
KEYWORDS      EST.
```

SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 465)  
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Bala,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.  
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
MEDLINE 20202663  
COMMENT Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br  
This sequence was derived from the FAPESP/LICR Human Cancer Genome project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=et2=MR3-TN0048-280800-001-e05&tl3=2000-08-28&tl4=1)  
Seq primer: puc 18 forward  
High quality sequence stop: 465.  
FEATURES  
source  
1. 465  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="TN0048"  
/dev\_stage="Adult"  
/note="Organ: testis\_normal; Vector: puc18; Site\_1: SmaI; Site\_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."  
BASE COUNT 129 a 112 c 116 g 108 t  
ORIGIN  
Query Match 69.4%; Score 347.2; DB 12; Length 465;  
Best Local Similarity 98.9%; Pred. No. 3.3e-98;  
Matches 360; Conservative 0; Mismatches 3; Indels 1; Gaps 1;  
QY 1 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 60  
|||||  
Db 102 AGTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCAC 161  
QY 61 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATCTTCCATGTCAAGCTGACAAC 120  
|||||  
Db 162 TCAGCTGCATGAAAAGCACCACCTGTTGCTCACAATCTTCCATGTCAAGCTGACAAC 221  
QY 121 AAGTAAAGGAAGCAGGAAGAGGATGTCGTTGAACCCCAAGTTGGCTACTCCTGGCT 180  
|||||  
Db 222 AAGTAAAGGAAGCAGGAAGAGGATGTCGATGAACCCCAAGTGGGCTACTCCTGGCT 281  
QY 181 TCCCCTCTGAAAGACGGAAGG- TGGTGACAAGCGAGCAGACATCCCGGTCTCGGCGA 239  
|||||  
Db 282 TCCCCTCTGAAAGACGGAAGGTTGGTGACAAGCGAGCAGACATCCCGGTCTCGGCGA 341  
QY 240 ACCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCGAGGCATTAATGTCGG 299  
|||||  
Db 342 ACCTTCCTCGGGCTATCTTGGCTACCAAGAGCTTGGGATGGGCGAGGCATTAATGTCGG 401  
QY 300 AAATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTA 359  
|||||  
Db 402 AAATTAATGGGTAGATGAGGCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTA 461

QY 360 CAGT 363  
|||||  
Db 462 CAGT 465  
RESULT 4  
BO919716 891 bp mRNA linear EST 20-AUG-2002  
LOCUS BO919716  
DEFINITION AGENCOURT\_8858966 NCI\_CGAP\_Mam2 Mus musculus cDNA clone  
IMAGE:6441934 5', mRNA sequence.  
ACCESSION BO919716 GI:22334414  
VERSION BO919716  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 891)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgabs-remail.nih.gov  
Tissue Procurement: Gilbert Smith, Ph.D.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Agencourt Bioscience Corporation  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: L1AM13965 row: 0 column: 23  
High quality sequence stop: 412.  
FEATURES  
source  
1. 891  
/organism="Mus musculus"  
/strain="FVB/N-3"  
/db\_xref="taxon:10090"  
/clone="IMAGE:6441934"  
/clone\_lib="NCI\_CGAP\_Mam2"  
/tissue\_type="tumor, biopsy sample"  
/dev\_stage="5 months"  
/lab\_host="DH10B"  
/note="Organ: mammary; Vector: PCMV-SPORT6; Site\_1: SalI; Site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigator providing samples: Gilbert Smith, NIH"  
BASE COUNT 243 a 209 c 236 g 201 t 2 others  
ORIGIN  
Query Match 61.6%; Score 308; DB 14; Length 891;  
Best Local Similarity 87.1%; Pred. No. 1e-85;  
Matches 338; Conservative 0; Mismatches 50; Indels 0; Gaps 0;  
QY 113 GACAACTAAGTAAAGGAAGCAGGAAGAGGAGTGTGTTGAACCCCAAGTTGGCTAC 172  
|||  
Db 1 GATAACTCACCAAAAGGAAGCAGGAAGAGGAGCGCTGTGAACCGCAGTTGGCTTT 60  
QY 173 TCCTGGCTTCCCCTCCTGAAAGCAGGAGGGTGTGACAAGCGCAGCAGACATCCCGGTC 232  
|||||  
Db 61 TCCTGGCTTCCCCTCCTGAAAGATGGAAGGGTGTGTGACGAGTGCAGCAGCAGCATCCCGTC 120  
QY 233 TCGGCGAACCTTCCTTCGGGCTATCTTGGCTACCAAGAGCTTGGATGGGCGAGGCATTAT 292  
|||||  
Db 121 TCGGCTAACCTGCCATCTGGCTAACCTCGGCTACCAAGAGCTCGGCGATGGGCGAGGCATTAT 180  
QY 293 GGTCCGGAAATTAATGGGTAGATGAGAGCGAAGCCACTGCTGAATAATTTCCACTCATCTG 352  
|||||  
Db 181 GGTCCAGAGGTTAAGTGGGTGGAAGGAGGCAAGCCACTGTTGAAGATCTCCACTCATCTG 240  
QY 353 GTTCTACAGTGTATACTAGAGATCAGCATTTACATTAATTTTCCAGTACTGTCAGAAA 412  
|||||  
Db 241 GTTCCACAGTGTACACTCAGGATCAACATTTACATTAATTTTCCATACTACTGTCAGAAA 300

QY	413	ACCGAATCTGGAGCCCCAAGCCCTTAGGAACGAACTTGTAAAGTACTACCTTAAGAGTCTGCAT	472
Db	301	ACCGAATCTGGAGCCCCAAGCCCTTAGGAACGAACTTGTAAAGTACTACCTTAAGAGTCTGCAT	360
QY	473	GGCATGGAAGCCACGTGATGATCGCCT	500
Db	361	GGCATGGAAGCCACGTGATGATCGCCT	388
RESULT 5	BB672508		
LOCUS			
DEFINITION	BB672508	412 bp	mus musculus
ACCESSION	BB672508	RIKEN full-length enriched, adult male brain	mus musculus
VERSION	BB672508	GI:15971729	
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
COMMENT			

/note="Site\_1: Sali; Site\_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5', GAGAGAGAGAGGATCCAGAGGCTCTTTTCTTTTCTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. Second strand cDNA was prepared with the primer adapter of sequence [5', GAGAGAGAGATTTCTCGAGTTAATTAATTAATCCCCCCCCCC 3']. cDNA was cloned into the XhoI and BamHI sites. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLX I"

BASE COUNT	130 a	100 c	76 g	106 t
ORIGIN				
Query Match	33.2%;	Score 166;	DB 10;	Length 412;
Best Local Similarity	63.1%;	Pred. NO. 3.8e-41;		
Matches 256;	Conservative 0;	Mismatches 150;	Indels 0;	Gaps 0;
QY	2	GTTTTACACCATCACC	AAAAAACCAGAATTTTATGATGAGATTAAATAGACTTGCCCACT	61
Db	7	GTGCTACACCAATCTCA	AAAATCCAGATTCTCTGATGAGGTGAAAAATGAACCTACCAACA	66
QY	62	CAGCTGCATGAAAAGC	ACCACCTGTTGCTCACAATCTTCCATGTCAGCTGAGCAACTCA	121
Db	67	CAACTCCATGGAATAAC	ATCACCCTTTGTTCTCTTTTACACACATCAGATGTGACATCAAT	126
QY	122	AGTAAAGGAAGCAGCA	GGAAGAGGATGTGCTGTGAAACC	CAAGTGGCTACTCTGGCTT
Db	127	GCCAAAGCCAATGCCA	AAAAAAGAAGAGGCTTTGGAGACATCAGTGGGCTATGATGAGCTT	186
QY	182	CCCCCTCTGAAAGAC	GGAAGGTGTGACAAAGCAGACACATCCCGTCTCGCGAAC	241
Db	187	CCTGTGATGAACATGAT	CAATAGCTTCTCAGGAGTACACATCCCAATAGCAACGACC	246
QY	242	CTTCCTTCGGGCTATCT	TGGCTACCAAGAGCTTGGATGGCAGGCATTATGTCGGAA	301
Db	247	CTGCTCTCAATTAATT	TTTAAGCATTCAGATCCTCAAGTGCAAAAGCATGTGGAAGTGAC	306
QY	302	ATTAATAGGGTAGATG	GAGGCAAGCCACTGCTGAAAAATTTCCACTCATCTGTTTCTACA	361
Db	307	ATTAATAGGGTGCATG	TGTGCAAAACCGCTTTTCAAGTGTCCACATTTCTGTATCAACA	366
QY	362	GTGTATACTCAGGATC	AGCATTTACATTAATTTTCCAGTACTGTC	407
Db	367	GTGAACACTCAGGACC	ACACATGTAATGATTTTCCGTCAGTGCC	412
RESULT 6				
LOCUS	BB819621	441 bp	mRNA	linear EST 19-NOV-2001
DEFINITION	BB819621	RIKEN full-length enriched, lung	RCB-0558 LLC	CDNA Mus
ACCESSION	BB819621	musculus cDNA clone G730050N08 3',	mRNA sequence.	
VERSION	BB819621.1	GI:16992250		
KEYWORDS	EST.			
SOURCE	house mouse.			
ORGANISM	Mus musculus			
REFERENCE				
AUTHORS				



TITLE RIKEN Encyclopedia of Mouse Full-length cDNAs (Akimura,T., et al. 2001)  
JOURNAL Unpublished (2001)  
COMMENT Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: genome-res@gsc.riken.go.jp,  
URL:http://genome.gsc.riken.go.jp/  
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.  
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. . 10 (10), 1617-1630 (2000)  
wagi,K., Fujiwake,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.  
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res. . 10 (11), 1757-1771 (2000)  
Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara,Y. and Hayashizaki,Y.  
Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res. . 11 (2), 281-289 (2001)  
Please visit our web site (http://genome.gsc.riken.go.jp) for further details.  
e mouse tissues.

FEATURES  
source Location/Qualifiers  
1.441  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone\_lib="G730050N08"  
/clone\_lib="RIKEN full-length enriched, lung RCB-0558 LLC cDNA"  
/tissue\_type="lung"  
/cell\_line="RCB-0558 LLC"  
/note="pooled cell lines ; (cell\_line=CRL-1751 WEHI 164), (cell\_line=CRL-2116 JC), (cell\_line=RCB-0035 WEHI-3), (cell\_line=RCB-0464 Meth-A), (cell\_line=RCB-0545 OMTA), (cell\_line=RCB-0559 K-1. F1), (cell\_line=RCB-1283 B16 melanoma), (cell\_type=B cells, cell\_line=CRL-1702 WEHI 231), (cell\_type=leydig cells, cell\_line=CRL-2065 MLTC-1), (cell\_type=Nullipotent stem cell, cell\_line=CRL-2070 NE), (tissue\_type=bladder, cell\_line=RCB-0544 MBT-2), (tissue\_type=bone marrow, cell\_type=stroma cell, cell\_line=CRL-2028 SR-4987), (tissue\_type=colon, cell\_line=RCB-0549 Cle-H3), (tissue\_type=kidney, cell\_line=CCl-142 RAG), (tissue\_type=submandibular gland, cell\_line=CRL-1734 SCA-9 clone 15), (strain=BALB/C, cell\_type=B cells, cell\_line=CRL-1669 BCL1 Clone 13, 20-3B3), (strain=C3H, tissue\_type=brain, cell\_line=CRL-1443 BC3H1)"

BASE COUNT 133 a 113 c 81 g 114 t  
ORIGIN

Query Match 33.2%; Score 166; DB 10; Length 441;  
Best Local Similarity 63.1%; Pred. NO. 4e-41;  
Matches 256; Conservative 0; Mismatches 150; Indels 0; Gaps 0;

OY 2 GTTTTACACCATCACCACCAATTTTATGAGAGATTAAATAGAGTTGCCACT 61  
|| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 36 GTGCTACACCATCTCAAAATCCAGATTCTGATGAGGTGAATAATTGAACTACCAACA 95  
62 CAGCTGCATGAAAGACACACCTGTGCTCACAATCTTCATGTGAGCTGTGACAACACTCA 121  
|| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 96 CAACTCCATGGAAGAACATCACCTTTTGTCTCTCTTTTACCAACATCACATGTGACATCAAT 155  
OY 122 AGTAAAGGAAGCAGAAAGAGGATGTGTTGAAACCAAGTTGGCTACTCCTGGCTT 181

Db 156 GCCAAGCCATGCGCCAAAAGAAAGAGAGCGCTTTGGAGACATCAGTGGGCTATGCAATGGCTT 215  
OY 182 CCCCTCCTGAAGACGGAGGAGGTGTGACACGAGCAGACATCCCGGTCTCGGCGAAC 241  
|| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 216 CCTCTATGAACATGATCAATAGCTTTCAGAGAGTACACATCCCAATAGCAGCAGACC 275  
OY 242 CTCCTTCGGGCTATCTGTGGCTACCAAGAGCTGGGATGGGCGCATATATGTCGGAA 301  
|| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 276 CTGCCCTCAATATTTAAGCATTCACAGATCCTCAAGTGCAGAACATGTGTGAAGTGAC 335  
OY 302 ATTAATGGGTAGATGAGGCCAAGCCACTGCTGAATAATTTCCACTCATCTGTTCTACA 361  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 336 ATTAATGGGTGATGATGGTGGCAACCGCTTTTCAAGTGTCCACATTTGTTGTATCAACA 395  
OY 362 GTGTACTCAGGATCAGCATTTACATATTTTTCAGTACTGTC 407  
|| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 396 GTGACACTCAGGACCCACATCTAATGCATTTTTCGTCAGTGCC 441

RESULT 7  
BF948041  
LOCUS BF948041 245 bp mRNA linear EST 22-JAN-2001  
DEFINITION MR3-NN0215-311000-007-b01 NN0215 Homo sapiens cDNA, mRNA sequence.  
ACCESSION BF948041  
VERSION BF948041.1 GI:12365316  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 245)  
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.  
Shotgun sequencing of the human transcriptome with ORF expressed sequence tags  
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
20202663  
Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br  
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=MR3&tl2=MR3-NN0215-311000-007-b01&tl3=2000-10-31&tl4=1)  
Seq primer: puc 18 forward  
High quality sequence stop: 77.

FEATURES  
source Location/Qualifiers  
1.245  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="NN0215"  
/dev\_stage="Adult"  
/note="Organ: nervous\_normal; Vector: puc18; Site\_1: SmaI; Site\_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."

BASE COUNT 62 a 52 c 76 g 55 t  
ORIGIN  
Query Match 29.6%; Score 148.2; DB 12; Length 245;

Best Local Similarity 89.9%; Pred. No. 1.2e-35;  
Matches 204; Conservative 0; Mismatches 18; Indels 5; Gaps 4;  
QY 195 ACCGAGGGGTGGTGACAA-GCGAGCAGACATCCGGTCTCGGCGAACCCTTCCTCGGGC 253  
Db 19 ACGGAGGGGTGGTGAGAGGCGAGCAGTACATCCGGCTCTCGGCGAAGCTTCCTCGGGC 78  
QY 254 TATCT-TGGCTACCAAGAGCTTGGGATGGGCAGGCATTATGTCGCCGAATTAATGGGT 312  
Db 79 GATCTGTGATACCAAGAGCTTGGGATGGGCAGGCATTATGTCGCCGAATGAATGGGT 138  
QY 313 AGATGAGGCCAAGCCACTGCTGAAATTTTC-CATCATCTGTGTTTCTACAGTGTACTC 371  
Db 139 AGATGAGGCCAGCCACTGCTGAAATGTCGCACATCTGTTTCTACAGTGTACTC 198  
QY 372 AGATCAGCATTTACATAATTTT--TTCAGTACTGTGAGAAACCG 416  
Db 199 AGGATCAGGATTTACGATAATATGCTCATGTACTGTCAAGAAACCG 245

RESULT 8  
BF472403 538 bp mRNA linear EST 04-DEC-2000  
LOCUS UI-M-BH3-awc-c-08-0-UI.r1 NIH\_BMAP\_M\_S4 Mus musculus cDNA clone  
DEFINITION UI-M-BH3-awc-c-08-0-UI 5', mRNA sequence.  
ACCESSION BF472403  
VERSION BF472403.1 GI:11541586  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 538)  
REFERENCE Bonaldo,M.F., Lennon,G. and Soares,M.B.  
AUTHORS Normalization and subtraction: two approaches to facilitate gene  
TITLE discovery  
JOURNAL Genome Res. 6 (9), 791-806 (1996)  
MEDLINE 97044477  
COMMENT Contact: Chin, H  
National Institute of Mental Health  
6001 Executive Blvd. Room 7N-7190, MSC 9643, Bethesda, MD  
20892-9643, USA  
Tel: 301 443 1706  
Fax: 301 443 9890  
Email: MEST@mail.nih.gov  
CDNA Library Preparation: M.B. Soares Lab Clone distribution:  
Researchers may obtain BMAP cDNA clones from RESEARCH GENETICS. It  
should be noted that Bento Soares is generating a small number of  
additional specialized non-redundant arrays of BMAP cDNAs whose  
availability will be considered under appropriate and limited  
collaborative arrangements  
Seq primer: M13 Reverse.  
FEATURES  
source Location/Qualifiers  
1..538  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="UI-M-BH3-awc-c-08-0-UI"  
/clone\_lib="NIH\_BMAP\_M\_S4"  
/dev\_stage="27-32 days"  
/lab\_host="DH10B (Life Technologies)"  
/note="vector: pT7T3D-Pac (Pharmacia) with a modified  
polylinker; Site\_1: Not I; Site\_2: Eco RI; The  
NIH\_BMAP\_M\_S4 library is a subtracted library of a series,  
ultimately derived from a mixture of individually tagged  
normalized libraries from ten regions of the mouse brain  
(cerebellum, brain stems, olfactory bulbs, hypothalamus,  
cortex, amygdala, basal ganglia, pineal gland, striatum,  
hippocampus) after a series of subtractions to reduce the  
representation of cDNAs from which ESTs had already been  
generated. The following serially subtracted libraries  
were generated in this process: NIH\_BMAP\_M\_S4,  
NIH\_BMAP\_M\_S3.3, NIH\_BMAP\_M\_S3.2, NIH\_BMAP\_M\_S3.1,

NIH\_BMAP\_M\_S2, NIH\_BMAP\_M\_S1. The subtracted library  
(NIH\_BMAP\_M\_S4) was constructed as follows: PCR amplified  
cDNA inserts from NIH\_BMAP\_M\_S3.3, NIH\_BMAP\_M\_S3.2, and  
NIH\_BMAP\_M\_S3.1 clones from which 3' ESTs had been derived  
was used as a driver in a hybridization with a pool of  
the NIH\_BMAP\_M\_S3.3, NIH\_BMAP\_M\_S3.2, and NIH\_BMAP\_M\_S3.1  
libraries in the form of single-stranded circles. The  
remaining single-stranded circles (subtracted library)  
was purified by hydroxyapatite column chromatography,  
converted to double-stranded circles and electroporated  
into DH10B bacteria (Life Technologies) to generate the  
NIH\_BMAP\_M\_S4 library. This procedure has been previously  
described (Bonaldo, Lennon and Soares, Genome Research  
6:791-806, 1996)"  
BASE COUNT 150 a 122 c 123 g 143 t  
ORIGIN

Query Match 28.9%; Score 144.4; DB 12; Length 538;  
Best Local Similarity 90.6%; Pred. No. 2.8e-34;  
Matches 154; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 331 GCTGAAATTTCCACTCATCTGTTTCTACAGTGTATACTCAGATCAGCATTTACATAA 390  
Db 13 GTTGAAGATCTCCACTCATCTGTTTCCACAGGTACACTCAGATCAACATTTACATAA 72  
QY 391 TTTTTCAGTACTGTCAGAAACCGAATCTGAGGCCAAGCCTTAGGAACGAACCTTGT 450  
Db 73 TTTTTCCAATACGTGTCAGAAACCGAATCTGAGGCCAAGCCTTAGGAACGAACCTTGT 132  
QY 451 AAAGTACCTTAAGAGTCTGCATGCGATGGAAGGCCACGATGATGATCGCT 500  
Db 133 AAATATACCTTAAGAGTCTGCATGCGATGGAAGGCCACGATGATGATCGCT 182

RESULT 9  
BB763030 543 bp mRNA linear EST 17-OCT-2001  
LOCUS BB763030 RIKEN full-length enriched, B16 F10Y cells Mus musculus  
DEFINITION cDNA clone G370018M23 3', mRNA sequence.  
ACCESSION BB763030  
VERSION BB763030.1 GI:16207943  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 543)  
REFERENCE Akimura,T., Arakawa,T., Carninci,P., Furuno,M., Hanagaki,T.,  
AUTHORS Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Imotani,K., Ishii  
Y., Ito,M., Kawai,Y., Kojima,Y., Konno,H., Kouda,M., Matsuyama,T.,  
Nakamura,M., Nishi,K., Nomura,K., Numasaki,R., Okazaki,Y., Okido,T.,  
, Saito,R., Sakai,C., Sakai,K., Sakazume,N., Sasaki,D., Sato,K.,  
Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Suzuki,H., Tagawa  
, A., Takahashi,F., Takaku-Akahira,S., Tanaka,T., Tomaru,A., Toya,T.,  
, Watabiki,A., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y.  
RIKEN Encyclopedia of Mouse Full-length cDNAs (Akimura,T., et al.  
2001)  
unpublished (2001)  
Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic  
Sciences Center(GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: genome-res@gsc.riken.go.jp,  
URL:http://genome.gsc.riken.go.jp/  
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh  
, M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.  
Normalization and subtraction of cap-trapper-selected cDNAs to  
prepare full-length cDNA libraries for rapid discovery of new  
genes. Genome Res. 10 (10), 1617-1630 (2000)  
wagi,K., Fujiwake,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E.,

Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.  
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res. 10 (11), 1757-1771 (2000)  
Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara,Y. and Hayashizaki,Y.  
Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)  
Please visit our web site (<http://genome.gsc.riken.go.jp>) for further details.

FEATURES  
source

Location/Qualifiers  
1..543  
/organism="Mus musculus"  
/strain="C57Bl/6J"  
/db\_xref="taxon:10090"  
/clone="G370018M23"  
/clone\_lib="RIKEN full-length enriched, B16 F10Y cells"  
/cell\_type="B16 F10Y cells"  
/note="pooled tissues ; (tissue\_type=cerebellum, dev\_stage=16 days neonate, sex=mixed), (tissue\_type=cerebellum, dev\_stage=0 day neonate, sex=mixed), (tissue\_type=hippocampus, dev\_stage=adult, sex=male), (tissue\_type=whole body, dev\_stage=9 days embryo, sex=mixed); (tissue\_type=lung, dev\_stage=13 days embryo, sex=mixed)"  
BASE COUNT 164 a 137 c 101 g 141 t  
ORIGIN

Query Match 27.0%; Score 134.8; DB 10; Length 543;  
Best Local Similarity 63.0%; Pred. No. 3e-31;  
Matches 257; Conservative 0; Mismatches 147; Indels 4; Gaps 3;

OY 2 GTTTTACACCATCACCAAAACCAGAAATTTATGATGAGATTAAATAGAGTTGCCACT 61  
|| ||||| |||| |||| |||| |||| |||| |||| |||| |||| |||| |||| |||| ||||  
Db 138 GTGGTACACCATTTCTCAAAATCCAGATTCTGTGATGAGTGAAATTGAACCTACCAACA 197  
OY 62 CAGCTGCATGAAAGCACCACCTGTGCTCAGATTCTTCCATGTCAGCTGTGACAACTCA 121  
|| ||||| |||| |||| |||| |||| |||| |||| |||| |||| |||| |||| |||| ||||  
Db 198 CAACTCATGAAAA-CATCACCTTTGTTCTCTTTTACCATCATCATGTGACATCAAT 256  
OY 122 AGTAAAGGAGCAGCAGAAGAGGATGCTTGAAAACCCAAAGTTGGCTACTCCGCGCT 181  
||| | ||||| || ||||| || ||||| |||| ||||| |||| ||||| |||| |||||  
Db 257 GCCAAAGCCAAATGCCAAAAAGAGGCTTTGGAGACATCAGTGGGCTATGATGGCTT 316  
OY 182 CCCCTCTGAAAGAGGGAAGGGTGTGACAAGCAGACGACATCCCGCTCGGCGAAC 241  
|| || ||||| || || || ||||| |||| ||||| |||| ||||| |||| |||||  
Db 317 CCTCTGATGAACATGATCAAAATAGCTTTCAGAGATACAAACATCCCAATACCAACCAC 376  
OY 242 CTTCCTTCGGGCTATCTTGCTTACCAAGAGCTTGGATGGC--AGGCATTATGGTCCGG 299  
|| ||| | ||| || ||||| |||| ||||| |||| ||||| |||| ||||| ||||  
Db 377 CTCCCTCCTAATTATTAAGCATTTCAAGATTCCTAGCAAGTCCAAAGGCATGGTGAAGTG 436  
OY 300 AATTAATGGGTAGATGAGGCAAGCCACTGCTGAAAATTTCCACTCATCTGTTCTTA 359  
| ||||| ||| | ||||| ||| | ||||| ||||| ||||| ||||| ||||| |||||  
Db 437 ACATTAATGTTGCAT-GTGGCAAAACCGCTTTCAAAAGTGTCCACATTTGTTGATCAA 495  
OY 360 CAGTGATACTCAGGATCAGCATTTACATAATTTTTCAGTACTGTC 407  
|||| | ||||| || ||| || || ||||| ||||| ||||| |||||  
Db 496 CAGTGAACACTCAGAGCCACATGTAATGCAATTTTCCGTCAATTGCC 543

RESULT 10  
LOCUS BB222768 345 bp mRNA linear EST 01-JUL-2000  
DEFINITION BB222768 RIKEN full-length enriched, adult male aorta and vein Mus  
musculus cDNA clone A530079G09 3', mRNA sequence.  
ACCESSION BB222768  
VERSION BB222768.1 GI:8891380  
KEYWORDS EST.

SOURCE house mouse.  
ORGANISM Mus musculus  
REFERENCE 1 (bases 1 to 345)  
AUTHORS Konno,H., Aizawa,K., Akahira,S., Akiyama,J., Arakawa,T., Carninci,P., Endo,T., Fukuda,S., Fukunishi,Y., Hara,A., Hayatsu,N., Hirozane,T., Horii,F., Ishi,Y., Ishikawa,J., Ishikawa,T., Itoh,M., Izawa,M., Kadota,K., Kagawa,I., Kai,C., Kawai,J., Kikuchi,N., Kiyosawa,H., Kojima,Y., Kondo,S., Koya,S., Kurihara,C., Kusakabe,M., Matsuyama,T., Miki,R., Mizuno,Y., Nakamura,M., Oda,H., Okazaki,Y., Ono,T., Owa,C., Saito,H., Sakai,C., Sato,K., Shibata,K., Shibata,Y., Shigemoto,Y., Shinagawa,A., Shiraki,T., Sogabe,Y., Sugahara,Y., Suzuki,H., Suzuki,H., Tagawa,A., Takahashi,F., Tominaga,N., Toya,T., Tsunoda,Y., Watahiki,A., Watanabe,S., Yamamura,T., Yamanaka,I., Yano,R., Yasunishi,A., Yokota,T., Yoshida,K., Yoshiki,A., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.  
RIKEN Mouse ESTs (Konno,H., et al.)  
Unpublished (2000)  
Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: genome-res@gsc.riken.go.jp,  
URL: <http://genome.gsc.riken.go.jp/>,  
Carninci,P., Nishiyama,Y., Westover,A., Itoh,M., Nagaoka,S., Sasaki,N., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.  
Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)  
Itoh,M., Kitsuana,T., Akiyama,J., Shibata,K., Izawa,M., Kawai,J., Tomaru,Y., Carninci,P., Shibata,Y., Ozawa,Y., Muramatsu,M., Okazaki,Y. and Hayashizaki,Y.  
Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)  
Carninci,P. and Hayashizaki,Y.  
High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)  
Please visit our web site (<http://genome.rtc.riken.go.jp>) for further details.

TITLE  
JOURNAL  
COMMENT

FEATURES  
source

Location/Qualifiers  
1..345  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone="A530079G09"  
/clone\_lib="RIKEN full-length enriched, adult male aorta and vein"  
/sex="male"  
/tissue\_type="aorta and vein"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/note="Site\_1: SalI; Site\_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5', GAGAGAGAGAGATCCAGAGCTCTTTTCTTTTCTTTTCTTTVN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. cDNA went through one round of normalization to Rot = 20.0 and subtraction to Rot = 459.0. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGAGATCTCGAGTTAATTAATTAATCCCCCCCCC 3']. cDNA was cleaved with XhoI and BamHI. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLX I."

BASE COUNT 105 a 92 c 61 g 87 t  
ORIGIN







VERSION	BB225426.1	GI:8894037
KEYWORDS	EST.	
SOURCE	house mouse.	
ORGANISM	Mus musculus	
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 285)	
REFERENCE	Konno,H., Aizawa,K., Akahira,S., Akiyama,J., Arakawa,T., Carninci,P., Endo,T., Fukuda,S., Fukunishi,Y., Hara,A., Hayatsu,N., Hirozane,T., Hori,F., Ishii,Y., Ishikawa,J., Ishikawa,T., Itoh,M., Izawa,M., Kadota,K., Kagawa,I., Kai,C., Kawai,J., Kikuchi,N., Kiyosawa,H., Kojima,Y., Kondo,S., Koya,S., Kurihara,C., Kusakabe,M., Matsuyama,T., Miki,R., Mizuno,Y., Nakamura,M., Oda,H., Okazaki,Y., Ono,T., Owa,C., Saito,H., Sakai,C., Sato,K., Shibata,K., Shibata,Y., Shigemoto,Y., Shinagawa,A., Shiraki,T., Sogabe,Y., Sugahara,Y., Suzuki,H., Suzuki,H., Tagawa,A., Takahashi,F., Tominaga,N., Toya,T., Tsunoda,Y., Watahiki,A., Watanabe,S., Yamamura,T., Yamanaka,I., Yano,R., Yasunishi,A., Yokota,T., Yoshida,K., Yoshiki,A., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.	
TITLE	RIKEN Mouse ESTs (Konno,H., et al.)	
JOURNAL	unpublished (2000)	
COMMENT	Contact: Yoshihide Hayashizaki	

Email: genome-res@gsic.riken.go.jp,  
url: <http://genome.gsic.riken.go.jp/>  
Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki,  
N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.  
Thermostabilization and thermoactivation of thermolabile enzymes by  
trehalose and its application for the synthesis of full length  
cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)  
Itoh, M., Kitsunai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,  
Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki,  
Y. and Hayashizaki, Y.  
Automated filtration-based high-throughput plasmid preparation  
system. Genome Res. 9 (5), 463-470 (1999)  
Carninci, P. and Hayashizaki, Y.  
High-efficiency full-length cDNA cloning. Methods Enzymol. 303,  
19-44 (1999)  
Please visit our web site (<http://genome rtc.riken.go.jp>) for  
further details.

FEATURES

source

Location/Qualifiers

1. .285

/organism="Mus musculus"

/db\_xref="taxon:10090"

/clone="A530092E21"

/clone\_lib="RIKEN full-length enriched, adult male aorta and vein"

/sex="male"

/tissue\_type="aorta and vein"

/dev\_stage="adult"

/lab\_host="DH10B"

/note="Site\_1: SalI; Site\_2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5', GAGAGAGAGAGATCCAGAGCTCTTTTTTTTTTTTTTTVN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. cDNA went through one round of normalization to Rot = 20.0 and subtraction to Rot = 459.0. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGAGATCTCGAGTTAATTAATTCACCCCCCCCC 3']. cDNA was cleaved with XhoI and BamHI. Vector: a modified pBluescript KS(+) after bulk excision from Lambda PLC I."

BASE COUNT	88 a	68 c	60 g	69 t
ORIGIN				

Query Match	20.0%;	Score 100.2;	DB 10;	Length 285;
Best Local Similarity	59.8%;	Pred. No. 1.8e-20;		
Matches 168; Conservative	0;	Mismatches 113;	Indels 0;	Gaps 0;

[illegible]

RESULT 13	LOCUS	DEFINITION	LOCUS	DEFINITION
BB177025	274 bp	mRNA	BB177025	linear
BB177025	RIKEN full-length enriched, adult male	hypothalamus	BB177025	musculus
musculus	CDNA clone A230064N07 3', mRNA sequence.			

VERSION BB177025.1 GI:8836108  
KEYWORDS EST.

SOURCE	house mouse.
ORGANISM	Mus musculus

REFERENCE	1 (bases 1 to 274)
AUTHORS	Kono, H., Aizawa, K., Akahira, S., Akiyama, J., Arakawa, T., Carninci

KONNO, H., AIZAWA, K., AKAHIRA, S., AKIYAMA, J., ARAKAWA, T., CARNINCI  
 P., ENDO, T., FUKUDA, S., FUKUNISHI, Y., HARA, A., HAYATSU, N.,  
 HIROZANE, T., HORI, F., ISHII, Y., ISHIKAWA, J., ISHIKAWA, T., ITOH, M.,  
 IZAWA, M., KADOTA, K., KAGAWA, I., KAI, C., KAWAI, J., KIKUCHI, N.,  
 KIYOSAWA, H., KOJIMA, Y., KONDO, S., KOYA, S., KURIHARA, C., KUSAKABE, M.,  
 MATSUYAMA, T., MIKI, R., MIZUNO, Y., NAKAMURA, M., ODA, H., OKAZAKI, Y.,  
 ONO, T., OWA, C., SAITO, H., SAKAI, C., SATO, K., SHIBATA, K., SHIBATA  
 Y., SHIGEMOTO, Y., SHINAGAWA, A., SHIRAKI, T., SOGABE, Y., SUGAHARA, Y.,  
 SUZUKI, H., SUZUKI, H., TAGAWA, A., TAKAHASHI, F., TOMINAGA, N., TOYA  
 T., TSUNODA, Y., WATAHIKI, A., WATANABE, S., YAMAMURA, T., YAMANAKA, I.,  
 YANO, R., YASUNISHI, A., YOKOTA, T., YOSHIDA, K., YOSHIKI, A., YOSHINO  
 M., MURAMATSU, M., AND HAYASHIZAKI, Y.  
 RIKEN MOUSE ESTS (Konno, H., et al.)

TITLE	JOURNAL	COMMENT
RIKEN Mouse ESTs (Konno, H., et al.)	Unpublished (2000)	Contact: Yoshihide Hayashizaki Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute The Institute of Physical and Chemical Research (RIKEN) 1-7-22 Suehiro-cho, Tsurumi-Ku, Yokohama, Kanagawa 230-0045, Japan Tel: 81-45-503-9222 Fax: 81-45-503-9216 Email: genome-res@gsc.riken.go.jp, URL: <a href="http://genome.gsc.riken.go.jp/">http://genome.gsc.riken.go.jp/</a> Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki, N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y. Thermotabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998) Itoh, M., Kitsunai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J., Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki, Y. and Hayashizaki, Y. Automated filtration-based high-throughput plasmid preparation



[illegible]

RESULT 15	LOCUS	DEFINITION	ACCESION
BB538596	BB538596	BB538596	BB538596
249 bp	RIKEN full-length enriched, 0 day neonate	EST 31-JUL-2000	
musculus	cdna clone F130012K13 3', mRNA sequence.	eyeball Mus	
U0520602			

VERSION	BB538596.1	GI:9594096
KEYWORDS	EST.	
SOURCE	house mouse.	
ORGANISM	Mus musculus	

TITLE	REFERENCE
RIKEN MOUSE ESTS (Konno, H., et al.)	1 (bases 1 to 249)
	Konno, H., Aizawa, K., Akahira, S., Akiyama, J., Arakawa, T., Carninci, P., Endo, T., Fukuda, S., Fukunishi, Y., Hara, A., Hayatsu, N., Hirozane, T., Hori, F., Ishii, Y., Ishikawa, J., Ishikawa, T., Itoh, M., Izawa, M., Kadota, K., Kagawa, I., Kai, C., Kawai, J., Kikuchi, N., Kiyosawa, H., Kojima, Y., Kondo, S., Koya, S., Kurihara, C., Kusakabe, M., Matsuyama, T., Miki, R., Mizuno, Y., Nakamura, M., Oda, H., Okazaki, Y., Ono, T., Owa, C., Saito, H., Sakai, C., Sato, K., Shibata, K., Shibata, Y., Shigemoto, Y., Shinagawa, A., Shiraki, T., Sogabe, Y., Sugahara, Y., Suzuki, H., Suzuki, H., Tagawa, A., Takahashi, F., Tomiura, N., Toya, T., Tsunoda, Y., Watabiki, A., Watanabe, S., Yamamura, T., Yamanaka, I., Yano, R., Yasunishi, A., Yokota, T., Yoshida, K., Yoshiki, A., Yoshino, M., Muramatsu, M., and Hayashizaki, Y.

**TITLE** RIKEN Mouse ESTs (Konno, H., et al.)  
**JOURNAL** Unpublished (2000)  
**COMMENT** Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic  
Sciences Center(GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216

email: genome-resesc.riken.go.jp,  
URL: <http://genome-gsc.riken.go.jp/>  
Carninci, P., Nishiyama, Y., Westover, A., Itoh, M., Nagaoka, S., Sasaki,  
N., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.  
Thermotabilization and thermoactivation of thermolabile enzymes by  
trehalose and its application for the synthesis of full length  
cDNA. *Proc. Natl. Acad. Sci. U.S.A.* 95 (2), 520-524 (1998)  
Itoh, M., Kitsuai, T., Akiyama, J., Shibata, K., Izawa, M., Kawai, J.,  
Tomaru, Y., Carninci, P., Shibata, Y., Ozawa, Y., Muramatsu, M., Okazaki,  
Y. and Hayashizaki, Y.  
Automated filtration-based high-throughput plasmid preparation  
system. *Genome Res.* 9 (5), 463-470 (1999)  
Carninci, P. and Hayashizaki, Y.  
High-efficiency full-length cDNA cloning. *Methods Enzymol.* 303,  
19-44 (1999)  
Please visit our web site (<http://genome.rtc.riken.go.jp>) for

FEATURES	further details.
source	Location/Qualifiers
	1. .249

```

/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="E130012K13"
/clone_1b="RIKEN full-length enriched, 0 day neonate
eyeball"
/tissue_type="eyeball"
/dev_stage="0 day neonate"
/lab_host="DH10B"
/note="Site_1: SalI; Site_2: BamHI; cDNA library was
prepared and sequenced in Mouse Genome Encyclopedia
Project of Genome Exploration Research Group in Riken
Genomic Sciences Center and Genome Science Laboratory in
RIKEN. Division of Experimental Animal Research in Riken
contributed to prepare mouse tissues. 1st strand cDNA was
primed with a primer [5',
GAGAGAGAGAGCGCGCCGACACTCGAGTTTTTTTTTNN 3'], cDNA was
prepared by using trehalose thermo-activated reverse
transcriptase and subsequently enriched for full-length by
cap-trapper. Second strand cDNA was prepared with the
primer adapter of sequence [5',
GAGAGAGAGATTCTCGAGTTAATTAATTAATCCCCCCCCCCC 3']. cDNA
was cleaved with BamHI and XhoI. Vector: a modified
pBluescript KS(+) after bulk excision from Lambda FLX I."

```

Query Match	18.0%;	Score 89.8;	DB 10;	Length 249;
Best Local Similarity	60.4%;	Pred. No. 3.1e-17;		
Matches 148; Conservative	0;	Mismatches 97;	Indels 0;	Gaps 0;

[illegible]

Search completed: February 7, 2003, 08:49:31  
Job time : 1016.32 secs





GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 05:39:15 ; Search time 996.663 Seconds  
(without alignments)  
14629.322 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_2500\_3000  
Perfect score: 501  
Sequence: 1 ttacactggaagaagtcct.....gaggagccctcatgatga 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues  
Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vi:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vi:\*  
30: em\_htg\_hum:\*  
31: em\_htg\_inv:\*  
32: em\_htg\_other:\*  
33: em\_htg\_mus:\*  
34: em\_htg\_pln:\*  
35: em\_htg\_rod:\*  
36: em\_htg\_mam:\*  
37: em\_htg\_vrt:\*  
38: em\_sy:\*  
39: em\_htgo\_hum:\*  
40: em\_htgo\_mus:\*  
41: em\_htgo\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	499.4	99.7	2469	9	AK090793	AK090793 Homo sapi
2	499.4	99.7	3899	6	AX058220	AX058220 Sequence
3	475.4	94.9	2516	9	AB049841	AB049841 Macaca fa
4	426.4	85.1	7506	6	AX255048	AX255048 Sequence
5	426.4	85.1	7522	9	AF527605	AF527605 Homo sapi
6	426.4	85.1	7545	9	AB028981	AB028981 Homo sapi
7	366.2	73.1	2998	10	BC009134	BC009134 Mus muscu
8	359.8	71.8	3227	10	RNTRG	X68101 R.norvegicu
9	274.4	54.8	2610	6	AX058192	AX058192 Sequence
10	274.4	54.8	3152	9	AK056684	AK056684 Homo sapi
11	274.4	54.8	6454	6	AX173022	AX173022 Sequence
12	269.6	53.8	3472	6	AX173120	AX173120 Sequence
13	269.6	53.8	4391	6	AX173028	AX173028 Sequence
14	269.6	53.8	4393	6	AX173118	AX173118 Sequence
15	263.4	52.6	2299	9	AK054649	AK054649 Homo sapi
16	248	49.5	139887	9	CNS01RGX	AL160233 Human chr
17	243.4	48.6	2768	9	AB056820	AB056820 Macaca fa
18	222.2	44.4	163316	9	AL161420	AL161420 Human DNA
19	216.4	43.2	2413	9	BC015018	BC015018 Homo sapi
20	216.4	43.2	2422	9	AK000227	AK000227 Homo sapi
21	190.6	38.0	192825	2	AC119357	AC119357 Rattus no
22	179.4	35.8	182640	2	AC126253	AC126253 Mus muscu
23	171.4	34.2	10103	2	AC020032	AC020032 Drosophil
24	171.4	34.2	159350	3	AC008354	AC008354 Drosophil
25	171.4	34.2	257224	3	AE003617	AE003617 Drosophil
26	168.2	33.6	1476	6	AX399260	AX399260 Sequence
27	146.2	29.2	153026	9	AL391280	AL391280 Human DNA
28	143	28.5	147556	2	AC110359	AC110359 Rattus no
29	140.2	28.0	162378	2	AC105541	AC105541 Rattus no
30	138.6	27.7	168684	2	AC023985	AC023985 Homo sapi
31	138.6	27.7	171811	9	AC011739	AC011739 Homo sapi
32	138.2	27.6	181127	10	AL672038	AL672038 Mouse DNA
33	131.6	26.3	174041	2	AL772340	AL772340 Danio rer
34	116.4	23.2	2149	6	AX173233	AX173233 Sequence
35	116.4	23.2	2825	9	BC008335	BC008335 Homo sapi
36	116.4	23.2	6372	6	AX173175	AX173175 Sequence
37	112.8	22.5	1900	10	BC021414	BC021414 Mus muscu
38	102.6	20.5	4886	9	AB037816	AB037816 Homo sapi
39	93.4	18.6	2303	10	BC024917	BC024917 Mus muscu
40	93.4	18.6	2972	10	BC024823	BC024823 Mus muscu
41	88.2	17.6	73515	2	AC017375	AC017375 Drosophil
42	88.2	17.6	166626	3	AC008318	AC008318 Drosophil
43	88.2	17.6	301639	3	AE003590	AE003590 Drosophil
44	83.2	16.6	2014	6	AX174662	AX174662 Sequence
45	83.2	16.6	4026	6	AX174571	AX174571 Sequence

ALIGNMENTS

RESULT 1  
AK090793 2469 bp mRNA linear PRI 15-JUL-2002  
LOCUS Homo sapiens cDNA FLJ33474 fis, clone BRAMY2002369, highly similar  
to Trg protein.  
ACCESSION AK090793  
VERSION AK090793.1 GI:21749019  
KEYWORDS Oligo capring; fis (full insert sequence).  
SOURCE Homo sapiens amygdala cDNA to mRNA, clone\_lib:BRAMY2  
clone:BRAMY2002369.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE 1 Tashiro,H., Yamazaki,M., Watanabe,K., Kumagai,A., Itakura,S.,  
AUTHORS

Fukuzumi,Y., Fujimori,Y., Komiyama,M., Sugiyama,T., Irie,R., Otsuki,T., Sato,H., Wakamatsu,A., Ishii,S., Yamamoto,J., Isono,Y., Kawai-Hio,Y., Saito,K., Nishikawa,T., Kimura,K., Yamashita,H., Matsuo,K., Nakamura,Y., Sekine,M., Kikuchi,H., Kanda,K., Wagatsuma,M., Murakawa,K., Kanehori,K., Takahashi-Fujii,A., Oshima,A., Sugiyama,A., Kawakami,B., Suzuki,Y., Sugano,S., Nagahari,K., Masuko,Y., Nagai,K. and Isogai,T.  
NEDO human cDNA sequencing project  
Unpublished  
2 (bases 1 to 2469)  
Isogai,T. and Yamamoto,J.  
Direct Submission  
Submitted (04-JUL-2002) Takao Isogai, FLJ Project(HRI Team): 2-6-7 Kazusa-Kamatari, Kisarazu, Chiba 292-0812, Japan  
(E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology (RAB); cDNA library construction: Helix Research Institute (HRI) (supported by Japan Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB, HRI, and Biotechnology Center, National Institute of Technology and Evaluation; clone selection for full insert sequencing: HRI and RAB; annotation: HRI and RAB.  
FEATURES  
source  
1. 2469  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="BRAMY2002369"  
/tissue\_type="amygdala"  
/clone\_lib="BRAMY2"  
/note="cloning vector: PME18SFL3"  
BASE COUNT 666 a 561 c 556 g 686 t  
ORIGIN  
Query Match 99.7%; Score 499.4; DB 9; Length 2469;  
Best Local Similarity 99.8%; Pred. No. 2.7e-122;  
Matches 500; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 TTACACTGGAAGAAGTCTTTGTCCGGACACATTTGCAAGTCATCATATCTGTACGCCA 60  
Db 1641 TTACACTGGAAGAAGTCTTTGTCCGGACACATTTGCAAGTCATCATATCTGTACGCCA 1700  
QY 61 GCTGATAGCAGACGTTGTTGGCATTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 120  
Db 1701 GCTGATAGCAGACGTTGTTGGCATTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 1760  
QY 121 CAACAACGTGTGCCAACAGTAGCAGCGGCTTATTAAAGCACACACAGCTTCTCCTGTATGTGA 180  
Db 1761 CAACAACGTGTGCCAACAGTAGCAGCGGCTTATTAAAGCACACACAGCTTCTCCTGTATGTGA 1820  
QY 181 GGACTTAACCAAAAGGATACGACACGGTGCTAATGGCCACCGCCCAAGATGAAGAGCATGA 240  
Db 1821 GGACTTAACCAAAAGGATACGACACGGTGCTAATGGCCACCGCCCAAGATGAAGAGCATGA 1880  
QY 241 GAACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
Db 1881 GAACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 1940  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 360  
Db 1941 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 2000  
QY 361 TCTCTCAGAGGACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2001 TCTCTCAGAGGACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 2060  
QY 421 ACGGAAGGCGTGTTTAGACAAGGATGACCGCCTTCAGAGGTTCATTAACCCAAACATCGA 480  
Db 2061 ACGGAAGGCGTGTTTAGACAAGGATGACCGCCTTCAGAGGTTCATTAACCCAAACATCGA 2120  
QY 481 CGAGGAGGCGCTCCATGATGA 501  
Db 2121 CGAGGAGGCGCTCCATGATGA 2141

RESULT 2  
AX058220  
LOCUS AX058220 3899 bp DNA linear PAT 17-JAN-2001  
DEFINITION Sequence 90 from patent WO0077040.  
ACCESSION AX058220  
VERSION AX058220.1 GI:12310721  
KEYWORDS human.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 3899)  
Yue,H., Tang,Y.T., Hillman,J.L., Lal,P., Bandman,O., Baughn,M.R., Azimzai,Y., Yang,J., Reddy,R. and Lu,D.A.  
Human intracellular signaling molecules  
JOURNAL Patent: WO 0077040-A 90 21-DEC-2000;  
Incyte Genomics, Inc. (US)  
FEATURES  
source  
1. 3899  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
BASE COUNT 1078 a 929 c 949 g 943 t  
ORIGIN  
Query Match 99.7%; Score 499.4; DB 6; Length 3899;  
Best Local Similarity 99.8%; Pred. No. 2.7e-122;  
Matches 500; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 TTACACTGGAAGAAGTCTTTGTCCGGACACATTTGCAAGTCATCATATCTGTACGCCA 60  
Db 1922 TTACACTGGAAGAAGTCTTTGTCCGGACACATTTGCAAGTCATCATATCTGTACGCCA 1981  
QY 61 GCTGATAGCAGACGTTGTTGGCATTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 120  
Db 1982 GCTGATAGCAGACGTTGTTGGCATTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 2041  
QY 121 CAACAACGTGTGCCAACAGTAGCAGCGGCTTATTAAAGCACACACAGCTTCTCCTGTATGTGA 180  
Db 2042 CAACAACGTGTGCCAACAGTAGCAGCGGCTTATTAAAGCACACACAGCTTCTCCTGTATGTGA 2101  
QY 181 GGACTTAACCAAAAGGATACGACACGGTGCTAATGGCCACCGCCCAAGATGAAGAGCATGA 240  
Db 2102 GGACTTAACCAAAAGGATACGACACGGTGCTAATGGCCACCGCCCAAGATGAAGAGCATGA 2161  
QY 241 GAACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
Db 2162 GAACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2221  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 360  
Db 2222 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 2281  
QY 361 TCTCTCAGAGGACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2282 TCTCTCAGAGGACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 2341  
QY 421 ACGGAAGGCGTGTTTAGACAAGGATGACCGCCTTCAGAGGTTCATTAACCCAAACATCGA 480  
Db 2342 ACGGAAGGCGTGTTTAGACAAGGATGACCGCCTTCAGAGGTTCATTAACCCAAACATCGA 2401  
QY 481 CGAGGAGGCGCTCCATGATGA 501  
Db 2402 CGAGGAGGCGCTCCATGATGA 2422  
RESULT 3  
AB049841 2516 bp mRNA linear PRI 14-OCT-2000  
LOCUS AB049841  
DEFINITION Macaca fascicularis brain cDNA, clone:QnpA-17096.  
ACCESSION AB049841  
VERSION AB049841.1 GI:10801619

KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
FEATURES  
source  
CDS  
BASE COUNT  
ORIGIN  
Query Match  
Best Local Similarity  
Matches  
485; Conservative  
0; Mismatches  
16; Indels  
0; Gaps  
0;

1 1700 61 1760

TTTACACTGGAAGAAGTCTTGTTCGCGACACATTTGCAAGTCATCATATCTGCAGCCA 60  
TT  
TTTACACTGGAAGAAGTCTTGTTCGCGACACATTTGCAAGTCATCATATCTGCAGCCA 1759  
GCTGATAGCAGACGTTGTTGGCATTTGGGGAACACAGATTCACAGAGTCCCTGTCCATCAT 120  
TT  
GCTGATAGCAGACGTTGTTGGCATTTGGGGAACACAGATTCACAGAGTCCCTGTCCATCAT 1819

QY 121 CAACAACCTGTGCCAACAGTACCGGGCTTATTAAGCACACACACAGCTTCTCCTGTGATGTGA 180  
1820 CAACAACCTGTGCCAACAGTACCGGGCTTATTAAGCACACACACAGCTTCTCCTGTGATGTGA 1879  
QY 181 GGACTTAAACCAAAAGGATACGCACGGTGCTATATGCCCCACCGGCCAGATGAAGAGCATGA 240  
1880 GGACTTAAACCAAAAGGATACGCACGGTGCTATATGCCCCACCGGCCAGATGAAGAGCATGA 1939  
QY 241 GAACGACCCAGAGATGCTGTGGAGCCTCCAGTACAGCCTTGCCCAAAATCTATGCGCAGCAC 300  
1940 GAATGACCCAGAGATGCTGTGGAGCCTCCAGTACAGCCTTGCCCAAAATCTATGCGCAGCAC 1999  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAATGCGCGA 360  
2000 GCCTGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAATGCGCGA 2059  
QY 361 TCTCTCAGAGGCGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCAC 420  
2060 TCTCTCAGAGGCGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCAC 2119  
QY 421 ACGGAAAGCGGTGTTAGACAGGATGCACCGCCTTCAGGGTCAATTAACCCCAACATCGA 480  
2120 CCGGAAAGCGGTGTTAGACAGGATGCACCGCCTTCAGGGTCAATTAACCCCAACATCGA 2179  
QY 481 CGAGGAGCGCTCCATGATGA 501  
2180 CGAGGAGCGCTCCATGATGA 2200  
RESULT 4  
AX255048  
LOCUS  
DEFINITION  
SEQUENCE  
AX255048  
ACCESSION  
AX255048  
VERSION  
AX255048.1 GI:16074541  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens  
human.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1 (bases 1 to 7506)  
Rastelli, L.K. and Gerritsen, M.  
Angiogenesis-associated proteins, and nucleic acids encoding the  
same  
JOURNAL  
Patent: WO 0170808-A 7 27-SEP-2001;  
Curagen Corporation (US); GENENTECH, INC. (US)  
FEATURES  
source  
1. 7506  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
BASE COUNT  
2147 a 1689 c 1764 g 1906 t  
ORIGIN  
Query Match  
Best Local Similarity  
Matches  
427; Conservative  
0; Mismatches  
1; Indels  
0; Gaps  
0;

QY 1 121 4632 181 4752

TTTACACTGGAAGAAGTCTTGTTCGCGACACATTTGCAAGTCATCATATCTGTGAGCCA 60  
TT  
TTTACACTGGAAGAAGTCTTGTTCGCGACACATTTGCAAGTCATCATATCTGTGAGCCA 4631  
GCTGATAGCAGACGTTGTTGGCATTTGGGGAACACAGATTCACAGAGTCCCTGTCCATCAT 120  
TT  
GCTGATAGCAGACGTTGTTGGCATTTGGGGAACACAGATTCACAGAGTCCCTGTCCATCAT 4691  
CAACAACCTGTGCCAACAGTACCGGGCTTATTAAGCACACACAGCTTCTCCTGTGATGTGA 180  
TT  
CAACAACCTGTGCCAACAGTACCGGGCTTATTAAGCACACACAGCTTCTCCTGTGATGTGA 4751  
GGACTTAAACCAAAAGGATACGCACGGTGCTATATGCCCCACCGGCCAGATGAAGAGCATGA 240  
TT  
GGACTTAAACCAAAAGGATACGCACGGTGCTATATGCCCCACCGGCCAGATGAAGAGCATGA 4811

QY 241 GAACGACCCAGAGATGCTGGTGGACCTCCAGCTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
|||||  
Db 4812 GAACGACCCAGAGATGCTGGTGGACCTCCAGCTACAGCCTGGCCAAATCCTATGCCAGCAC 4871  
QY 301 GCCCGAGCTCAGGAAGAGCTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGCA 360  
|||||  
Db 4872 GCCCGAGCTCAGGAAGAGCTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGCA 4931  
QY 361 TCTCTCAGAGGACCAATGCTATGTCTCAGCTAACAGCCCTAGTGGCAGAATATCTCTAC 420  
|||||  
Db 4932 TCTCTCAGAGGACCAATGCTATGTCTCAGCTAACAGCCCTAGTGGCAGAATATCTCTAC 4991  
QY 421 ACGGAAG 428  
|||||  
Db 4992 ACGGAAG 4999

RESULT 5  
AF527605  
LOCUS AF527605 7522 bp mRNA linear PRI 01-AUG-2002  
DEFINITION Homo sapiens zizimin1 mRNA, complete cds.  
ACCESSION AF527605  
VERSION AF527605.1 GI:22038158  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE 1 (bases 1 to 7522)  
AUTHORS Meller,N., Irani-Tehrani,M., Kiosses,W.B., Del Pozo,M.A. and Schwartz,M.A.  
TITLE zizimin1, a novel Cdc42 activator, reveals new guanine nucleotide exchange-exchange factor domain for rho proteins  
Natl. Cell Biol. (2002) In press  
2 (bases 1 to 7522)  
AUTHORS Meller,N. and Schwartz,M.A.  
TITLE Direct Submission  
JOURNAL Submitted (05-JUL-2002) Cell Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA  
FEATURES  
source Location/Qualifiers  
1. 7522  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
56. 6265  
/note="guanine nucleotide exchange factor; Cdc42 activator"  
/codon\_start=1  
/product="zizimin1"  
/protein\_id="AA090306.1"  
/db\_xref="GI:22038159"  
/translation="MSQPELLPASAETRKFTRLSKPGTAELRQSVSEVVRGSLVLA  
KPKLIEPLDYENVIYOKTQIQLNDCLREMLFPYDDEQTAALRQGRYICSTVPAKAE  
EEAQSLEFVTECIKTYNDSMHLVNYKYEDYSGEPRQLPNKVKLDPYHAYEVDEEVD  
KDEDAASLGSOKGITKHGMLYKGNMSAISVTMRSEKRRFFHLIQLDGSYNLNFK  
DEKISKEPKGSIFLDSGMYQNNKVRFAFELKMDKSSYLLAADSEVEMEEMITIL  
NKILQNEEAMQEKRNGBDEHDEQSKLESGSGIDSYLPELAKSAREAEIKLSES  
RVKLFYLDPAQKLDFFSSAPEYKSFEEKFGKRIIVKCNDSLNFNOCVAENEGPT  
NVEPFYTLSEFDIKYNRKISADEHVDLNHFSVRMLATTSPALMNGSGQSPVLKGI  
LHEAMQYPKQGISVTCPPHDIPLVARIKVLQGSITHCAPYMKSSDSSKVAQKVL  
KNAQAQORLQYRMPEFAMARLLEKDAAGNLKNARESAIYRQDSNKLSDMDLKL  
ADFRKPERMAKLPVILGNLDTIDNVSSDFPNYNSSYIPTKQFETCKTPTFEVEE  
FVPCIRKHTQPYTITNHLVYVPPKYLKYSOKSFAKARNIAICIEFKDSEEDSOLK  
CIYGRPGPVEFTRSAFAVLHHQNPFIYDEIKLEPTQLHEKHLLLTFFHVSCDNS  
SKGSTKRVDVETQVGSWMLPKDGRVVTSEQHIPVANSANPSGYLQELGMRHYG  
PEIKWVDGSKPLKISTHLFVTVYTDQDHLNFEQYQCTESGAQALNELVKYLSL  
HAMEGHVIAFLPTILNQLFRLTRATQOEVAVNVTRVILHVAQCHEEGLESLSRY  
VKYAYKAEPYVASEYKTVHEELTKSMITILKPSADFLTSNKLKYSWFFDYLIKSM  
OHLIENSKYKLLRNQRPASVHAHAYETVVMMLPHITQKFRDNPEASKNANHSLAVFI  
KRCFTFMDRGFEVKOINNYISCPADGPKTLFEYKFEPLRVNCNHEHYIPLMPFG  
KGRIQRYQDLQLDYSLTDEFGRNHFVLGLLREVGTALQEFREVRLIAISVLKLLIK  
HSFDDRYASRSHQARIATLYLPLFGLLIENVQRINVDVSPFPVAGMTVDESLLAP  
AVNPLVTPOKGSTLDNSLHKDLGAISGIASPYTTSTPINSVNRADSRGSLISTDSG

CDS  
56. 6265  
/note="guanine nucleotide exchange factor; Cdc42 activator"  
/codon\_start=1  
/product="zizimin1"  
/protein\_id="AA090306.1"  
/db\_xref="GI:22038159"  
/translation="MSQPELLPASAETRKFTRLSKPGTAELRQSVSEVVRGSLVLA  
KPKLIEPLDYENVIYOKTQIQLNDCLREMLFPYDDEQTAALRQGRYICSTVPAKAE  
EEAQSLEFVTECIKTYNDSMHLVNYKYEDYSGEPRQLPNKVKLDPYHAYEVDEEVD  
KDEDAASLGSOKGITKHGMLYKGNMSAISVTMRSEKRRFFHLIQLDGSYNLNFK  
DEKISKEPKGSIFLDSGMYQNNKVRFAFELKMDKSSYLLAADSEVEMEEMITIL  
NKILQNEEAMQEKRNGBDEHDEQSKLESGSGIDSYLPELAKSAREAEIKLSES  
RVKLFYLDPAQKLDFFSSAPEYKSFEEKFGKRIIVKCNDSLNFNOCVAENEGPT  
NVEPFYTLSEFDIKYNRKISADEHVDLNHFSVRMLATTSPALMNGSGQSPVLKGI  
LHEAMQYPKQGISVTCPPHDIPLVARIKVLQGSITHCAPYMKSSDSSKVAQKVL  
KNAQAQORLQYRMPEFAMARLLEKDAAGNLKNARESAIYRQDSNKLSDMDLKL  
ADFRKPERMAKLPVILGNLDTIDNVSSDFPNYNSSYIPTKQFETCKTPTFEVEE  
FVPCIRKHTQPYTITNHLVYVPPKYLKYSOKSFAKARNIAICIEFKDSEEDSOLK  
CIYGRPGPVEFTRSAFAVLHHQNPFIYDEIKLEPTQLHEKHLLLTFFHVSCDNS  
SKGSTKRVDVETQVGSWMLPKDGRVVTSEQHIPVANSANPSGYLQELGMRHYG  
PEIKWVDGSKPLKISTHLFVTVYTDQDHLNFEQYQCTESGAQALNELVKYLSL  
HAMEGHVIAFLPTILNQLFRLTRATQOEVAVNVTRVILHVAQCHEEGLESLSRY  
VKYAYKAEPYVASEYKTVHEELTKSMITILKPSADFLTSNKLKYSWFFDYLIKSM  
OHLIENSKYKLLRNQRPASVHAHAYETVVMMLPHITQKFRDNPEASKNANHSLAVFI  
KRCFTFMDRGFEVKOINNYISCPADGPKTLFEYKFEPLRVNCNHEHYIPLMPFG  
KGRIQRYQDLQLDYSLTDEFGRNHFVLGLLREVGTALQEFREVRLIAISVLKLLIK  
HSFDDRYASRSHQARIATLYLPLFGLLIENVQRINVDVSPFPVAGMTVDESLLAP  
AVNPLVTPOKGSTLDNSLHKDLGAISGIASPYTTSTPINSVNRADSRGSLISTDSG

NSLPERNSEKNSLDKHQOOSTLGNVVRCDKLDQSEIKSLMCFYLKMSDDALF  
TYWNKASTSELMDEFTISEVCLHOFQYMGKRYIARTGMHARLQQLGSLDNLSTFNHS  
YGHSDADVLHQSLEANIATEVCLTALDLSLFTLAFKQDLADHGNPLMKKVEDVY  
LCFLQKHQSEFALKNVFTALRSLEYKEPSTFEYEGRADMCALCYEILKCCNSKLSIR  
TEASQLYFLMRNNDYTGKKSFVTRHLQVYIISVSQILDADVIGGTRFOQSLSTINN  
CANSDRLIKHTSSSDVKDLTKRIRYLMATQMKHEHNDMLVDLQSLAKSYAST  
PELRKTLWDSMARLHVKNGLDSEAMCYVHTALVAEYLTRKEAVQWEPPLPHSHSA  
CLRSRGVFRQGTAFRVITPNIDEASMEDVDGMDVHFNEVDLMELLECQADGLW  
KAERYELIADLYKLIPIYERKRDFERLAHLIDTLHRAYSKTEVMSGRRLGTYFR  
VAFEGQAQYQFTNDESETDVEGFEEDEGKEYIKPKLTPLEISORLKLKLYSPKES  
ENVKMIQDSGKYNPKDLDSKTYAYIQVTHVIPFDEKELQEKTEFERSHNIRREM  
PPTQTKRQGVVEQCKRRTILTAIHCFPYKKRIPVMYOHHTDNLPIEVAIDENSKK  
VAELROLCSAEVDMIKLQKLQGSVSVQVNAAGPLAYARAFLLDNTKRYPDNKVALL  
KEVFRQFVEACGQALAVNERLIKEDOLEYQOEMKANYREMAKELSEIMHEQLG"

BASE COUNT 2146 a 1694 c 1774 g 1908 t  
ORIGIN  
Query Match 85.1%; Score 426.4; DB 9; Length 7522;  
Best Local Similarity 99.8%; Pred. No. 8.1e-103;  
Matches 427; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCCCTTGTGTCGACACATTTGCACAGTCATCATATCTGTGACCCA 60  
|||||  
Db 4585 TTACACTGGAAGAAGTCCCTTGTGTCGACACATTTGCACAGTCATCATATCTGTGACCCA 4644  
QY 61 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCCACAGATCCCTGTCCATCAT 120  
|||||  
Db 4645 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCCACAGATCCCTGTCCATCAT 4704  
QY 121 CAACAACTGTGCCAAGTGTGACCGGCTTATTAAACACACACACAGCTTCTCTCTGATGTGAA 180  
|||||  
Db 4705 CAACAACTGTGCCAAGTGTGACCGGCTTATTAAACACACACACAGCTTCTCTCTGATGTGAA 4764  
QY 181 GGACTTAACCAAAAGATACGCACGCGTGTATATGCGCACCGCCAGATGAAGAGCATGA 240  
|||||  
Db 4765 GGACTTAACCAAAAGATACGCACGCGTGTATATGCGCACCGCCAGATGAAGAGCATGA 4824  
QY 241 GAACGACCCAGAGATGCTGGTGGACCTCCAGCTAACAGCCTGGGCCAAATCCTATGCCAGCAC 300  
|||||  
Db 4825 GAACGACCCAGAGATGCTGGTGGACCTCCAGCTAACAGCCTGGGCCAAATCCTATGCCAGCAC 4884  
QY 301 GCCCGAGCTCAGGAAGAGCTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGCA 360  
|||||  
Db 4885 GCCCGAGCTCAGGAAGAGCTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGCA 4944  
QY 361 TCTCTCAGAGGACCAATGCTATGTCTCAGCTAACAGCCCTAGTGGCAGAATATCTCTAC 420  
|||||  
Db 4945 TCTCTCAGAGGACCAATGCTATGTCTCAGCTAACAGCCCTAGTGGCAGAATATCTCTAC 5004  
QY 421 ACGGAAG 428  
|||||  
Db 5005 ACGGAAG 5012

RESULT 6  
AB028981 7545 bp mRNA linear PRI 10-MAY-2002  
LOCUS AB028981  
DEFINITION Homo sapiens mRNA for KIAA1058 protein, partial cds.  
ACCESSION AB028981  
VERSION AB028981.2 GI:20521745  
KEYWORDS  
SOURCE Homo sapiens brain cDNA to mRNA, clone\_lib:pb1uescriptII SK plus  
clone:hh12146s1.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE 1  
AUTHORS kikuno,R., Nagase,T., Ishikawa,K., Hirose,M., Miyajima,N.,  
Tanaka,A., Kotani,H., Nomura,N. and Ohara,O.  
TITLE prediction of the coding sequences of unidentified human genes.  
XIV. The complete sequences of 100 new cDNA clones from brain which  
code for large proteins in vitro  
JOURNAL DNA Res. 6 (3), 197-205 (1999)



MEDLINE 99397452  
PUBMED 10470851  
REFERENCE 2 (bases 1 to 7545)  
AUTHORS Ohara,O., Nagase,T. and Kikuno,R.  
TITLE Direct Submission  
JOURNAL Submitted (17-JUN-1999) Osamu Ohara, Kazusa DNA Research Institute, Laboratory of DNA Technology, Yana 1532-3, Kisarazu, Chiba 292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp, Tel:+81-438-52-3913, Fax:+81-438-52-3914)  
COMMENT On May 9, 2002 this sequence version replaced gi:5689452.  
FEATURES  
Location/Qualifiers  
1..7545  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
/clone="h12146s1"  
/tissue\_type="brain"  
/clone\_1b="pbluescriptII sr plus"  
/note="This sequence was obtained bysubcloning of the DNA fragments derived from two cDNA clones (1 - 1846 was derived from ef00877 and 1847 - 7545 was derived from h12146)."  
1..7545  
/gene="KIAA1058"  
/gene="KIAA1058"  
/gene="KIAA1058"  
/codon\_start=1  
/product="KIAA1058 protein"  
/protein\_id="BA83010.2"  
/db\_xref="GI:20521746"  
/translation="LACICLARPGRTRSCSSCRSLSDLRFQPRMQADKRTSSRYKKELVIESPLQYKDAAGEVEAESEPGVPAPKPKLIEPIDYENVIYQKTOIILNDCLEMLLEPYDFEQTAILRRGRTICSTVPAKAEEOASLFVTECIKTNSDWHLVNKKYEDYSGEFRLPNKVVKLDKLPVHYEVEDEVDKDEDAISGSGITKHGWLKGNMSAISYTMRSFKRRFFHLIQLDGSYNLFYKDEKISKPKSGIFLDSMGVVQNKKVRRFAFELKMODKSSYLLAADSEVEEMEWITILNKLIQINFEAAMOEKRNKGDHEDDEOSKLEGS GSGDLSYLPDLAKSAREAEIKLSESRVCLFYLDPAQKLEDESSAEPEVKSFEKFGKRLVVCNDSYFNLQCCVAENEGPTTNEPEFVTLISLFDIKYNRKISADFHVDLHNSVRQMLATTSPLALMGSGOSPVLKGLLHEAAMQPKQIGFVTCPPHDFILVARIKYLQGSITHCAPRYMKSDDSKVAKVLKNAKQACORLGOYRMPFAARTLIFKDSGNL DKNARFSAIYRQDSNKLSDMDMLKLADFRPEKMAKLPVILGNLDTIDNVSDFPNYVNSGYIPTKOFETCSKPTTFEEVEEFVPCIPKHTQPTIYTNHLVYPKLYKDSOKSEKARNIAICIEFKSDDEEDSQPKLCITGRPGGPVFTRSAFAAVALHHQNPETDEIKIELPTQLHEKHHLITFEFHVSCDSSSKTKRDVETQGYSWLPLIKDGRVLTSEQHIVYSANLPSGYLQYQLGMGRHYGPEIKWVDGKPLKISTHLVSTVYTQDQHLHNFFOYCOKTESGAOALGNELVKYKLSLHAMEGHVIAFLPTILNQLEFVLTRATQDEVA VNVTRVYIIHVAQCHERGLESLSRSYKYAKAEPYVASEYKTVHEELTKSMITILKPSADELTSNKLKYSWFEPDVLIKSMAQHLIENSKVKLLRNQRPASVYHHAETVYNMLMPHTQKERDNPESAKNANHSIAVETIKRCFTFMDRGFVFQKINNYISCFAGDGKTLLEYKEFEFLRVVCNHEHYIPNLMPFEGKRIQRYODLQLDYSLTDECRNHFVGLLLREYGTALQEFREVRLIAISVKNLILKHSFDDRYASRSHQARIATLYLPLFGSLIENVO RINVRDVSPEPVNAGMTVKDESILPAPVNPVLPYTPQKSTLDSNLKDLGALISGASAP YTTSTPNINSVRNADSRGSLISTDSGNSLPERNSEKSNSLDKHQSSTLGNSVVRCDKLDQSEIKSLMCFLYILKMSDDALFTYWNKASTSEIMDEFTISEVCLHQFYVGRKRYIARTGMMHARLQQLGSLDNSLTFNHSHGSDADVLHQSLELANIATEVCLITADTSLSFLLAFKNQLLADHGHNPLMKKVFDDVYLCLQKHQSETALKNYETALRSLIYKRPSTFYEGRADMCAALCYEILKCNKSLSSIRTEASQLLYFLMRNPDYTGKKSFVTRTHQVYIISVSOLIADVIGIGTRFQOQSLSIINNCANSDRLIKHTSFSDVKDLTKRIRITVMATAOMKEHENDPEMLVDLOYSLAKSYASTPELRKTWLDSMARIHVKNKGDLSAAMCYAVHTALVAEYLTRKEAVOWNEPDLPHSHSACLRRSRGVRFQGCVAFRVITPNIDEASME DVGMODVHFNEDVIMELLEQCADGLWKAREYELIADYIKLIPIYEKRRDFERLAHLYDTLHRAYSKVTVEVMSGRLLGTFRVAFRGOAAQYQFTDSFTDVEGFEDEDEGKEYIYKEPKLTPLEISIQRLIKLYSDKFGSENVKMIQDSKVNPKDLDSKYAYIQVTHVILPF FDEKELQERKTEFERSHNIRFMEFMPQTQTKRGQVEQCKRRTIITAIHCFEYVVK KRIPYMTQHTDNLNPIEYAIDEMKSVAELRQLCSSAEVDMITKLQKLQGSVSQVNA GPLAYARAFLDDTNTKRRYPDNKVKLLKEVFRQFVEACGQALAVNERLIKEDQLEREQEE MKANIREMAKELSEIMHQLG"

BASE COUNT 2175 a 1687 c 1753 g 1930 t  
ORIGIN

Query Match 85.1%; Score 426.4; DB 9; Length 7545;  
Best local Similarity 99.8%; Pred. No. 8.1e-103;  
Matches 427; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCTTTGTCCGGACACATTGGCAAGTCATCATCTGTCAACCA 60  
|||||  
Db 4608 TTACACTGGAAGAAGTCTTTGTCCGGACACATTGGCAAGTCATCATCTGTCAACCA 4667  
QY 61 GCTGATAGCAGACGTTGTGGCATTGGGAAACCAAGATTCCAGACAGTCCCTGTCCATCAT 120  
|||||  
Db 4668 GCTGATAGCAGACGTTGTGGCATTGGGGAAACCAAGATTCCAGACAGTCCCTGTCCATCAT 4727  
QY 121 CAACAACCTGTGCCAACACAGTGAACCGCTTATTTAAGCACACACAGCTTCTCTGATGTGAA 180  
|||||  
Db 4728 CAACAACCTGTGCCAACACAGTGAACCGCTTATTTAAGCACACACAGCTTCTCTGATGTGAA 4787  
QY 181 GGACTTAAACCAAAAGGATACGACGCTGCTAATGCCACCGCCAGATGAAGAGCATGA 240  
|||||  
Db 4788 GGACTTAAACCAAAAGGATACGACGCTGCTAATGCCACCGCCAGATGAAGAGCATGA 4847  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCACAC 300  
|||||  
Db 4848 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCACAC 4907  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCAGATGCCAGATCCATGTCAAAAATGGCCA 360  
|||||  
Db 4908 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCAGATGCCAGATCCATGTCAAAAATGGCCA 4967  
QY 361 TCTCTCAGAGCCAGCAATGTGCTATGTCCACGTAAACAGCCCTAGTGGCAGATATCTCAC 420  
|||||  
Db 4968 TCTCTCAGAGCCAGCAATGTGCTATGTCCACGTAAACAGCCCTAGTGGCAGATATCTCAC 5027  
QY 421 ACGGAAAG 428  
|||||  
Db 5028 ACGGAAAG 5035  
RESULT 7  
BC009134  
LOCUS  
DEFINITION  
2998 bp mRNA linear ROD 07-AUG-2002  
BC009134  
MUS musculus, similar to hypothetical protein FLJ20220, clone  
MG:11827 IMAGE:3596515, mRNA, complete cds.  
ACCESSION  
BC009134  
VERSION  
BC009134.1 GI:14318664  
KEYWORDS  
MGC.  
SOURCE  
house mouse.  
ORGANISM  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
1 (bases 1 to 2998)  
AUTHORS  
Strausberg,R.  
TITLE  
Direct Submission  
JOURNAL  
Submitted (05-JUN-2001) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
REMARK  
NIH-MGC Project URL: http://mgc.nci.nih.gov  
COMMENT  
Contact: MGC help desk  
Email: cgabs-remail.nih.gov  
Tissue Procurement: Jeffrey Green M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Baylor College of Medicine Human Genome  
Sequencing Center  
Center code: BCM-HGSC  
Web site: http://www.hgsc.bcm.tmc.edu/cdna/  
Contact: amgebcm.tmc.edu  
Gunaratne, P.H., Garcia, A.M., Lu, X., Huiyk, S.W., Hale, S.M.,  
Yoon, V.S., Kowis, C.R., Lawrence, S., Martin, R.G., Muzny, D.M.,  
Richards, S., Gibbs, R.A.  
Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov  
Series: IRAK Plate: 16 Row: 1 Column: 2  
This clone was selected for full length sequencing because it  
passed the following selection criteria: Hexamer frequency ORF



QY	362	CTCTCAGAGGCACGCAATGTGCTATGTCCACGTAACAGCCCCCTAGTGGCAGAATAATCTCAC	421
Db	635	CTCTCAGAGGCACGCAATGTGCTATGTCCACGTAACAGCCCCCTAGTGGCAGAATAATCTCAC	694
QY	422	CGGAAG 428 	
Db	695	CGGAAG 701	
RESULT	9		
LOCUS	AX058192	2610 bp	DNA
DEFINITION	Sequence 62 from Patent WO0077040.		Linear
ACCESSION	AX058192		PAT 17-JAN-2001
VERSION	AX058192.1	GI:12310693	
KEYWORDS	human.		
SOURCE	human.		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 2610)		
AUTHORS	Yue,H., Tang,Y.T., Hillman,J.L., Lal,P., Bandman,O., Baughn,M.R., Azimzai,Y., Yang,J., Reddy,R. and Lu,D.A.		
TITLE	Human intracellular signaling molecules		
JOURNAL	Patent: WO 0077040-A 62 21-DEC-2000;		
FEATURES	Incyte Genomics, Inc. (US) Location/Qualifiers 1..2610		
BASE COUNT	878 a 467 c 529 g 736 t		
ORIGIN	/organism="Homo sapiens" /db_xref="taxon:9606"		
Query Match	54.8%; Score 274.4; DB 6; Length 2610;		
Best Local Similarity	71.8%; Pred.No. 2.5e-62;		
Matches	359; Conservative 0; Mismatches 141; Indels 0; Gaps 0;		
QY	2	TACACTGGAAGAAGTCCTTTGTGCCGACACATTGGCAAGTCATCATATCTGTACGCCAG	61
Db	591	TATACCAAAAGAAACCTTTTGAGGACACATCTACAGATAATAATTGCTGTAAGCCA	650
QY	62	CTGATAGCAGACGTTGTCATTGGGGAACCAAGATTCACAGACAGTCCCCTGCATCATC	121
Db	651	CTGATAGCTATGATGACACTAAGCGGAGATCAAGATTTCAAGAGTCTTTATTCATTATC	710
QY	122	AACAACGTGCCAACAGTAGACCGGCTTATTAAAGCACACCAAGCTTCTCCTGTGATGAAG	181
Db	711	AATAATTTGCAATAAGTAGACAGACCTATGAAGGCAACTGCCTTTCCCGCAGAGTCAAA	770
QY	182	GACTTAACCAAAAGATACGCACGGTCTAATGGCCACCGCCAGATGAAGAGCATGAG	241
Db	771	GACTTGACCAAGACAATCCGCACTGTTCTTATGGCCACTGCCCAAATGAAGAGCATGAG	830
QY	242	AACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGGCAGCAG	301
Db	831	AAAGACCCCTGAATGCTAATTGATCTCCAGTATAGCTTAGCCAAAGTCCATGCAAGCACC	890
QY	302	CCCGAGCTCAGGAAGACGTGGCTGCACAGCATGGCCAGATCCATGTCAAAAAATGGCGAT	361
Db	891	CCAGAGCTCAGGA AAAACCTGGCTGATAGCATGGCCAAAGATTCATGTAAAAATGGAGAT	950
QY	362	CTCTCAGAGGCACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTACA	421
Db	951	TTTTTCAGAGGCTGCGATGTGTTATGTCCATGTAGCAGCTCTAGTTGCAGAGTTTCTTCAT	1010
QY	422	CGAAAAGCGTGT TAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAAAACATCGAC	481
Db	1011	CGAAAAAAATATTTCTTACCGGATGTTCAAGCGTTCAAGAAAATTTACTCCAAATATAGAT	1070
QY	482	GAGGAGGCTCCATGATGA 501	
Db	1071	GAAGAAGCAATGAAAGA 1090	

RESULT 10	AK056684	3152 bp	mRNA	linear	PRI 01-AUG-2002
LOCUS	AK056684				
DEFINITION	Homo sapiens cDNA FLJ32122 fis, clone PEBL1000144, moderately similar to Trg.				
ACCESSION	AK056684				
VERSION	AK056684.1	GI:16552156			
KEYWORDS	oligo capping; fis (full insert sequence).				
SOURCE	Homo sapiens peripheral blood mononuclear cells (HPBMC5939) cDNA to mRNA, clone_lib:PEBL1 clone:PEBL1000144.				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
AUTHORS	1				
	Ishibashi,T., Kanehori,K., Yosida,M., Watanabe,S., Ishida,S., Ono,Y., Hotuta,T., Hiraoka,K., Murakawa,K., Takiguchi,S., Kusano,J., Watanabe,M., Fujimori,K., Tanai,H., Ishida,M., Yamashita,H., Chiba,Y., Sugiyama,T., Irie,R., Otsuki,T., Wakamatsu,A., Ishii,S., Yamamoto,J., Isono,Y., Kawai-Hio,Y., Saito,K., Nishikawa,T., Kimura,K., Matsuo,K., Nakamura,Y., Sekine,M., Kikuchi,H., Kanda,K., Wagatsuma,M., Takahashi-Fujii,A., Oshima,A., Sugiyama,A., Kawakami,B., Suzuki,Y., Sugano,S., Nagahari,K., Masuhio,Y., Nagai,K. and Isogai,T.				
TITLE	NEDO human cDNA sequencing project				
JOURNAL	Unpublished				
REFERENCE	2 (bases 1 to 3152)				
AUTHORS	Isogai,T., Otsuki,T. and Sugiyama,T.				
TITLE	Direct Submission				
JOURNAL	Submitted (24-OCT-2001) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986) NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology (RAB); cDNA library construction: Helix Research Institute (HRI) (supported by Japan Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB, HRI, and Biotechnology Center, National Institute of Technology and Evaluation; clone selection for full insert sequencing: RAB and HRI.				
FEATURES					
source	Location/Qualifiers				
	1..3152				
	/organism="Homo sapiens"				
	/db_xref="taxon:9606"				
	/clone="PEBL1000144"				
	/cell_type="peripheral blood mononuclear cells (HPBMC5939)"				
	/clone_lib="PEBL1"				
	/note="cloning vector: pME18SFL3-primary culture, peripheral blood mononuclear cells"				
	154..2799				
	/note="unnamed protein product"				
	/codon_start=1				
	/protein_id="BAB71253.1"				
	/db_xref="GI:16552157"				
	/translation="MPNSASRDEFPCCGFTSPANRGSISTDKDTAYGSGFQNGHGTRKREDSRGLPEGATGFPDQNGTNGTROSSTRSSVSQYNRDLQYEIRSLMKCYLIYKMSIEDTLTYWNKVSPOELINILILEVCLFHERYMGKRIARVHADWLSKMFGIDRKSQTMALRNKSGVMQARLQHLSSLESFSLNHSSTTTEEDIFHQALLGNLTATEVSLVIDTISEFTQCFKTLQNLNDGNHMDLKKVFDIHLAFLNKQSEVSLKHVAFSLRAFLSKPFAFFKGRVNMCAAFCEYELKCTSKISSTRNEASALLYLMRNNFEYTRKTFPLRTHLQIIAVSQLIADVALESGSRFQESLFIINNEANSRPMKATAFAPAEVKDLTKRIRTVLMATAQMEHEKDEPEMLIDQYSLAKSYASTPELRKTWDSMAKIHVKNGDSEAMCYVHYAALVAEFLHRKKLFPNGCSAFKKITPNIDEGAMKEDAGMDVHYSEVLELLEOCVDGLMKAERYEIISEISKLVIPIYEKRRREFKLTQVYRTLHGAVTKILEVMHTKKRLIGTFRRVAFYGGQSFEEEDGKEYIKPEKLTGLSEISLRVLKLYGKEFGTENVKIIQDSDVNAKELDPKYAHIOVTYVVKPYEDDKELTERTEEFERNHNISRFVEAPYTLSGKKGCIIEQCRRITILTSNSFPYVKRIPINCEQINLKPIDVATDEIKDTAELQKLCSSSTDVMIQLOLKGCVSQVNAGPLAYARAFPLNDSQASKYPKKSVELEDMFRKEIQACSIALELNERLIKEDOVEYHEGLKSNFRDMVKELSDIIHQILQEDTMHSPWMSNTLHVCAISGTSSDRGCSPRYAFV"				
CDS					
	1058 a 576 c 638 g 880 t				



ORIGIN									
Query Match 54.8%; Score 274.4; DB 9; Length 3152;									
Best Local Similarity 71.8%; Pred. No. 2.5e-62;									
Matches 359; Conservative 0; Mismatches 141; Indels 0; Gaps 0;									
QY	2	TACACTGGAAGAAGTCCCTTGTTCGGACACATTTGGACATCATCATATCTGTACGCCAG	61						
Db	1120	TATACCAAAAGGAAAACCTTTTGGAGGACACATCTACAGATATAATTTGCTGTAAGCCAA	1179						
QY	62	CTGATAGCAGACGTTGTTGGCATTTGGGAAACAGATTCCAGCAGTCCCTGTCCATCATC	121						
Db	1180	CTGATAGCTGATGTAGCAGTAAGCGGAGAGATCAAGATTTCAGGAGTCTTATTCATTATC	1239						
QY	122	AACAAGTGTGCCAACAGTGAACCGGCTTATTAAACACACAGCAGCTTCTCTCATGTGAAG	181						
Db	1240	AATAATTTGCAAAATAGTGACAGACCTATGAAGCAACTGCCTTTCCCGCAGAAGTCAAA	1299						
QY	182	GACTTAACCAAAAGGATACGACGCGTGTAAATGCGCACCGCCAGATGAAGGAGCATGAG	241						
Db	1300	GACTTGACCAAGAGAATCCGCACTGTTCTTATGCGCACTGCCCCAAATGAAGGAGCATGAG	1359						
QY	242	AACGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAGC	301						
Db	1360	AAAGACCTCGAAATGCTAATTGATCTCCAGTATAGCTTAGCCAAAGTCTATGCAAGCACC	1419						
QY	302	CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGCATTCATGTCAAAAATGGCGAT	361						
Db	1420	CCAGAGCTCAGGAAAAACCTGGCTTGATGACATGGCCAGATTCATGTAAAAATGGAGAT	1479						
QY	362	CTCTCAGAGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCACA	421						
Db	1480	TTTTCAGAGGCTGCGATGTTATGTCCATGTAGCAGGCTTAGTTGACAGAGTTTCTTCAT	1539						
QY	422	CGGAAAGCGCTGTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGAC	481						
Db	1540	CGAAAAAAATTATTTCTTAACGAGATGTTCAAGCGTTCAAGAAAAATTACTCCCAATATAGAT	1599						
QY	482	GAGAGGCGCTCCATGATGGA	501						
Db	1600	GAAGAAGGAGCAATGAAGA	1619						
RESULT 11									
AX173022 6454 bp DNA linear PAT 03-JUL-2001									
LOCUS AX173022 Sequence 1 from Patent WO0142294.									
DEFINITION AX173022									
ACCESSION AX173022									
VERSION AX173022.1 GI:14597975									
KEYWORDS									
SOURCE human.									
ORGANISM Homo sapiens									
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;									
Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.									
REFERENCE 1 (bases 1 to 6454)									
AUTHORS Lu, P., Garman, J.D. and Candia, A.F.									
TITLE Clasp-4 transmembrane protein									
JOURNAL Patent: WO 0142294-A 1 14-JUN-2001;									
Arbor Vita Corporation (US)									
FEATURES									
source location/Qualifiers									
1..6454									
/organism="Homo sapiens"									
/db_xref="taxon:9606"									
/note="full length human CLASP-4 cDNA"									
95..6121									
CDS									
/note="human CLASP-4"									
/codon_start=1									
/protein_id="CAC43729.1"									
/db_xref="GI:14597976"									
/translation="MFPEDISISVIGRORTVOSTVPEDAERKRAOSLFVKECIKTY									
TDMHYVNYKYEDFSGDFRMLPCKSLRPEKIPNHVEFIDEDCEKEDSSSLCSQKGV									
KOGWLHKANVNSTITVTMKVFKRYFYITOLPDGSYIINSYKDEKNSKESKCIYLD									
A CIDVYQCPKMRRHAFELKMDKYSHYLAETQEEMEWLITLKKIIQINTSLVQEK									

BASE COUNT 2119 a 1234 c 1303 g 1798 t									
ORIGIN									
Query Match 54.8%; Score 274.4; DB 6; Length 6454;									
Best Local Similarity 71.8%; Pred. No. 2.6e-62;									
Matches 359; Conservative 0; Mismatches 141; Indels 0; Gaps 0;									
QY	2	TACACTGGAAGAAGTCCCTTGTTCGGACACATTTGCAAGTCAATCATCTGTCAGCCAG	61						
Db	4442	TATACCAAAAGGAAAACCTTTTGGAGGACACATCTACAGATAATATGCTGTAAGCCAA	4501						
QY	62	CTGATAGCAGACGTTGTTGGCATTTGGGGAACAGATTCCAGCAGTCCCTGTCCATCATC	121						
Db	4502	CTGATAGCTGATGTAGCAGTAAGCGGAGAGATCAAGATTTCAGGAGTCTTATTTCATTATC	4561						
QY	122	AACAAGTGTGCCAACAGTGACCGGCTTATTAAACACACAGCAGCTTCTCTGTGATGAAG	181						
Db	4562	AATAATTTTGCAAATAGTGACAGACCTATGAAGCCAACCTGCTTCCCGCAGAAGTCAAA	4621						
QY	182	GACTTAACCAAAAGGATACGACGCGTGTAAATGCGCACCGCCAGATGAAGGAGCATGAG	241						
Db	4622	GACTTGACCAAGAGAATCCGCACTGTTCTTATGCCACTGCCCAAAATGAAGGAGCATGAG	4681						
QY	242	AACGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAGC	301						
Db	4682	AAAGACCTCGAAATGCTAATTGATCTCCAGTATAGCTTAGCCAAAGTCTATGCAAGCACC	4741						
QY	302	CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGAT	361						
Db	4742	CCAGAGCTCAGGAAAACCTGGCTTGATAGCATGGCCAAAGATTCAATGTAAAAAATGGAGAT	4801						
QY	362	CTCTCAGAGCAGCAATGTGCTATGTCCACAGTAAACAGCCCTAGTGGCAGAAATATCTACA	421						
Db	4802	TTTTCAGAGGCTGCGATGTTATGTCCATGTAGCAGCCTAGTTGACAGATTCTTCAT	4861						
QY	422	CGGAAAGCGCTGTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGAC	481						
Db	4862	CGAAAAAAATTATTTCTTAACGAGATGTTCAAGCGTTCAAGAAAAATTACTCCCAATATAGAT	4921						
QY	482	GAGGAGGCGCTCCATGATGGA	501						
Db	4922	GAAGAAGGAGCAATGAAGA	4941						



RESULT	12
LOCUS	AXI73120
DEFINITION	AXI73120 Sequence 99 from Patent WO0142294.
ACCESSION	AXI73120
VERSION	AXI73120.1
KEYWORDS	GI:14598013
SOURCE	.
ORGANISM	synthetic construct. synthetic construct artificial sequences.
REFERENCE	1 (bases 1 to 3472).
AUTHORS	Lu, P., Garman, J.D. and Candia, A.F.
TITLE	ClaSP-4 transmembrane protein
JOURNAL	Patent: WO 0142294-A 99 14-JUN-2001; Arbor Vita Corporation (US)
FEATURES	Location/Qualifiers
Source	1..3472 /organism="synthetic construct" /db_xref="taxon:32630" /note="polynucleotide fragment"
BASE COUNT	1153 a       640 c       696 g       983 t
ORIGIN	

Query Match	53.8%;	Score 269.6;	DB 6;	Length 3472;
Best Local Similarity	71.2%;	pred. No. 4.8e-61;		
Matches 356; Conservative	0;	Mismatches 144;	Indels 0;	Gaps 0;

QY	2	TACACTGGAAGAAGTCCTTTGTGCCGACACATTTGCAGTCAATCATATCTGTCCAGCAG	61
Db	1461	TATACCAAAAGSAAACCCTTTTGAGGACACATCTACAGATAATTAATTGCTGTAAGCCA	1520
QY	62	CTGATAGCAGACGTTGTTGGCATTGGGGAAACCAGATTCCAGCAGTCCCCTGTCCATATC	121
Db	1521	CTGATAGCTGATGTATGACACTAAGCGGAGGATCAAGATTTCAGGAGTCTTATTATTCATTATC	1580
QY	122	AACAACGTGCCCCAACAGTAGCACCGGCTTATTAAAGCAGACACCAAGCTTCTCCTGTATGTAAG	181
Db	1581	AATAATTTTGCATAATAGTGACAGACCTATGTGGCAAGAGCCTTTCCCGCAGAAGTCAA	1640
QY	182	GACTTAACCAAAAAGGATACGCACGGTGCTAATGCGCACCGCCAGATGAAGAGCATGAG	241
Db	1641	GACTTGACCAAGAAGATCCGCACCTGTTCTTATGGCCACTGCCCAATGAAGAGAGCATGAG	1700
QY	242	AACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCGCAGCAG	301
Db	1701	AAAGACCCGTGAATGCTTAATTGATCTCCAGTATAGCTTAGCCAAAGTCCATGCAAGCACC	1760
QY	302	CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAAATGGCGAT	361
Db	1761	CCAGAGCTCAGSAAACCTGGCTTGATAGCATGGCCAGAAGATTCATGTAAAAAATGGAGAT	1820
QY	362	CTCTCAGAGGCAACAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTACA	421
Db	1821	TTTTACAGAGGCTGCGATGTGTATGTCCATGTAGCAGCCTTAGTTGCAGAGCTTCTTCAT	1880
QY	422	CGGAAGGCGTGTTTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGAC	481
Db	1881	CGAAAAAAATTAATTTCCCTAACGGATGTTACGCGTTCAAGAAAAATTACTCCCAATATAGAT	1940
QY	482	GAGGAGGCTTCATGATGGA	501
Db	1941	GAAGAAGGAGCAATGAAAGA	1960

RESULT	13
LOCUS	AX173028
DEFINITION	Sequence 7 from Patent WO014294.
ACCESSION	AX173028
VERSION	AX173028.1
KEYWORDS	. GI:14597978
	4391 bp DNA linear PAT 03-JUL-2001

SOURCE	human.
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	1 (bases 1 to 4391)
TITLE	Lu, P., Garman, J.D. and Candia, A.F.
JOURNAL	Clasp-4 transmembrane protein Patent: WO 0142294-A 7 14-JUN-2001;
FEATURES	Arbor Vita Corporation (US)
	Location/Qualifiers
source	1. .4391

CDS

/note="human CLASP-4"  
 /codon\_start=1  
 /protein\_id="CAC43730.1"  
 /db\_xref="GI:14597979"  
 /translation="MEIQVLRFLSVILMQLFWVLPNMTHEDVPISCPMLFHIYSK  
 CHEEGLDYSLSSEIKYSFRPGKPSAPQAPLIHETLATMTALLKQSAFLAINKLKY  
 SWFFETIAKSMATYLLLEENKIKITLQGRPEKAYHNHALHSFLAITIVESQYAEIKRE  
 SRNVNYSLASLEKCCCLTLMDRGFVNLINDYISGFSPKDRVLAEEKFEELQTCNHE  
 HYIPLNPMFAFAPKPLQRVQDSNLEYSLSDEYCKHFLVGLLRETSIALQDNEYTRY  
 TAIISVTKNLLIKHAFDTRYQHKNOAKIAQLYPFVGLLENIQRLAGRDTLYSCAM  
 PNSARDEFPFCGFTSPANRGLSTDYKFGYSGFONGHGIKREDSRGLIPEGATFED  
 QGNTGENTRQSTRSSVSQYNRLDQYETRSLMCLYLYAKMISEDLLTYWNKVSPOE  
 LNILILEVCLFHEFRYMGKRNRLARVDAWLSKHGFIDRSQTMPLARNRSGVMQARL  
 QHLSLESSFTLNHSSTTTEADIFHQALLEGNATATEVSLTVLDTISFTQCFKTHPLN  
 NDGHNPLMKQVFDIHAFLEKNGQSEVSLKHVEASLRAPISKPSAFKGRVNMCAFC  
 YEVLCCTSKISSTRNEASALLYLMLRNNEEYTKRKTFRFLTHLIIAIVSOLIAVADP  
 SGGSRQESLEIINNPFANDSRMLARAFAEVDKTRKTRVTLMTAIAQMEHEKDEPM  
 LIDLOYSLAKSYASTPELRKRTWLDMAKIHVKNQGFSEAMCYVHVAALVAEFLHKK  
 LEPNGCSAFKKITPNIDEGAMKEDAGMDVDHYSEVLELLEQCVNGLMAKEREIT  
 SEISKLIGPIYENRREFENLTOYRTLGHAYTKILEVMHTRKRLGTFFRVAFYQGSF  
 FEEEDGKEYIKPEKPLTGLSEISRLVLYGKEFGTENKIIQSDKVNAKELDPKYA  
 HIQVTYVKKPYFDDELTERKTEFERNNHISRFVEAPAYLSGKKQGCIEEOCKRRTIL  
 TTSNFSFYVKKRIPINCEQQLNLKPIDGATDEIKDKTAELQKLCSSSTDVDMIOQLKL  
 QGWVSQVQAGPLAYARAFLENDSSAKYPPKVSSELKMERKFIQACSIALLENRLIK  
 KEDQVEYHGLKSNFRDMKELSDIIHQIQLQEDTMHSPWMSNTLHVFCALISGTSSDR  
 GYGSRYAEV"

Query Match	53.8%;	Score 269.6;	DB 6;	Length 4391;
Best Local Similarity	71.2%;	Pred. No. 4.8e-61;		
Matches 356;	Conservative 0;	Mismatches 144;	Indels 0;	Gaps 0;

QY	2	TACACTGGAAAGAAGCTCCTTTGTGCCGACACATTTGGCAAGTCATCATATCTGTCAGCCAG	61
Dd	2379	TATACCMAAAGCAAACCTTTTTTGAGGACACATCTACAGATAATATGTGCTGTAAGCCAA	2438
QY	62	CTGATAGCAGACCGTGTGTTGGCATTTGGGGAAAACCAATTCCAGCAGTCCCCTGCATCATC	121
Dd	2439	CTGATAGCTGATGTAGCACTAAAGCGGAGGATCAAGATTTCAAGAGTCTTTATTCATTTATC	2498
QY	122	AACAACGTGTGCCAACAGTAGCACCGGCTTATTTAAGCACACCAAGCTTCTCCTCTGATGTGAAG	181
Dd	2499	AATAATTTTGCAATATAGTGCACAGACCTATAGTTGGCAAGAGCCTTTCCCGCAGAGTCAAA	2558
QY	182	GACTTTAACCAAAAGGATAGCGCACGGTGTCTAATGGCCACCGCCAGATGAAGAGCATGAG	241
Dd	2559	GACTTGACCAAGAGAAATCCGCACCTGTTCTTATGGCCACTGCCCAAAATGAAGAGCATGAG	2618
QY	242	AACGACCCAGAGATGCTGTGGACCTCCAGATPACAGCCTGGCCAAATCCTATGCCAGCAG	301
Dd	2619	AAAGACCCCTGAATATGCTAATTTGATCTCCAGTATPAGCTTTAGCCAAAGTCTCATGCAAGCACC	2678
QY	302	CCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATTCATGTCAAAAAATGGCGAT	361
Dd	2679	CCAGAGCTCAGGAAGAAACCTGGCTTGATAGCATGGCCCAAGATTCTATGTA AAAAATGGAGAT	2738
QY	362	CTCTCAGAGGCGAGCAATGTGCTATATGTCCACAGTAAACAGCCCTAGTGGCAGATAATCTCACA	421

Db 2739 TTTTCAGAGCGCTGCATGTGTATGTCCATGTAGCAGCTCTAGTTCAGAGTTCCTTCAT 2798  
QY 422 CGGAAGGCGGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTTACCCCAACATCGAC 481  
Db 2799 CGAAAAAATATTTCTTAACGGATGTTCCAGCGCTTCAGAAAATTAATCTCCCATATAGAT 2858  
QY 482 GAGGAGGCGCTTCATGATGA 501  
Db 2859 GAAGAAGGAGCAATGAAGA 2878  
RESULT 14  
AX173118  
LOCUS AX173118 4393 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 97 from Patent WO0142294.  
ACCESSION AX173118  
VERSION AX173118.1 GI:14598012  
KEYWORDS .  
SOURCE synthetic construct.  
ORGANISM synthetic construct.  
REFERENCE 1 (bases 1 to 4393)  
AUTHORS Lu,P., Garman,J.D. and Candia,A.F.  
TITLE Clasp-4 transmembrane protein  
JOURNAL Patent: WO 0142294-A 97 14-JUN-2001;  
Arbor Vita Corporation (US)  
FEATURES  
source 1.4393  
/organism="synthetic construct"  
/db\_xref="taxon:32630"  
/note="polynucleotide fragment"  
BASE COUNT 1359 a 852 c 910 g 1272 t  
ORIGIN

Query Match 53.8%; Score 269.6; DB 6; Length 4393;  
Best Local Similarity 71.2%; Pred. No. 4.8e-61;  
Matches 356; Conservative 0; Mismatches 144; Indels 0; Gaps 0;

QY 2 TACACTGGAAGAAGTCTTGTCTCCGACACATTTGCCAAGTCATCATCTGTCTCAGCCAG 61  
Db 2379 TATACCAAAAGAAACCTTTTGAAGACACATCTACAGATAATATGCTGTAAGCCAA 2438  
QY 62 CTGATAGCAGACGTTGTTGGCATTGGGGAACAGATTCCAGCAGTCCCTGTCATCATC 121  
Db 2439 CTGATAGCTGATGTAGCACTAAGCGGAGGATCAAGATTTCAGGAGTCTTTATTCATTATC 2498  
QY 122 AACAACTGTGCCAACAGTGAACGGCTTATTAAGCACACAGCCTTCTCTGTGATGGAAG 181  
Db 2499 AATAATTTTGCAAAATAGTACAGACCTATGTTGGCAAGAGCCTTTCGCCGAGAAGTCAAA 2558  
QY 182 GACTTTAACCAAAAGATACGACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGAG 241  
Db 2559 GACTTGACCAAGAGATCCGCACTGTCTTATGGCCACTGCCCAATGAAGAGCATGAG 2618  
QY 242 AACGACCCAGAGATGCTGTGAGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAG 301  
Db 2619 AAAGACCCGTGAATGCTAATTGATCTCCAGTATAGCTTAGCCAAAGTCTTATGCCAAGCACC 2678  
QY 302 CCCGAGCTCAGGAAGAGCTGGCTCGACAGCATGGCCAGGATTCATGTCAAAAATGGCGAT 361  
Db 2679 CCAGAGCTCAGGAAGAACTGGCTTGATAGCAATGGCCAAAGATTCAATTAATAAATGGAGAT 2738  
QY 362 CTCTCAGAGGCAGCAATGTCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCACA 421  
Db 2739 TTTTCAGAGGCTGCGATGTGTATGTCCATGTAGCAGCTCTAGTTGCAAGATTCTTCAT 2798  
QY 422 CGGAAGGCGGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTTACCCCAACATCGAC 481  
Db 2799 CGAAAAAATATTTCTTAACGGATGTTCCAGCGCTTCAGAAAATTAATCTCCCATATAGAT 2858  
QY 482 GAGGAGGCGCTTCATGATGA 501  
II III I IIII II

Db 2859 GAAGAAGGAGCAATGAAGA 2878  
RESULT 15  
AK054649  
LOCUS AK054649 2299 bp mRNA linear PRI 01-AUG-2002  
DEFINITION Homo sapiens CDNA FLJ30087 fls, clone BNGH4100003, moderately similar to R.norvegicus trf mRNA.  
ACCESSION AK054649  
VERSION AK054649.1 GI:16549234  
KEYWORDS oligo capping; fls (full insert sequence).  
SOURCE Homo sapiens neuroglioma cell\_line:H4 CDNA to mRNA,  
clone\_lib:BNGH41 clone:BNGH41000003.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1  
AUTHORS Nishi,T., Nakagawa,S., Senoh,A., Mizuguchi,H., Inagaki,H., Sugiyama,T., Irie,R., Otsuki,T., Sato,H., Ota,T., Wakamatsu,A., Ishii,S., Yamamoto,J., Isono,Y., Kawai-Hio,Y., Saito,K., Nishikawa,T., Kimura,K., Yamashita,H., Matsuo,K., Nakamura,Y., Sekine,M., Kikuchi,H., Kanda,K., Wagatsuma,M., Murakawa,K., Kanehori,K., Takahashi-Fujii,A., Oshima,A., Sugiyama,A., Kawakami,B., Suzuki,Y., Sugano,S., Nagahari,K., Masuho,Y., Nagai,K. and Isogai,T.  
TITLE MEDO human cDNA sequencing project  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 2299)  
AUTHORS Isogai,T., Otsuki,T. and Sugiyama,T.  
TITLE Direct Submission  
JOURNAL Submitted (24-OCT-2001) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
MEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; CDNA full insert sequencing: Research Association for Biotechnology (RAB); CDNA library construction: Helix Research Institute (HRI) (supported by Japan Key Technology Center etc.); 5'- & 3'-end one pass sequencing: RAB, HRI, and Biotechnology Center, National Institute of Technology and Evaluation; clone selection for full insert sequencing: RAB and HRI.

FEATURES  
source 1.2299  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="BNGH41000003"  
/cell\_line="H4"  
/cell\_type="neuroglioma"  
/clone\_lib="BNGH41"  
/note="cloning vector: pME18SFL3"  
BASE COUNT 780 a 392 c 471 g 656 t  
ORIGIN

Query Match 52.6%; Score 263.4; DB 9; Length 2299;  
Best Local Similarity 71.7%; Pred. No. 2.1e-59;  
Matches 359; Conservative 0; Mismatches 141; Indels 1; Gaps 1;

QY 2 TACACTGGAAGAAGTCTTGTCCGACACATTTGCCAAGTCATCATCTGTCTCAGCCAG 61  
Db 287 TATACCAAAAGAAACCTTTTGAAGGACACATCTACAGATAATATTCGTGAAGCCAA 346  
QY 62 CTGATAGCAGAGCTGTTGGCATTGGGGAACACAGATTCCAGCAGTCCCTGTCCATCATC 121  
Db 347 CTGATAGCTGATGTAGCACTAAGCGGAGGATCAAGATTTCAGGAGTCTTTATTCATTATC 406  
QY 122 AACAACTGTGCCAACAGTGAACGGCTTATTAAGCACACAGCTTCTCTGTGATGGAAG 181  
Db 407 AATAATTTTGCAAAATAGTACAGACCTATGAAGCAACTGCCCTTCCCGCAGAAGTCAAA 466  
QY 182 GACTTTAACCAAAAGATACGACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGAG 241  
Db 467 GACTTGACCAAGAGATCCGCACTGTTCTTATGGCCACTGCCCAATGAAGAGCATGAG 526  
II III I IIII II

QY 242 AACGACCCAGAGATGCTGGTGACCTCCAGTACAGCCCTGGCCAATCCCTATGCCAGCAGC 301  
  || ||||| || ||||| | || ||||| ||| | ||||| ||||| |||||  
Db 527 AAAGACCCCTGAATGCTATGTGATCTCCAGTATAGCTTAGCCAAGTCCCTATGCAAGCACC 586  
  || ||||| ||||| || ||||| || ||||| || ||||| ||||| |||||  
QY 302 CCCGAGCTCAGGAGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGAT 361  
  || ||||| ||||| || ||||| || ||||| || ||||| ||||| |||||  
Db 587 CCAGAGCTCAGGAAAACCTGGCTTGATAGCATGGCCAGATTCATGTAAAAAATGGAGAT 646  
  || ||||| ||||| || ||||| || ||||| || ||||| ||||| |||||  
QY 362 CTCTCAGAGGCAGCAATGTGCTATGTCCACGTAAACAGCCCTAGTGGCAGAAATATC-TCAC 420  
  | ||||| || ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 647 TTTCAGAGGCTGCGATGTGTATGTCCATGTAGCAGCTCTAGTGCAGAGTTTCTTCAAT 706  
  || ||||| || ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 421 ACGGAAAGGCGTGTAGACAAGCATGCACCGCCCTTCAGGGTCATTACCCCAACATCGA 480  
  ||| | ||| | ||||| || ||||| || ||||| ||||| ||||| |||||  
Db 707 CGAAAAAAATTAATTCCTAACGGATGTTCAGCGTTCAGAAAAATTACTCCCAATATAGA 766  
  ||| | ||| | ||||| || ||||| || ||||| ||||| ||||| |||||  
QY 481 CGAGGAGGCTTCATGATGA 501  
  || ||| | ||||| ||  
Db 767 TGAAGAAGGAGCAATGAAGA 787  
  || ||| | ||||| ||

Search completed: February 7, 2003, 08:03:39  
Job time : 1021.66 secs







XX  
PI Lu PS;  
XX  
DR WPI; 2002-416861/44.  
DR P-PSDB; ABG61673.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis -  
XX  
PS Disclosure; Figure 3A; 245bp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.  
XX  
SQ Sequence 3614 BP; 1009 A; 834 C; 874 G; 897 T; 0 other;  
  
Query Match 100.0%; Score 501; DB 24; Length 3614;  
Best Local Similarity 100.0%; Pred. No. 9.9e-142;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1487 GGACTTAACCAAAAGGATACGCACGGTGCTAATATGGCCACCGCCAGATGAAGAGCATGA 1546  
|||||  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
|||||  
DB 1547 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 1606  
|||||  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAATGGCGGA 360  
|||||  
DB 1607 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAATGGCGGA 1666  
|||||  
QY 361 TCTCTCAGAGGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCAC 420  
|||||  
DB 1667 TCTCTCAGAGGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCAC 1726  
|||||  
QY 421 ACGGAAGCGCTGTTAGACAAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 480  
|||||  
DB 1727 ACGGAAGCGCTGTTAGACAAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 1786  
|||||  
QY 481 CGAGGAGCGCTCCATGATGA 501  
|||||  
DB 1787 CGAGGAGCGCTCCATGATGA 1807  
|||||  
  
RESULT 2  
ABK84971  
ID ABK84971 standard; cDNA; 3642 BP.  
XX  
AC ABK84971;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #6.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; DiGeorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI; 2002-416861/44.  
DR P-PSDB; ABG61677.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis -  
XX  
PS Disclosure; Figure 3A; 245bp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that

CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g., an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.

XX SQ Sequence 3642 BP; 1005 A; 899 C; 877 G; 861 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 3642;  
Best Local Similarity 100.0%; Pred. No. 9.9e-142;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCCCTTGTCCGACACATTTGCAAGTCATCATCTGCAGCCA 60  
|||||  
Db 2028 TTACACTGGAAGAAGTCCCTTGTCCGACACATTTGCAAGTCATCATCTGCAGCCA 2087  
QY 61 GCTGATAGACAGCGTTGTTGGCATTTGGGAAACAGATTCACGACAGTCCCTGCCATCAT 120  
|||||  
Db 2088 GCTGATAGACAGCGTTGTTGGCATTTGGGAAACAGATTCACGACAGTCCCTGCCATCAT 2147  
QY 121 CAACAACGTGTGCCAACAGATGACCGGCTTATTAGCACACACAGCTTCTCCTGTGATGAA 180  
|||||  
Db 2148 CAACAACGTGTGCCAACAGATGACCGGCTTATTAGCACACACAGCTTCTCCTGTGATGAA 2207  
QY 181 GGACTTAACCAAAAGGATACCGCAGCGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
|||||  
Db 2208 GGACTTAACCAAAAGGATACCGCAGCGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2267  
QY 241 GAACGACCCAGAGATGCTGTGTGACCTCCAGTACAGCGCTGGCCAAATCCTATGCCAGCAC 300  
|||||  
Db 2268 GAACGACCCAGAGATGCTGTGTGACCTCCAGTACAGCGCTGGCCAAATCCTATGCCAGCAC 2327  
QY 301 GCCCGAGCTCAGAGAAGACGTGGCTGCACAGCATGCGCCAGAGATCCATGTCAAAAATGGCGA 360  
|||||  
Db 2328 GCCCGAGCTCAGAGAAGACGTGGCTGCACAGCATGCGCCAGAGATCCATGTCAAAAATGGCGA 2387  
QY 361 TCTCTCAGAGGACGACATGTGCTATGTCCACGTACACAGCCCTAGTGGCAGAATATCTCAC 420  
|||||  
Db 2388 TCTCTCAGAGGACGACATGTGCTATGTCCACGTACACAGCCCTAGTGGCAGAATATCTCAC 2447  
QY 421 ACGGAAGGCGGTGTTAGACAAGATGACCGCCTTCAGGGTCAATTACCCCAACATCGA 480  
|||||

Db 2448 ACGGAAGGCGGTGTTAGACAAGATGACCGCCTTCAGGGTCAATTACCCCAACATCGA 2507  
QY 481 CGAGGAGGCTTCATGATGGA 501  
|||||  
Db 2508 CGAGGAGGCTTCATGATGGA 2528

RESULT 3  
ID ABK84968 standard; cDNA: 3705 BP.  
XX  
AC ABK84968;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #3.

KW Human; autoimmune disease; haematopoietic disorder; DiGeorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.

XX Homo sapiens.  
XX  
XX WO200231117-A2.  
XX  
XX 18-APR-2002.  
XX  
XX 15-OCT-2001; 2001WO-US32202.  
XX  
XX 13-OCT-2000; 2000US-0687837.

PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.

XX Lu PS;  
XX  
XX WPI: 2002-416861/44.  
XX  
XX P-PSDB; ABG61674.

PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis

PS Disclosure; Figure 3A; 245pp; English.

XX The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g., an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or



disorders of the immune system, by activating or inhibiting the activation, differentiation of immune cells and can treat or detect deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides or polynucleotides can increase differentiation and proliferation of haematopoietic cells, including the pluripotent stem cells to treat those disorders associated with a decrease in certain (or many) types of haematopoietic cells e.g., immunologic deficiency syndromes including blood protein disorders (e.g., agammaglobulinaemia, dysgammaglobulinaemia, ataxia telangiectasia, common variable immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia, Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus, endometriosis, autoimmune thyroiditis, and autoimmune pulmonary inflammation. CLASP-2 can be used to treat anaphylaxis or hypersensitivity to an antigenic molecules, organ rejection or graft-versus-host disease (GVHD) and inflammation. ABK84922-ABK85018 represent cadherin-like asymmetry protein (CLASP) coding sequences and PCR primers of the invention.

Sequence 3705 BP; 1017 A; 911 C; 899 G; 878 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 3705;  
Best Local Similarity 100.0%; Pred. No. 1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTACACTGGAAGAAGTCCTTTGTCCGACACATTTGCAGTCATCATCTGTCAGCCA 60  
2022 TTACACTGGAAGAAGTCCTTTGTCCGACACATTTGCAGTCATCATCTGTCAGCCA 2081  
61 GCTGATAGCAGACGTTGTTGGCAATTGGGAACAGATTCAGCAGTCCCTGTCCATCAT 120  
2082 GCTGATAGCAGACGTTGTTGGCAATTGGGAACAGATTCAGCAGTCCCTGTCCATCAT 2141  
121 CAACAACCTGTGCCACACAGTGACCGGCTTATTAAAGCACACACAGCTTCTCTGATGTGAA 180  
2142 CAACAACCTGTGCCACACAGTGACCGGCTTATTAAAGCACACACAGCTTCTCTGATGTGAA 2201  
181 GGACTTAACCAAAAGGATACGACGGGTCTAATGGCCACCGCCAGATGAAGGAGCATGA 240  
2202 GGACTTAACCAAAAGGATACGACGGGTCTAATGGCCACCGCCAGATGAAGGAGCATGA 2261  
241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
2262 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2321  
301 GCCGAGCTCAGGAAGACGTTGGTCGACAGCATGCGCCAGATTCATGCAAAAATGGCGA 360  
2322 GCCGAGCTCAGGAAGACGTTGGTCGACAGCATGCGCCAGATTCATGCAAAAATGGCGA 2381  
361 TCTCTCAGAGCAGCAATGTGCTATGTCACAGTACAGCCCTAGTGGCAGAATATCTCAC 420  
2382 TCTCTCAGAGCAGCAATGTGCTATGTCACAGTACAGCCCTAGTGGCAGAATATCTCAC 2441  
421 ACGGAAAGGCGTGTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 480  
2442 ACGGAAAGGCGTGTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 2501  
481 CGAGGAGGCTTCATGATGA 501  
2502 CGAGGAGGCTTCATGATGA 2522

RESULT 4  
ABK84964  
ID ABK84964 standard; cDNA; 4806 BP.  
XX ABK84964;  
XX ABK84964;  
XX 13-AUG-2002 (first entry)  
DT  
XX DNA encoding cadherin-like asymmetry protein (CLASP).  
DE  
XX

Human; autoimmune disease; haematopoietic disorder; DiGeorge syndrome; blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia; ataxia telangiectasia; common variable immunodeficiency; lymphopenia; thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease; haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus; endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity; autoimmune pulmonary inflammation; organ rejection; inflammation; CLASP; gene; ss.

Homo sapiens.  
WO200231117-A2.  
18-APR-2002.  
15-OCT-2001; 2001WO-US32202.  
13-OCT-2000; 2000US-0687837.

(ARBO-) ARBOR VITA CORP.  
(GARW/) GARMAN J D.  
(CAND/) CANDIA A F.

Lu PS;

WPI; 2002-416861/44.  
P-PSDB; ABG61670.

New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating an immune response, and for treating multiple sclerosis, rheumatoid arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock, and sepsis

Disclosure; Figure 1; 245pp; English.

The invention relates to an isolated polypeptide (I) comprising an amino acid sequence that has 90 % sequence identity to one of the human cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E) sequences (PS). (I) is useful for identifying a compound or agent that binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for detecting a CLASP-2 polypeptide in a sample. (II) is useful for inhibiting a immune response in a subject. A pharmaceutical composition comprising a nucleic acid encoding (I), or (II) is useful for preventing or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where the autoimmune disease is caused or exacerbated by increased activity of Th1 cells. CLASP-2 polynucleotides are useful as probes or primers for detection or inhibition of CLASP-2 expression (e.g., antisense or ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2 polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-2 antibodies or are used as therapeutic polypeptides. The CLASP-2 polynucleotide or fragments can be used in diagnostics (e.g., as probes for CLASP-2 expression), as a lymphocyte marker and for therapeutic purposes. CLASP-2 polynucleotides can construct transgenic and knockout animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2 polynucleotides can screen for CLASP-2 agonists and antagonists. CLASP-2 polypeptides or polynucleotides can treat deficiencies or disorders of the immune system, by activating or inhibiting the activation, differentiation of immune cells and can treat or detect deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides or polynucleotides can increase differentiation and proliferation of haematopoietic cells, including the pluripotent stem cells to treat those disorders associated with a decrease in certain (or many) types of haematopoietic cells e.g., immunologic deficiency syndromes including blood protein disorders (e.g., agammaglobulinaemia, dysgammaglobulinaemia, ataxia telangiectasia, common variable immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia, Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus, endometriosis, autoimmune thyroiditis, and autoimmune pulmonary inflammation. CLASP-2 can be used to treat anaphylaxis or hypersensitivity to an antigenic molecules, organ rejection or graft-versus-host disease (GVHD) and inflammation. ABK84922-ABK85018



```
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and
CC PCR primers of the invention.
XX
SQ Sequence 4806 BP; 1352 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match          100.0%; Score 501; DB 24; Length 4806;
Best Local Similarity 100.0%; Pred. No. 1.1e-141;
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGAGTCTTGTGTCGGGACACATTTGGCAAGTCATCATATCTGTGCAGCCA 60
Db 2499 TTACACTGGAAGAAGAGTCTTGTGTCGGGACACATTTGGCAAGTCATCATATCTGTGCAGCCA 2558

QY 61 GCTGATAGCAGACGTTGTTGGCATGGGGAAACCAGATTCCAGCAGTCCCTGTCCATCAT 120
Db 2559 GCTGATAGCAGACGTTGTTGGCATGGGGAAACCAGATTCCAGCAGTCCCTGTCCATCAT 2618

QY 121 CAACAACCTGTGCCAACAGTAGCCGGCTTATTAAGCACACACAGCTTCTCCTCTGATGTGAA 180
Db 2619 CAACAACCTGTGCCAACAGTAGCCGGCTTATTAAGCACACACAGCTTCTCCTCTGATGTGAA 2678

QY 181 GGACTTAACCAAAAGGATACGCACGGTGCTTAATGGCCACCGCCAGATGAAGAGCATGA 240
Db 2679 GGACTTAACCAAAAGGATACGCACGGTGCTTAATGGCCACCGCCAGATGAAGAGCATGA 2738

QY 241 GAAGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300
Db 2739 GAAGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2798

QY 301 GCCCGAGCTCAGGAAGACGTTGGCTGCAGACGATGGCCAGAGTCATGTCAAAAATGGCGA 360
Db 2799 GCCCGAGCTCAGGAAGACGTTGGCTGCAGACGATGGCCAGAGTCATGTCAAAAATGGCGA 2858

QY 361 TCTCTCAGAGCAGCAATGTGCTATGTCCACGTAACAGGCCCTAGTGGCAGAATATCTCAC 420
Db 2859 TCTCTCAGAGCAGCAATGTGCTATGTCCACGTAACAGGCCCTAGTGGCAGAATATCTCAC 2918

QY 421 ACGGAAAGCGGTGTTTAGACAAGGATGCACCGCCTTCAGGGTCATTTACCCCAAAACATCGA 480
Db 2919 ACGGAAAGCGGTGTTTAGACAAGGATGCACCGCCTTCAGGGTCATTTACCCCAAAACATCGA 2978

QY 481 CGAGAGGCGCTCCATGATGGA 501
Db 2979 CGAGAGGCGCTCCATGATGGA 2999

RESULT 5
AAC87972
ID AAC87972 standard; cDNA; 4807 BP.
XX
AC AAC87972;
XX
DT 07-MAR-2001 (first entry)
XX
DE Human CLASP-2 nucleotide sequence.
XX
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;
KW hypersensitivity; transplantation rejection response; immunodeficiency;
KW proliferation; differentiation; inflammatory response; arthritis;
KW inflammatory bowel disease; hematopoietic cell; blood protein disorder;
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;
KW endometriosis; pregnancy induced hypertension; ss.
XX
OS Homo sapiens.
XX
PN WO200061747-A2.
XX
PD 19-OCT-2000.
XX
PF 13-APR-2000; 2000WO-US10158.
```

```
XX
PR 14-APR-1999; 99US-0129171.
PR 14-MAY-1999; 99US-0134114.
PR 14-MAY-1999; 99US-0134117.
PR 14-MAY-1999; 99US-0134118.
PR 21-OCT-1999; 99US-0160860.
PR 29-OCT-1999; 99US-0162498.
PR 13-DEC-1999; 99US-0170453.
PR 14-JAN-2000; 2000US-0176195.
PR 14-FEB-2000; 2000US-0182296.
XX
PA (ARBO-) ARBOR VITA CORP.
XX
PI Lu PS;
XX
DR WPI; 2000-619230/59.
DR P-PSDB; AAB36527.
XX
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and
PT inflammatory responses -
XX
PS Example 1; Fig 1; 286pp; English.
XX
CC The present invention describes cadherin-like asymmetry protein-2
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be
CC used to inhibit an immune response in a subject by interfering with the
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An
CC immune response in a subject may also be inhibited by administering an
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,
CC proteins and antibodies can be used to prevent or treat a CLASP-2
CC mediated disease, such as an autoimmune disease caused or exacerbated
CC by increased activity of TH1 cells. They can also be used to treat
CC hypersensitivities, prevent transplantation rejection responses and
CC augment immune responsiveness in immunodeficiency states, inhibit
CC proliferation and differentiation of cells involved in an inflammatory
CC response e.g, arthritis, inflammatory bowel disease and increase
CC differentiation and proliferation of haematopoietic cells e.g. to treat
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders
CC treated by disrupting CLASP-2 function include multiple sclerosis,
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.
CC The present sequence encodes human CLASP-2, which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match          100.0%; Score 501; DB 21; Length 4807;
Best Local Similarity 100.0%; Pred. No. 1.1e-141;
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGAGTCTTGTGTCGGGACACATTTGCAAGTCATCATATCTGTGAGCCA 60
Db 2500 TTACACTGGAAGAAGAGTCTTGTGTCGGGACACATTTGCAAGTCATCATATCTGTGAGCCA 2559

QY 61 GCTGATAGCAGACGTTGTTGGCATTGGGAAACCAGATTCCAGACAGTCCCTGTCCATCAT 120
Db 2560 GCTGATAGCAGACGTTGTTGGCATTGGGAAACCAGATTCCAGACAGTCCCTGTCCATCAT 2619

QY 121 CAACAACCTGTGCCAACAGTAGCCGGCTTATTAAGCACACACAGCTTCTCCTCTGATGTGAA 180
Db 2620 CAACAACCTGTGCCAACAGTAGCCGGCTTATTAAGCACACACAGCTTCTCCTCTGATGTGAA 2679

QY 181 GGACTTAACCAAAAGGATACGCACGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240
Db 2680 GGACTTAACCAAAAGGATACGCACGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2739

QY 241 GAAGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300
Db 2740 GAAGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2799

QY 301 GCCCGAGCTCAGGAAGACGTTGGCTGCAGAGATGGCCAGAGTCCATGTCAAAAATGGCGA 360
```

|||||  
Db 2800 GCCCGAGCTCAGAGAAGACGTCGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGA 2859  
QY 361 TCTCTCAGAGGAGCAATGTGCTATGTCACGTAACAGAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2860 TCTCTCAGAGGAGCAATGTGCTATGTCACGTAACAGAGCCCTAGTGGCAGAATATCTCAC 2919  
QY 421 ACGGAAAGGCGTGTAGACAAGGATGACCGCCTTCAGGGGTCATTACCCCAACATCGA 480  
Db 2920 ACGGAAAGGCGTGTAGACAAGGATGACCGCCTTCAGGGGTCATTACCCCAACATCGA 2979  
QY 481 CGAGGAGGCTCCATGATGGA 501  
Db 2980 CGAGGAGGCTCCATGATGGA 3000  
  
RESULT 6  
AAC87973  
ID AAC87973 standard; cDNA; 4807 BP.  
XX AC AAC87973;  
XX DT 07-MAR-2001 (first entry)  
XX DE Human CLASP-2A nucleotide sequence.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosiis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX PD 19-OCT-2000.  
XX PF 13-APR-2000; 2000MO-US10158.  
XX PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI: 2000-619230/59.  
DR P-PSDB; AAB36528.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Example 1; Fig 2B; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An

CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e,g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosiis and pregnancy induced hypertension.  
CC The present sequence encodes human CLASP-2A, which is used in the  
CC exemplification of the present invention.  
XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;  
  
Query Match 100.0%; Score 501; DB 21; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 TTACACTGGAAGAAGATCCCTTTGTGCCGACACATTTGCAAGTCATCATCTGTACGCCA 60  
Db 2500 TTACACTGGAAGAAGATCCTTTGTGCCGACACATTTGCAAGTCATCATCTGTACGCCA 2559  
  
QY 61 GCTGATAGCAGACGCTGTGGCATTTGGGGAAACAGATTCACAGACAGTCCCTGTCCATCAT 120  
Db 2560 GCTGATAGCAGACGCTGTGGCATTTGGGGAAACAGATTCACAGACAGTCCCTGTCCATCAT 2619  
  
QY 121 CAACAACTGTGCCAACAGTGAACGGCTTATTAAAGCACACACAGCCTTCTCCTGTATGTGAA 180  
Db 2620 CAACAACTGTGCCAACAGTGAACGGCTTATTAAAGCACACACAGCCTTCTCCTGTATGTGAA 2679  
  
QY 181 GGACTTAACCAAAAGGATACGCACGGTGTCTAATGCCCACCGCCAGATGAAGAGCATGA 240  
Db 2680 GGACTTAACCAAAAGGATACGCACGGTGTCTAATGCCCACCGCCAGATGAAGAGCATGA 2739  
  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
Db 2740 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2799  
  
QY 301 GCCCGAGCTCAGAGAAGAGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 360  
Db 2800 GCCCGAGCTCAGAGAAGAGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 2859  
  
QY 361 TCTCTCAGAGGAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2860 TCTCTCAGAGGAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 2919  
  
QY 421 ACGGAAAGGCGTGTAGACAAGGATGACCGCCTTCAGGGGTCATTACCCCAACATCGA 480  
Db 2920 ACGGAAAGGCGTGTAGACAAGGATGACCGCCTTCAGGGGTCATTACCCCAACATCGA 2979  
  
QY 481 CGAGGAGGCTCCATGATGGA 501  
Db 2980 CGAGGAGGCTCCATGATGGA 3000  
  
RESULT 7  
ABK84966  
ID ABK84966 standard; cDNA; 4807 BP.  
XX AC ABK84966;  
XX DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #1.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;

KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
PI Lu PS;  
XX  
XX WPI; 2002-416861/44.  
DR P-PSDB; ABG61672.  
XX  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis -  
XX  
XX  
PS Disclosure; Figure 3A; 245pp; English.  
XX  
XX The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening for CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.  
XX  
XX Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 TTACACTGGAAAGAGTCCCTTTGTCGGAGACATTTGCAAGTCATCATATCTGTCAGCCA 60  
DB 2500 TTACACTGGAAAGAGTCCCTTTGTCGGAGACATTTGCAAGTCATCATATCTGTCAGCCA 2559  
QY 61 GCTGATAGCAGACGTTGTTGGCAATTGGGGAAACCAGATTCCAGCAGTCCCTGTCCATCAT 120  
DB 2560 GCTGATAGCAGACGTTGTTGGCAATTGGGGAAACCAGATTCCAGCAGTCCCTGTCCATCAT 2619  
QY 121 CAACAACCTGTGCCAACACAGTACCAGCGGCTTATTAAACACACACAGCTTCTCCTGTGATGTA 180  
DB 2620 CAACAACCTGTGCCAACACAGTACCAGCGGCTTATTAAACACACACAGCTTCTCCTGTGATGTA 2679  
QY 181 GGACTTAAACCAAAAGGATACGCACGGGTGCTAATGGCCACCGCCAGATGAAGGAGCATGA 240  
DB 2680 GGACTTAAACCAAAAGGATACGCACGGGTGCTAATGGCCACCGCCAGATGAAGGAGCATGA 2739  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGGCCAGCAC 300  
DB 2740 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGGCCAGCAC 2799  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCATGTCAAAAATGGCGA 360  
DB 2800 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCATGTCAAAAATGGCGA 2859  
QY 361 TCTCTCAGAGGCGAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
DB 2860 TCTCTCAGAGGCGAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 2919  
QY 421 ACGGAAAGCGCTGTTTAGACAAGATGACACCGCCTTCAGGGTCAATTACCCCAACATCGA 480  
DB 2920 ACGGAAAGCGCTGTTTAGACAAGATGACACCGCCTTCAGGGTCAATTACCCCAACATCGA 2979  
QY 481 CGAGGAGCCTTCATGATGA 501  
DB 2980 CGAGGAGCCTTCATGATGA 3000  
RESULT 8  
ABK84973  
ID ABK84973 standard; DNA; 4807 BP.  
XX  
AC ABK84973;  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; DiGeorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ds.  
XX  
XX Homo sapiens.  
OS  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.



PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI: 2002-416861/44.  
DR P-PSDB; ABG61686.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis -  
XX  
PS Example 4: Figure 6A; 245bp; English.  
XX

CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists.  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences  
CC and PCR primers of the invention.  
XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCCTTTGTCGACACATTTCAGATCATATCTGTACGCCA 60  
DB 2500 TTACACTGGAAGAAGTCCTTTGTCGACACATTTCAGATCATATCTGTACGCCA 2559  
QY 61 GCTGATAGCAGAGCTTGTGGCATTGGGGAACACAGATTCACAGATCCCTGTCATCAT 120  
DB 2560 GCTGATAGCAGAGCTTGTGGCATTGGGGAACACAGATTCACAGATCCCTGTCATCAT 2619  
QY 121 CAACAACTGTGCCAACAGTGAACCGGCTTATTAAACACACACAGCTTCTCTGATGTGAA 180  
PB 2620 CAACAACTGTGCCAACAGTGAACCGGCTTATTAAACACACACAGCTTCTCTGATGTGAA 2679

QY 181 GGACTTAACCAAAAGATACGACGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
DB 2680 GGACTTAACCAAAAGGATACGACCGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2739  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
DB 2740 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2799  
QY 301 GCGCGAGCTCAGGAGACGCGTGGCTGCACAGCATGGCCAGCATCCATGTCAAAAATGGCGA 360  
DB 2800 GCGCGAGCTCAGGAGACGCGTGGCTGCACAGCATGGCCAGCATCCATGTCAAAAATGGCGA 2859  
QY 361 TCTCTCAGAGGCGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
DB 2860 TCTCTCAGAGGCGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 2919  
QY 421 ACGGAAAGCGGTGTTAGACAAGGATGCACCGCCTCAGGGTCAATTACCCCAACATCGA 480  
DB 2920 ACGGAAAGCGGTGTTAGACAAGGATGCACCGCCTCAGGGTCAATTACCCCAACATCGA 2979  
QY 481 CGAGGAGGCGCTCCATGATGA 501  
DB 2980 CGAGGAGGCGCTCCATGATGA 3000

RESULT 9  
AAC87974  
ID AAC87974 standard; cDNA; 4898 BP.  
XX  
XX AAC87974;  
XX  
XX AC  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #1.  
XX  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritis; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX  
DR WPI: 2000-619230/59.  
DR P-PSDB; AAB36529.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -



XX Disclosure; Fig 10A; 286pp; English.  
PS  
CC The present invention describes cadherin-like asymmetry protein-2  
XX (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;  
  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
OY 1 TTACACTGGAAAGAGTCCCTTGTCCGGACACATTTGCAGTCATCATCTGTCAGCCA 60  
Db 2591 TTACACTGGAAAGAGTCCCTTGTCCGGACACATTTGCAGTCATCATCTGTCAGCCA 2650  
OY 61 GCTGATAGCAGACGTTGTTGGCATGGGGAAACAGATTCACAGTCCCTGTCATCAT 120  
Db 2651 GCTGATAGCAGACGTTGTTGGCATGGGGAAACAGATTCACAGTCCCTGTCATCAT 2710  
OY 121 CAACAACTGTGCCAACAGTGCACCGGCTTATTAGCACACAGCCTTCTCCTGTGATGAA 180  
Db 2711 CAACAACTGTGCCAACAGTGCACCGGCTTATTAGCACACAGCCTTCTCCTGTGATGAA 2770  
OY 181 GGACTTAAACCAAAGGATAGCAGCGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
Db 2771 GGACTTAAACCAAAGGATAGCAGCGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2830  
OY 241 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
Db 2831 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2890  
OY 301 GCCCGAGCTCAGSAGAAGCGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAAATGGCGA 360  
Db 2891 GCCCGAGCTCAGSAGAAGCGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAAATGGCGA 2950  
OY 361 TCTCTCAGAGGAGCAATGTGCTATGTCACAGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2951 TCTCTCAGAGGAGCAATGTGCTATGTCACAGTAACAGCCCTAGTGGCAGAATATCTCAC 3010  
OY 421 ACGGAAAGGCGTCTTAGACAAGGATGACCGCCTTCAGGGTCAATTACCCCAACATCGA 480  
Db 3011 ACGGAAAGGCGTCTTAGACAAGGATGACCGCCTTCAGGGTCAATTACCCCAACATCGA 3070  
OY 481 CGAGGAGGCGCTCCATGATGA 501  
Db 3071 CGAGGAGGCGCTCCATGATGA 3091

RESULT 10  
AAC87975  
ID AAC87975 standard; cDNA; 4898 BP.  
XX  
AC AAC87975;

XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #2.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX  
DR WPI; 2000-619230/59.  
XX  
XX Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
XX Disclosure; Fig 10B; 286pp; English.  
PS  
XX The present invention describes cadherin-like asymmetry protein-2  
XX (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;  
  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCTTTGTGCCGACACATTTGCAAGTCATATCTGTACGCCA 60  
|||  
Db 2591 TTACACTGGAAGAAGTCTTTGTGCCGACACATTTGCAAGTCATATCTGTACGCCA 2650  
QY 61 GCTGATAGCAGACGTTGTTGGCATTGGGGAACCAAGATTCAGACAGTCCCTGTCATCAT 120  
|||  
Db 2651 GCTGATAGCAGACGTTGTTGGCATTGGGGAACCAAGATTCAGACAGTCCCTGTCATCAT 2710  
QY 121 CAACAACCTGTGCCAACAGTGAACCGGCTTATTAAGCACACCAGCTTCTCCTGATGTGAA 180  
|||  
Db 2711 CAACAACCTGTGCCAACAGTGAACCGGCTTATTAAGCACACCAGCTTCTCCTGATGTGAA 2770  
QY 181 GGACTTAACCAAAAGATACGCACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
|||  
Db 2771 GGACTTAACCAAAAGATACGCACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2830  
QY 241 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 300  
|||  
Db 2831 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 2890  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 360  
|||  
Db 2891 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 2950  
QY 361 TCTCTCAGAGGACGCAATGCTATGTCTCCACGTTACAGCCCTAGTGGCAGATATCTCAC 420  
|||  
Db 2951 TCTCTCAGAGGACGCAATGCTATGTCTCCACGTTACAGCCCTAGTGGCAGATATCTCAC 3010  
QY 421 ACGGAAGGCGTGTTTAGACAAGATGACACCGGCTTCAGGGTCAATTACCCCAACATCGA 480  
|||  
Db 3011 ACGGAAGGCGTGTTTAGACAAGATGACACCGGCTTCAGGGTCAATTACCCCAACATCGA 3070  
QY 481 CGAGAGGCGCTCCATGATGA 501  
|||  
Db 3071 CGAGAGGCGCTCCATGATGA 3091

RESULT 11  
AAC87976  
ID AAC87976 standard; cDNA; 4898 BP.  
XX  
AC AAC87976;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #3.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
hypersensitivity; transplantation rejection response; immunodeficiency;  
proliferation; differentiation; inflammatory response; arthritis;  
inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
endometriosis; pregnancy induced hypertension; ss.  
KW  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.

PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI; 2000-619230/59.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10C; 286pp; English.

CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAAGTCTTTGTCCGACACATTTGCAAGTCATCATATCTGTACGCCA 60  
|||  
Db 2591 TTACACTGGAAGAAGTCTTTGTCCGACACATTTGCAAGTCATCATATCTGTACGCCA 2650  
QY 61 GCTGATAGCAGACGTTGTTGGCATTGGGGAACCAAGATTCAGACAGTCCCTGTCATCAT 120  
|||  
Db 2651 GCTGATAGCAGACGTTGTTGGCATTGGGGAACCAAGATTCAGACAGTCCCTGTCATCAT 2710  
QY 121 CAACAACCTGTGCCAACAGTGAACCGGCTTATTAAGCACACCAGCTTCTCCTGATGTGAA 180  
|||  
Db 2711 CAACAACCTGTGCCAACAGTGAACCGGCTTATTAAGCACACCAGCTTCTCCTGATGTGAA 2770  
QY 181 GGACTTAACCAAAAGATACGCACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
|||  
Db 2771 GGACTTAACCAAAAGATACGCACGCTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2830  
QY 241 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 300  
|||  
Db 2831 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 2890  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 360  
|||  
Db 2891 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAAATGGCGA 2950  
QY 361 TCTCTCAGAGGACGCAATGCTATGTCTCCACGTTACAGCCCTAGTGGCAGATATCTCAC 420  
|||  
Db 2951 TCTCTCAGAGGACGCAATGCTATGTCTCCACGTTACAGCCCTAGTGGCAGATATCTCAC 3010  
QY 421 ACGGAAGGCGTGTTTAGACAAGATGACACCGGCTTCAGGGTCAATTACCCCAACATCGA 480  
|||  
Db 3011 ACGGAAGGCGTGTTTAGACAAGATGACACCGGCTTCAGGGTCAATTACCCCAACATCGA 3070

QY 481 CGAGGAGGCTCCATGATGGA 501  
|||||  
Db 3071 CGAGGAGGCTCCATGATGGA 3091

RESULT 12

AAC87977  
ID AAC87977 standard; cDNA; 4898 BP.

AC AAC87977;

DT 07-MAR-2001 (first entry)

DE Preliminary CLASP-2 nucleotide sequence #4.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.

PN WO200061747-A2.

XX 19-OCT-2000.

PF 13-APR-2000; 2000WO-US10158.

XX 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.

PA (ARBO-) ARBOR VITA CORP.

PI Lu PS;

DR WPI; 2000-619230/59.

XX Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -

XX Disclosure; Fig 10D; 286pp; English.

XX The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders

CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1,1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAGAGTCTTTGTCCGACACATTGGCAAGTCATCATATCTGTCAGCCA 60  
Db 2591 TTACACTGGAAGAGTCTTTGTCCGACACATTGGCAAGTCATCATATCTGTCAGCCA 2650  
QY 61 GCTGATAGCAGACGTTGTTGGCATTTGGGAAACAGATTCCAGCAGTCCTGTCATCAT 120  
Db 2651 GCTGATAGCAGACGTTGTTGGCATTTGGGAAACAGATTCCAGCAGTCCTGTCATCAT 2710  
QY 121 CAACAACGTGCCCAACAGTGCACCGGCTTATTAAGCACACACAGCTTCTCTGATGTGAA 180  
Db 2711 CAACAACGTGCCCAACAGTGCACCGGCTTATTAAGCACACACAGCTTCTCTGATGTGAA 2770  
QY 181 GGACTTAACCAAAAGGATACGACGCGTGCTAATGGCCACCGCCAGATGAGAGCATGA 240  
Db 2771 GGACTTAACCAAAAGGATACGACGCGTGCTAATGGCCACCGCCAGATGAGAGCATGA 2830  
QY 241 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCTATGCCAGCAC 300  
Db 2831 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCTATGCCAGCAC 2890  
QY 301 GCCCGAGCTCAGGAAGACGCTGGCTGCACAGCATGGCCAGATCCATGTCAAAATGGCGA 360  
Db 2891 GCCCGAGCTCAGGAAGACGCTGGCTGCACAGCATGGCCAGATCCATGTCAAAATGGCGA 2950  
QY 361 TCTCTCAGAGGCAGCAATGTGCTATGTCCACGTACAGCCCTAGTGGCAGAAATATCTCAC 420  
Db 2951 TCTCTCAGAGGCAGCAATGTGCTATGTCCACGTACAGCCCTAGTGGCAGAAATATCTCAC 3010  
QY 421 ACGGAAAGCGGTGTTAGACAAGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 480  
Db 3011 ACGGAAAGCGGTGTTAGACAAGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 3070  
QY 481 CGAGGAGGCTCCATGATGGA 501  
Db 3071 CGAGGAGGCTCCATGATGGA 3091

RESULT 13

AAC87978  
ID AAC87978 standard; cDNA; 4898 BP.

AC AAC87978;

DT 07-MAR-2001 (first entry)

DE Preliminary CLASP-2 nucleotide sequence #5.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.

PN WO200061747-A2.

XX 19-OCT-2000.



XX 13-APR-2000; 2000WO-US10158.  
PF  
XX 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI; 2000-619230/59.  
DR  
XX  
XX Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
XX  
PS Disclosure; Fig 10E; 286pp; English.  
XX  
XX The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;  
  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 TTACACTGGAAAGAGTCCTTGTGTCGGGACACATTTGCAAGTCATCATATCTGTCAGCCA 60  
Db 2591 TTACACTGGAAAGAGTCCTTGTGTCGGGACACATTTGCAAGTCATCATATCTGTCAGCCA 2650  
  
QY 61 GCTGATAGCAGACGTTGTGGCATTGGGAAACAGATTCCAGCAGTCCCTGTCCATCAT 120  
Db 2651 GCTGATAGCAGACGTTGTGGCATTGGGAAACAGATTCCAGCAGTCCCTGTCCATCAT 2710  
  
QY 121 CAACAACTGTGCCAACAGTGACCGGCTTATTTAAGCACACACAGCTTCTCCTGTGATGTGAA 180  
Db 2711 CAACAACTGTGCCAACAGTGACCGGCTTATTTAAGCACACACAGCTTCTCCTGTGATGTGAA 2770  
  
QY 181 GGACTTTAACCAAAAGATACGCACGGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
Db 2771 GGACTTTAACCAAAAGATACGCACGGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2830  
  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300  
Db 2831 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 2890

QY 301 GCCCGAGCTCAGSAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGA 360  
Db 2891 GCCCGAGCTCAGSAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGA 2950  
  
QY 361 TCTCTCAGAGGACCAATGTGCTATGTCCACGTTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2951 TCTCTCAGAGGACCAATGTGCTATGTCCACGTTAACAGCCCTAGTGGCAGAATATCTCAC 3010  
  
QY 421 ACGGAAAGGCGGTGTTTGAACAAGATGCAACCCGCTTCAGGGGTCAATTACCCCAACATCGA 480  
Db 3011 ACGGAAAGGCGGTGTTTGAACAAGATGCAACCCGCTTCAGGGGTCAATTACCCCAACATCGA 3070  
  
QY 481 CGAGGAGGCGCTCCATGATGGA 501  
Db 3071 CGAGGAGGCGCTCCATGATGGA 3091

RESULT 14  
AAC87979  
ID AAC87979 standard; cDNA; 4898 BP.  
XX  
AC AAC87979;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #6.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.  
XX WO200061747-A2.  
XX  
XX 19-OCT-2000.  
XX  
XX 13-APR-2000; 2000WO-US10158.

PF 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.

XX  
PA (ARBO-) ARBOR VITA CORP.  
XX

PI Lu PS;  
XX WPI; 2000-619230/59.  
DR  
XX

XX Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX

PS Disclosure; Fig 10F; 286pp; English.

XX The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An



CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;  
SQ  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAAGAAGTCCTTTGTCCGGACACATTTGCCAAGTCATCATCTGTCCAGCCA 60  
Db 2591 TTACACTGGAAAGAAGTCCTTTGTCCGGACACATTTGCCAAGTCATCATCTGTCCAGCCA 2650  
QY 61 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 120  
Db 2651 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 2710  
QY 121 CAACAACCTGTGCCAACAGATGACCGGCTTATTAAACACACCAAGCTTCTCCTCTGATGTGAA 180  
Db 2711 CAACAACCTGTGCCAACAGATGACCGGCTTATTAAACACACCAAGCTTCTCCTCTGATGTGAA 2770  
QY 181 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 240  
Db 2771 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGCCACCGCCAGATGAAGAGCATGA 2830  
QY 241 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 300  
Db 2831 GAACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCAGCAC 2890  
QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGGA 360  
Db 2891 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAATGGCGGA 2950  
QY 361 TCTCTCAGAGGCACGAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420  
Db 2951 TCTCTCAGAGGCACGAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 3010  
QY 421 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAAAACATCGA 480  
Db 3011 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAAAACATCGA 3070  
QY 481 CGAGGAGGCGCTCCATGATGGA 501  
Db 3071 CGAGGAGGCGCTCCATGATGGA 3091

RESULT 15  
AAC87980  
ID AAC87980 standard; cDNA; 4898 BP.  
XX  
AC AAC87980;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #7.  
XX

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;

KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX

PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.

PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX  
DR WPI; 2000-619230/59.  
XX

PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses .  
XX  
PS Disclosure; Fig 10G; 286pp; English.

XX The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX Sequence 4898 BP; 1379 A; 1134 C; 1166 G; 1219 T; 0 other;  
SQ  
Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 1.1e-141;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTACACTGGAAAGAAGTCCTTTGTCCGGACACATTTGCCAAGTCATCATCTGTCCAGCCA 60  
Db 2591 TTACACTGGAAAGAAGTCCTTTGTCCGGACACATTTGCCAAGTCATCATCTGTCCAGCCA 2650  
QY 61 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 120  
Db 2651 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACAGATTCCAGCAGTCCCTGTCCATCAT 2710  
QY 121 CAACAACCTGTGCCAACAGATGACCGGCTTATTAAACACACCAAGCTTCTCCTCTGATGTGAA 180

Db 2711 CAACAACCTGTGCCACACAGTGCACCGGCTTATTAAGCACACACAGCTTCTCCTGTGATGTGA 2770

QY 181 GGACTTAACCAAAAGGATACCGCACGGTCTAATGGCCACCGCCACAGATGAAGGAGCATGA 240

Db 2771 GGACTTAACCAAAAGGATACCGCACGGTCTAATGGCCACCGCCACAGATGAAGGAGCATGA 2830

QY 241 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAATCCTATGCCAGCAC 300

Db 2831 GAACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCCTGGCCAATCCTATGCCAGCAC 2890

QY 301 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAAATGGCGA 360

Db 2891 GCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAAAATGGCGA 2950

QY 361 TCTCTCAGAGCGACAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 420

Db 2951 TCTCTCAGAGCGACAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCAC 3010

QY 421 ACGGAAAGGCGTGTTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 480

Db 3011 ACGGAAAGGCGTGTTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGA 3070

QY 481 CGAGGAGGCTTCATGATGA 501

Db 3071 CGAGGAGGCTTCATGATGA 3091

Search completed: February 7, 2003, 07:08:07  
Job time : 158.085 secs

Gencore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:00:34 ; Search time 28.6858 Seconds  
(without alignments)  
5356.145 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_2500\_3000  
Perfect score: 501  
Sequence: 1 ttacactggaagaagtcct.....gagagagccctcatgatgga 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued patents\_NA:\*  
1: /cgn2\_6/ptodata/1/ina/5A\_COMB.seq:\*  
2: /cgn2\_6/ptodata/1/ina/5B\_COMB.seq:\*  
3: /cgn2\_6/ptodata/1/ina/6A\_COMB.seq:\*  
4: /cgn2\_6/ptodata/1/ina/6B\_COMB.seq:\*  
5: /cgn2\_6/ptodata/1/ina/PCTUS\_COMB.seq:\*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	43	8.6	4722	4	US-08-979-608A-14
2	37.4	7.5	1432	1	US-07-914-282D-3
3	37.4	7.5	1432	1	US-08-276-887A-3
4	37.4	7.5	1432	5	PCT-US93-02460-3
5	36.4	7.3	1111	2	US-08-997-080-169
6	36.4	7.3	1111	2	US-08-997-362-169
7	36.4	7.3	1111	4	US-09-095-855-169
8	36.4	7.3	1111	4	US-09-324-542-169
9	36.4	7.3	1111	4	US-08-997-080-93
10	36.4	7.3	1341	2	US-08-997-362-93
11	36.4	7.3	1341	3	US-08-873-970-93
12	36.4	7.3	1341	3	US-08-873-970-93
13	36.4	7.3	1341	4	US-09-095-855-93
14	36.4	7.3	1341	4	US-09-324-542-93
15	36.4	7.3	1341	4	US-09-095-855-93
16	35	7.0	1854	5	PCT-US94-01101-1
17	35	7.0	4697	4	US-08-979-608A-17
18	33.6	6.7	28171	4	US-08-961-527-22
19	32.6	6.5	4972	3	US-09-035-648-17
20	32.6	6.5	4972	4	US-09-001-951-17
21	32.6	6.5	4972	4	US-08-818-829-17
22	32.2	6.4	1136	1	US-08-106-981-5
23	32.2	6.4	4403765	4	US-09-103-840A-2
24	32.2	6.4	4411529	4	US-09-103-840A-1
25	32	6.4	2419	4	US-09-245-041-8
26	32	6.4	8827	4	US-09-245-041-1
27	32	6.4	62804	4	US-09-800-960-3

28	31.8	6.3	4443	4	US-09-425-453A-1	Sequence 1, Appli
29	31.8	6.3	4443	4	US-09-425-453A-3	Sequence 3, Appli
30	31.8	6.3	4443	4	US-09-425-453A-5	Sequence 5, Appli
31	31.8	6.3	4443	4	US-09-425-453A-7	Sequence 7, Appli
32	31.8	6.3	4443	4	US-09-425-453A-9	Sequence 9, Appli
33	31.8	6.3	4443	4	US-09-425-453A-11	Sequence 11, Appli
34	31.8	6.3	4443	4	US-09-425-453A-13	Sequence 13, Appli
35	31.8	6.3	4443	4	US-09-425-453A-15	Sequence 15, Appli
36	31.8	6.3	4443	4	US-09-425-453A-17	Sequence 17, Appli
37	31.8	6.3	4443	4	US-09-425-453A-19	Sequence 19, Appli
38	31.8	6.3	4560	4	US-09-256-703-1	Sequence 1, Appli
39	31.8	6.3	5635	1	US-08-136-742A-3	Sequence 3, Appli
40	31.8	6.3	5635	3	US-09-248-026-3	Sequence 3, Appli
41	31.8	6.3	5635	5	PCT-US93-11667-3	Sequence 3, Appli
42	31.8	6.3	6126	2	US-08-951-912-3	Sequence 3, Appli
43	31.8	6.3	6126	4	US-09-174-077-3	Sequence 3, Appli
44	31.8	6.3	6129	1	US-07-637-621-1	Sequence 1, Appli
45	31.8	6.3	6129	1	US-08-136-742A-1	Sequence 1, Appli

ALIGNMENTS

RESULT 1  
US-08-979-608A-14  
; Sequence 14, Application US/08979608A  
; Patent No. 6355451  
; GENERAL INFORMATION:  
; APPLICANT: Lees, Ann M.  
; Lees, Robert S.  
; Law, Simon W.  
; Arjona, Anibal A.  
; TITLE OF INVENTION: NOVEL LOW DENSITY LIPOPROTEIN  
; BINDING PROTEINS AND THEIR USES IN DIAGNOSING AND  
; TREATING ATHEROSCLEROSIS  
; NUMBER OF SEQUENCES: 42  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/979,608A  
; FILING DATE: 26-No. 6355451-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 60/048,547  
; FILING DATE: 03-JUN-1997  
; APPLICATION NUMBER: US 60/031,930  
; FILING DATE: 27-NOV-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Myers, Louis  
; REGISTRATION NUMBER: 35,965  
; REFERENCE/DOCKET NUMBER: 10797-002001 (formerly 3983/59818)  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617/542-5070  
; TELEFAX: 617/542-8906  
; INFORMATION FOR SEQ ID NO: 14:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4722 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; FEATURE:  
; NAME/KEY: Coding Sequence  
; LOCATION: 61...1731  
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-08-979-608A-14

Query Match	8.6%;	Score 43;	DB 4;	Length 4722;
Best Local Similarity	50.7%;	Pred. No. 0.0011;		
Matches 103;	Conservative	0;	Mismatches 100;	Indels 0;
				Gaps 0;

[illegible]

## RESULT 2

US-07-914-282D-3  
Sequence 3, Application US/07914282D  
Patent No. 5364787  
GENERAL INFORMATION:  
APPLICANT: Orser, Cindy S. and Xun, Luying  
TITLE OF INVENTION: GENES AND ENZYMES INVOLVED IN  
TITLE OF INVENTION: THE MICROBIAL DEGRADATION OF  
TITLE OF INVENTION: PENTACHLOROPHENOL  
NUMBER OF SEQUENCES: 11  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Ramon A. Klitzke II  
STREET: One World Trade Center  
STREET: 121 S.W. Salmon Street  
STREET: Suite 1600  
CITY: Portland  
STATE: Oregon  
COUNTRY: United States of America  
ZIP: 97204  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3-1/2 inch  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS DOS  
SOFTWARE: Wordperfect 5.1/PC Gene  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07/914,282D  
FILING DATE: July 13, 1992  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/856,015  
FILING DATE: March 23, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Ramon A. Klitzke II  
REGISTRATION NUMBER: 30,188  
REFERENCE/DOCKET NUMBER: 2815-36746  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (503) 226-7391  
TELEFAX: (503) 228-9446  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1432 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: Double-stranded  
TOPOLOGY: Linear  
MOLECULE TYPE: Genomic DNA  
DESCRIPTION:  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE:  
ORIGINAL SOURCE:

ORGANISM: Flavobacterium sp. Strain ATCC 39723  
; US-07-914-282D-3

Query Match	7.5%;	Score 37.4;	DB 1;	Length 1432;
Best Local Similarity	48.0%;	Pred. No. 0.036;		
Matches 107;	Conservative	0;	Mismatches 116;	Indels 0;
				Gaps 0;

QY	121	CAACA	CTGTG	CCCA	CACAG	TGAC	CGGG	CTTA	TTAAG	CACAC	CAAC	AGCT	TCTC	CTCT	GATGT	GAA	180									
	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11										
Db	819	CATCT	ACAGG	CGCG	CACG	ACCG	CGAT	CGTG	GAA	CATAT	GGCA	TATG	CGCC	TATG	ACG	CGA	878									
	181	GGACT	TAAC	CAAA	AGGAT	ACG	CAC	GGTG	CTA	TATG	GGC	CAC	CGCC	CCAG	ATGA	AGG	AGC	ATGA	240							
	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11										
Db	879	CACGT	TGCCC	CAGG	CGGA	AGT	CGAC	CTGC	CAAA	AGCG	CC	CTG	CA	CA	ACTG	GAC	TG	CA	TCT	938						
	241	GAACG	ACC	CAG	AGAT	GCT	TG	TG	GAC	CTC	CA	GTAC	AG	CC	TG	GC	CA	AA	TCT	TAT	GC	CAG	CA	300		
	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11			
Db	939	GCGG	CA	CAAG	CCGT	CA	TCC	CGG	G	CAG	CA	CTA	CAG	CA	CTC	GC	CG	CA	TAT	CA	TGT	G	AC	CGT	998	
	301	GCCCC	AGCT	CAG	GA	AG	AG	CGT	GCT	CG	AC	AG	CA	TG	GC	CG	AG	AT	G	C	C	G	A	T	C	343
	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11		
Db	999	CTGCT	TG	CGCG	CGG	AT	CG	AG	AT	GCT	CA	CA	CA	TG	AC	GC	GC	CT	G	A	T	C	1041			

### RESULT 3

```

US-08-276-887A-3
; Sequence 3, Application US/08276887A
; Patent No. 5512478
;
; GENERAL INFORMATION:
; APPLICANT: Orser, Cindy S. and Xun, Luying
; TITLE OF INVENTION: GENES AND ENZYMES INVOLVED
; TITLE OF INVENTION: IN THE MICROBIAL
; TITLE OF INVENTION: DEGRADATION OF
; TITLE OF INVENTION: PENTACHLOROPHENOL
; NUMBER OF SEQUENCES: 13
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ramon A. Kiltzke II
; STREET: One World Trade Center
; STREET: 121 S.W. Salmon Street
; STREET: Suite 1600
; CITY: Portland
; STATE: Oregon
; COUNTRY: United States of America
; ZIP: 97204
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3-1/2 inch
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: WordPerfect 5.1/PC Gene
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,887A
; FILING DATE: July 18, 1994
; CLASSIFICATION: 435
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/914,282
; FILING DATE: July 13, 1992
; APPLICATION NUMBER: 07/856,015
; FILING DATE: March 23, 1992
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Ramon A. Kiltzke II
; REGISTRATION NUMBER: 30,188
; REFERENCE/DOCKET NUMBER: 2815-36746
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 226-7391
; TELEFAX: (503) 228-9446
;
; INFORMATION FOR SEQ ID NO: 3:
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1432 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Double-stranded
; TOPOLOGY: Linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION:
;

```



```

;      HYPOTHETICAL: NO
;      ANTI-SENSE: NO
;      FRAGMENT TYPE:
;      ORIGINAL SOURCE:
;      ORGANISM: Flavobacterium sp. Strain
;      ORGANISM: ATCC 39723
;      US-08-276-887A-3

```

Query Match	7.58;	Score 37.4;	DB 1;	Length 1432;
Best Local Similarity	48.08;	Pred. No. 0.036;		
Matches 107;	Conservative	0;	Mismatches 116;	Indels 0;
				Gaps 0;

QY	121	CACACACTGTGCCACACAGTGAACCGGCTTATTAAGCACACACAGCTTCTCTCTGATGTGA	180
Db	819	CATCTACCAAGCGCCGCCACGACCGCATCGTGGAACATGGCAATTGGCGCTATGACGCGGA	878
QY	181	GGACTTAAACCAAAAGATACGACAGGCTGCTAATGGCCACCGCCAGATGAAGAGCATGA	240
Db	879	CACGGTGGCCACGGCGGAAGTCGACCTGCAAAAGCGGCTCGACGAACCTGGACGTGCATCT	938
QY	241	GAACGACCCAGAGATGCTGTGGACCTCCAGTACACGCTGGCCAAATCTATGCCAGCAC	300
Db	939	GGCGGACAAGCCGCTTCATCGCGGGGCGACCACTACAGATCGCCGACATCATGTGGACCGT	998
QY	301	GCCCGAGCTCAGGAAGACGTGGCTCGACACGATGGCCAGGATC	343
Db	999	CCTGCTGGCGCGGATCGAGATGCTCAACATGACGGCGCTGGATC	1041

RESULT 4  
PCT-US93-02460-3

Sequence 3; Application PC/US9302460  
GENERAL INFORMATION:  
APPLICANT: Orser, Cindy S. and Xun, Luying  
TITLE OF INVENTION: GENES AND ENZYMES INVOLVED IN THE  
TITLE OF INVENTION: MICROBIAL DEGRADATION OF PENTACHLOROPHENOL  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: William D. Noonan, M.D.  
STREET: One World Trade Center  
STREET: 121 S.W. Salmon Street  
STREET: Suite 1600  
CITY: Portland  
STATE: Oregon  
COUNTRY: United States of America  
ZIP: 97204  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.5-inch  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS DOS  
SOFTWARE: Wordperfect 5.1/PC Gene  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/02460  
FILING DATE: 19930319  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/07/856,015  
FILING DATE: March 23, 1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/07/914,282  
FILING DATE: July 13, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: William D. Noonan, M.D.  
REGISTRATION NUMBER: 30878  
REFERENCE/DOCKET NUMBER: 2815-36746-WDN  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (503) 226-7391  
TELEFAX: (503) 228-9446  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1432 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: Double-stranded

```

; TOPLOGY: Linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION:
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; ORGANISM: Flavobacterium sp. Strain ATCC 39723
; PCT-US93-02460-3

```

Query Match	7.58;	Score 37.4;	DB 5;	Length 1432;
Best Local Similarity	48.08;	Pred. No. 0.036;		
Matches 107;	Conservative	0;	Mismatches 116;	Indels 0;
				Gaps 0;

[illegible]

## RESULT 5

```

US-08-997-080-169
; Sequence 169, Application US/08997080
; Patent No. 5968524
;
; GENERAL INFORMATION:
; APPLICANT: WATSON, JAMES D.
; APPLICANT: TAN, PAUL L.J.
; TITLE OF INVENTION: METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-
; NUMBER OF SEQUENCES: 194
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Ann W. Speckman
; STREET: 2601 Elliott Avenue, Suite 4185
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98121
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/997,080
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sleath, Janet
; REGISTRATION NUMBER: 37,007
; REFERENCE/DOCKET NUMBER: 11000.1007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-269-0565
; TELEFAX: 206-269-0563
;
; TELEX:
;
; INFORMATION FOR SEQ ID NO: 169:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1111 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;

```



```
; INFORMATION FOR SEQ ID NO: 169:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 1111 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
us-09-095-855-169
```

```
Query Match          7.3%; Score 36.4; DB 4; Length 1111;
Best Local Similarity 46.2%; Pred. No. 0.066;
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;
```

```
QY 100 CCAGCAGTCCCTGTCATCATCAACAACACTGTGCCACAGATGACCGGCTTATTAGCACAC 159
      ||| ||| | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 805 CGAGGCGTGGATCGACTACATCTACGACCGAGCCAACTAGCCAAAGCTGGTCGGTTAC 864
QY 160 CAGCTTCTCCTGTGATGTGAAGACTTAACCAAAAGGATACGACGCTGCTAATGGCCAC 219
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 865 CCAGTTCGTGCGCCGCACTCTCGACATGACCGACGAACCTGCCAAGGTGATCCTGCATC 924
QY 220 CGCCAGATGAAGAGCATGAGAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCT 279
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 925 GCGGAGAACCCGCTGATCAACCCGTCGCGGAGGTGCGAGCGAACCTGAATCGTGGGC 984
QY 280 GGCCAAATCCTATGCCACGACGCGCCGAGCTCAGAGACGCTGGCTCGACAGCATGGCCAG 339
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 985 GGCACGTGACCGACGACGACGACGAGAGTTCACACTGCGGTACGCCGCCGTCACCGGGCG 1044
QY 340 GATCCATGTCAAAAATGGCGAT 361
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1045 CTGACGCGGTGTAGTGCCGAT 1066
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

## RESULT 8

```
US-09-324-542-169
; Sequence 169, Application US/09324542
; Patent No. 6328978
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Watson, James D.
```

```
; APPLICANT: Tan, Paul L.J.
```

```
; APPLICANT: Prestidge, Ross
```

```
; TITLE OF INVENTION: Methods and Compounds for the Treatment
```

```
; FILE REFERENCE: 11000.1007c1
```

```
; CURRENT APPLICATION NUMBER: US/09/324,542
```

```
; CURRENT FILING DATE: 1999-06-02
```

```
; EARLIER APPLICATION NUMBER: US 08/997,080
```

```
; EARLIER FILING DATE: 1997-12-23
```

```
; NUMBER OF SEQ ID NOS: 194
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 169
```

```
; LENGTH: 1111
```

```
; TYPE: DNA
```

```
; ORGANISM: Mycobacterium vaccae
```

```
US-09-324-542-169
```

```
Query Match          7.3%; Score 36.4; DB 4; Length 1111;
Best Local Similarity 46.2%; Pred. No. 0.066;
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;
```

```
QY 100 CCAGCAGTCCCTGTCATCATCAACAACACTGTGCCACAGATGACCGGCTTATTAGCACAC 159
      ||| ||| | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 805 CGAGGCGTGGATCGACTACATCTACGACCGAGCCAACTAGCCAAAGCTGGTCGGTTAC 864
QY 160 CAGCTTCTCCTGTGATGTGAAGACTTAACCAAAAGGATACGACGCTGCTAATGGCCAC 219
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 865 CCAGTTCGTGCGCCGCACTCTCGACATGACCGACGAACCTGCCAAGGTGATCCTGCATC 924
QY 220 CGCCAGATGAAGAGCATGAGAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCT 279
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 925 GCGGAGAACCCGCTGATCAACCCGTCGCGGAGGTGCGAGCGAACCTGAATCGTGGGC 984
QY 280 GGCCAAATCCTATGCCACGACGCGCCGAGCTCAGAGACGCTGGCTCGACAGCATGGCCAG 339
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
Db 985 GGCACGTGACCGACGACGACGAGAGTTCACACTGCGGTACGCCGCCGTCACCGGGCGG 1044
QY 340 GATCCATGTCAAAAATGGCGAT 361
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1045 CTGACGCGGTGTAGTGCCGAT 1066
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

## RESULT 9

```
US-09-205-426-169
; Sequence 169, Application US/09205426
; Patent No. 6406704
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Watson, James D.
```

```
; APPLICANT: Tan, Paul L. J.
```

```
; TITLE OF INVENTION: Compounds and Methods for Treatment and
```

```
; FILE REFERENCE: 11000.1002c4
```

```
; CURRENT APPLICATION NUMBER: US/09/205,426
```

```
; EARLIER FILING DATE: 1998-12-04
```

```
; EARLIER APPLICATION NUMBER: 09/095,855
```

```
; EARLIER FILING DATE: 1998-06-11
```

```
; EARLIER APPLICATION NUMBER: 08/997,362
```

```
; EARLIER FILING DATE: 1997-12-23
```

```
; EARLIER APPLICATION NUMBER: 08/873,970
```

```
; EARLIER FILING DATE: 1997-06-12
```

```
; EARLIER APPLICATION NUMBER: 08/705,347
```

```
; EARLIER FILING DATE: 1996-08-29
```

```
; NUMBER OF SEQ ID NOS: 208
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 169
```

```
; LENGTH: 1111
```

```
; TYPE: DNA
```

```
; ORGANISM: Mycobacterium vaccae
```

```
US-09-205-426-169
```

```
Query Match          7.3%; Score 36.4; DB 4; Length 1111;
Best Local Similarity 46.2%; Pred. No. 0.066;
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;
```

```
QY 100 CCAGCAGTCCCTGTCATCATCAACAACACTGTGCCACAGATGACCGGCTTATTAGCACAC 159
      ||| ||| | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 805 CGAGGCGTGGATCGACTACATCTACGACCGAGCCAACTAGCCAAAGCTGGTCGGTTAC 864
QY 160 CAGCTTCTCCTGTGATGTGAAGACTTAACCAAAAGGATACGACGCTGCTAATGGCCAC 219
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 865 CCAGTTCGTGCGCCGCACTCTCGACATGACCGACGAACCTGCCAAGGTGATCCTGCATC 924
QY 220 CGCCAGATGAAGAGCATGAGAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCT 279
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 925 GCGGAGAACCCGCTGATCAACCCGTCGCGGAGGTGCGAGCGAACCTGAATCGTGGGC 984
QY 280 GGCCAAATCCTATGCCACGACGCGCCGAGCTCAGAGACGCTGGCTCGACAGCATGGCCAG 339
      ||| ||| | | | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 985 GGCACGTGACCGACGACGACGAGAGTTCACACTGCGTACGCCGCCGTCACCGGGCGG 1044
QY 340 GATCCATGTCAAAAATGGCGAT 361
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1045 CTGACGCGGTGTAGTGCCGAT 1066
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
RESULT 10
US-08-997-080-93
; Sequence 93, Application US/08997080
; Patent No. 5968524
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: WATSON, JAMES D.
```

```
; APPLICANT: TAN, PAUL L.J.
```

```
; TITLE OF INVENTION: METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-
```

```
; NUMBER OF SEQUENCES: 194
```

```
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Law Offices of Ann W. Speckman
```

```
; STREET: 2601 Elliott Avenue, Suite 4185
```

CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98121  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSEQ for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/997,080  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Sleath, Janet  
REGISTRATION NUMBER: 37,007  
REFERENCE/DOCKET NUMBER: 11000.1007  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-269-0565  
TELEFAX: 206-269-0563  
TELEX:  
INFORMATION FOR SEQ ID NO: 93:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1341 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
US-08-997-080-93

Query Match 7.3%; Score 36.4; DB 2; Length 1341;  
Best Local Similarity 46.2%; Pred. No. 0.072;  
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;

QY 100 CCAGCAGTCCCTGTCATCATCAACAACACTGTGCCAACAGTGACCGCTTATTAGCACAC 159  
DB 979 CGAGGCGTGATCGACTACATCTACGACCGAGCCAACTACGCTGTCGCGTTTCAC 1038  
QY 160 CAGCTTCTCTCTGATGTGAAGACTTAACCAAAAGGATACGACGGTGCTAATGGCCAC 219  
DB 1039 CCAGTTCGTGCCCCGCACTCTCGACATGACCGAGACTCGCCAAAGTGCATCCATGCATC 1098  
QY 220 CGCCAGATGAAGAGCATGAGACGACCCAGAGATGCTGTGAGCTCCAGTACAGCCT 279  
DB 1099 GCGGAGAACCCGCTGATCAACCCGTCGCGGAGGTGACGGGAACCTGAAGTCTGTGGC 1158  
QY 280 GGCCAAATCCTATGCCAGCAGCGCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAG 339  
DB 1159 GGCACGTGACCGACGAGCAGACGACGAGAGTTCAACACTGCGTACGCCGCCGTCACCGGCGG 1218  
QY 340 GATCCATGTCAAAATGGCGAT 361  
DB 1219 CTGACGCGGTGTAGTGCCGAT 1240

RESULT 11  
US-08-997-362-93

; Sequence 93, Application US/08997362  
; Patent No. 5985287

; GENERAL INFORMATION:

; APPLICANT: Tan, Paul  
; APPLICANT: Hiyama, Jun  
; APPLICANT: Visser, Elizabeth  
; APPLICANT: Skinner, Margot  
; APPLICANT: Scott, Linda  
; APPLICANT: Prestidge, Ross  
; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR  
; MYCOBACTERIAL INFECTIONS  
; NUMBER OF SEQUENCES: 194  
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Ann W. Speckman  
STREET: 2601 Elliott Avenue, Suite 4185  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98121  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSEQ for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/997,362  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: U.S. Patent Application No. 5985287 08/873,970  
FILING DATE: June 12, 1997  
APPLICATION NUMBER: U.S. Patent Application No. 5985287 08/705,347  
FILING DATE: August 29, 1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Sleath, Janet  
REGISTRATION NUMBER: 37,007  
REFERENCE/DOCKET NUMBER: 11000.1002c2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-269-0565  
TELEFAX: 206-269-0563  
TELEX:  
INFORMATION FOR SEQ ID NO: 93:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1341 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
US-08-997-362-93

Query Match 7.3%; Score 36.4; DB 2; Length 1341;  
Best Local Similarity 46.2%; Pred. No. 0.072;  
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;

QY 100 CCAGCAGTCCCTGTCATCATCAACAACACTGTGCCAACAGTGACCGGCTTATTAGCACAC 159  
DB 979 CGAGGCGTGATCGACTACATCTACGACCGAGCCAACTACGCTGTCGCGTTTCAC 1038  
QY 160 CAGCTTCTCTCTGATGTGAAGACTTAACCAAAAGGATACGACGGTGCTAATGGCCAC 219  
DB 1039 CCAGTTCGTGCCCCGCACTCTCGACATGACCGAGACTCGCCAAAGTGCATCCATGCATC 1098  
QY 220 CGCCAGATGAAGAGCATGAGAACGACCCAGAGATGCTGTGAGCTCCAGTACAGCCT 279  
DB 1099 GCGGAGAACCCGCTGATCAACCCGTCGCGGAGGTGACGGGAACCTGAAGTCTGTGGC 1158  
QY 280 GGCCAAATCCTATGCCAGCAGCGCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAG 339  
DB 1159 GGCACGTGACCGACGAGCAGACGACGAGAGTTCAACACTGCGTACGCCGCCGTCACCGGCGG 1218  
QY 340 GATCCATGTCAAAATGGCGAT 361  
DB 1219 CTGACGCGGTGTAGTGCCGAT 1240

RESULT 12  
US-08-873-970-93

; Sequence 93, Application US/08873970  
; Patent No. 6001361

; GENERAL INFORMATION:

; APPLICANT: Tan, Paul  
; APPLICANT: Hiyama, Jun  
; APPLICANT: Visser, Elizabeth  
; APPLICANT: Skinner, Margot  
; APPLICANT: Scott, Linda  
; APPLICANT: Prestidge, Ross



```

; TITLE OF INVENTION: COMPOUNDS AND METHODS FOR
; TITLE OF INVENTION: TREATMENT AND DIAGNOSIS OF MYCOBACTERIAL INFECTIONS
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Law Offices of Ann W. Speckman
; STREET: 2601 Elliott Avenue, Suite 4185
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/873,970
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/705,347
; FILING DATE: 29-AUG-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Sleath, Janet
; REGISTRATION NUMBER: 37,007
; REFERENCE/DOCKET NUMBER: 11000.1002c1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-269-0565
; TELEFAX: 206-269-0563
; TELEX:
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1341 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; US-08-873-970-93

Query Match          7.3%; Score 36.4; DB 3; Length 1341;
Best Local Similarity 46.2%; Pred. No. 0.072;
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;

QY 100 CCAGCAGTCCCTGTCCATCATCAACAACACTGTGCCAACAGTAGACCGGCTTATTAAGCACAC 159
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 979 CGAGGCGGTGATCGACTACATCTACGACCGAGCCAACTACGCCAAGCTGCGCTTCAC 1038

QY 160 CAGCTTCTCCTGTGATGTGAAGGACTTAACCAAAAAGGATACGCACGCTGCTAATGGCCAC 219
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 1039 CCAGTTCGTGCCCCGCACTCTCGGACATGACCGAAGTCCGCAAGGTCGATCCTGCATC 1098

QY 220 CGCCAGATGAAGGAGCATGAGAAGCAGACCGCAGAGATGCTGTGGACCTCCAGTACAGCCT 279
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 1099 GCGCGAGAACCCGCTGATCAACCCGTCGCGCGAGGTGCAGGCGAAGCTGAAGTCGTGGGC 1158

QY 280 GGGCAAAATCCTATGCGCAGACGCGCCGAGCTCAGGAAGACGTGGCTGACAGCATGGCCAG 339
   |||||  ||  ||  |  |||||  |||||  |||||  |||||  |||||  |||||
Db 1159 GGCACCTGACCGAGCAGACGACGAGAGTTCAACACTGCGTACGCGCGCTCACCGGCGG 1218

QY 340 GATCCATGTCAAAAATGGCGAT 361
   |  |  |  |  |||||
Db 1219 CTGACGCGGTGTAGTGCCGAT 1240

RESULT 13
US-09-095-855-93
; Sequence 93, Application US/09095855
; Patent No. 6160093
; GENERAL INFORMATION:
; APPLICANT: Tan, Paul
; APPLICANT: Visser, Elizabeth
; APPLICANT: Skinner, Margot
; APPLICANT: Prestidge, Ross
```

```

; TITLE OF INVENTION: Compounds and Methods for
; TITLE OF INVENTION: Treatment and Diagnosis of Mycobacterial Infections
; NUMBER OF SEQUENCES: 208
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Law Offices of Ann W. Speckman
; STREET: 2601 Elliott Avenue, Suite 4185
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/095,855
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/705,347
; FILING DATE: 29-AUG-1996
; APPLICATION NUMBER: 08/873,970
; FILING DATE: 12-JUN-1997
; APPLICATION NUMBER: 08/997,362
; FILING DATE: 23-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Sleath, Janet
; REGISTRATION NUMBER: 37,007
; REFERENCE/DOCKET NUMBER: 11000.1002c3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-269-0565
; TELEFAX: 206-269-0563
; TELEX:
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1341 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; US-09-095-855-93

Query Match          7.3%; Score 36.4; DB 4; Length 1341;
Best Local Similarity 46.2%; Pred. No. 0.072;
Matches 121; Conservative 0; Mismatches 141; Indels 0; Gaps 0;

QY 100 CCAGCAGTCCCTGTCCATCATCAACAACACTGTGCCAACAGTAGACCGGCTTATTAAGCACAC 159
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 979 CGAGGCGGTGATCGACTACATCTACGACCGAGCCAACTACGCCAAGCTGCGCTTCAC 1038

QY 160 CAGCTTCTCCTGTGATGTGAAGGACTTAACCAAAAAGGATACGCACGCTGCTAATGGCCAC 219
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 979 CGAGGCGGTGATCGACTACATCTACGACCGAGCCAACTACGCCAAGCTGCGCTTCAC 1038

QY 220 CGCCAGATGAAGGAGCATGAGAAGCAGACCGCAGAGATGCTGTGGACCTCCAGTACAGCCT 279
   |||||  |  |  |||||  ||  |||||  ||  |||||  |  |||||  |  |||||
Db 1039 CCAGTTCGTGCCCCGCACTCTCGGACATGACCGGAGTCCGCAAGGTCGATCCTGCATC 1098

QY 280 GGGCAAAATCCTATGCGCAGACGCGCCGAGCTCAGGAAGACGTGGCTGACAGCATGGCCAG 339
   |||||  ||  ||  |  |||||  |||||  |||||  |||||  |||||  |||||
Db 1159 GGCACCTGACCGAGCAGACGAGAGTTCAACACTGCGTACGCGCGCTCACCGGCGG 1218

QY 340 GATCCATGTCAAAAATGGCGAT 361
   |  |  |  |  |||||
Db 1219 CTGACGCGGTGTAGTGCCGAT 1240

RESULT 14
US-09-324-542-93
; Sequence 93, Application US/09324542
; Patent No. 6328978
; GENERAL INFORMATION:
```

```

; APPLICANT: Watson, James D.
; APPLICANT: Tan, Paul L.J.
; APPLICANT: Prestidge, Ross
; TITLE OF INVENTION: Methods and Compounds
; TITLE OF INVENTION: of Immunologically-Me
; FILE REFERENCE: 11000.1007c1
; CURRENT APPLICATION NUMBER: US/09/324,542
; CURRENT FILING DATE: 1999-06-02
; EARLIER APPLICATION NUMBER: US 08/997,080
; EARLIER FILING DATE: 1997-12-23
; NUMBER OF SEQ ID NOS: 194
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 93
; LENGTH: 1341
; TYPE: DNA
; ORGANISM: Mycobacterium vaccae
US-09-324-542-93

```

Query Match	7.38;	Score 36.4;	DB 4;	Length 1341;
Best Local Similarity	46.28;	Pred. No. 0.072;		
Matches 121; Conservative	0;	Mismatches 141;	Indels 0;	Gaps 0;

[illegible]

```

RESULT 15
US-09-205-426-93
; Sequence 93, Application US/09205426
; Patent No. 6406704
;
; GENERAL INFORMATION:
;
; APPLICANT: Watson, James D.
; APPLICANT: Tan, Paul L. J.
; TITLE OF INVENTION: Compounds and Methods for Treatment and
; TITLE OF INVENTION: Diagnosis of Mycobacterial Infections
; FILE REFERENCE: 11000.1002c4
; CURRENT APPLICATION NUMBER: US/09/205,426
; CURRENT FILING DATE: 1998-12-04
; EARLIER APPLICATION NUMBER: 09/095,855
; EARLIER FILING DATE: 1998-06-11
; EARLIER APPLICATION NUMBER: 08/997,362
; EARLIER FILING DATE: 1997-12-23
; EARLIER APPLICATION NUMBER: 08/873,970
; EARLIER FILING DATE: 1997-06-12
; EARLIER APPLICATION NUMBER: 08/705,347
; EARLIER FILING DATE: 1996-08-29
; NUMBER OF SEQ ID NOS: 208
; SOFTWARE: FastSeq for Windows Version 3.0
;
; SEQ ID NO 93
;
; LENGTH: 1341
;
; TYPE: DNA
;
; ORGANISM: Mycobacterium vaccae
;
US-09-205-426-93

```

Query Match	7.38;	Score 36.4;	DB 4;	Length 1341;
Best Local Similarity	46.28;	Pred. No. 0.072;		

	Matches	121, Conservative	0;	Mismatches	141; Indels	0;	Gaps	0;
QY	100	CCAGCAGTCCCTGTCCATCATCAACAACACTGTGCCAACAGTAGCCGGCTTATTAAACACAC	159					
Db	979	CGAGCGGTGGATCGACTACATCTACGACCGAGCCAACTACGCCAAGCTGGTCGGCGTTAC	1038					
QY	160	CAGCTTCTCCTGTGATGTGAAGACCTTAACCAAAAGGATACGCACGGTGCTAATGCGCAC	219					
Db	1039	CCAGTTCTGTCGCCCGCACTCTCGACATGACCGACGAACACTCGCCCAAGTCCGATCCTGCATC	1098					
QY	220	CGCCCAGATGAAGCAGCATGAGAAGCAGCCAGAGATGCTGCTGAGCTCCAGTACAGCCT	279					
Db	1099	GCGCGAGAACCCTGTGATCAACCCGTGCGCGGAGGTGACAGGCGCAACTGAAGTCGTGGGC	1158					
QY	280	GGCCAAATCCTATGCGCAGCAGCGCCGAGCTCAGGAAGACGTGGCTGCACAGCATGGCCAG	339					
Db	1159	GGCACCTGACCGCAGCAGACGACGACGAGAGATTCAACACTGCGTACGCCGCCGTCAACCGCGCG	1218					
QY	340	GATCCATGTCAAAAATGGCGAT	361					
Db	1219	CTGACGCGGTGGTAGTGCCTGAT	1240					

Search completed: February 7, 2003, 09:05:47  
Job time : 43.6858 secs

•

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:01:14 ; Search time 32.3549 Seconds  
(without alignments)  
7339.716 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_2500\_3000

Perfect score: 501

Sequence: 1 ttacactggaagaagtcct.....gagagagccctcatgatgga 501

Scoring table:

IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 408267 seqs, 237001491 residues

Total number of hits satisfying chosen parameters: 816534

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published\_Applications\_NA:\*  
1: /cgn2\_6/ptodata/2/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/2/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/2/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/2/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/2/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/2/pubpna/PCTUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/2/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/2/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/2/pubpna/US09\_NEW\_PUB.seq:\*  
10: /cgn2\_6/ptodata/2/pubpna/US09\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/2/pubpna/US10\_NEW\_PUB.seq:\*  
12: /cgn2\_6/ptodata/2/pubpna/US10\_PUBCOMB.seq:\*  
13: /cgn2\_6/ptodata/2/pubpna/US60\_NEW\_PUB.seq:\*  
14: /cgn2\_6/ptodata/2/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	274.4	54.8	6454	10 US-09-736-969A-1	Sequence 1, Appli
2	269.6	53.8	4391	10 US-09-736-969A-7	Sequence 7, Appli
3	130.6	26.1	483	10 US-09-864-761-13960	Sequence 13960, A
4	116.4	23.2	2149	9 US-09-736-968A-59	Sequence 59, Appli
5	116.4	23.2	6372	9 US-09-736-968A-1	Sequence 1, Appli
6	115.4	23.0	212	10 US-09-864-761-30524	Sequence 30524, A
7	83.2	16.6	4026	10 US-09-736-960-3	Sequence 3, Appli
8	83.2	16.6	7215	10 US-09-736-960-1	Sequence 1, Appli
9	79.4	15.8	427	9 US-09-796-692-5465	Sequence 5465, Ap
10	69	13.8	444	9 US-09-796-692-3710	Sequence 3710, Ap
11	57.4	11.5	271	9 US-09-736-968A-98	Sequence 98, Appli
12	57.4	11.5	512	10 US-09-864-761-7634	Sequence 7634, Ap
13	50	10.0	194	10 US-09-864-761-24339	Sequence 24339, A
14	48.8	9.7	266	10 US-09-736-960-76	Sequence 76, Appli
15	48.8	9.7	66686	10 US-09-736-960-86	Sequence 86, Appli
16	46.2	9.2	379	9 US-10-046-935-2206	Sequence 2206, Ap
17	46.2	9.2	379	9 US-09-878-178-2206	Sequence 2206, Ap
18	45.4	9.1	181	9 US-09-736-968A-97	Sequence 97, Appli
19	43	8.6	4722	9 US-09-976-740-14	Sequence 14, Appli

20	43	8.6	4722	10 US-09-962-055-14	Sequence 14, Appli
21	43	8.6	4722	12 US-10-023-529-14	Sequence 14, Appli
22	43	8.6	4722	12 US-10-023-523-14	Sequence 14, Appli
23	36.4	7.3	1111	9 US-10-051-643-169	Sequence 169, App
24	36.4	7.3	1111	9 US-09-880-505-169	Sequence 169, App
25	36.4	7.3	1341	9 US-10-051-643-93	Sequence 93, Appli
26	36.4	7.3	1341	9 US-09-880-505-93	Sequence 93, Appli
27	35.4	7.1	292	10 US-09-815-242-872	Sequence 872, App
28	35.4	7.1	405	10 US-09-815-242-3815	Sequence 3815, Ap
29	35.4	7.1	435	10 US-09-815-242-6463	Sequence 6463, Ap
30	35.4	7.1	558	10 US-09-815-242-112	Sequence 112, App
31	35.4	7.1	558	10 US-09-815-242-133	Sequence 133, App
32	35.4	7.1	583	10 US-09-815-242-147	Sequence 147, App
33	35.4	7.1	14557	10 US-09-070-927A-367	Sequence 367, App
34	35	7.0	1638	9 US-09-976-740-46	Sequence 46, Appli
35	35	7.0	1638	12 US-10-023-529-46	Sequence 46, Appli
36	35	7.0	1638	12 US-10-023-523-46	Sequence 46, Appli
37	35	7.0	4697	9 US-09-976-740-17	Sequence 17, Appli
38	35	7.0	4697	10 US-09-962-055-17	Sequence 17, Appli
39	35	7.0	4697	12 US-10-023-529-17	Sequence 17, Appli
40	35	7.0	4697	12 US-10-023-523-17	Sequence 17, Appli
41	33.6	6.7	891	10 US-09-815-242-9579	Sequence 9579, Ap
42	32.8	6.5	88421	9 US-09-976-059-1	Sequence 1, Appli
43	32.2	6.4	2133	9 US-10-124-800-17	Sequence 17, Appli
44	32.2	6.4	2930	10 US-09-745-763-198	Sequence 198, App
45	32.2	6.4	8730	9 US-10-124-800-1	Sequence 1, Appli

ALIGNMENTS

RESULT 1  
US-09-736-969A-1  
; Sequence 1, Application US/09736969A  
; Patent No. US20020068302A1  
; GENERAL INFORMATION:  
; APPLICANT: Lu, Peter  
; APPLICANT: Garman, Jonathan David  
; APPLICANT: Candia III, Albert Frederick  
; APPLICANT: Arbor Vita Corporation  
; TITLE OF INVENTION: CLASP-4 Transmembrane Protein  
; FILE REFERENCE: 020054-000411US  
; CURRENT APPLICATION NUMBER: US/09/736,969A  
; CURRENT FILING DATE: 2000-12-13  
; PRIOR APPLICATION NUMBER: US 60/160,860  
; PRIOR FILING DATE: 1999-10-21  
; PRIOR APPLICATION NUMBER: US 60/162,498  
; PRIOR FILING DATE: 1999-10-29  
; PRIOR APPLICATION NUMBER: US 60/170,453  
; PRIOR FILING DATE: 1999-12-13  
; PRIOR APPLICATION NUMBER: US 60/176,195  
; PRIOR FILING DATE: 2000-01-14  
; PRIOR APPLICATION NUMBER: US 60/182,296  
; PRIOR FILING DATE: 2000-02-14  
; PRIOR APPLICATION NUMBER: US 09/547,276  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,267  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,460  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,527  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,528  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 09/687,837  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,503  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,508  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,539  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,543

```

; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 153
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 6454
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-4 cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (95)..(6121)
; OTHER INFORMATION: human CLASP-4
US-09-736-969A-1

```

Query Match	54.88;	Score 274.4;	DB 10;	Length 6454;
Best Local Similarity	71.88;	Pred. No. 2.6e-74;		
Matches 359;	Conservative	0;	Mismatches 141;	Indels 0;
			Gaps	0;

QY	2	TACACTGGAAGAGTCCCTTTGTGCCGACACATTTGCCAAGTCATCATATCTGTACACCAG	61
Dd	4442	TATACCAAAAGGAAAACCTTTTTTGAGGACACATCTACAGATAATTAATTGCCTGTAAGCCAA	4501
QY	62	CTGATAGCAGACCTGTTGTGGCATTGGGGAACCAAGATTCCAGCAGTCCCCTGTCATCATC	121
Dd	4502	CTGATAGCTGATGTAGCACTAAGCGGAGGATCAAGATTTTAGGAGTCTTTATTCATTATC	4561
.QY	122	AACAACGTGGCCAACAGTGAACCGGCTTATTAAGCACACCAGCTTCTCTCTGTGTGAAG	181
Dd	4562	AATAATTTTGCAAATAGTGACAGACCTATGAAGGCAACTGCCCTTCCCGCAGAGTCAAA	4621
QY	182	GACTTAACCAAAGGATACGCACGGTGTAAATGGCCACCGCCAGATGAAGAGCATGAG	241
Dd	4622	GACTTGACCAAGAGAATCCGCACCTGTTCTTAATGGCCACTGCCCAATGAAGAGCATGAG	4681
QY	242	AAGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCACG	301
Dd	4682	AAAGACCCTGAAATGCTAATTGATCTCCAGTATAGCTTAGCCAAAGTCCATATGCAGCAC	4741
QY	302	CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGTCCATGTCAAAAAATGGCGAT	361
Dd	4742	CCAGAGCTCAGGAANAACCTGGCTTGATAGCATGGCCAAAGATTCTATGTAAAAAATGGAGAT	4801
QY	362	CTCTCAGAGGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCACA	421
Dd	4802	TTTTTCAGAGCGCTGGCATGTGTATGTCCATGTAGCAGCCTCTAGTGCAGAGATTCTTCAT	4861
QY	422	CGGAAAGGCGTGTTTAGACAAGGATGCACCGCCTTCAGGGTCAATTACCCCAACATCGAC	481
Dd	4862	CGAAAAAAATTAATTTCTTAACGGATGTTACAGCGTTCAAGAAAATTACTCCCATATAGAT	4921
QY	482	GAGAGGCGCTCCATGATGA	501
Dd	4922	GAAGAAAGAGCAATGAAGA	4941

RESULT 2  
 US-09-736-969A-7  
 : Sequence 7, Application US/09736969A  
 : Patent No. US20020068302A1  
 : GENERAL INFORMATION:  
 : APPLICANT: Lu, Peter  
 : APPLICANT: Garman, Jonathan David  
 : APPLICANT: Candia III, Albert Frederick  
 : APPLICANT: Arbor Vita Corporation  
 : TITLE OF INVENTION: CLASP-4 Transmembrane Protein  
 : FILE REFERENCE: 020054-00041US  
 : CURRENT APPLICATION NUMBER: US/09/736, 969A  
 : CURRENT FILING DATE: 2000-12-13  
 : PRIOR APPLICATION NUMBER: US 60/160, 860  
 : PRIOR FILING DATE: 1999-10-21  
 : PRIOR APPLICATION NUMBER: US 60/162, 498  
 : PRIOR FILING DATE: 1999-10-29

```

? PRIOR APPLICATION NUMBER: US 60/170,453
? PRIOR FILING DATE: 1999-12-13
? PRIOR APPLICATION NUMBER: US 60/176,195
? PRIOR FILING DATE: 2000-01-14
? PRIOR APPLICATION NUMBER: US 60/182,296
? PRIOR FILING DATE: 2000-02-14
? PRIOR APPLICATION NUMBER: US 09/547,276
? PRIOR FILING DATE: 2000-04-11
? PRIOR APPLICATION NUMBER: US 60/196,267
? PRIOR FILING DATE: 2000-04-11
? PRIOR APPLICATION NUMBER: US 60/196,460
? PRIOR FILING DATE: 2000-04-11
? PRIOR APPLICATION NUMBER: US 60/196,527
? PRIOR FILING DATE: 2000-04-11
? PRIOR APPLICATION NUMBER: US 60/196,528
? PRIOR FILING DATE: 2000-04-11
? PRIOR APPLICATION NUMBER: US 09/687,837
? PRIOR FILING DATE: 2000-10-13
? PRIOR APPLICATION NUMBER: US 60/240,503
? PRIOR FILING DATE: 2000-10-13
? PRIOR APPLICATION NUMBER: US 60/240,508
? PRIOR FILING DATE: 2000-10-13
? PRIOR APPLICATION NUMBER: US 60/240,539
? PRIOR FILING DATE: 2000-10-13
? PRIOR APPLICATION NUMBER: US 60/240,543
? PRIOR FILING DATE: 2000-10-13
? NUMBER OF SEQ ID NOS: 153
? SOFTWARE: PatentIn Ver. 2.1
? SEQ ID NO 7
? LENGTH: 4391
? TYPE: DNA
? ORGANISM: Homo sapiens
? FEATURE:
? OTHER INFORMATION: human CLASP-4 cDNA
? NAME/KEY: CDS
? LOCATION: (414)..(4058)
? OTHER INFORMATION: human CLASP-4
US-09-736-969A-7

```

[illegible]



DB	QY	DB	QY
2799	CGAANAATTTATTTCTAACGGATGTTCAGCGTTCAAGAAATTTACTCCCAATATAGAT	2859	GAAGGAAGGAGCAATGAAGA
482	GAGAGGCTTCATGATGA	501	

### RESULT 3

```

US-09-864-761-13960
; Sequence 13960, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: Aecmica-X-1
; CURRENT APPLICATION NUMBER: US/09/864, 761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 13960
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC011739.2
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1
US-09-864-761-13960

```

Query Match	26.1%;	Score 130.6;	DB 10;	Length 483;
Best Local Similarity	78.1%;	Pred. No. 1.2e-30;		
Matches 157; Conservative	0;	Mismatches 44;	Indels 0;	Gaps 0;

OY	171	CTGATGTGAAGSACTTAAACCAAAAGGATACGCACCGTGCTAATGGCCACC6CCAGATGA	230
Dd	269	CAGAGGTGAAGCACCCTGACTAAGCGTATAAGGACTCTTTTGATGGCCACAGCTCAGATGA	328
OY	231	AGGAGCATGAGAAGACGCCAGAGATGCTGTGTAACCTCCAGTACAGCCTGGCCAAATCT	290
Dd	329	AGGAGCACGAGAAGAACCCCGAGATGCTGTGATCTTCAGTACAGCCTGGCAAACCTCT	388
OY	291	ATGCCAGCACGCCCGAGCTCAGGAAAGACGTGGCTCGACAAGCATGGCCAGATCCATGTCA	350
Dd	389	ACGCAAGCACCTCTGAACTACGCGAGACCTGGCTGGAAGTATGGCCAAAGATTCAATGCCA	448
OY	351	AAAATGGCGATCTCTCAGAGG	371
Dd	449	GAAACGGAGATTATCTGAGG	469

## RESULT 4

```

US-09-736-968A-59
; Sequence 59, Application US/09736968A
; Patent No. US20020169283A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-7 Transmembrane Protein
; FILE REFERENCE: 020054-000611US
; CURRENT APPLICATION NUMBER: US/09/736,968A
; CURRENT FILING DATE: 2000-12-13
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 59
; LENGTH: 2149
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: preliminary human CLASP-7 CDNA sequence
; NAME/KEY: CDS
; LOCATION: (2)..(1933)
; OTHER INFORMATION: human CLASP-7
US-09-736-968A-59

```

Query Match	23.28;	Score 116.4;	DB 9;	Length 2149;
Best Local Similarity	55.48;	Pred. No. 5.6e-26;		
Matches 225;	Conservative	0;	Mismatches 181;	Indels 0;
				Gaps 0;

OY		19	CYTTCGCCGGACACATTTGCAAGTCACTCATATCTGTGCACCAGCAGTGTATGACAGCGTG	78
Dd		283	CTTTGCCCGGTGAAGATGCAGGTCACCATGTCTCTCTGTCCTGTTGGGGAGCACGCA	342
OY		79	TGGCATTTGGGAACACAGATTTCACAGAGTCCCCTGTCCATCATCAACAACACTGTGCCAACAG	138
Dd		343	GAACTTCAGTAGAAGACACCTGCGACGTTCACTCAA AACATCTCACTATGCTGAGGA	402
OY		139	TGACCGGCTTATTAAACACACACAGCTTCTCTCTGTAGTGAAGACTTAACCAAAAGAT	198
Dd		403	GGACATGGGGCTGCGGGACACGACACCTTCGACAGACAGGTCCAGGACCTGATGTTCAACT	462
OY		199	ACGACAGGTGCTAATGACCACCCGCCAGATGAAGAAGCATGGAACGACCAGAGATGCT	258
Dd		463	GCACATGATCTGACGGGACAGGTTGAAGATGAAGSAACACAGAGGACCTGAGATGCT	522
OY		259	GGTGACCTCCAGTACAGCCTGGCCAATCTATGCCAGCAGCCCCGAGCTCAGGAAGAC	318
Dd		523	CATCGACCTCATGTACAGAATTGCCGCGGGCTACCAGGGCTCACC CGGACCTTGCGCTGAC	582
OY		319	GTCGCTCGACAGCATGGCCAGAGATCATGTCAA AAAATGGCGATCTCTCAGAGGACGAAT	378
Dd		583	CTGGTTGCAGAACATGGCCCCGGGAAGCACCGGAGCTGGGGCAACACGCGGAGCGCCCA	642
OY		379	GTCCTATGTCACACGTAACAGCCCTAGTTGGCAGATAATCTCACACGG	424
Dd		643	GTGCATGCTGCACGCGGCGCCCTGCTGGCTGAGTACTCGCCCTG	688

```

RESULT 5
US-09-736-968A-1
; Sequence 1, Application US/09736968A
; Patent No. US20020169283A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-7 Transmembrane Protein
; FILE REFERENCE: 020054-000611US
; CURRENT APPLICATION NUMBER: US/09/736, 968A
; CURRENT FILING DATE: 2000-12-13
; PRIOR APPLICATION NUMBER: US 60/160, 860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162, 498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170, 453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176, 195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182, 296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547, 276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196, 267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196, 460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196, 527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196, 528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687, 837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240, 503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240, 508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240, 539

```

```

; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 6372
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-7 cDNA
; NAME/KEY: CDS
; LOCATION: (13)..(6156)
; OTHER INFORMATION: human CLASP-7
US-09-736-968A-1

```

Query Match	23.28;	Score 116.4;	DB 9;	Length 6372;
Best Local Similarity	55.48;	Pred. No. 9.2e-26;		
Matches 225; Conservative	0;	Mismatches 181;	Indels 0;	Gaps 0;

[illegible]

```

RESULT 6
US-09-864-761-30524
; Sequence 30524, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; APPLICANT: Chen, Wensheng
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
; FILE REFERENCE: Aeomica-X-1
; CURRENT APPLICATION NUMBER: US/09/864,761
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/180,312
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/632,366
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 30524
; LENGTH: 212
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC011739.2
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1
; OTHER INFORMATION: EST HUMAN HIT: BE896788.1, EVALUE 9.00e-93
; OTHER INFORMATION: SWISSPROT HIT: Q24696, EVALUE 3.90e-01
; OTHER INFORMATION: NT HIT: g111429300, EVALUE 6.00e-93
US-09-864-761-30524
```

```
Query Match      23.0%; Score 115.4; DB 10; Length 212;
Best Local Similarity 79.2%; Pred. No. 4e-26;
Matches 137; Conservative 0; Mismatches 36; Indels 0; Gaps 0;
```

```
QY 199 ACGCAGCGTGCTAATGCGCCACCGCCAGATGAGGAGCATGAGAACGACCCAGAGATGCT 258
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1 AAGGACTGTTTGTATGGCCACAGCTCAGATGAGGAGGACGAGAGAGACCCCGAGATGCT 60

QY 259 GGTGACCTCCAGTACAGCTGGCCAAATCTATGCCAGCAGCGCCGAGCTCAGGAAGAC 318
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 61 GGTGATCTCCAGTACAGCTGGCCAAACTCTTACGCAAGCAGCAGCTCTGAACCTACGCGAGAC 120

QY 319 GTGCTCGACAGCAGGCGCAGATGTCAAAATGGCGATCTCTCAGAGG 371
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 121 CTGCTGGAAGTATGGCCAAAGATTCAATGCCAGAAACGAGATTTATCTGAGG 173
```

## RESULT 7

```
US-09-736-960-3
; Sequence 3, Application US/09736960
; Patent No. US20020102267A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-000511US
; CURRENT APPLICATION NUMBER: US/09/736,960
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
```

```
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 4026
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: preliminary human CLASP-5 cDNA sequence
; NAME/KEY: CDS
; LOCATION: (1)..(3066)
; OTHER INFORMATION: human CLASP-5
US-09-736-960-3
```

```
Query Match      16.6%; Score 83.2; DB 10; Length 4026;
Best Local Similarity 50.5%; Pred. No. 1.2e-15;
Matches 202; Conservative 0; Mismatches 198; Indels 0; Gaps 0;
```

```
QY 20 TTTGTCCGACACATTTTGCAGTCATCATCTGTGACGCCAGCTGATAGCAGCTTGT 79
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1300 TTTGCAAGAGTAAGATGCAAGTAACCATGTCTCCCTGGCATCTTTGGTGGAAGACACCA 1359

QY 80 GGCATTTGGGAACACAGATTCACAGAGTCCCTGTCCATCATCAACAATGTGCCAACAGT 139
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1360 GACTTTAATGAGAGACACCTGAGAGATCCTTGAGGACAAATTTGGCTATTCAAGAAAG 1419

QY 140 GACCGCTTATTAAGCACACACAGCTTCTCTGTGATGTAAGGACTTAACCAAAAGATA 199
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1420 GACACAGCCATGCAGATGACTCTTTTCCACCCAGGTGAGGAACCTTCTGTAAATCTG 1479

QY 200 CGCAGGTGCTAATGCGCACCGCCAGATGAAGAGCATGAGAAGCAACCCAGAGATGCTG 259
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1480 AATAGCATCTTATATGACACAGTGAATAATGAGGAATTTCAAGAAAGATCCTGAGATGCT 1539

QY 260 GTGACCTCCAGTACAGCTGGCCAAATCTATGCCAGCAGCCCGAGCTCAGGAAGACG 319
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1540 ATGATCTCATGTACAGAAATGGCAAGATTAACAGCATCTCTGATCTGGGCTGACG 1599

QY 320 TGGCTGACAGCATGGCCAGATCCATGTCAAAAATGGCGAATCTCTCAGAGGCAAGATG 379
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1600 TGGCTCCAGAACATGGCAGAGAAACACCAAGAAAGATGCTTACACGAGGCTGCCATG 1659

QY 380 TGCTATGTCACGTAACAGCCCTAGTGCGAAGATATCTCA 419
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 1660 TGCTGTGTCAGCGCCGCTGCTAGTGCGTGAAGTATCTGA 1699
```

```
RESULT 8
US-09-736-960-1
; Sequence 1, Application US/09736960
; Patent No. US20020102267A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-00051US
; CURRENT APPLICATION NUMBER: US/09/736,960
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 7215
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-5 cDNA
; NAME/KEY: CDS
; LOCATION: (112)..(6159)
; OTHER INFORMATION: human CLASP-5
; US-09-736-960-1

Query Match      16.6%; Score 83.2; DB 10; Length 7215;
Best Local Similarity 50.5%; Pred. No. 1.5e-15;
Matches 202; Conservative 0; Mismatches 198; Indels 0; Gaps 0;
```

```
Db      4669 AATAGCATCTTATATGACACAGTGAATAATGAGGAAATTCAGGAAGATCCTGAGATGCTT 4728
QY      260 GTGACCTCCAGTACAGCCCTGGCCAAATCCTATGCCCAGCAGCCCGAGCTCAGAGACG 319
Db      4729 ATGATCTCATGTACAGAAATGGCCAGAGTTACCAGGCATCTCTGATCTGCGGCTGACC 4788
QY      320 TGGCTGCAGCATGGCCAGATGCATGTCAAAAATGGCGATCTCTCAGAGCAGCAATG 379
Db      4789 TGGCTCCAGACATGGCAGAGAAACACACCAAGAAGAAGTCTTACACGAGGCTGCATG 4848
QY      380 TGCTATGTCCACGTAACAGCCCTAGTGGCAGATATCTCA 419
Db      4849 TGCCGTGTGCACGCCCTGCGTTAGTGGCTGAGTATCTGA 4888
```

```
RESULT 9
US-09-796-692-5465
; Sequence 5465, Application US/09796692
; Publication No. US20020198362A1
; GENERAL INFORMATION:
; APPLICANT: Gaiger, Alexander
; APPLICANT: Algate, Paul A.
; APPLICANT: Mannion, Jane
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THER
; FILE REFERENCE: 2077.001200
; CURRENT APPLICATION NUMBER: US/09/796,692
; CURRENT FILING DATE: 2001-03-01
; PRIOR APPLICATION NUMBER: 60/186,126
; PRIOR FILING DATE: 2000-03-01
; PRIOR APPLICATION NUMBER: 60/190,479
; PRIOR FILING DATE: 2000-03-17
; PRIOR APPLICATION NUMBER: 60/200,545
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 60/200,303
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,779
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,999
; PRIOR FILING DATE: 2000-05-01
; PRIOR APPLICATION NUMBER: 60/202,084
; PRIOR FILING DATE: 2000-05-04
; PRIOR APPLICATION NUMBER: 60/206,201
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: 60/218,950
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/222,903
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 60/223,416
; PRIOR FILING DATE: 2000-08-04
; PRIOR APPLICATION NUMBER: 60/223,378
; PRIOR FILING DATE: 2000-08-07
; NUMBER OF SEQ ID NOS: 9597
; SOFTWARE: FastSeq for windows Version 3.0
; SEQ ID NO 5465
; LENGTH: 427
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-796-692-5465

Query Match      15.8%; Score 79.4; DB 9; Length 427;
Best Local Similarity 53.4%; Pred. No. 6.3e-15;
Matches 167; Conservative 0; Mismatches 146; Indels 0; Gaps 0;
```

```
QY      107 TCCTGTGCATCATCAACAACGTGTGCCAACAGTACCGGCTTATTAAGCACACGACTTC 166
Db      10 TCCTTGAGGACAATTTGGCCATTTCAGAAAGAGACACAGCCATGCAGATGACTCTTTT 69
QY      167 TCCTGTGATGTGAAGACCTTAACCAAAAGGATACGACGGTGCTAATGCGCACCGCCAG 226
Db      70 CCCACCCAGGTGAGAGACTTCTCTGTAACTGAATAGCATCTTATATGACACAGTGAAA 129
```







```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 09/608,408
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: US 09/774,203
; PRIOR FILING DATE: 2001-01-29
; NUMBER OF SEQ ID NOS: 49117
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 24339
; LENGTH: 194
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC011472.3
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 5.6
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 4.9
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 5.2
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 5.1
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 5.7
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 5.4
; OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 5.1
; OTHER INFORMATION: NT HIT: AB037816.1, EVALUATE 2.00e-58
; OTHER INFORMATION: SWISSPROT HIT: Q02817, EVALUATE 3.40e-01
; OTHER INFORMATION: EST_HUMAN HIT: BE531136.1, EVALUATE 2.00e-87
US-09-864-761-24339

```

	Query Match	10.0%	Score 50;	DB 10;	Length 194;
	Best Local Similarity	58.9%;	Pred. No.	4.8e-06;	
Matches	86;	Conservative	0;	Mismatches	60;
				Indels	0;
				Gaps	0;
OY	279	TGCGCAATCTATGCCAGCAGCCCGAGCTCAGAGAAGCTGGCTCGACAGCATGGCCA	338		
Dd	3	TTGCCCGGGGTACCAGGGCTCACCGGACCTTCGGCTGACTTGTCAGAACATGGCCG	62		
OY	339	GGATCCATGTCAAAAATGGGCATCTCTCAGAGGCAGCAATGTCTATGTCCACGTAACAG	398		
Dd	63	GGAAGCACGCCGAGCGTGGGGACAACCAAGCCGAGGCCGCCACGTGCATGGTGACAGCGGGCCG	122		
OY	399	CCCTAGTGGCAGAAATATCTCACACGG	424		
Dd	123	CCCTCGTGGGTAGTAGCTCGCCCTG	148		

```

RESULT 14
US-09-736-960-76
; Sequence 76, Application US/09736960
; Patent No. US20020102267A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-00051US
; CURRENT APPLICATION NUMBER: US/09/736,960
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21

```

```

; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 76
; LENGTH: 266
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: 13th exon
US-09-736-960-76

```

	Query Match	9.7%	Score 48.8;	DB 10;	Length 266;	
	Best Local Similarity	58.1%;	Pred. No.	1.3e-05;		
	Matches	86; Conservative	0;	Mismatches 62;	Indels 0;	Gaps 0;
QY	272 TACAGCCTGGCCAAATCCTATTGCCAGCACGCCCCGAGCTCAGAGAAGACTGTGCCTGCAGACG					331
Dd	31 TTTCAGAAATTGCCAAGAGTTACCAGGCATCTCCTGATCTCGCGCTGAACCTTGGCTCCAGAAC					90
QY	332 ATGGCCAGGATCCATGTCAAAAATGGCGATCTCTCAGAGGCACGACAATGTGCTATGTCCAC					391
Dd	91 ATGGCAGAGAACAACACCAACCAAGAGAAGTGCTACACGAGGCTGCCATGTGCCGTGGCCAC					150
QY	392 GTACAGGCCCTAGTGGCAGAAATATCTCA					419
Dd	151 GCCGCTGCCGTTAGTGGCTGAGTAICTGA					178

```

RESULT 15
US-09-736-960-86
; Sequence 86, Application US/09736960
; Patent NO. US20020102267A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-000511US
; CURRENT APPLICATION NUMBER: US/09/736,960
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: US 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: US 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: US 60/170,453

```

```

; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: US 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,527
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,528
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 86
; LENGTH: 66686
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: ordered human genomic DNA at CLASP-5 locus
US-09-736-960-86

```

Query Match	9.7%;	Score 48.8;	DB 10;	Length 66686;
Best Local Similarity	58.18;	Pred. No. 0.00016;		
Matches	86;	Conservative	0;	Mismatches 62;
			Indels	0;
			Gaps	0;

QY	272	TACAGCCTGGCCAAATCCTATGCCAGCAGCCCGAGCTCAGGAGACGTGGCTGCACAGC	331
Db	33658	TTTCAGAAATGGCCAAAGAGTTACACGAGCATCTCTGATCTGCGGCTGACCTGCAGAAC	33717
QY	332	ATGGCCAGATCCATGTCAAAAATGGCGATCTCTCAGAGGCAGCAATGTGCTATGTCAC	391
Db	33718	ATGGCAGAGAAACACACCAAGAGAAGTGTCTACACGGAGGCTGCCATGTGCTGTGCAC	33777
QY	392	GTACACAGCCCTAGTGGCAGAAATATCTCA	419
Db	33778	GCCGCTGCGTTAGTGGCTGAGTATCTGA	33805

Search completed: February 7, 2003, 09:14:41  
Job time : 69.3549 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 06:53:49 ; Search time 1010.34 Seconds  
(without alignments)  
8030.908 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_2500\_3000  
Perfect score: 501  
Sequence: 1 ttacactggaagaagtcct.....gaggagcctccatgatgga 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 16154066 segs, 8097743376 residues  
Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST:\*  
1: em\_estba:\*  
2: em\_esthum:\*  
3: em\_estlin:\*  
4: em\_estmu:\*  
5: em\_esttov:\*  
6: em\_esttpl:\*  
7: em\_esttro:\*  
8: em\_htc:\*  
9: gb\_est1:\*  
10: gb\_est2:\*  
11: gb\_htc:\*  
12: gb\_est3:\*  
13: gb\_est4:\*  
14: gb\_est5:\*  
15: em\_estfun:\*  
16: em\_estom:\*  
17: gb\_gss:\*  
18: em\_gss\_hum:\*  
19: em\_gss\_inv:\*  
20: em\_gss\_pln:\*  
21: em\_gss\_vrt:\*  
22: em\_gss\_fun:\*  
23: em\_gss\_mam:\*  
24: em\_gss\_mus:\*  
25: em\_gss\_other:\*  
26: em\_gss\_pro:\*  
27: em\_gss\_rtd:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	499.4	99.7	869	14	BQ434370	BQ434370 AGENCOURT
2	488.8	97.6	994	14	BQ067940	BQ067940 AGENCOURT
3	417.4	83.3	454	10	BE163028	BE163028 QV3-HT045
4	410.2	81.9	632	12	BG777371	BG777371 602664635
5	401.4	80.1	694	13	BI691316	BI691316 603309631
6	370	73.9	889	13	BI695006	BI695006 603345307

7	341.6	68.2	558	13	BJ070645	BJ070645
8	337.8	67.4	658	10	BB627919	BB627919
9	330	65.9	503	10	AW909665	AW909665 ur72d11.y
10	303.8	60.6	520	10	BE533728	BE533728 601232874
11	295	58.9	922	14	BQ424615	BQ424615 AGENCOURT
12	294.8	58.8	871	13	BI249092	BI249092 602992423
13	291.4	58.2	589	13	BI006821	BI006821 QV3-RT006
14	276.8	55.2	738	14	BQ179803	BQ179803 UI-M-EW0-
15	268.6	53.6	1042	13	BMA56770	BMA56770 AGENCOURT
16	263	52.5	615	12	BG087170	BG087170 H3136D04-
17	249.6	49.8	554	10	AW231163	AW231163 uc040c09.y
18	243.4	48.6	600	12	BG806790	BG806790 2041-42 M
19	240.4	48.0	733	13	BG919189	BG919189 602818013
20	232	46.3	346	14	D58813	D58813 HUM512E07B
21	230.6	46.0	283	10	AW607903	AW607903 RC0-HT050
22	228.6	45.6	493	12	BG000343	BG000343 RC3-GN004
23	216	43.1	224	10	AW837402	AW837402 QV2-LT003
24	209.8	41.9	545	13	BI535492	BI535492 399059 MA
25	209	41.7	595	10	AW211391	AW211391 uc080d10.y
26	207	41.3	1042	9	AL544595	AL544595 AL544595
27	206.8	41.3	349	9	AA384900	AA384900 EST98484
28	204.8	40.9	875	12	BE896788	BE896788 601437471
29	202	40.3	672	10	AW959926	AW959926 EST371997
30	195.2	39.0	327	9	AA384941	AA384941 EST98518
31	194.6	38.8	742	10	BE382198	BE382198 601271772
32	191.2	38.2	201	12	BF875977	BF875977 RC3-ET013
33	183.4	36.6	948	14	BQ213756	BQ213756 AGENCOURT
34	182.6	36.4	314	9	AA327686	AA327686 EST31082
35	173	34.5	870	14	BQ735599	BQ735599 AGENCOURT
36	172.4	34.4	731	10	AV383524	AV383524 AV383524
37	171.4	34.2	838	17	CNS0020E	AL097064 Drosophil
38	142.6	28.5	1101	17	CNS050F6	AL315483 Tetradon
39	140.4	28.0	652	12	BF979009	BF979009 602147696
40	136.6	27.3	622	14	BQ390482	BQ390482 NISC_mq13
41	136.6	27.3	773	12	BG664949	BG664949 DRABTD07
42	133	26.5	744	13	BG915748	BG915748 602814273
43	128.6	25.7	466	12	BG345674	BG345674 dd90f03.y
44	125	25.0	555	12	BF075158	BF075158 223976 MA
45	121	24.2	966	14	BM905401	BM905401 AGENCOURT

ALIGNMENTS

RESULT 1  
BQ434370  
LOCUS BQ434370 869 bp mRNA linear EST 24-MAY-2002  
DEFINITION AGENCOURT\_7827049 NIH\_MGC\_67 Homo sapiens CDNA clone IMAGE:6152826  
5', mRNA sequence.  
ACCESSION BQ434370  
VERSION BQ434370.1 GI:21173446  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 869)  
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: [cgapbs-remail.nih.gov](mailto:cgapbs-remail.nih.gov)  
Tissue Procurement: ATCC  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Agencourt Bioscience Corporation  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
plate: LLAM13491 row: e column: 19  
High quality sequence stop: 631.  
Location/Qualifiers  
1. .869

FEATURES  
source

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:5152826"
/tissue_lib="NIH_MGC_67"
/tissue_type="retinoblastoma"
/lab_host="DH10B (phage-resistant)"
/note="Organ: eye; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.75 kb. Library constructed by Life
Technologies."

BASE COUNT      223 a      232 c      236 g      178 t
ORIGIN

Query Match      99.7%; Score 499.4; DB 14; Length 869;
Best Local Similarity 99.8%; Pred. No. 1.2e-130;
Matches 500; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1 TTACACTGGAAGAAGTCCCTTTGTCGGGACACATTTGCAAGTCATCATATCTGTACGCCA 60
      |||||||
Db      117 TTACACTGGAAGAAGTCCCTTTGTCGGGACACATTTGCAAGTCATCATATCTGTACGCCA 176

QY      61 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCACAGCAGTCCCTGTCCATCAT 120
      |||||||
Db      177 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCACAGCAGTCCCTGTCCATCAT 236

QY      121 CAACAACGTGTGCCAACAGTGAACCGGCTTATTAAAGCACACACAGCTTCTCTCTGATGTGAA 180
      |||||||
Db      237 CAACAACGTGTGCCAACAGTGAACCGGCTTATTAAAGCACACACAGCTTCTCTCTGATGTGAA 296

QY      181 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGGCCACCGCCAGATGAAGAGCATGA 240
      |||||||
Db      297 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGGCCACCGCCAGATGAAGAGCATGA 356

QY      241 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCCAATCCTATGCCAGCAC 300
      |||||||
Db      357 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCCAATCCTATGCCAGCAC 416

QY      301 GCCCGAGCTCAGAGAAGAGCTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 360
      |||||||
Db      417 GCCCGAGCTCAGAGAAGAGCTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 476

QY      361 TCTCTCAGAGGACGACATGTGCTATATGCCACGTAACAGCCCTAGTGGCAGATATCTCAC 420
      |||||||
Db      477 TCTCTCAGAGGACGACATGTGCTATATGCCACGTAACAGCCCTAGTGGCAGATATCTCAC 536

QY      421 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 480
      |||||||
Db      537 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 596

QY      481 CGAGGAGGCGCTCCATGATGA 501
      |||||||
Db      597 CGAGGAGGCGCTCCATGATGA 617

RESULT 2
LOCUS      BQ067940      994 bp      mRNA      linear      EST 02-APR-2002
DEFINITION AGENCOURT_6792185 NIH_MGC_121 Homo sapiens cDNA clone IMAGE:5768931
5', mRNA sequence.
ACCESSION      BQ067940
VERSION      BQ067940.1 GI:19896986
KEYWORDS
SOURCE      EST.
ORGANISM      human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE      1 (bases 1 to 994)
AUTHORS      NIH-MGC http://mgc.ncl.nih.gov/.
TITLE      National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL      Unpublished (1999)
COMMENT      Contact: Robert Strausberg, Ph.D.
      Email: cgabbs-r@mail.nih.gov
      Tissue Procurement: Life Technologies, Inc.
```

```

CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LNL at:
http://image.lnl.gov
Plate: LLM12829 row: j column: 04
High quality sequence stop: 499.
Location/Qualifiers
1.994
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:5768931"
/tissue_lib="NIH_MGC_121"
/lab_host="DH10B"
/note="Organ: brain; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: EcoRV (destroyed); RNA source anonymous pool of 3
fetal brains, female age 20 weeks, female age 24 weeks,
and male age 26 weeks. Library is oligo-dT primed and
directionally cloned (EcoRV site is destroyed upon
cloning). Average insert size 1.7 kb, insert size range
0.7-3.5 kb. Library is normalized and enriched for
full-length clones and was constructed by C. Gruber
(Invitrogen). Research Genetics tracking code 017. Note:
this is a NIH-MGC Library."

BASE COUNT      274 a      255 c      244 g      220 t      1 others
ORIGIN

Query Match      97.6%; Score 488.8; DB 14; Length 994;
Best Local Similarity 98.4%; Pred. No. 1.3e-127;
Matches 493; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY      1 TTACACTGGAAGAAGTCCCTTTGTCGGGACACATTTGCAAGTCATCATATCTGTACGCCA 60
      |||||||
Db      187 TTACACTGGAAGAAGTCCCTTTGTCGGGACACATTTGCAAGTCATCATATCTGTACGCCA 246

QY      61 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCACAGCAGTCCCTGTCCATCAT 120
      |||||||
Db      247 GCTGATAGCAGACGTTGTTGGCATTTGGGGAACCAGATTCACAGCAGTCCCTGTCCATCAT 306

QY      121 CAACAACGTGTGCCAACAGTGAACCGGCTTATTAAAGCACACACAGCTTCTCTCTGATGTGAA 180
      |||||||
Db      307 CAACAACGTGTGCCAACAGTGAACCGGCTTATTAAAGCACACACAGCTTCTCTCTGATGTGAA 366

QY      181 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGGCCACCGCCAGATGAAGAGCATGA 240
      |||||||
Db      367 GGACTTTAACCAAAAGGATACGCACGGTGCTAATGGGCCACCGCCAGATGAAGAGCATGA 426

QY      241 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 300
      |||||||
Db      427 GAACGACCCAGAGATGCTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAC 486

QY      301 GCCCGAGCTCAGAGAAGAGCTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 360
      |||||||
Db      487 GCCCGAGCTCAGAGAAGAGCTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGA 546

QY      361 TCTCTCAGAGGACGACATGTGCTATATGCCAGTAAACAGCCCTAGTGGCAGATATCTCAC 420
      |||||||
Db      547 TCTCTCAGAGGACGACATGTGCTATATGCCAGTAAACAGCCCTAGTGGCAGATATCTCAC 606

QY      421 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 480
      |||||||
Db      607 ACGGAAAGGCGTGTTTAGACAAGATGCACCGCCTTCAGGGTCATTACCCCAACATCGA 666

QY      481 CGAGGAGGCGCTCCATGATGA 501
      |||||||
Db      667 CGAGGAGGCGCTCCATGATGA 687

RESULT 3
LOCUS      BE163028      454 bp      mRNA      linear      EST 21-JUN-2000
DEFINITION QV3-HT0457-070300-113-c03 HT0457 Homo sapiens cDNA, mRNA sequence.
```

ACCESSION BE163028  
VERSION BE163028.1 GI:8625749  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 454)  
Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.  
TITLE Shotgun sequencing of the human transcriptome with ORF expressed sequence tags  
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
MEDLINE 20202663  
COMMENT Contact: Simpson A.J.G.  
Laboratory of Cancer Genetics  
Ludwig Institute for Cancer Research  
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil  
Tel: +55-11-2704922  
Fax: +55-11-2707001  
Email: asimpson@ludwig.org.br  
This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL  
(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=st2=QY3-HT0457-070300-113-c03&t3=2000-03-07&t4=1)  
Seq primer: puc 18 forward  
High quality sequence start: 3  
High quality sequence stop: 454.  
FEATURES  
source  
1. 454  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone\_lib="HT0457"  
/dev\_stage="Adult"  
/note="Organ: head neck; Vector: puc18; Site\_1: SmaI; Site\_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."  
BASE COUNT 88 a 112 c 124 g 130 t  
ORIGIN  
Query Match 83.3%; Score 417.4; DB 10; Length 454;  
Best Local Similarity 99.8%; Pred. No. 1.4e-107;  
Matches 418; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 10 AAAGAAGTCCTTGTCCGGACACATTTGCAGTCATCATATCTGTCAGCCAGCTGATAGC 69  
Db 454 AAAGAAGTCCTTGTCCGGACACATTTGCAGTCATCATATCTGTCAGCCAGCTGATAGC 395  
QY 70 AGACGTGTGTGGCATGGGGAAACCAGATTCACAGCAGTCCCTGTCCATCATCAACAAC 129  
Db 394 AGACGTGTGTGGCATTTGGGGAAACCAGATTCACAGCAGTCCCTGTCCATCATCAACAAC 335  
QY 130 TGCCACACAGTGACCGGCTTATTAAAGCACACAGCTTCTCCTCTGATGTGAAGACTTAAC 189  
Db 334 TGCCACACAGTGACCGGCTTATTAAAGCACACAGCTTCTCCTCTGATGTGAAGACTTAAC 275  
QY 190 CAAAAGGATACGCACGGTGCTAATGGCCACCCCCACAGATGAAGAGCATGAAGAGACCC 249  
Db 274 CAAAAGGATACGCACGGTGCTAATGGCCACCCCCACAGATGAAGAGCATGAAGAGACCC 215  
QY 250 AGAGATGCTGTGTGACCTTCAGTACAGCCTGGCCAAATCCTATGCGACGACGCCGAGCT 309  
Db 214 AGAGATGCTGTGTGACCTTCAGTACAGCCTGGCCAAATCCTATGCGACGACGCCGAGCT 155

QY 310 CAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGATCTCTCAGA 369  
Db 154 CAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGATCTCTCAGA 95  
QY 370 GGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCACACGGAAAG 428  
Db 94 GGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAAATATCTCACACGGAAAG 36

RESULT 4  
BG777371 632 bp mRNA linear EST 15-MAY-2001  
LOCUS 603664635F1 NIH\_MGC\_60 Homo sapiens cDNA clone IMAGE:4804592 5', mRNA sequence.  
DEFINITION BG777371  
ACCESSION BG777371 GI:14047688  
VERSION BG777371.1  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 632)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgabs-remail.nih.gov  
Tissue procurement: DCTD/DTP  
cDNA Library Preparation: CLONETECH Laboratories, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LLCM1651 row: e column: 09  
High quality sequence stop: 620.

FEATURES  
source  
1. 632  
Location/Qualifiers  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="IMAGE:4804592"  
/clone\_lib="NIH\_MGC\_60"  
/tissue\_type="adenocarcinoma"  
/lab\_host="DH10B (T1 phage-resistant)"  
/note="Organ: prostate; Vector: pDNR-LIB (Clontech); Site\_1: SfiI (ggccgcctcgcc); Site\_2: SfiI (ggccattatggcc ); Double-stranded cDNA was prepared from cell line RNA. 5' and 3' adaptors were used in cloning as follows: 5' adaptor sequence: 5'-ATCTAGAGGCGGCGGCGGCACATG-dT(30)BN-3' (where B = A, C, or G and N = A, C, G, or T). Average insert size 1.5 kb (range 0.9-4.0 kb). 14/15 colonies contained inserts by PCR. This library was enriched for full-length clones and was constructed by Clontech Laboratories (Palo Alto, CA). Note: this is a NIH\_MGC Library."

BASE COUNT 173 a 175 c 167 g 117 t  
ORIGIN

Query Match 81.9%; Score 410.2; DB 12; Length 632;  
Best Local Similarity 99.3%; Pred. No. 1.9e-105;  
Matches 412; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 87 GGAACCCAGATTCCAGAGTCCCTGTCCATCATCAACAACGTGCGCAACAGTGACCGGC 146  
Db 1 GGGGAACCCAGATTCCAGAGTCCCTGTCCATCATCAACAACGTGCGCAACAGTGACCGGC 60  
QY 147 TTATTAAGCACACCAAGCTTCTCCTCTGATGTGAAGGACTTAAACCAAAAGGATACGCACGG 206  
Db 61 TTATTAAGCACACCAAGCTTCTCCTCTGATGTGAAGGACTTAAACCAAAAGGATACGCACGG 120  
QY 207 TGCTAATGGCCACCGCCAGATGAAGAGCATGAGAAGCAACCCAGAGATGCTGTGGACC 266  
|||||

Db	121	TGCTAATGGCCACCCGCCACGATGAAGGAGCATGAGAACGACCCAGAGATGCTGGTGGACC	180
QY	267	TCCAGTACAGCCTGGGCCAAATCCTATGCGCAGCACGCCCCGAGCTCAGGAAGACGTGGCTCG	326
Db	181	TCCAGTACAGCCTGGGCCAAATCCTATGCGCAGCACGCCCCGAGCTCAGGAAGACGTGGCTCG	240
QY	327	ACAGCATGGCCAGGATCCATGTCAAAAATGGCGATCTCTCAGAGCGCAGCAATGTGCTATG	386
Db	241	ACAGCATGGCCAGGATCCATGTCAAAAATGGCGATCTCTCAGAGCGCAGCAATGTGCTATG	300
QY	387	TCCACGTAACAGCCCTAGTGGCAGAATATCTCACACGGAAGGCGTGTTAGACAAGGAT	446
Db	301	TCCACGTAACAGCCCTAGTGGCAGAATATCTCACACGGAAGGCGTGTTAGACAAGGAT	360
QY	447	GCACCGCCTTCAGGGTCATTACCCCAAAACATCGACGAGGAGGCTCCATGATGGA	501
Db	361	GCACCGCCTTCAGGGTCATTACCCCAAAACATCGACGAGGAGGCTCCATGATGGA	415

RESULT 5  
 BI691316  
 LOCUS  
 DEFINITION  
 694 bp mRNA linear EST 18-SEP-2001  
 603309631F1 NCI\_CGAP\_Mam6 Mus musculus cDNA clone IMAGE:5345838 5',  
 mRNA sequence.  
 BI691316  
 ACCESSION  
 BI691316.1 GI:15653945  
 VERSION  
 EST,  
 KEYWORDS  
 house mouse.  
 SOURCE  
 Mus musculus  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 694)  
 REFERENCE  
 NIH-MGC <http://mgc.nci.nih.gov/>.  
 AUTHORS  
 National Institutes of Health, Mammalian Gene Collection (MGC)  
 TITLE  
 Unpublished (1999)  
 JOURNAL  
 Contact: Robert Strausberg, Ph.D.  
 Email: [cgabs-remail.nih.gov](mailto:cgabs-remail.nih.gov)  
 COMMENT  
 Tissue Procurement: Jeffrey Green M.D.  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Incyte Genomics, Inc.  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
<http://image.llnl.gov>  
 Plate: L1AM11878 row: m column: 07  
 High quality sequence stop: 693.  
 FEATURES  
 location/Qualifiers  
 1..694

```

/organism="Mus musculus"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="IMAGE:5345838"
/clone_lib="NCI_CGAP_Mam6"
/sex="female, virgin"
/tissue_type="infiltrating ductal carcinoma"
/dev_stage="5 months"
/lab_host="DH10B"
/note="Organ: mammary; Vector: pCMV-SPORT6; Site_1: SalI; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigator providing samples: Jeffrey Green, M.D., NIH"

```

Query Match	80.1%;	Score 401.4;	DB 13;	Length 694;
Best Local Similarity	87.6%;	Pred. No. 6.2e-103;		
Matches 438;	Conservative 0;	Mismatches 62;	Indels 0;	Gaps 0
QY 2	TACACTGGAAGAAGCTCTTTGTCCGGACACATTTGCAGTCAATCATATCTGTACGCCAG	61		
Db 146	TACACAGGAAGAAGCTCTTNTGTTCGGACGCACATTACAGGTCAATCATCTCTGTACGCCAA	205		
QY 62	CTGATAGCAGACGCTGTGTGGCAATTTGGGGAACACGATTCACAGCAGTCCCTGTTCATCATC	121		

DB 206 CTGATTGCAGATGTGGTTGGCATTGGAGGAACCAAGATCCAGCAGTCCCTTGCTATCATC 265

QY 122 AACCACTGTGCCAACACTGCACCGGCTTATTAAAGCAACCAAGCTTCTCCTGTGATGTGAAG 181

DB 266 AACCACTGTGCCAACACCGCAGCCGGATCATCAAGCACACCAAGCTTTCCCTGTGATGTGA 325

QY 182 GACTTAACCAAAAGGATACGCAACGGGTGCTAATGGCCACCGCCCAAGATGAAGAGCATGAG 241

DB 326 GATTTGACTAAGAGGATCCGCACAGTCTGTGATGGCCACAGCCCAAGATGAAGAGCACGAG 385

QY 242 AACGACCCAGAGATGCTGTGTGACCTCCAGTACAGCCTGGCCAAATCCTATGCCACGACG 301

DB 386 AACGACCCGAGATGCTGTGTGACCTCCAGTACAGCCTGGCTAAGTCCTAAGCCACGACCC 445

QY 302 CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAAATGGCGAT 361

DB 446 CCTGAGCTCAGGAAGACGTGGCTAGACAGTATGGCGAGATTCACGTTAAAAATGGGGAC 505

QY 362 CTCTCAGAGGCGACAATGTGCTATGTCCACGTAACAGCCCCTAGTGGCAGAATATCTCACA 421

DB 506 CTCTCAGAGGCGGCAATGTGCTATGTCCACGTGACAGCCTTGGTGGCAGAAATATCTCACA 565

QY 422 CGGAAGAGCGGTGTAGACAAGCATGCACCGCCTTCAGGGTCAATTACCCCAACATGCAG 481

DB 566 CGGAAGAGCATGTTCAGACAGAGGGTGCACAGCCTTCAGGGTATCAACACCAACATCATG 625

QY 482 GAGGAGGCTCCATGATGGA 501

DB 626 GAAGAGGCTTCATGATGGA 645

RESULT	6
BI695006	
LOCUS	
DEFINITION	889 bp mRNA linear EST 18-SEP-2001 603345307F1 NCI_CGAP_Mam2 Mus musculus cDNA clone IMAGE:5373121 5', mRNA sequence.
ACCESSION	BI695006
VERSION	BI695006.1 GI:15657635
KEYWORDS	EST.
SOURCE	house mouse.
ORGANISM	Mus musculus
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 889)
AUTHORS	NIH-MGC http://mgc.nci.nih.gov/.
TITLE	National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL	Unpublished (1999)
COMMENT	Contact: Robert Strausberg, Ph.D. Email: cgabbs-r@mail.nih.gov Tissue Procurement: Gilbert Smith, Ph.D. cDNA Library Preparation: Life Technologies, Inc. cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Incyte Genomics, Inc. Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <a href="http://image.llnl.gov">http://image.llnl.gov</a> Plate: LAM11949 row: n column: 02 High quality sequence stop: 652.
FEATURES	location/Qualifiers
source	1..889

```

/organism="Mus musculus"
/strain="FVB/N-3"
/db_xref="taxon:10090"
/clone="IMAGE:5373121"
/clone_lib="NCI_CGAP_Mam2"
/tissue_type="tumor, biopsy sample"
/dev_stage="5 months"
/lab_host="DH10B"
/note="Organ: mammary; Vector: pCMV-SPORT6; Site_1: SalI;
Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Library constructed by Life Technologies. Investigator
providing samples: Gilbert Smith, NIH"

```





TITLE Muramatsu,M. and Hayashizaki,Y.  
JOURNAL RIKEN Mouse ESTs (Arakawa,T., et al. 2001)  
COMMENT Unpublished (2001)  
Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic  
Sciences Center(GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suenhiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: genome-res@gsc.riken.go.jp,  
URL:http://genome.gsc.riken.go.jp/  
Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh  
,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.  
Normalization and subtraction of cap-trapper-selected cDNAs to  
prepare full-length cDNA libraries for rapid discovery of new  
genes. Genome Res. 10 (10), 1617-1630 (2000)  
wagi,K., Fujiwake,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E.,  
Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura  
,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and  
Hayashizaki,Y.  
RIKEN integrated sequence analysis (RISA) system--384-format  
sequencing pipeline with 384 multicapillary sequencer. Genome Res.  
10 (11), 1757-1771 (2000)  
Konno,H., Fukunishi,Y., Shibata,K., Itoh,M., Carninci,P., Sugahara  
,Y. and Hayashizaki,Y.  
Computer-based methods for the mouse full-length cDNA  
encyclopedia: real-time sequence clustering for construction of a  
nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)  
Kondo,S., Shinagawa,A., Saito,T., Kiyosawa,H., Yamanaka,I., Aizawa  
,K., Fukuda,S., Hara,A., Itoh,M., Kawai,J., Shibata,K. and  
Hayashizaki,Y.  
Computational Analysis of Full-length Mouse cDNAs Compared with  
Human Genome Sequences. Mamm. Genome. 12, 673-677 (2001)  
Please visit our web site (http://genome.gsc.riken.go.jp) for  
further details.  
e mouse tissues.

FEATURES  
source  
1. 658  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
/clone="9530048J06"  
/clone\_lib="RIKEN full-length enriched, adult male urinary  
bladder"  
/sex="male"  
/tissue\_type="urinary bladder"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/note="Site\_1: Sali; Site\_2: BamHI; cDNA library was  
prepared and sequenced in Mouse Genome Encyclopedia  
Project of Genome Exploration Research Group in Riken  
Genomic Sciences Center and Genome Science Laboratory in  
RIKEN. Division of Experimental Animal Research in Riken  
contributed to prepare mouse tissues. 1st strand cDNA was  
primed with a primer [5',  
GAGAGAGAGAGATCCACAGAGCTCTTTTCTTTTCTTTTCTTTVN 3'], cDNA was  
prepared by using trehalose thermo-activated reverse  
transcriptase and subsequently enriched for full-length by  
cap-trapper. cDNA went through one round of normalization  
to Rot = 20.0 and subtraction to Rot = 370.0. Second  
strand cDNA was prepared with the primer adapter of  
sequence [5' GAGAGAGAGATTCGAGTTAATTAAATTAAATCCCCCCCC  
3']. cDNA was cleaved with XhoI and BamHI. Vector: a  
modified pBluescript KS(+) after bulk excision from  
lambda FLC I."

BASE COUNT 167 a 176 c 164 g 151 t  
ORIGIN

Query Match 67.4%; Score 337.8; DB 10; Length 658;  
Best Local Similarity 87.8%; Pred. No. 6.5e-85;  
Matches 380; Conservative 0; Mismatches 52; Indels 1; Gaps 1;  
QY 2 TACACTGGAAGAAGTCCTTGTCCGGACACATTGTGCAAGTCATCATATCTGTGACCCAG 61

Db 226 TACACAGAAAGAAGTCCTTGTTCGGACGCACTTACAGGTCATCATCTCTGACCCAA 285  
QY 62 CTGATAGCAGACGTTGTTGGCATTGGGAAACAGATTCCAGCAGTCCCTGTCATCATC 121  
Db 286 CTGATTGCAGATGTGGTTGGCATTGGAGAACAGATTCCAGCAGTCCCTGTCATCATC 345  
QY 122 AACAACTGTGCCAACAGATGACCGGCTTATTAAACACACCAGCTTCTCTGATGTGAAG 181  
Db 346 AACAACTGTGCCAACAGCAGCCGATCATCAAGCACACCAGCTTTTCTCTGATGTGAAA 405  
QY 182 GACTTAACCAAAAGATACGCCACGCTGCTAATGGCCACCGCCAGATGAAGACATGAG 241  
Db 406 GATTTGACTAAGAGGATCCGCACAGTCTCTGATGGCCACAGCCAGATGAAGACAGAG 465  
QY 242 AACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAGC 301  
Db 466 AACGACCCGAGAGATGCTGTGGACCTCCAGTACAGCCTGGCTAAGTCTACGCCAGCACC 525  
QY 302 CCCGAGCTCAGGAAGACGTGGCTCGACAGCAGATGGCCAGATCCATGTCAAAATGGCGAT 361  
Db 526 CCTGAGCTCAGGAAGACGTGGCTTAGACAGTATGGCGAGATTTCACGTTAAATAATGGGGAC 585  
QY 362 CTCTCAGAGCGCAATGTGCTATGTCCACGTAACAGCC-CTAGTGGCAGATATCTCAC 420  
Db 586 CTCTCAGAGCGCGCAATGTGCTATGTCCACGTAACAGCCTTGTGTGGCAGATATCTCAC 645  
QY 421 ACGGAAGCGCTG 433  
Db 646 ACGGCAAGGCATG 658

RESULT 9  
AW909665 503 bp mRNA linear EST 25-MAY-2000  
LOCUS ur72d11.y1 NCI\_CGAP\_Mam3 Mus musculus cDNA clone IMAGE:3155829 5'  
DEFINITION similar to TR:Q63603 Q63603 TRG mRNA ;, mRNA sequence.

ACCESSION AW909665  
VERSION AW909665.1 GI:8074903  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 503)  
AUTHORS NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index  
Unpublished (1997)  
JOURNAL Other\_ESTs: ur72d11.x1

COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-r@mail.nih.gov  
Tissue Procurement: Lothar Hennighausen Ph.D., Chu-Xia Deng Ph.D.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
image.llnl.gov/image/html/resources.shtml

MG1:1058585  
Seq primer: -40RP from Gibco  
High quality sequence stop: 416.  
FEATURES  
source  
1. 503  
/organism="Mus musculus"  
/strain="129,C57BL/6J,FVB/N"  
/db\_xref="taxon:10090"  
/clone="IMAGE:3155829"  
/clone\_lib="NCI\_CGAP\_Mam3"  
/tissue\_type="tumor, gross tissue"  
/dev\_stage="10 months"  
/lab\_host="DH10B"

/note="Organ: mammary; Vector: PCMV-SPORT6; Site\_1: Salt; Site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigators providing samples: Lothar Hennighausen/Chu-Xia Deng, NIH Reference for transgenic model: Xu et al., Nature Genetics 22, 37-43 (1999)."

BASE COUNT 130 a 136 c 130 g 107 t  
ORIGIN

Query Match 65.9%; Score 330; DB 10; Length 503;  
Best Local Similarity 87.8%; Pred. No. 9e-83;  
Matches 360; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

QY 2 TACACTGGAAGAAGTCCTTTGTCGGACACATTTGCCAAGTCATCATATCTGTACGCCAG 61  
Db 93 TACACAGGAAGAAGTCTTTGTCGGACGCGACTTACAGGTCATCATCTGTACGCCAA 152  
QY 62 CTGATAGCAGACGTTGTCGATTTGGGAAACCAGATTCCAGCAGTCCCTGTCCATCATC 121  
Db 153 CTGATTGCAGATGTGTTGGCATTGGAGGAACCAGATTCCAGCAGTCCCTGTCTATCATC 212  
QY 122 AACAACTGTGCCAACAGTGACCGGCTTATTAAAGCACACAGCCTTCTCCTGATGTGAAG 181  
Db 213 AACAACTGTGCCAACAGCGACCGGATCATCAAGCACACAGCCTTTTCTCTGATGTGAAA 272  
QY 182 GACTTAACCAAAAGGATACGCACGGTGTATATGGCCACCGCCAGATGAAGAGCATGAG 241  
Db 273 GATTTGACTAAGAGATCCGCACAGTCTGATGGCCACAGCCAGATGAAGAGCAGCAG 332  
QY 242 AACGACCCAGAGATGCTGTGGAGCTCCAGTACAGCCTGGCCAAATCTATGCCAGCAGC 301  
Db 333 AACGACCCGGAGATGCTGTGGAGCTCCAGTACAGCCTGGCTAAGTCTACGCCAGCAGCC 392  
QY 302 CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGAT 361  
Db 393 CCTGAGCTCAGGAAGACGTGGCTAGACAGTATGGCGAGATTTCACGTTAAAAATGGGGAC 452  
QY 362 CTCTCAGAGGCACCAATGTGCTATGTCCACGTAAACAGCCCTAGTGGCAGA 411  
Db 453 CTCTCAGAGCGCGCAATGTGCTATGTCCACGTGACAGCCTTGTGGCAGA 502.

RESULT 10 BE533728 520 bp mRNA linear EST 09-AUG-2000  
LOCUS BE533728 601232874F1 NCI\_CGAP\_Mam6 Mus musculus cDNA clone IMAGE:3596515 5',  
DEFINITION mRNA sequence.

ACCESSION BE533728  
VERSION BE533728.1 GI:9762373  
KEYWORDS EST.

SOURCE house mouse.  
ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 520)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgabbs-remail.nih.gov  
Tissue Procurement: Jeffrey Green M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
plate: LLAM8774 row: d column: 20  
High quality sequence stop: 520.

FEATURES

source 1..520  
/organism="Mus musculus"  
/strain="FVB/N"

/db\_xref="taxon:10090"  
/clone="IMAGE:3596515"  
/clone\_lib="NCI\_CGAP\_Mam6"  
/sex="female, virgin"  
/tissue\_type="infiltrating ductal carcinoma"  
/dev\_stage="5 months"  
/lab\_host="DH10B"  
/note="Organ: mammary; Vector: PCMV-SPORT6; Site\_1: Salt; Site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigator providing samples: Jeffrey Green, M.D., NIH"

BASE COUNT 136 a 127 c 155 g 102 t  
ORIGIN

Query Match 60.6%; Score 303.8; DB 10; Length 520;  
Best Local Similarity 87.1%; Pred. No. 2.5e-75;  
Matches 379; Conservative 0; Mismatches 52; Indels 4; Gaps 4;

QY 71 GACGTTGTGGCATTTGGGAAACCAGATTCCAGCAGTCCCTGTCCATCATCAA-CACTG 129  
Db 1 GATGTGTTGGCAGTGGAGGAACCAAGATTCAGCAGTCTGTCTATCATCAAGCAACTG 60  
QY 130 TGCCAACAGTGAACCGGCTTATTAAAGCACACACAGCCTTCTCCTGATGTGAAGACTT-AA 188  
Db 61 TGCCAACAGCAGCCGGATCATCAAGCACACACAGCCTTTCTCTGATGTGAAGATTGGA 120  
QY 189 CCAAAAGGATACGCACGGTGTCTAATGGCCACCGCCAGATGAAGAGCATGAGAAGCAGC 248  
Db 121 CTAAGAGGATCCGCACAGTCTCTGATGGCCACAGCCAGATGAAGAGCAGAGAAGCAGC 180  
QY 249 CAGAGATGCTGGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGCCAGCAGCCGAGC 308  
Db 181 CGGAGATGCTGGTGGACCTCCAGTACAGCCTGGCTTAAGTCTACGCCAGCACACCCCTGAGC 240  
QY 309 TCAGGAAGACGTGGCTCGACAGCATGGCCAGGATCCATGTCAAAA-TGGCGATCTCTCA 367  
Db 241 TCAGGAAGACGTGGCTAGACAGTATGGCGAGGATTCACGTTAAAAAGTGGGAGCCTCTCA 300  
QY 368 GAGGACGCAATGTGCTATGTCCACGTAAACAGCCCTAGTGGCAGAAATCTCACACGGAA- 426  
Db 301 GAGGCGGCAATGTGCTATGTCCACGTGACAGCCTTGTGGCAGAAATCTCACACGGAAAC 360  
QY 427 AGCGGTGTTAGACAAGATGACACCGCCTTCAGGCTCATTAACCCAAACATCGACGAGA 486  
Db 361 AGGCATGTTCCAGACAGGGGTGACAGCCTTCAGGGTTATCACACCAACATCGATGAGA 420  
QY 487 GGCCTTCATGATGGA 501  
Db 421 GGCTTCATGATGGA 435

RESULT 11 BQ424615 922 bp mRNA linear EST 23-MAY-2002  
LOCUS BQ424615 AGENCOURT\_7834017 NIH\_MGC\_67 Homo sapiens cDNA clone IMAGE:6153210  
DEFINITION 5', mRNA sequence.

ACCESSION BQ424615  
VERSION BQ424615.1 GI:21119930  
KEYWORDS EST.

SOURCE human.  
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 922)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgabbs-remail.nih.gov  
Tissue Procurement: ATCC  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Plate: L1AM13492 row: e column: 19  
High quality sequence stop: 577.  
Location/Qualifiers

FEATURES  
Source  
1. 922  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="IMAGE:6153210"  
/clone\_lib="NIH\_MGC\_67"  
/tissue\_type="retinoblastoma"  
/lab\_host="DH10B (phage-resistant)"  
/note="Organ: eye; Vector: PCMV-SPORT6; Site\_1: NotI; Site\_2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.75 kb. Library constructed by Life Technologies."

BASE COUNT 251 a 237 c 249 g 185 t  
ORIGIN

Query Match 58.9%; Score 295; DB 14; Length 922;  
Best Local Similarity 99.7%; Pred. No. 1.1e-72;  
Matches 306; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 122 AACAACTGTGCCAACAGTACCGGCTTATTAAACACACAGCTTCTCTGTGATGTGAAG 181  
|||||  
Db 1 AACAACTGTGCC-ACAGTACCGGCTTATTAAACACACAGCTTCTCTGTGATGTGAAG 59  
QY 182 GACTTAACCAAAAGGATACGCACGGTGTCTAATGGCCACCGCCAGATGAAGAGCATGAG 241  
|||||  
Db 60 GACTTAACCAAAAGGATACGCACGGTGTCTAATGGCCACCGCCAGATGAAGAGCATGAG 119  
QY 242 AACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGGCAGCAG 301  
|||||  
Db 120 AACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGGCAGCAG 179  
QY 302 CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGAT 361  
|||||  
Db 180 CCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGATCCATGTCAAAAATGGCGAT 239  
QY 362 CTCTCAGAGGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCACA 421  
|||||  
Db 240 CTCTCAGAGGCAGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATATCTCACA 299  
QY 422 CGGAAG 428  
|||||  
Db 300 CGGAAG 306

RESULT 12  
BI249092/c 871 bp mRNA linear EST 17-JUL-2001  
LOCUS 602992423F1 NCI\_CGAP\_Mam5 Mus musculus cDNA clone IMAGE:5148461 5',  
DEFINITION mRNA sequence.  
ACCESSION BI249092  
VERSION BI249092.1 GI:14796120  
KEYWORDS EST.  
SOURCE house mouse.  
ORGANISM Mus musculus.  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 871)  
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: [cgabs-remail.nih.gov](mailto:cgabs-remail.nih.gov)  
Tissue Procurement: Lothar Hennighausen Ph.D., Robin Humphreys  
cDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:

<http://image.llnl.gov>  
Plate: L1AM1366 row: m column: 06  
High quality sequence stop: 716.  
Location/Qualifiers

FEATURES  
Source  
1. 871  
/organism="Mus musculus"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="IMAGE:5148461"  
/clone\_lib="NCI\_CGAP\_Mam5"  
/tissue\_type="tumor, gross tissue"  
/dev\_stage="7 months"  
/lab\_host="DH10B"  
/note="Organ: mammary; Vector: PCMV-SPORT6; Site\_1: SalI; Site\_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Library constructed by Life Technologies. Investigators providing samples: Lothar Hennighausen/Robin Humphreys, NIH"

BASE COUNT 175 a 245 c 225 g 226 t  
ORIGIN

Query Match 58.8%; Score 294.8; DB 13; Length 871;  
Best Local Similarity 80.3%; Pred. No. 1.2e-72;  
Matches 408; Conservative 0; Mismatches 92; Indels 8; Gaps 5;

QY 2 TACACTGGAAGAAGTCTTTGTCGGACACATTGCA---AGTCATCATATCTGCACG 58  
|||  
Db 848 TACCCAGGAAGAAGTCTTTGTCAGAGACGGCACGTACAGGGTCATCATCTCTGCACG 789  
QY 59 CAGC-TGATAGCAGACGTTGTGGCATTTGGGAACCAAGATCCAGCAGTCCCTGCTCAT 117  
|||  
Db 788 CAACCTGATGCAAGATGTGTGCCATTTGGAGGAACCAAGATCCAGCAGTCCCTGCTCA 729  
QY 118 CATCAACAAGTGTGCCAACAGTACCGGCTT--ATTAAGACA-CCAGCTTCTCTCTGA 174  
|||  
Db 728 TCATCACACTGTGCCAACAGCGGACCGGATTCATCAAGCACACCCAGCTTCTCTGA 669  
QY 175 TGTGAAGACTTAACCAAAAGGATACGACGCGTCTAATGGCCACCGCCAGATGAAGA 234  
|||||  
Db 668 TGTGAAGATTTGACTAAGAGATCCGCACAGTCTGATGGCCACAGCCAGATGAAGA 609  
QY 235 GCATGAGACGACCCAGAGATGCTGTGGACCTCCAGTACAGCCTGGCCAAATCCTATGC 294  
|||||  
Db 608 GCACGAGAACGACCCGAGATGCTGTGGACCTCCAGTACAGCCTGGCTAAGTCTACGC 549  
QY 295 CAGCAGCCCCGAGCTCAGGAAGACGTGGCTCGACAGCATGGCCAGAGATCCATGTCAAAA 354  
|||||  
Db 548 CAGCAGCCCTGAGCTCAGGAAGACGTGGCTAGACAGTATGGCGAGATTCACGTTAAAA 489  
QY 355 TGGCATCTCTCAGAGGCGACCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATA 414  
|||||  
Db 488 TGGGACCTCTCAGAGGCGGCAATGTGCTATGTCCACGTAACAGCCCTAGTGGCAGAATA 429  
QY 415 TCTCA-CACGGAAGCGGTGTTAGACAAGGATGCACCGCCTTCAGGGTCATTACCCCAA 473  
|||||  
Db 428 TCTCACACGGAAGGCAATGTTAGACAGAGGGGTGCACAGCCTTCAGGGTTATCACACCAA 369  
QY 474 ACATGACGAGAGAGCGCTCCATGATGA 501  
|||||  
Db 368 ACATCGATGAAGAGGCTTCATGATGA 341

RESULT 13  
BI006821 589 bp mRNA linear EST 13-JUN-2001  
LOCUS BI006821  
DEFINITION QV3-RT0067-150101-538-a01 RT0067 Homo sapiens cDNA, mRNA sequence.  
ACCESSION BI006821  
VERSION BI006821.1 GI:14410879  
KEYWORDS EST.  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.



REFERENCE	1 (bases 1 to 589)
AUTHORS	Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Brites,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deoliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare ,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.
TITLE	Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
MEDLINE	20202663
COMMENT	Contact: Simpson A.J.G. Laboratory of Cancer Genetics Ludwig Institute for Cancer Research Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil Tel: +55-11-2704922 Fax: +55-11-2707001 Email: asimpson@ludwig.org.br This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL (http://www.ludwig.org.br/scripts/gethtml2.pl?tl=qv3&lt2=qv3-RT0067-150101-538-a01&t3=2001-01-15&t4=1) Seq primer: puc 18 forward High quality sequence stop: 584. Location/Qualifiers 1..589 /organism="Homo sapiens" /db_xref="taxon:9606" /clone_lib="RT0067" /dev_stage="Adult" /note="Organ: Kidney_tumor; Vector: puc18; Site_1: SmaI; Site_2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."
BASE COUNT	146 a 164 c 168 g 111 t
ORIGIN	
Query Match	58.2%; Score 291.4; DB 13; Length 589;
Best Local Similarity	99.7%; Pred. No. 8.6e-72;
Matches 292; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	209 CTAATGCCACCGCCAGATGAAGAGCATGAGAACGACCAGAGATGCTGGTGAACCTC 268
Db	17 CCAATGCCACCGCCAGATGAAGAGCATGAGAACGACCAGAGATGCTGGTGAACCTC 76
QY	269 CAGTACAGCCTGGCCAAATCTATGCCAGCAGCGCCGAGCTCAGGAAGACGTGGCTCGAC 328
Db	77 CAGTACAGCCTGGCCAAATCTATGCCAGCAGCGCCGAGCTCAGGAAGACGTGGCTCGAC 136
QY	329 AGCATGGCCAGGATCCATGTCAAAAATGGCGATCTCTCAGAGGCAGCAATGTGCTATGTC 388
Db	137 AGCATGGCCAGGATCCATGTCAAAAATGGCGATCTCTCAGAGGCAGCAATGTGCTATGTC 196
QY	389 CACGTACAGCCCTAGTGGCAGAATATCTCACACGGAAGAGCGTGTTTAGACAAGATGC 448
Db	197 CACGTACAGCCCTAGTGGCAGAATATCTCACACGGAAGAGCGTGTTTAGACAAGATGC 256
QY	449 ACCGCTTCAGGGTCATTACCCCAAAACATCGACGAGGAGCGCTCCATGATGGA 501
Db	257 ACCGCTTCAGGGTCATTACCCCAAAACATCGACGAGGAGCGCTCCATGATGGA 309
RESULT 14	
LOCUS	B0179803 738 bp mRNA linear EST 30-APR-2002
DEFINITION	UI-M-EM0-bwu-d-19-0-UI.r1 NIH_BMAP_EM0 Mus musculus cDNA clone
ACCESSION	B0179803
VERSION	B0179803.1 GI:20355295

	KEYWORDS	EST.
SOURCE	house mouse.	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	
REFERENCE	1 (bases 1 to 738)	NIH-MGC http://mgc.nci.nih.gov/. National Institutes of Health, Mammalian Gene Collection (MGC) Unpublished (1999)
AUTHORS	Contact: Robert Strausberg, Ph.D. Email: cgraphs-rr@mail.nih.gov Tissue Procurement: Dr. James Lin, University of Iowa CDNA Library preparation: Dr. M. Bento Soares, University of Iowa CDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa DNA Sequencing by: Dr. M. Bento Soares, University of Iowa Clone Distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at: <a href="http://image.lnl.gov">http://image.lnl.gov</a>	This clone was contributed by the Brain Molecular Anatomy Project (BMAP) Seq primer: PYX-5. Location/Qualifiers 1..738
JOURNAL	/organism="Mus musculus" /strain="C57BL/6" /db_xref="taxon:10090" /clone="IMAGE:5703138" /clone_lib="NIH_BMAP_ENO" /tissue_type="whole brain" /dev_stage="embryo 15.5 dpc" /lab_host="DH10B (TI phage resistant)" /note="Organ: brain; Vector: PYX-Asc; Site_1: EcoR I; Site_2: Not I; The library was constructed according to Bonaldo, Lennon and Soares, Genome Research, 6:791-806, 1996. Denatured mRNA was size fractionated on a 1% agarose gel. First strand cDNA synthesis was primed with an oligo-dT primer containing a Not I site. Double stranded cDNA was size selected according to mRNA size fraction, ligated with EcoR I adaptor, digested with Not I, and then cloned directionally into PYX-Asc vector. The library tag sequence located between the Not I site and the polyA tail , is GTGCGTGGA. This library was created for the University of Iowa Mouse Brain Molecular Anatomy Project (BMAP); 'Gene Discovery in the Developing Mouse Nervous System', supported by National Institutes of Mental Health (NIMH), Hemlin Chin, Ph.D., program coordinator."	
COMMENT		
BASE COUNT	182 a      209 c      173 g      174 t	
ORIGIN		
	Query Match                  55.2%; Score 276.8; DB 14; Length 738; Best Local Similarity    87.8%; Pred. No. 1.4e-67;	
	Matches 302; Conservative     0; Mismatches    42; Indels        0; Gaps        0;	
Db	2 TACACTGGAAAGAGTCCTTTGCCGACACATTTGCAAGTCATCATATTGTCCAGCCAG 61 	
Db	395 TCACACAGAAGAAGTCTTTGTTCGACGACACTTACAGTCACTCTGTCCAGCCA 454 	
Db	62 CTGATAGCACAGCTGTGTGGCATTTGGGAACAACCAGATTCACAGCAGTCCCTGCCATCATC 121 	
Db	455 CTGATTGCAGATGTGTGGCATTTGGGAACAACCAGATTCACAGCAGTCCCTGTCTATCATC 514 	
Db	515 AACAACTGTGCCAACACAGTAGCCGCTTAATTAAACACACACAGCTTCTCTGTATGTGAAG 181 	
Db	575 GA TT TG ACT TA AG A GG AT C CG CA C AG T CC T GA T GG C CA CA G CCC A G AT GA A G A GC AC G AG 634	
Db	242 AACGACCCAGAGATGCTGGTGGACCTCCAGTACAGCCTGGCCAAATCTATGCCAGCAGC 301 	
Db	635 AACGACCCGAGATGCTGGTGGACCTCCAGTACAGCCTGGCTAAGTCTTAAGCCAGCACC 694	



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 05:39:15 ; Search time 996.663 Seconds  
(without alignments)  
14629.322 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_3800\_4300  
Perfect score: 501  
Sequence: 1 caatttgtggaagctgtgcg.....ttgtgtcttaacaaagtgt 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues  
Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_htg:\*  
3: gb\_in:\*  
4: gb\_om:\*  
5: gb\_ov:\*  
6: gb\_pat:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_sts:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vi:\*  
15: em\_ba:\*  
16: em\_fun:\*  
17: em\_hum:\*  
18: em\_in:\*  
19: em\_mu:\*  
20: em\_om:\*  
21: em\_or:\*  
22: em\_ov:\*  
23: em\_pat:\*  
24: em\_ph:\*  
25: em\_pl:\*  
26: em\_ro:\*  
27: em\_sts:\*  
28: em\_un:\*  
29: em\_vi:\*  
30: em\_htg\_hum:\*  
31: em\_htg\_inv:\*  
32: em\_htg\_other:\*  
33: em\_htg\_mus:\*  
34: em\_htg\_pln:\*  
35: em\_htg\_rod:\*  
36: em\_htg\_mam:\*  
37: em\_htg\_vrt:\*  
38: em\_sy:\*  
39: em\_htgo\_hum:\*  
40: em\_htgo\_mus:\*  
41: em\_htgo\_other:\*

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	501	100.0	7506	6	AX255048	AX255048 Sequence
2	490	97.8	3899	6	AX058220	AX058220 Sequence
3	471	94.0	7522	9	AF527605	AF527605 Homo sapi
4	471	94.0	7545	9	AB028981	AB028981 Homo sapi
5	365	72.9	155198	2	AL357553	AL357553 Homo sapi
6	365	72.9	163316	9	AL161420	AL161420 Human DNA
7	328.4	65.5	2998	10	BC009134	BC009134 Mus muscu
8	278.8	55.6	3227	10	RNTRG	X68101 R.norvegicu
9	220.6	44.0	182640	2	AC126253	AC126253 Mus muscu
10	220.6	44.0	209372	2	AC126033	AC126033 Mus muscu
11	206.2	41.2	175281	2	AC109966	AC109966 Rattus no
12	175.6	35.0	192825	2	AC119357	AC119357 Rattus no
13	79.4	15.8	2768	9	AB056820	AB056820 Macaca fa
14	78.2	15.6	2036	9	AK001253	AK001253 Homo sapi
15	78.2	15.6	2413	9	BC015018	BC015018 Homo sapi
16	77.6	15.5	168684	2	AC023985	AC023985 Homo sapi
17	77.6	15.5	171811	9	AC011739	AC011739 Homo sapi
18	74.4	14.9	51808	5	AC104683	AC104683 Danio rer
19	71.2	14.2	162378	2	AC105541	AC105541 Rattus no
20	71	14.2	174041	2	AL772340	AL772340 Danio rer
21	67.8	13.5	2422	9	AK000227	AK000227 Homo sapi
22	67.4	13.5	2299	9	AK054649	AK054649 Homo sapi
23	67.4	13.5	2610	6	AX058192	AX058192 Sequence
24	67.4	13.5	3152	9	AK056684	AK056684 Homo sapi
25	67.4	13.5	3472	6	AX173120	AX173120 Sequence
26	67.4	13.5	4391	6	AX173028	AX173028 Sequence
27	67.4	13.5	4393	6	AX173118	AX173118 Sequence
28	67.4	13.5	6454	6	AX173022	AX173022 Sequence
29	65	13.0	153026	9	AL391280	AL391280 Human DNA
30	63.4	12.7	103906	2	AC094791	AC094791 Rattus no
31	63.4	12.7	181127	10	AL672038	AL672038 Mouse DNA
32	56.2	11.2	139887	9	CNS01RGX	AL160233 Human chr
33	44.4	8.9	200100	2	AC115789	AC115789 Mus muscu
34	42.4	8.5	146383	2	AC116367	AC116367 Oryza sat
35	41.8	8.3	244	6	AX174652	AX174652 Sequence
36	41.8	8.3	1476	6	AX399260	AX399260 Sequence
37	41.8	8.3	1605	6	AX174666	AX174666 Sequence
38	41.8	8.3	1669	9	HSB02936	AL583913 Homo sapi
39	41.8	8.3	2014	6	AX174662	AX174662 Sequence
40	41.8	8.3	2904	9	BC019102	BC019102 Homo sapi
41	41.8	8.3	4026	6	AX174571	AX174571 Sequence
42	41.8	8.3	4027	6	AX174664	AX174664 Sequence
43	41.8	8.3	4577	9	AK024436	AK024436 Homo sapi
44	41.8	8.3	5564	9	AK074081	AK074081 Homo sapi
45	41.8	8.3	6422	9	AK090429	AK090429 Homo sapi

ALIGNMENTS

RESULT 1  
AX255048 LOCUS AX255048 7506 bp  
DEFINITION Sequence 7 from Patent WO0170808.  
ACCESSION AX255048  
VERSION AX255048.1 GI:16074541  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 7506)  
AUTHORS Rastelli,L.K. and Gerritsen,M.  
TITLE Angiogenesis-associated proteins, and nucleic acids encoding the  
same

Pred. No. is the number of results predicted by chance to have a

JOURNAL Patent: WO 0170808-A 7 27-SEP-2001;  
Curagen Corporation (US) ; GENENTECH, INC. (US)  
FEATURES Location/Qualifiers  
source 1..7506  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
BASE COUNT 2147 a 1689 c 1764 g 1906 t  
ORIGIN

Query Match 100.0%; Score 501; DB 6; Length 7506;  
Best Local Similarity 100.0%; Pred. No. 2.8e-133;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGGAAGCTTGGGGTCAAGCCTTAGCGGTAAACGAACGCTGTGATTTAAGAAGAC 60  
|||  
Db 6106 CAATTTGTGGAAGCTTGGCGGTCAAGCCTTAGCGGTAAACGAACGCTGTGATTTAAGAAGAC 6165  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGGAGCTTTCT 120  
|||  
Db 6166 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGGAGCTTTCT 6225  
QY 121 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGAAGACGAGCGTCTTACCGAATTCC 180  
|||  
Db 6226 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGAAGACGAGCGTCTTACCGAATTCC 6285  
QY 181 CTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGGTTCACGGGATGACC 240  
|||  
Db 6286 CTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACAATGGTTCACGGGATGACC 6345  
QY 241 AGCTCGTCTTCGGTCTGTGATTTACATCTCATGCCCCGTGTGGGGACTTGCTTTGTCA 300  
|||  
Db 6346 AGCTCGTCTTCGGTCTGTGATTTACATCTCATGCCCCGTGTGGGGACTTGCTTTGTCA 6405  
QY 301 TTTCGCAAACTCAGGATGCTTCCAAAGCCAACTCAGTGGGAGACCGACAGGAGGAGAC 360  
|||  
Db 6406 TTTCGCAAACTCAGGATGCTTCCAAAGCCAACTCAGTGGGAGACCGACAGGAGGAGAC 6465  
QY 361 CAAGGGGAAGGGGAGAGAAAGAAATAAGAACACGTTATTCTTAAACAGACTTTCTAT 420  
|||  
Db 6466 CAAGGGGAAGGGGAGAGAAAGAAATAAGAACACGTTATTCTTAAACAGACTTTCTAT 6525  
QY 421 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 480  
|||  
Db 6526 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 6585  
QY 481 ATTGTGTCTTAACAAGGTGT 501  
|||  
Db 6586 ATTGTGTCTTAACAAGGTGT 6606

RESULT 2  
AX058220 3899 bp DNA linear PAT 17-JAN-2001  
LOCUS AX058220  
DEFINITION Sequence 90 from Patent WO0077040.  
ACCESSION AX058220  
VERSION AX058220.1 GI:12310721  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Yue,H., Tang,Y.T., Hillman,J.L., Lal,P., Bandman,O., Baughn,M.R.,  
Azimzai,Y., Yang,J., Reddy,R. and Lu,D.A.  
TITLE Human intracellular signaling molecules  
JOURNAL Patent: WO 0077040-A 90 21-DEC-2000;  
Incyte Genomics, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..3899  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
BASE COUNT 1078 a 929 c 949 g 943 t  
ORIGIN

Query Match 97.8%; Score 490; DB 6; Length 3899;  
Best Local Similarity 99.8%; Pred. No. 3.9e-130;  
Matches 501; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 CAATTTGTGGAAGCTTGGGGTCAAGCCTTAGCGGTAAACGAACGCTGTGATTTAAGAAGAC 60  
|||  
Db 3345 CAATTTGTGGAAGCTTGGCGGTCAAGCCTTAGCGGTAAACGAACGCTGTGATTTAAGAAGAC 3404  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGGAGCTTTCT 120  
|||  
Db 3405 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGGAGCTTTCT 3464  
QY 121 GAAATCATGCATGAGCAGATCTGCCCTTGAGGA -GAGAAGAGCGTCTTACCGAATTTC 179  
|||  
Db 3465 GAAATCATGCATGAGCAGATCTGCCCTTGAGGAGACGAGCGTCTTACCGAATTTC 3524  
QY 180 CCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGGTTACGGGATGAC 239  
|||  
Db 3525 CCTTCACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGGTTACGGGATGAC 3584  
QY 240 CAGCTCGTCTTCGGTCTGTGATTTACATCTCATGCCCCGTGTGGGAGCTTGCTTTGTC 299  
|||  
Db 3585 CAGCTCGTCTTCGGTCTGTGATTTACATCTCATGCCCCGTGTGGGAGCTTGCTTTGTC 3644  
QY 300 ATTTGCAAACTCAGGATGCTTTCAAAGCCAACTCAGTGGGAGACCGGAGCAGGGAGGA 359  
|||  
Db 3645 ATTTGCAAACTCAGGATGCTTTCAAAGCCAACTCAGTGGGAGACCGGAGCAGGGAGGA 3704  
QY 360 CCAAGGGGAAGGGGAGAGAAAGAAATAAGAACACGTTATTCTTAAACAGACTTTCTA 419  
|||  
Db 3705 CCAAGGGGAAGGGGAGAGAAAGAAATAAGAACACGTTATTCTTAAACAGACTTTCTA 3764  
QY 420 TAGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 479  
|||  
Db 3765 TAGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 3824  
QY 480 CATTGTGTCTTAACAAGGTGT 501  
|||  
Db 3825 CATTGTGTCTTAACAAGGTGT 3846

RESULT 3  
AF527605 7522 bp mRNA linear PRI 01-AUG-2002  
LOCUS AF527605  
DEFINITION Homo sapiens zizimin1 mRNA, complete cds.  
ACCESSION AF527605  
VERSION AF527605.1 GI:22038158  
KEYWORDS  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Meller,N., Iranl-Tehrani,M., Kiosses,W.B., Del Pozo,M.A. and  
Schwartz,M.A.  
TITLE Zizimin1, a novel Cdc42 activator, reveals new guanine nucleotide  
exchange-exchange factor domain for rho proteins  
JOURNAL Nat. Cell Biol. (2002) In press  
AUTHORS Meller,N. and Schwartz,M.A.  
TITLE Direct Submission  
JOURNAL Submitted (05-JUL-2002) Cell Biology, The Scripps Research  
Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037, USA  
FEATURES Location/Qualifiers  
source 1..7522  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
56..6265  
/note="guanine nucleotide exchange factor; Cdc42  
activator"  
/codon\_start=1  
CDS



/product="zizimhl"  
/protein\_id="AAM90306.1"  
/db\_xref="GI:22038159"  
/translation="MSQPLLPASAEPTRKFTRLSKPGTAELROSVEVGRSVILA  
KPKLIEPLDYENVIVQKTOILNDCIREMLLPYDDFQTAIRROGRYICSTVPKAE  
EEAQSLEFTECIKTYNSDMHLVNYKEDYSGEEROLPNKVVKLDKLPVHVEDEVD  
KDEDAASLGSQKGITKHGWLKGNMNSAISVTMRSKRRFPHLIQLGDGSYNLNEYK  
DEKISKEPKGSIFLDSGMSGVQNNKVRRAPELKMOKSSYLLAADSEVEMEWITIL  
NKLQNLFEAAMQEKRNDSHEDDEQSKLEGGSGLDYLLPELAARSAREAEIKLSES  
RVKLFYLDPAQKLDSESSAEPEVKSFEKFGKRLLVKCNDSLQCCVAENEGETT  
NVEPEFVTLISLFDIKYNRKISADPEHVDLNFHVRQMLATTSALMNGSGQSPVLKGI  
LHEAAMOYPKQGISVTCPPHPIFLVARIKYLQGSITHCAPYMKSSDSSKVAQKVL  
KNAKQACQRLGOYRMPFAWAARTLFKDGAGNLDKNARFSAIYRQDSNKLISNDMLKLL  
ADFRKPEKMAKLPVILGNLIDITIDNVSSDEPNVNSSYIPTKQFETCSKPTITEVEE  
FVPCIPKHTQPTIYTNHLVYPKYLKXDSQKSEAKARNIAICIEFKDSDEDSQPLK  
CIYGRPGPVFTRSAFAVLHHQNPFEYDEIKIELPTQLHEKHLLLTFFHVSCDNS  
SKGSTKKRDVETQGYSWLPLKDGRAVYTSQHIIPVSANLPSGYLGQELGMGRHYG  
PEIKWVDGKPLKISTHLSVSTVYTQDQHLNFEQYQCKTESGAQALGNELVKYLSL  
HAMEGHVMIATLPITLNLQFRVLTRATQEEVAVNVTRVLIHVAQCHEGLESLSRSY  
VKYAYKAEPYVASEYKTVHEELTKSMTTILKPSADELTSNKLKYSWEFEDVLIKSMA  
QHLIENSKVKLLRNQRPASVYHVAETVNMIMPHITQKFRDNPEASKNANSLAVEI  
KRCETEMDRGFVEKQINNYISCFAPEADPKTFEYKEEFLRVVCNHEHYPLNLPMFG  
KGRIQRYQDLQLDYSLTDEFRCRNHFLVGLLREYGTALOEFREVRNLAISVLKNLLIK  
HSFDDRYASRSHQARIATLPLFLGLLIENVRINRDVSPPEVNAWYKDESLALP  
AVNPVLPQKSTLDNSLHKLGLAISIASPYTSTPNINSVRNADSRGSLISTDSG  
NSLPERNSEKNSLKHQSSSTLGSVVRCDKLDQSEIKSLMCFYILKMSDDALF  
TYWNKASTSEIMDEFIISEVCLFALDITLDTLSFTLAFKNQULADHGNLPMKVEDVY  
YGHSDADVLHQSLEANITAEVCLTALDITLSFTLAFKNQULADHGNLPMKVEDVY  
LCFLQHOSEETALKNVFTALRSILYKFPSTFEGRADMCALCYEILKCNKSLSSIR  
TEASQLLYFLMRNNEDYTGKKSFVRTHLOVITISVQLIADVIGIGTRPOOSLITINN  
CANSDRLIKHTSFSSDVKDLTKRIRLTMAOTOMEKHEHNDPEMLVDLOYSLAKSYAST  
PELRKTLWDSMARIHVKNGLDSEAMCYVHTALVAEYLTRKEAVQWEPPLPHSHSA  
CLRSRSGVFEROGCTAFERYITPNIDEASMEDVGMQDHFNEVDVLMELLEOCADGLW  
KAERYELIADIKLLIPYEKRRDEFERLAHLVDTLHRAYSKVTVMHSGRLLGTYFR  
VAFEGQAAOYQFTDSEFVEGEFEDEDGEKEYIKPEKLTPLSEISQRLKYSDFGS  
ENVKMIQDSGKVNPKLDLSKYAYIQVTHVIPPEFEKELQERKTEFERSHNIRRMFEM  
PEPTQTKRGGVEEQCKRFTLLTAIHCFPYVKKRIPVMYQHTDLNPIEVALDEMSSK  
VAELRQLCSSAEVDMIKLQKLSQSVSVQVNAGPIAYARAFLLDNTKRYDPNKVKLL  
KEYFRQFVEACGGALAVNERLIKEDQLEYQEEMKANVREMAKELSEIMHEQLG"

BASE COUNT 2146 a 1694 c 1774 g 1908 t  
ORIGIN

Query Match 94.0%; Score 471; DB 9; Length 7522;  
Best Local Similarity 98.2%; Pred. No. 1.2e-124;  
Matches 500; Conservative 0; Mismatches 0; Indels 9; Gaps 2;

OY 1 CAATTTGTGAAGCTTGGCGTCAAGCCCTTAGCGGTAACGAACGCTGTGATTAAAGAAGAC 60  
|||||  
Db 6119 CAATTTGTGAAGCTTGGCGTCAAGCCCTTAGCGGTAACGAACGCTGTGATTAAAGAAGAC 6178  
OY 61 CAGCTCGAGTATCAGAGAATAATGAAGCCAACTACAGGGAATGGCGAAGAGAGCTTTCT 120  
|||||  
Db 6179 CAGCTCGAGTATCAGAGAATAATGAAGCCAACTACAGGGAATGGCGAAGAGAGCTTTCT 6238  
OY 121 GAAATCATGCATGAGCA-----GATCTGCCCCCTTGAGGAGAGAAGCAGCGTCTTAC 172  
|||||  
Db 6239 GAAATCATGCATGAGCAGCTGGGATGATCTGCCCCCTTGAGGAGAGAAGCAGCGTCTTAC 6298  
OY 173 CGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACATGGTTCACG 232  
|||||  
Db 6299 CGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCACAAGCACATGGTTCACG 6358  
OY 233 GGATGACCAGCTCGTCTTCGGTCTGTGATTACATCTCATGCGCCCGTGTGTGGGACTTG 292  
|||||  
Db 6359 GGATGACCAGCTCGTCTTCGGTCTGTGATTACATCTCATGCGCCCGTGTGTGGGACTTG 6418  
OY 293 CTTTGTCAATTTGCAAACTCAGGATGCTTTCCAAAGCCAAATCACTGGGAGAGACCGACACA 352  
|||||  
Db 6419 CTTTGTCAATTTGCAAACTCAGGATGCTTTCCAAAGCCAAATCACTGGGAGAGACCGACACA 6478  
OY 353 GGGAGAGACCAAGGGGAGAGAGAAGAATTAAGAACACGTTATTTCTTAACAGA 412  
|||||  
Db 6479 GGGAGAGACC-AGGGGAGAGGGAGAGAAAGAAATTAAGAACACACGTTATTTCTTAACAGA 6537

OY 413 CTTTCTATAGAGCTTGTAGAAGCTGCACATATTTTTTAAATCTCACTGGCAATATTC A 472  
|||||  
Db 6538 CTTTCTATAGAGCTTGTAGAAGCTGCACATATTTTTTAAATCTCACTGGCAATATTC A 6597  
OY 473 AAGTTTCAATGTGCTCTTAACAAGGTGT 501  
|||||  
Db 6598 AAGTTTCAATGTGCTCTTAACAAGGTGT 6626  
RESULT 4  
AB028981  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
MEDLINE  
PUBMED  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
FEATURES  
source

AB028981 7545 bp mRNA linear PRI 10-MAY-2002  
Homo sapiens mRNA for KIAA1058 protein, partial cds.  
AB028981  
AB028981.2 GI:20521745  
Homo sapiens brain cDNA to mRNA, clone\_lib:BluescriptII SK plus  
clone:hh12146s1.  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
Kikuno,R., Nagase,T., Ishikawa,K., Hiroseawa,M., Miyajima,N.,  
Tanaka,A., Kotani,H., Nomura,N. and Ohara,O.  
Prediction of the coding sequences of unidentified human genes.  
XIV. The complete sequences of 100 new cDNA clones from brain which  
code for large proteins in vitro  
DNA Res. 6 (3), 197-205 (1999)  
99397452  
10470851  
2 (bases 1 to 7545)  
Ohara,O., Nagase,T. and Kikuno,R.  
Direct Submission  
Submitted (17-JUN-1999) Osamu Ohara, Kazusa DNA Research Institute,  
Laboratory of DNA Technology, Yana 1532-3, Kisarazu, Chiba  
292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp, Tel:+81-438-52-3913,  
Fax:+81-438-52-3914)  
On May 9, 2002 this sequence version replaced gi:5689452.  
Location/Qualifiers  
1..7545  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
/clone="hh12146s1"  
/tissue.type="brain"  
/clone\_lib="pBluescriptII SK plus"  
/note="this sequence was obtained by subcloning of the DNA  
fragments derived from two cDNA clones (1 - 1846 was  
derived from ef00877 and 1847 - 7545 was derived from  
hh12146)."  
1..7545  
/gene="KIAA1058"  
/gene="KIAA1058"  
/gene="KIAA1058"  
/codon\_start=1  
/product="KIAA1058 protein"  
/protein\_id="BAA83010.2"  
/db\_xref="GI:20521746"

/translation="LACLCLARPGTRGSSCSRLSDLRFQPRMQADKRTSSRSVKKEL  
VIESPLQYKDAOGEVEAESPGVPAPAKKLIIEPLDYENVIVQKTOILNDCIREMLLF  
PYDDFOTAIRROGRYICSTVPKAEAEASQSLFTECIKTYNSDMHLVNYKYEDYSGE  
FRQLPNKVVKLDKLPVHVEVDEVDKEDDAASLGSQKGITKHGWLKGNMNSAISV  
TMRSEKRRFEHLIQLGDGSYNLNFYKDEKSKPEKGSIFLDSGMSGVQNNKVRRAFAE  
LKMQDKSSYLLAADSEVEMEWITILNKILQNLFEAAMQEKRNDSHEDDEQSKLEGS  
GSGLDYLLPELAKSAREAEIKLSERVKLFYLDPAQKLDSESAPEVKSFEKEFGK  
RILVKCNDSLQCCVAENEGETTNEPFFVTLSLFDIKYNRKISADPEHVDLNFHS  
VRQMLATSPALMNGSGQSPVLKGLIHEAAMOYPKQGISVTCPPHPIFLVARIKYL  
LQGSITHCAPYMKSSDSSKVAQKVLKNAKQACQRLGOYRMPFAWAARTLFKDGAGNL  
DKNARFSAIYRQDSNKLISNDMLKLADFRKPEKMAKLPVILGNLIDITIDNVSSDPN  
VNSSYIPTKQFETCSKPTITEVEEFPVPCIPKHTQPTIYTNHLVYVYPKYLKYSQK  
SFAKARNIAICIEFKDSDEEDSQPLKCIYGRPGGPVFTRSAFAVLHHQNPFEYDEI  
KIELPTQLHEKHLLLTFFHVSCDNSKSGSTKKRDVETQGYSWLPLKDGRAVVTSE

OHIPVSNLPSTGLGYOELGMRHYGPEIKWVGSKPLKISTHLVSTVYTQDOHLHN  
FFOYCKOTESGAQALGNELVKYLSLHAMEGHVMTAFLPTILNQLERVLTRATOEVA  
VNVTRVLIHVAAOCHEEGLSEHSLTVSKYAYKAEPYVASEYKTVHEELKSMTTILKP  
SADFLTSNKLKYSWEFFDVLIKSMQHLIENSKVKLLRNQRFAPASTHNAVETVNM  
MPHITOKFERDNEPASKMANISLAVFIKRCFTMERGFVEKOINNYISCPAPGDKTLE  
EYKFEELRVVCNHEHYIPLNMPFGKRIQRYODILODYSLTDEFCRNHFLVGLLR  
EVGTALQEFREVRLIAISVKNLTIKHSFDRYASRSHQARIATLYPLFGLIENVO  
RINVRDVSFPFVNAGMTVKDESLALPAVNPLVTPQKSTLDNSLHKDLGASIGIASP  
YTTSTPNINSVRNADSRGSLISTDSGNSLPERNSEKSNLKHOOSESTGNSVVRCDK  
LDQSEIKSLMCFLYILKSMDDALFTYWNKASTSELMDFITISEVCLHQFOYMGKRY  
IARTGMHARLQOLGSLDNSLTFNHSYGHSDADVLHQSLEANITAEVCLTALDLSL  
FTLAEKNOLLADHGNPLMKYFDVYLCFLQKHQSELTALKNFTALRSILYKEPSTFY  
EGRADMCALCYEILKCCNSKSSIRTEASQLYFLMRNNDYTGKSKSEVTRHLOVLI  
SVSOLADVVGIGCTRFQOSLTIINNCANSRLIKHTSPSSDVKDLTKRIRIVLMATA  
QMKEHENDPEMLVDLOYSLAKSYASTPELRKTWLDMSARIHVKNGLSEAMCYHVAT  
ALVAEYLTRKEAVQWEPPLPISHSACLRSRSGVFRQCTAFRVTIPNIDEASME  
DVGMQDVHFNEDVLMELEQADGLMKAERYELIADIKLIIPYEKRDFERLAHLX  
DTLHRAYSKVTEVMHSGRRLGTYFRVAFFGOAQOYFTDSETVGEFDEDEGKEYI  
YKEPKLTPLEISQRLKLSKFGSENVKMIODSGKVNPKDLDSKYAYIQVTHVIPF  
FDEKELDERKTEEFERSHNIRREMEFOTQGRQGVVEQCKRRTILTAIHCFPIVK  
KRIPVMOHHTDLNPIEVAIDEMSKVAELROLCSAEVDMIKLOLKGVSQVQVNA  
GPLAYARAFLLDNTNTRYPDNKYKLLKEVFRQFVEACQALAVNERLIKEDQLEYQEE  
MKANYREMAKELSEIMHEQLG"

BASE COUNT 2175 a 1687 c 1753 g 1930 t  
ORIGIN

Query Match 94.0%; Score 471; DB 9; Length 7545;  
Best Local Similarity 98.2%; Pred. No. 1.2e-124;  
Matches 500; Conservative 0; Mismatches 0; Indels 9; Gaps 2;

OY 1 CAATTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGACGCTGATTAAGAAGAC 60  
Db 6142 CAATTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGACGCTGATTAAGAAGAC 6201  
OY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGGAAGGAGCTTCT 120  
Db 6202 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGGAAGGAGCTTCT 6261  
OY 121 GAAATCATGCATGAGCA-----GATCTGCCCCCTGGAGGAGAAGCAGCGTCTTAC 172  
Db 6262 GAAATCATGCATGAGCAGCTGGGATGATCTGCCCCCTGGAGGAGAAGCAGCGTCTTAC 6321  
OY 173 CGAATTCCTTCACATCTTCAACGCCCATCAGTGGGACTCCACAAGACAAATGGTTCACG 232  
Db 6322 CGAATTCCTTCACATCTTCAACGCCCATCAGTGGGACTCCACAAGACAAATGGTTCACG 6381  
OY 233 GGATGACCAAGCTGCTTCGCTGTGTGATTACATCTCATGGCCCGTGTGGGACTTG 292  
Db 6382 GGATGACCAAGCTGCTTCGCTGTGTGATTACATCTCATGGCCCGTGTGTGGGACTTG 6441  
OY 293 CTTTGTCAATTTGCCAAACTCAGATGCTTTCCAAAGCCCAATCAGCTGGGAGACCGAGCACA 352  
Db 6442 CTTTGTCAATTTGCCAAACTCAGATGCTTTCCAAAGCCCAATCAGCTGGGAGACCGAGCACA 6501  
OY 353 GGGAGACCAAGGGGGAAGGAGAAAGAAATGAAGCAACGTTATTCTTTAACAGA 412  
Db 6502 GGGAGACCAAGGGGGAAGGAGAAAGAAATGAAGCAACGTTATTCTTTAACAGA 6560  
OY 413 CTTTCTAATAGAGATTGTAAGAGGTGCACATATTTTAAATCTCACTGGCAATATTCA 472  
Db 6561 CTTTCTAATAGAGATTGTAAGAGGTGCACATATTTTAAATCTCACTGGCAATATTCA 6620  
OY 473 AAGTTTCATGTGTCTTAACAAGGTGT 501  
Db 6621 AAGTTTCATGTGTCTTAACAAGGTGT 6649

RESULT 5  
AL357553/c AL357553 155198 bp DNA linear HTG 10-JUL-2001  
LOCUS Homo sapiens chromosome 13 clone Rpl1-56D6, \*\*\* SEQUENCING IN  
DEFINITION PROGRESS \*\*\*, 2 unordered pieces.  
ACCESSION AL357553

VERSION AL357553.8 GI:13620383  
KEYWORDS HTG; HTGS\_PHASE1; HTGS\_CANCELLED.  
SOURCE human.  
ORGANISM Homo sapiens  
REFERENCE Submitted (09-JUL-2001) Sanger Centre, Hinxton, Cambridgeshire,  
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homindae; Homo.  
TITLE 1 (bases 1 to 155198)  
JOURNAL Peck,A.  
COMMENT Direct Submission  
Submitted (09-JUL-2001) Sanger Centre, Hinxton, Cambridgeshire,  
CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk  
requests: clonerequest@sanger.ac.uk  
On Apr 12, 2001 this sequence version replaced gi:12956937.  
----- Genome Center  
Center: Sanger Centre  
Center code: SC  
Web site: http://www.sanger.ac.uk  
Contact: humquery@sanger.ac.uk  
----- Project Information  
Center project name: BA56D6  
----- Summary Statistics  
Assembly program: XGAP4; version 4.5  
Sequencing vector: plasmid; L08752; 100% of reads  
Chemistry: Dye-terminator Big Dye; 100% of reads  
Consensus quality: 152143 bases at least Q40  
Consensus quality: 153069 bases at least Q30  
Consensus quality: 153660 bases at least Q20  
Insert size: 155098; sum-of-contigs  
Insert size: 144134; 11.1% error; agarose-fp  
Quality coverage: 5.59x in Q20 bases; sum-of-contigs quality  
coverage: 6.57x in Q20 bases; agarose-fp  
-----

\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 2 contigs. The true order of the pieces  
\* is not known and their order in this sequence record is  
\* arbitrary. Gaps between the contigs are represented as  
\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.

\* 1 2153: contig of 2153 bp in length  
\* 2154 2253: gap of 100 bp  
\* 2254 155198: contig of 152945 bp in length.  
FEATURES  
Location/Qualifiers  
source 1. 155198  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/chromosome="13"  
/clone="RP11-56D6"  
/clone\_lib="RPCI-11.1"  
misc\_feature 1. 2153  
/note="assembly\_fragment:00588"  
misc\_feature 2254. 155198  
/note="assembly\_fragment:02529  
clone\_end:SP6  
vector\_side:right"

BASE COUNT 43663 a 34926 c 34669 g 41836 t 104 others  
ORIGIN

Query Match 72.9%; Score 365; DB 2; Length 155198;  
Best Local Similarity 100.0%; Pred. No. 6.2e-94;  
Matches 365; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 137 AGATCTGCCCCCTGGAGGAGAGACGAGCGCTTACCGAATTCCTTCACATCTTCAACG 196  
Db 130593 AGATCTGCCCCCTGGAGGAGAGACGAGCGCTTACCGAATTCCTTCACATCTTCAACG 130534  
OY 197 CCATCAGTGGGACTCCACAAGCACATGCTTCACGGGATGACCAGCTCGTCTTGGCTCG 256  
Db 130533 CCATCAGTGGGACTCCACAAGCACATGCTTCACGGGATGACCAGCTCGTCTTGGCTCG 130474  
OY 257 TGTGATTACATTCATGCCCCGTGTGGGGGAGCTTGTGTCATTGTGCAAACTCAGGAT 316  
|||||

Db	130473	TGTGATTCATCTCATGCGCCCGTGTGTGTGGGACTTGCTTGTGCAATTGGCAAACTCAGAT	130414
QY	317	GCCTTCCAAAGCCCAATCACTGGGGAGACCGAGCACAGGAGACCAAGGCGAAGGGAGA	376
Db	130413	GCCTTCCAAAGCCCAATCACTGGGGAGACCGAGCACAGGAGACCAAGGCGAAGGGAGA	130354
QY	377	GAAAGGAAATTAAGAACCAACGTTATTTCTTAACAGACTTCTATAGAGTTGTAGAAGG	436
Db	130353	GAAAGGAAATTAAGAACCAACGTTATTTCTTAACAGACTTCTATAGAGTTGTAGAAGG	130294
QY	437	TGCACATATTTTTTTTAAATCTCACTGGCAATATTCAAAGTTTCATTGTGCTTAACAAA	496
Db	130293	TGCACATATTTTTTTTAAATCTCACTGGCAATATTCAAAGTTTCATTGTGCTTAACAAA	130234
QY	497	GGTGT 501	
Db	130233	GGTGT 130229	
RESULT	6		
AL161420/c			
LOCUS			
DEFINITION	AL161420	163316 bp	DNA linear PRI 01-FEB-2001
			Human DNA sequence from clone RP11-155N3 on chromosome 13 Contains ESTs, STSS and GSSs. Contains the 3' part of a novel gene similar to KIAA0694, the KIAA1058 gene and a putative novel gene, complete sequence.
ACCESSION	AL161420		
VERSION	AL161420.10	GI:10443397	
KEYWORDS	HTG; KIAA0694; KIAA1058.		
SOURCE	human.		
ORGANISM	Homo sapiens		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
REFERENCE	1 (bases 1 to 163316)		
AUTHORS	Smith, M.		
TITLE	Direct Submission		
JOURNAL	Submitted (31-JAN-2001) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail enquiries: humquerry@sanger.ac.uk		
COMMENT	On Oct 1, 2000 this sequence version replaced gi:10039689. During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above. The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Em; EMBL; Sw; SWISSPROT; Tr; TREMBL; Wp; WORMPEP; Information on the WORMPEP database can be found at http://www.sanger.ac.uk/projects/C_elegans/wormpep This sequence was generated from part of bacterial clone contigs of human chromosome 13, constructed by the Sanger Centre Chromosome 13 Mapping Group. Further information can be found at http://www.sanger.ac.uk/HGP/Chr13 This sequence is the entire insert of clone RP11-155N3 The true left end of clone RP11-318G11 is at 114983 in this sequence. The true right end of clone RP11-56D6 is at 42341 in this sequence. The true right end of clone RP11-551M18 is at 43464 in this sequence. This sequence has been finished according to sequence map criteria as follows. An attempt is made to resolve all sequencing problems, such as compressions and repeats, but not necessarily within known annotated repeat sequence elements. Where the sequence is ambiguous, there is an annotation using the 'unsure' feature key. RP11-155N3 is from the library RPOI-11.1 constructed by the group of Pieter de Jong. For further details see http://www.chori.org/bacpac/home.htm VECTOR: pBACE3.6.		
FEATURES			
source			
	Location/Qualifiers		
	1..163316		
	/organism="Homo sapiens"		
	/db_xref="taxon:9606"		
	/chromosome="13"		

```

misc_feature      /clone="RP11-155N3"
repeat_region     /clone_lib="RPC1-11.1"
                  6. .510
                  /note="match: GSS: Em:AQ372034"
                  75. .372
repeat_region     /note="Aluub repeat: matches 1. .298 of consensus"
                  447. .742
repeat_region     /note="AluSp repeat: matches 1. .296 of consensus"
                  745. .1025
repeat_region     /note="L1MC1 repeat: matches 6019. .6327 of consensus"
                  1250. .1566
repeat_region     /note="AluX repeat: matches 2. .311 of consensus"
                  1631. .2325
repeat_region     /note="L1MC5 repeat: matches 6683. .7400 of consensus"
                  2326. .2619
repeat_region     /note="AluSx repeat: matches 1. .295 of consensus"
                  2620. .2890
repeat_region     /note="L1MC5 repeat: matches 7400. .7665 of consensus"
                  complement(3019. .3311)
misc_feature      /note="match: STS: Em:HSa273ZH1"
                  3060. .3191
misc_feature      /note="match: GSS: Em:BI7811"
                  complement(3065. .3246)
misc_feature      /note="match: STS: Em:AF009212"
                  3067. .3190
misc_feature      /note="match: GSS: Em:AQ114323"
                  3087. .3122
repeat_region     /note="18 copies 2 mer tg 97% conserved"
                  3089. .3124
repeat_region     /note="6 copies 6 mer tgtgtg 97% conserved"
                  3123. .3280
misc_feature      /note="match: GSS: Em:AQ459714"
                  3191. .3475
repeat_region     /note="AluSx repeat: matches 1. .288 of consensus"
                  3692. .3773
repeat_region     /note="MIR repeat: matches 3. .94 of consensus"
                  3887. .4074
repeat_region     /note="L2 repeat: matches 1607. .1787 of consensus"
                  4082. .4144
repeat_region     /note="3 copies 21 mer 88% conserved"
                  4418. .4630
repeat_region     /note="L2 repeat: matches 1354. .1587 of consensus"
                  7208. .7609
repeat_region     /note="L1B repeat: matches 8. .390 of consensus"
                  9220. .9344
repeat_region     /note="MIR repeat: matches 71. .196 of consensus"
                  9586. .9667
repeat_region     /note="L1ME repeat: matches 5569. .5651 of consensus"
                  9714. .9813
repeat_region     /note="L2 repeat: matches 771. .874 of consensus"
                  9869. .10202
repeat_region     /note="L2 repeat: matches 971. .1261 of consensus"
                  10203. .10581
repeat_region     /note="MSTA repeat: matches 1. .426 of consensus"
                  10582. .11267
repeat_region     /note="L2 repeat: matches 1261. .2121 of consensus"
                  11460. .11570
repeat_region     /note="L2 repeat: matches 2377. .2497 of consensus"
                  11603. .11778
repeat_region     /note="L1MB3 repeat: matches 5996. .6166 of consensus"
                  11779. .12160
repeat_region     /note="MER51A repeat: matches 1. .371 of consensus"
                  12161. .12729
repeat_region     /note="L1MB3 repeat: matches 5403. .5996 of consensus"
                  12682. .12950
repeat_region     /note="L1MD repeat: matches -1. .274 of consensus"
                  12945. .13209
repeat_region     /note="L1MC5 repeat: matches 7249. .7517 of consensus"
                  13323. .13413
repeat_region     /note="AluJ/FRAM repeat: matches 221. .311 of consensus"
                  13711. .13846
misc_feature      /note="AluSg/x repeat: matches 1. .136 of consensus"
                  13955. .14417

```



misc\_feature /note="match: GSS: Em:AQ475161"  
complement(14122..14590)  
/note="match: GSS: Em:AQ349540"  
repeat\_region 14334..14400  
/note="L1MA10 repeat: matches 6204..6272 of consensus"  
repeat\_region 14407..14693  
/note="AluX repeat: matches 1..288 of consensus"  
misc\_feature 14584..15413  
/note="match: GSS: Em:AQ739876"  
repeat\_region 14719..14793  
/note="L1MC/D repeat: matches 5744..5818 of consensus"  
repeat\_region 15013..15193  
/note="L1MB3 repeat: matches 5993..6184 of consensus"  
gene complement(join(16480..17741,19199..19206,20108..20246,  
20382..20482,23281..23471,27992..28202,30654..30800,  
31633..31668,32116..32121,32345..32458,33162..33284,  
47391..47497,48865..48933,49823..49880,52300..52515,  
52636..52749,54341..54523,54642..54779,60487..60602,  
68322..68365,68917..69053,71585..71632,73040..73106,  
76401..76515,78891..79024,83174..83515,86012..86125,  
86363..86541,90418..90529,90921..91004,91224..91370,  
102891..102962,103540..103665,104551..104620,  
104885..105000,106035..106124,106806..106892,  
107964..108085,108701..108824,109525..109617,  
111151..111216,111353..111540,111625..111704,  
120481..120603))  
/gene="bA155N3.2"  
mRNA complement(join(16480..17741,19199..19206,20108..20246,  
20382..20482,23281..23471,27992..28202,30654..30800,  
31633..31668,32116..32121,32345..32458,33162..33284,  
47391..47497,48865..48933,49823..49880,52300..52515,  
52636..52749,54341..54523,54642..54779,60487..60602,  
68917..68984,71585..71632,73040..73106,76401..76515,  
78891..79024,83398..83515,86012..86125,86363..86541,  
90418..90529,90921..91004,91224..91370,102891..102962,  
103540..103665,104551..104620,104885..105000,  
106035..106124,106806..106892,107964..108085,  
108701..108824,109525..109617,111151..111216,  
111353..111540,111625..111704,120481..>120603))  
/gene="bA155N3.2"  
/product="bA155N3.2.1 (K1AA1058)"  
/note="match: CDNAS: Em:AB028981 Em:U79289  
match: ESTs: Em:W27872 Em:H29845 Em:H29936 Em:AW160928  
Em:AW457794 Em:T62004 Em:R64450 Em:D58813 Em:H10596  
Em:AW380042 Em:AW344638 Em:AW450751 Em:AF188523  
Em:AA151055 Em:T33337 Em:AW466130 Em:AI014329 Em:Z42960  
Em:AI372817 Em:AI372818 Em:AW389763 Em:AW230012  
Em:AL133724 Em:AW162535 Em:AW607903 Em:AA484945 Em:H28862  
Em:Z39079 Em:AI767696 Em:AW576807 Em:AI078244 Em:R78583  
Em:AA705585 Em:AI271453 Em:AW512964 Em:W88550 Em:AI870702  
Em:AL079478 Em:AI693777 Em:AW576805 Em:AI467994  
Em:AI372819 Em:AI732576 Em:AI277278 Em:AI969485  
Em:AI768094 Em:AA779769 Em:AA502043 Em:R27124 Em:AW576813  
Em:AW576816 Em:AW168032 Em:AI365152 Em:AA165512  
Em:AI120344 Em:AI888868 Em:AA165554 Em:R73986 Em:AA523853  
Em:AI041815 Em:AL134605 Em:AW009821 Em:D62808 Em:AI769357  
Em:AW363093 Em:AI733873 Em:W88496 Em:T03019 Em:AW071481  
Em:AI034000"  
/evidence=not\_experimental  
polyA\_site complement(16480)  
/gene="bA155N3.2"  
polyA\_site complement(16482)  
/gene="bA155N3.2"  
polyA\_site complement(16483)  
/gene="bA155N3.2"  
polyA\_signal complement(16498..16503)  
misc\_feature /gene="bA155N3.2"  
16511..16637  
/note="match: STS: Em:G42960"  
polyA\_signal complement(16523..16528)  
/gene="bA155N3.2"  
polyA\_signal complement(16570..16575)  
/gene="bA155N3.2"

CDS complement(join(17741,19199..19206,20108..20246,  
20382..20482,23281..23471,27992..28202,30654..30800,  
31633..31668,32116..32121,32345..32458,33162..33284,  
47391..47497,48865..48933,49823..49880,52300..52515,  
52636..52749,54341..54523,54642..54779,60487..60602,  
68322..68365,68917..69053,71585..71632,73040..73106,  
76401..76515,78891..79024,83174..83515,86012..86125,  
86363..86541,90418..90529,90921..91004,91224..91370,  
102891..102962,103540..103665,104551..104620,  
104885..105000,106035..106124,106806..106892,  
107964..108085,108701..108824,109525..109617,  
111151..111216,111353..111540,111625..111704,  
120481..120603))  
Query Match 72.9%; Score 365; DB 9; Length 163316;  
Best Local Similarity 100.0%; Pred. No. 6.3e-94;  
Matches 365; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 137 AGATCTGCCCCCTGGAGAGAGACGAGCGCTTACCGAATTCCTTCATCTTCAACG 196  
|||||  
Db 17743 AGATCTGCCCCCTGGAGAGAGACGAGCGCTTACCGAATTCCTTCATCTTCAACG 17684  
QY 197 CCATCAGTGGAGCTCCACAAGCACAAATGTTACCGGATGACCAAGCTCGTCTCGTGC 256  
|||||  
Db 17683 CCATCAGTGGAGCTCCACAAGCACAAATGTTACCGGATGACCAAGCTCGTCTCGTGC 17624  
QY 257 TGTGATTACATCTCATGGCCCGTGTGTGGGACTTGTCTTGTCAATTTGCAAACTCAGGAT 316  
|||||  
Db 17623 TGTGATTACATCTCATGGCCCGTGTGTGGGACTTGTCTTGTCAATTTGCAAACTCAGGAT 17564  
QY 317 GCTTTCCAAAGCCAATCTGCGGAGAGACCGAGCACAGGAGGAGCAAGGGGAAGGGAGA 376  
|||||  
Db 17563 GCTTTCCAAAGCCAATCTGCGGAGAGACCGAGCACAGGAGGAGCAAGGGGAAGGGAGA 17504  
QY 377 GAAAGGAATTAAGAACACGTTATTTCTTAACAGACTTCTATAGAGTTGTAAGAAG 436  
|||||  
Db 17503 GAAAGGAATTAAGAACACGTTATTTCTTAACAGACTTCTATAGAGTTGTAAGAAG 17444  
QY 437 TGCACATATTTTTTAAATCTCACTGGCAATATTCAAAGTTTCATTTGCTTAACAA 496  
|||||  
Db 17443 TGCACATATTTTTTAAATCTCACTGGCAATATTCAAAGTTTCATTTGCTTAACAA 17384  
QY 497 GGTGT 501  
|||||  
Db 17383 GGTGT 17379  
RESULT 7 2998 bp mRNA linear ROD 07-AUG-2002  
BC009134 Mus musculus, similar to hypothetical protein FLJ20220, clone  
BC009134 MGC:11827 IMAGE:3596515, mRNA, complete cds.  
LOCUS BC009134.1 GI:14318664  
DEFINITION MGC.  
KEYWORDS house mouse.  
SOURCE Mus musculus  
ORGANISM Mus musculus  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 2998)  
AUTHORS Strausberg, R.  
TITLE Direct Submission  
JOURNAL Submitted (05-JUN-2001) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
REMARK NIH-MGC Project URL: http://mgc.ncl.nih.gov  
COMMENT Contact: MGC help desk  
Email: cgabs-remail.nih.gov  
Tissue Procurement: Jeffrey Green M.D.  
CDNA Library Preparation: Life Technologies, Inc.  
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Baylor College of Medicine Human Genome  
Sequencing Center  
Center code: BCM-HGSC  
Web site: http://www.hgsc.bcm.tmc.edu/cdna/  
Contact: amg@bcm.tmc.edu  
Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Hale, S.M.,  
Yoon, V.S., Kowis, C.R., Lawrence, S., Martin, R.G., Muzny, D.M.,  
Richards, S., Gibbs, R.A.  
Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov  
Series: IRAK Plate: 16 Row: 1 Column: 2





Db	2007	AGTTCAATCCTCAGTTGTGTGCACTTTACCTCATGACACACACGCTGGGACATGCTTGTCA	2066
QY	301	TTTGCAAACTCAGGATGCTTTCCAAAGCCAAATCACTGGGAGAGACCGAGCACAGGAGGA-	359
Db	2067	TGTGCAAACTCAGAGCAGACTTTCAGAGCTAATCACTGGTTTTCGCAAGCACAGGAAGAAG	2126
QY	360	CCAAGGGCAGGGGAGAGACAAGAATAAGACAACGTTATTTCTTAACAGACTTTCTA	419
Db	2127	CCATGGGGAATGGGAGAGAGAAGAAGCCCTGCACTGTGATATTTAATAGCAGA--TTTTA	2184
QY	420	TAGAGTTGTAGAAGAGTGACATATTTTTPAATCTCACTGGCAATATTCAAAGTTT	479
Db	2185	TAGGAGTTGGGGGAAGAGTGACACATATTTTTPAATCTCACTGGCAATGTT--TAGTTT	2242
QY	480	CATTGTGCTTTAACCAAGGTGT	501
Db	2243	CCTCATGTCTTAACAGAGGTAT	2264

RESULT	9
LOCUS	AC126253
DEFINITION	AC126253                182640 bp     DNA     linear   HTG_04-JUL-2002 Mus musculus chromosome UNK clone RP24-119M15, WORKING DRAFT SEQUENCE, 11 unordered pieces.
ACCESSION	AC126253
VERSION	AC126253.1     GI:21693957
KEYWORDS	HTG; HTGS_PHASE1; HTGS_DRAFT; HTGS_FULLTOP. house mouse.
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 182640) McPherson,J.D. and Waterston,R.H. The sequence of Mus musculus clone Unpublished 2 (bases 1 to 182640) Mcpherson,J.D. and Waterston,R.H. Direct Submission Submitted (04-JUL-2002) Genome Sequencing Center, 4444 Forest Park Parkway, St. Louis, MO 63108, USA
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
COMMENT	

```

----- Genome Center -----
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site: http://genome.wustl.edu/gsc/index.shtml
Contact: submissions@watson.wustl.edu
----- Project Information -----
Center project name: M_BB0119M15
----- Summary Statistics -----
Sequencing vector: M13; 0%
Sequencing vector: plasmid; 100%
Chemistry: Dye-primer ET; 0% of reads
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990319
Consensus quality: 177371 bases at least Q40
Consensus quality: 178021 bases at least Q30
Consensus quality: 178402 bases at least Q20
Insert size: 174000; agarose-ff
Insert size: 181640; sum-of-contigs
Quality coverage: 11.19 in Q20 bases; agarose-ff
Quality coverage: 9.89 in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 11 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
1 4276: contig of 4276 bp in length

```

*	4277	4376:	gap of unknown length
*	4377	8990:	contig of 4614 bp in length
*	8991	9090:	gap of unknown length
*	9091	14391:	contig of 5301 bp in length
*	14392	14491:	gap of unknown length
*	14492	23041:	contig of 8550 bp in length
*	23042	23141:	gap of unknown length
*	23142	37848:	contig of 14707 bp in length
*	37849	37948:	gap of unknown length
*	37949	52177:	contig of 14229 bp in length
*	52178	52277:	gap of unknown length
*	52278	75893:	contig of 23616 bp in length
*	75894	75993:	gap of unknown length
*	75994	113549:	contig of 37556 bp in length
*	113550	113649:	gap of unknown length
*	113650	177361:	contig of 63712 bp in length
*	177362	177461:	gap of unknown length
*	177462	179201:	contig of 1740 bp in length
*	179202	179301:	gap of unknown length
*	179302	182640:	contig of 3339 bp in length

```

source      1. .182640
            /organism="Mus musculus"
            /db_xref="taxon:10090"
            /chromosome="UNK"
            /clone="Rp24-119M15"
            1. .4276
            /note="assembly_name:Contig10"
            4377. .8990
            /note="assembly_name:Contig11"
            9091. .14391
            /note="assembly_name:Contig12"
            14492. .23041
            /note="assembly_name:Contig13"
            23142. .37848
            /note="assembly_name:Contig14"
            37949. .52177
            /note="assembly_name:Contig15"
            52278. .75893
            /note="assembly_name:Contig16"
            75994. .113549
            /note="assembly_name:Contig17"
            113650. .177361
            /note="assembly_name:Contig18"
            177462. .179201
            /note="assembly_name:Contig19"
            179302. .182640
            /note="assembly_name:Contig9"
BASE COUNT  49101 a 42136 c 41309 g 49052 t 1042 others
ORIGIN

```

Query Match	44.0%;	Score 220.6;	DB 2;	Length 182640;
Best Local Similarity	75.4%;	Pred. No. 2.8e-52;		
Matches 301;	Conservative 0;	Mismatches 94;	Indels 4;	Gaps 2;
QY 96	CAGGGAATGGCGAAGGAGCTTTCTGAAATCATGACATGACGACAGATCTGCCCTTGAGGA	155		
Db 162621	CAGAGCATTTGCCCTTTGATAACATTTCTTTCTGTACCTCGAGATTTGCCCTTGAGGA	162680		
QY 156	GAAGACGAGCGCTTTAACCGAATTCCTTCACATCTTCAACGCCATCAGTGGGACTCCAAC	215		
Db 162681	GAAGACAAGCGCTGCTAACCAATTCCTGCACATCTTCAACGCCATCAGCGGGACACCAAC	162740		
QY 216	AAGCACAAATGGTTTCACGGGATGACCAAGCTCGTCTTCGGTGTGTGATTACATCTCATGGC	275		
Db 162741	AAGCACAGTGGTTTCAAGGTTGACCAAGCTCGTCTCAGTTGTGATTTTACCTCATGAA	162800		
QY 276	CCGTGTGTGGGACTTGCCTTTGTTCATTTGCCAAACTCAGAGTGCCTTCCAAAGCCAAATCAC	335		
Db 162801	CCGTGTGTGGGACATGCTTTGTTCATGTGCCAAACTCAGAGTGCCTTCCAGAGCTTAATCAC	162860		
QY 336	TGGGGAGACCGACACAGGGAGGACCAAGGGGAGAGAAAGGAATTAAGAACA	395		

```

Db 162861 TGGTGTGCCCAAGCACACAGCAAGACCATTGGGGAATGGAGAGAGAGAAGACCCCTGGACTG 162920
QY 396 CGTATTTCCTTAACAGACTTCTCTATAGAGTGTGTAGAGAAGGTGCACATATTTTAAAT 455
1 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 162921 TGAATTTTAATAGCAGA--TTTATATAGAGTCGGGGGAAGGTGCACATATTTTAAAT 162978
QY 456 CTCACCTGGCAATATATCAAGCTTTTCATGTGTCTTAACA 494
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 162979 CTCACCTGGCAATAT--TAGTTTTCCTCATGTCTTAACA 163015

RESULT 10
AC126033
LOCUS
DEFINITION
AC126033 209372 bp DNA linear HTG 02-JUL-2002
MUS musculus chromosome UNK clone RP24-115A22, WORKING DRAFT
SEQUENCE, 12 unordered pieces.
AC126033
AC126033.1 GI:21672231
HTG; HTGS_PHASE1; HTGS_DRAFT.
house mouse.
SOURCE
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 209372)
McPherson,J.D. and Waterston,R.H.
The sequence of Mus musculus clone
Unpublished
2 (bases 1 to 209372)
McPherson,J.D. and Waterston,R.H.
Direct Submission
Submitted (02-JUL-2002) Genome Sequencing Center, 4444 Forest Park
Parkway, St. Louis, MO 63108, USA

COMMENT
----- Genome Center -----
Center: Washington University Genome Sequencing Center
Center code: WUGSC
Web site:http://genome.wustl.edu/gsc/index.shtml
Contact: submissions@watson.wustl.edu
----- Project Information -----
Center project name: M_BB0115A22
----- Summary Statistics -----
Sequencing vector: M13; 0%
Sequencing vector: plasmid: 100%
Chemistry: Dye-primer ET; 0% of reads
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990319
Consensus quality: 203478 bases at least Q40
Consensus quality: 204725 bases at least Q30
Consensus quality: 205702 bases at least Q20
Insert size: 161000; agarose-fp
Insert size: 208272; sum-of-contigs
Quality coverage: 14.47 in Q20 bases; agarose-fp
Quality coverage: 9.74 in Q20 bases; sum-of-contigs
-----
* NOTE: This is a 'working draft' sequence. It currently
* consists of 12 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
1 2828: contig of 2828 bp in length
* 2829: gap of unknown length
* 2929 7171: contig of 4243 bp in length
* 7172 7271: gap of unknown length
* 7272 12995: contig of 5724 bp in length
* 12996 13095: gap of unknown length
* 13096 23730: contig of 10635 bp in length
* 23731 23830: gap of unknown length
* 23831 34449: contig of 10619 bp in length
* 34450 34549: gap of unknown length

```

[illegible]

QY 456 CTCACGGCAATATTCAAAGTTTTCATGTGCTTACA 494  
Db 84613 CTCACGGCAATAT--TAGTTTCTCATGTCTTACA 84649

RESULT 11  
AC109966  
LOCUS  
DEFINITION Rattus norvegicus clone CH230-32315, \*\*\* SEQUENCING IN PROGRESS  
AC109966  
VERSION AC109966.3 GI:21738210  
KEYWORDS HTG; HTGS\_PHASE1.  
SOURCE Norway rat.  
ORGANISM Rattus norvegicus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
REFERENCE 1 (bases 1 to 175281)  
AUTHORS Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,  
Alsbrooks,S.L., Amaralunge,H.C., Are,J.R., Ayele,M., Banks,T.,  
Barbaria,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D.,  
Bouck,J., Bowie,S., Brileva,M., Brown,E., Brown,M., Bryant,N.P.,  
Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C.,  
Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D.,  
Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C.,  
Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R.,  
Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A.,  
Delaney,K.R., Delgado,O., Denn,A.L., Ding,Y., Dinh,H.H.,  
Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J.,  
Earnhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M.,  
Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P.,  
Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R.,  
Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K.,  
Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J.,  
Hernandez,O., Hodgson,A., Hognes,M., Holloway,C., Hollins,B.,  
Homsí,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Jackson,L.E.,  
Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S.,  
Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C.,  
Kratovic,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L.,  
Li,J., Li,Z., Lichtarge,O., Lieu,C., Liu,J., Liu,W., Loulseged,H.,  
Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J.,  
Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E.,  
Massey,E., Mawhiney,E., McLeod,M.P., Meador,M., Mel,G., Metzker,M.,  
Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S.,  
Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N.,  
Nguyen,N., Nickerson,E., Nwokenkwo,S., Oguh,M., Okwunu,G.,  
Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L.,  
Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y.,  
Rives,M., Rojas,A., Rojубokan,I., Rolfe,M., Ruiz,S., Savery,G.,  
Scherer,S., Scott,G., Shen,H., Shoostari,N., Sisson,I.,  
Sodergren,E., Sonaíke,T., Sparks,A., Stanley,H., Stone,H.,  
Sulton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H.,  
Tansey,J., Taylor,C., Taylor,T., Telfrod,B., Thomas,N., Thomas,S.,  
Usmani,K., Vasquez,L., Vera,V., Villalon,D., Vinson,R., Wang,Q.,  
Wang,S., Ward-Moore,S., Warren,R., Washington,C., Watlington,S.,  
Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K.,  
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D.,  
Weinstock,G. and Gibbs,R.  
TITLE  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 175281)  
AUTHORS Worley,K.C.  
JOURNAL Direct Submission  
Submitted (09-FEB-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
REFERENCE 3 (bases 1 to 175281)  
AUTHORS Worley,K.C.  
TITLE Direct Submission  
JOURNAL Submitted (13-JUL-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One

COMMENT

Baylor Plaza, Houston, TX 77030, USA  
On Jul 12, 2002 this sequence version replaced gi:18847026.  
----- Genome Center  
Center: Baylor College of Medicine  
Center code: BCM  
Web site: <http://www.hgsc.bcm.tmc.edu/>  
Contact: [hgsc-help@bcm.tmc.edu](mailto:hgsc-help@bcm.tmc.edu)  
----- Project Information  
Center project name: GOLP  
Center clone name: CH230-32315  
----- Summary Statistics  
Sequencing vector: Plasmid;  
Chemistry: Dye-terminator Big Dye; 100% of reads  
Assembly program: Phrap; version 0.990329  
Consensus quality: 105442 bases at least Q40  
Consensus quality: 111492 bases at least Q30  
Consensus quality: 116270 bases at least Q20  
-----  
\* NOTE: Estimated insert size may differ from sequence length  
\* (see [http://www.hgsc.bcm.tmc.edu/docs/Genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/docs/Genbank_draft_data.html)).  
\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 75 contigs. The true order of the pieces  
\* is not known and their order in this sequence record is  
\* arbitrary. Gaps between the contigs are represented as  
\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.  
\* 1 1290: contig of 1290 bp in length  
\* 1291 1390: gap of unknown length  
\* 1391 2414: contig of 1024 bp in length  
\* 2415 2514: gap of unknown length  
\* 2515 3639: contig of 1125 bp in length  
\* 3640 3739: gap of unknown length  
\* 3740 5063: contig of 1324 bp in length  
\* 5064 5163: gap of unknown length  
\* 5164 6243: contig of 1080 bp in length  
\* 6244 6343: gap of unknown length  
\* 6344 7536: contig of 1193 bp in length  
\* 7537 7636: gap of unknown length  
\* 7637 9071: contig of 1435 bp in length  
\* 9072 9171: gap of unknown length  
\* 9172 10200: contig of 1029 bp in length  
\* 10201 10300: gap of unknown length  
\* 10301 11505: contig of 1205 bp in length  
\* 11506 11605: gap of unknown length  
\* 11606 12680: contig of 1075 bp in length  
\* 12681 12780: gap of unknown length  
\* 12781 14056: contig of 1276 bp in length  
\* 14057 14156: gap of unknown length  
\* 14157 15413: contig of 1257 bp in length  
\* 15414 15513: gap of unknown length  
\* 15514 16580: contig of 1067 bp in length  
\* 16581 16680: gap of unknown length  
\* 16681 17692: contig of 1012 bp in length  
\* 17693 17792: gap of unknown length  
\* 17793 19013: contig of 1221 bp in length  
\* 19014 19113: gap of unknown length  
\* 19114 20418: contig of 1305 bp in length  
\* 20419 20518: gap of unknown length  
\* 20519 21880: contig of 1362 bp in length  
\* 21881 21980: gap of unknown length  
\* 21981 22985: contig of 1005 bp in length  
\* 22986 23085: gap of unknown length  
\* 23086 24156: gap of unknown length  
\* 24157 24256: contig of 1071 bp in length  
\* 24257 25732: contig of 1476 bp in length  
\* 25733 25832: gap of unknown length  
\* 25833 27196: gap of unknown length  
\* 27197 27296: contig of 1364 bp in length  
\* 27297 28615: gap of unknown length  
\* 28616 28715: contig of 1319 bp in length  
\* 28716 30145: contig of 1430 bp in length



*	30146	30245	gap of unknown length
*	30246	31418	contig of 1173 bp in length
*	31419	31518	gap of unknown length
*	31519	32896	contig of 1378 bp in length
*	32897	32996	gap of unknown length
*	32997	34142	contig of 1146 bp in length
*	34143	34242	gap of unknown length
*	34243	35262	contig of 1020 bp in length
*	35263	35362	gap of unknown length
*	35363	36924	contig of 1562 bp in length
*	36925	37024	gap of unknown length
*	37025	38670	contig of 1646 bp in length
*	38671	38770	gap of unknown length
*	38771	40612	contig of 1842 bp in length
*	40613	40712	gap of unknown length
*	40713	42724	contig of 2012 bp in length
*	42725	42824	gap of unknown length
*	42825	43829	contig of 1005 bp in length
*	43830	43929	gap of unknown length
*	43930	45818	contig of 1889 bp in length
*	45819	45918	gap of unknown length
*	45919	48183	contig of 2265 bp in length
*	48184	48283	gap of unknown length
*	48284	49887	contig of 1604 bp in length
*	49888	49987	gap of unknown length
*	49988	51568	contig of 1581 bp in length
*	51569	51668	gap of unknown length
*	51669	53251	contig of 1583 bp in length
*	53252	53351	gap of unknown length
*	53352	55636	contig of 2285 bp in length
*	55637	55736	gap of unknown length
*	55737	57159	contig of 1423 bp in length
*	57160	57259	gap of unknown length
*	57260	59519	contig of 2260 bp in length
*	59520	59619	gap of unknown length
*	59620	63392	contig of 3773 bp in length
*	63393	63492	gap of unknown length
*	63493	65130	contig of 1638 bp in length
*	65131	65230	gap of unknown length
*	65231	68145	contig of 2915 bp in length
*	68146	68245	gap of unknown length
*	68246	70070	contig of 1825 bp in length
*	70071	70170	gap of unknown length
*	70171	73494	contig of 3324 bp in length
*	73495	73594	gap of unknown length
*	73595	75991	contig of 2397 bp in length
*	75992	76091	gap of unknown length
*	76092	77867	contig of 1776 bp in length
*	77868	77967	gap of unknown length
*	77968	80318	contig of 2351 bp in length
*	80319	80418	gap of unknown length
*	80419	82211	contig of 1793 bp in length
*	82212	82311	gap of unknown length
*	82312	84412	contig of 2101 bp in length
*	84413	84512	gap of unknown length
*	84513	85982	contig of 1470 bp in length
*	85983	86082	gap of unknown length
*	86083	88348	contig of 2266 bp in length
*	88349	88448	gap of unknown length
*	88449	90746	contig of 2298 bp in length
*	90747	90846	gap of unknown length
*	90847	92600	contig of 1754 bp in length

Db	133706	CCCTGCACATCTTCAACGCCCATCAGTGGGACACCACAACAGCACAGTGGTTCAAGGGTTGA	133765
QY	239	CCAGCTCGTCTTGGGTGCTGATTTACATCTCATGCCCCGTGTGGGACTTGTGTGT	298
Db	133766	CCAGTTCATCCTCAGTTGTGTGACTTTACCTCATGAACACACAGTGGGACATGCTTGT	133825
QY	299	CATTTCGCAAACTCAGAGATGCTTTCCAAAGCCATCAGTGGGAGACCGAGACAGGAGG	358
Db	133826	CATGTGCAAACTCAGGACGACTTTCAGAGCTAATCAGTGGTTTGGCCAAGCACAGGAGA	133885
QY	359	ACCAAGGGGAGGGGAGAGAAAGGAATTAAGAACAACGTTATTTCTTAACAGACTTCT	418
Db	133886	AGCCATGGGGAATGGGAGAGAGAAAGAGCCTGGACTGTGATATTTAATAGCAGA--TTT	133943
QY	419	ATAGGAGTTGTAAGAGGTGCACATATTTTTTAAATCTCACTGGCAATATTTCAAGTTT	478
Db	133944	ATAGGAGTTGGGGAGAGGTGCACATATTTTTTTAAATATCACTGGCAATGTT--TAGTTT	134001
QY	479	TCATTGTGCTTAACAAGGTGT	501
Db	134002	TCCTCATGTCTTAACAGGTGTAT	134024

RESULT	12	.
AC119357/c		
LOCUS	AC119357	
DEFINITION	Rattus norvegicus clone CH230-473M19, ***	192825 bp DNA linear HTG 18-JUL-2002
ACCESSION	AC119357	*** SEQUENCING IN PROGRESS
VERSION	AC119357.3	
KEYWORDS	HTG; HTGS_PHASE1.	
SOURCE	Norway rat.	
ORGANISM	Rattus norvegicus	

REFERENCE  
AUTHORS

REFERENCE  
AUTHORS

1 (bases 1 to 192825)

Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C., Alsbrooks,S.L., Amaratunge,H.C., Are,J.R., Ayele,M., Banks,T., Barbara,J., Benton,J., Bimage,K., Blankenburg,K., Bonnin,D., Bouck,J., Bowie,S., Brieva,M., Brown,E., Brown,M., Bryant,N.P., Buhay,C., Burch,P., Burkett,C., Burrell,K.L., Byrd,N.C., Carron,T.F., Carter,M., Cavazos,S.R., Chacko,J., Chavez,D., Chen,G., Chen,R., Chen,Z., Chowdhry,I., Christopoulos,C., Cleveland,C.D., Cox,C., Coyle,M.D., Dathorne,S.R., David,R., Davila,M.L., Davis,C., Davy-Carroll,L., Dederich,D.A., Delaney,K.R., Delgado,O., Denu,A.L., Ding,Y., Dinh,H.H., Douthwaite,K.J., Draper,H., Dugan-Rocha,S., Durbin,K.J., Earnhart,C., Edgar,D., Edwards,C.C., Elhaj,C., Escotto,M., Falls,T., Ferraguto,D., Flagg,N., Ford,J., Foster,P., Frantz,P., Gabisi,A., Gao,J., Garcia,A., Garner,T., Garza,N., Gill,R., Gorrell,J.H., Guevara,W., Gunaratne,P., Hale,S., Hamilton,K., Harris,C., Harris,K., Hart,M., Havlak,P., Hawes,A., Hernandez,J., Hernandez,O., Hodgson,A., Hognes,M., Holloway,C., Hollins,B., Homsí,F., Howard,S., Huber,J., Hulyk,S., Hume,J., Jackson,L.E., Jacobson,B., Jia,Y., Johnson,R., Jolivet,S., Joudah,S., Karlsson,E., Kelly,S., Khan,U., King,L., Korvah,J., Kovar,C., Kratochvíl,J., Kureshi,A., Landry,N., Leal,B., Lewis,L.C., Lewis,L., Li,J., Li,Z., Lichtarge,O., Lieu,C., Liu,J., Liu,W., Loulseged,H., Lozado,R.J., Lu,X., Lucier,A., Lucier,R., Luna,R., Ma,J., Maheshwari,M., Mapua,P., Martin,R., Martindale,A., Martinez,E., Massey,E., Mawhiney,E., Mcleod,M.P., Meador,M., Mei,G., Metzker,M., Miner,G., Miner,Z., Mitchell,T., Mohabbat,K., Morgan,M., Morris,S., Moser,M., Neal,D., Newton,J., Newton,N., Nguyen,A., Nguyen,N., Nguyen,N., Nickerson,E., Nwokenkwo,S., Ogunh,M., Okwuonu,G., Oragunye,N., Oviedo,R., Pace,A., Payton,B., Peery,J., Perez,L., Peters,L., Pickens,R., Primus,E., Pu,L.L., Quiles,M., Ren,Y., Rives,M., Rojas,A., Rojubokan,I., Rolfe,M., Ruiz,S., Savery,G., Scherer,S., Scott,G., Shen,H., Shooshtari,N., Sisson,I., Sodergren,E., Sonaiké,T., Sparks,A., Stanley,H., Stone,H., Sutton,A., Svatek,A., Tabor,P., Tamerisa,A., Tamerisa,K., Tang,H., Tansey,J., Taylor,C., Taylor,T., Telford,B., Thomas,N., Thomas,S., Umami,K., Vasquez,L., Vera,V., Villalón,D., Vinson,R., Wang,Q.,

TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

Wang,S., Ward-Moore,S., Warren,R., Washington,C., Wallington,S.,  
Williams,G., Williamson,A., Wleczyk,R., Wooden,S., Worley,K.,  
Wu,C., Wu,Y., Wu,Y.F., Zhou,J., Zorrilla,S., Nelson,D.,  
Weinstock,G. and Gibbs,R.  
Direct Submission  
Unpublished  
2 (bases 1 to 192825)  
Worley,K.C.  
Direct Submission  
Submitted (26-APR-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
3 (bases 1 to 192825)  
Worley,K.C.  
Direct Submission  
Submitted (18-JUL-2002) Human Genome Sequencing Center, Department  
of Molecular and Human Genetics, Baylor College of Medicine, One  
Baylor Plaza, Houston, TX 77030, USA  
On Jul 14, 2002 this sequence version replaced gi:20429771.  
----- Genome Center  
Center: Baylor College of Medicine  
Center code: BCM  
Web site: <http://www.hgsc.bcm.tmc.edu/>  
Contact: hgsc-help@bcm.tmc.edu  
----- Project Information  
Center project name: GVFP  
Center clone name: CH230-473M19  
----- Summary Statistics  
Sequencing vector: Plasmid;  
Chemistry: Dye-terminator Big Dye: 100% of reads  
Assembly program: Phrap: version 0.990329  
Consensus quality: 117932 bases at least Q40  
Consensus quality: 124308 bases at least Q30  
Consensus quality: 129203 bases at least Q20  
-----  
\* NOTE: Estimated insert size may differ from sequence length  
\* (see [http://www.hgsc.bcm.tmc.edu/docs/genbank\\_draft\\_data.html](http://www.hgsc.bcm.tmc.edu/docs/genbank_draft_data.html)).  
\* NOTE: This is a 'working draft' sequence. It currently  
\* consists of 89 contigs. The true order of the pieces  
\* is not known and their order in this sequence record is  
\* arbitrary. Gaps between the contigs are represented as  
\* runs of N, but the exact sizes of the gaps are unknown.  
\* This record will be updated with the finished sequence  
\* as soon as it is available and the accession number will  
\* be preserved.  
\* 1 1129: contig of 1129 bp in length  
\* 1130 1229: gap of unknown length  
\* 1230 2849: contig of 1620 bp in length  
\* 2850 2949: gap of unknown length  
\* 2950 4125: contig of 1176 bp in length  
\* 4126 4225: gap of unknown length  
\* 4226 5644: contig of 1419 bp in length  
\* 5645 5744: gap of unknown length  
\* 5745 6997: contig of 1253 bp in length  
\* 6998 7097: gap of unknown length  
\* 7098 8757: contig of 1660 bp in length  
\* 8758 8857: gap of unknown length  
\* 8858 9860: contig of 1003 bp in length  
\* 9861 9960: gap of unknown length  
\* 9961 11605: contig of 1645 bp in length  
\* 11606 11705: gap of unknown length  
\* 11706 12751: contig of 1046 bp in length  
\* 12752 12851: gap of unknown length  
\* 12852 14490: contig of 1639 bp in length  
\* 14491 14590: gap of unknown length  
\* 14591 16101: contig of 1511 bp in length  
\* 16102 16201: gap of unknown length  
\* 16202 17628: contig of 1427 bp in length  
\* 17629 17728: gap of unknown length  
\* 17729 18883: contig of 1155 bp in length  
\* 18884 18983: gap of unknown length  
\* 18984 20211: contig of 1228 bp in length  
\* 20212 20311: gap of unknown length

\* 20312 21353: contig of 1042 bp in length  
\* 21354 21453: gap of unknown length  
\* 21454 22518: contig of 1065 bp in length  
\* 22519 22618: gap of unknown length  
\* 22619 24107: contig of 1489 bp in length  
\* 24108 24207: gap of unknown length  
\* 24208 25603: contig of 1396 bp in length  
\* 25604 25703: gap of unknown length  
\* 25704 27171: contig of 1468 bp in length  
\* 27172 27271: gap of unknown length  
\* 27272 28993: contig of 1722 bp in length  
\* 28994 29093: gap of unknown length  
\* 29094 30122: contig of 1029 bp in length  
\* 30123 30222: gap of unknown length  
\* 30223 31317: contig of 1095 bp in length  
\* 31318 31417: gap of unknown length  
\* 31418 33144: contig of 1727 bp in length  
\* 33145 33244: gap of unknown length  
\* 33245 34431: contig of 1187 bp in length  
\* 34432 34531: gap of unknown length  
\* 34532 35743: contig of 1212 bp in length  
\* 35744 35843: gap of unknown length  
\* 35844 37180: contig of 1337 bp in length  
\* 37181 37280: gap of unknown length  
\* 37281 38596: contig of 1316 bp in length  
\* 38597 38696: gap of unknown length  
\* 38697 40031: contig of 1335 bp in length  
\* 40032 40131: gap of unknown length  
\* 40132 41485: contig of 1354 bp in length  
\* 41486 41585: gap of unknown length  
\* 41586 42744: contig of 1159 bp in length  
\* 42745 42844: gap of unknown length  
\* 42845 45158: contig of 2314 bp in length  
\* 45159 45258: gap of unknown length  
\* 45259 46752: contig of 1494 bp in length  
\* 46753 46852: gap of unknown length  
\* 46853 48029: contig of 1177 bp in length  
\* 48030 48129: gap of unknown length  
\* 48130 49682: contig of 1553 bp in length  
\* 49683 49782: gap of unknown length  
\* 49783 51724: contig of 1942 bp in length  
\* 51725 51824: gap of unknown length  
\* 51825 53137: contig of 1313 bp in length  
\* 53138 53237: gap of unknown length  
\* 53238 55287: contig of 2050 bp in length  
\* 55288 55387: gap of unknown length  
\* 55388 57026: contig of 1639 bp in length  
\* 57027 57126: gap of unknown length  
\* 57127 58750: contig of 1624 bp in length  
\* 58751 58850: gap of unknown length  
\* 58851 60180: contig of 1330 bp in length  
\* 60181 60280: gap of unknown length  
\* 60281 61971: contig of 1691 bp in length  
\* 61972 62071: gap of unknown length  
\* 62072 63893: contig of 1822 bp in length  
\* 63894 63993: gap of unknown length  
\* 63994 65782: contig of 1789 bp in length  
\* 65783 65882: gap of unknown length  
\* 65883 67125: contig of 1243 bp in length  
\* 67126 67225: gap of unknown length  
\* 67226 69485: contig of 2260 bp in length  
\* 69486 69585: gap of unknown length  
\* 69586 71428: contig of 1843 bp in length  
\* 71429 71528: gap of unknown length  
\* 71529 73230: contig of 1702 bp in length  
\* 73231 73330: gap of unknown length  
\* 73331 75374: contig of 2044 bp in length  
\* 75375 75474: gap of unknown length  
\* 75475 77927: contig of 2453 bp in length  
\* 77928 78027: gap of unknown length  
\* 78028 79268: contig of 1241 bp in length  
\* 79269 79368: gap of unknown length  
\* 79369 81963: contig of 2595 bp in length

*	81964	82063: gap of unknown length
*	82064	83940: contig of 1877 bp in length
*	83941	84040: gap of unknown length
*	84041	85690: contig of 1650 bp in length
*	85691	85790: gap of unknown length
*	85791	88775: contig of 2985 bp in length

Query Match	35.0%;	Score 175.6;	DB 2;	Length 192825;
Best Local Similarity	73.5%;	Pred. No. 2.7e-39;		
Matches 238; Conservative	0;	Mismatches 84;	Indels 2;	Gaps 1;

QY	119	CTGAAATCATGCATGACGACAGATCTGCCCCCTGGAGGAGAGAAGACGCGTCTTACCGAATT	178
Db	62393	CTGTCTTCTGTGTACCTTCAGATTTTGCCCCCTGGAGGAGAGAAGACGCGTGTCTTACCAATT	62334
QY	179	CCCTTCACATCTTCAACGCCCATCAGTGGACTCCAACAGCACATGTTCCACGGGATGA	238
Db	62333	CCCTGCACATCTTCAACGCCCATCAGTGGAGACACCACCAAGCACAGTGTTCAAAGGGTTGA	62274
QY	239	CCAGCTCGTCTTCCGTCGTGTGATTACATCTCATGCGCCGTGTGTGGGACTTGCCTTGT	298
Db	62273	CCAGTTCATCCTCAGTTGTGTGACTTTACCTCATGAACACACGTTGGGACATGCTTTGT	62214
QY	299	CATTTCGCAAACTCAGSAGTCTTCCAAAGCCAAATCACTGGGGAGACCCGACACAGGAGG	358
Db	62213	CATGTGCAAACTCAGSAGCACTTTCAGAGCTAATCACTGCTTTTGGCCAAGCACAGAGA	62154
QY	359	ACCAAGGGGAGGGGAGAGAAAGGAATTAAGACACAACCTTATTCTTAACAGACTTCT	418
Db	62153	AGCCATGGGGAGATGGGAGAGAGAAAGAGCCCTGGACTGTGATATTTAATAGCAGA--TTT	62096
QY	419	ATAGGAGTTGTTAAGACAGTGCACA	442
Db	62095	ATAGGAGATGGGGGAGAGGTGCACA	62072

RESULT 13  
AB056820

LOCUS AB056820 2768 bp mRNA linear PRI 14-MAR-2001  
DEFINITION Macaca fascicularis brain cDNA clone:Of1A-15589, full insert  
sequence.

VERSION AB056820.1 GI:13365942  
KEYWORDS fis (full insert sequence); oligo capping.  
SOURCE Macaca fascicularis adult male frontal lobe left CDNA to mRNA,

ORGANISM    *Macaca fascicularis*  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;  
Cercopithecinae; *Macaca*.

REFERENCE	1 (sites)
AUTHORS	Osada, N., Hida, M., Kusuda, J., Tanuma, R., Iseki, K., Hirai, M., Terao, K., Suzuki, Y., Sugano, S. and Hashimoto, K.
TITLE	Isolation of full-length cDNA clones from macaque brain cDNA libraries
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 2768)
AUTHORS	Hashimoto, K., Osada, N., Hida, M., Kusuda, J. and Sugano, S.
TITLE	Direct Submission
JOURNAL	Submitted (09-MAR-2001) Katsuyuki Hashimoto, National Institute

Infectious Diseases, Division of Genetic Resources; 23-1, Toyama  
 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan  
 (E-mail: [khashi@nih.go.jp](mailto:khashi@nih.go.jp), URL: <http://www.nih.go.jp/yoken/genebank/>,  
 Tel: 81-3-5285-1111 (ex. 2120), Fax: 81-3-5285-1181)  
 Lab host: TOP10

COMMENT	TOP10
Lab host:	
Vector:	pME18S-FL3 (Acc.No. AB009864)

R. Site1: DraIII (CACTGTGTG)  
R. Site2: DraIII (CACCATGTG)

Description: 1st strand cDNA was primed with an oligo(dT) primer [ATGTGGCCTTTTCTTTTCTTTT]; double-stranded cDNA was synthesized using specific 5' and 3' primers and amplified by PCR. The PCR product was digested with SfiI and size selection was performed to exclude fragments <1.5kb. The SfiI-digested PCR product was cloned

## FEATURES

### source

into distinct DraIII sites of pME18S-FL3. XhoI sites just outside the DraIII sites can be used to isolate the cDNA insert. Libraries were constructed by Sugano et al. (University of Tokyo, Institute of Medical Science). Custom primer used for sequencing (5' end primer [CCTCTGCTCTAAAGCTGCG]; 3' end primer [CGACCTGCAGCTCGAGCACA]).

CDS

[illegible]

Query Match	15.8%;	Score 79.4;	DB 9;	Length 2768;
Best Local Similarity	71.7%;	Pred. No. 9.8e-12;		
Matches 104; Conservative	0;	Mismatches 41;	Indels 0;	Gaps 0;

QY	1	CAATTTGTGGAAAGCTTGGCGGTCAAGCCTTAGCGGTAACGAAACGCTGTGATTTAAAGAACAC	60
Db	1773	CAATTTGCAGATGCATGTGGGCCAAGGCCCTTGACGTGAATGAGCGCCTCATCAAGAGAGAC	1832
QY	61	CAGCTCGAGTATCAGGAAGAAATGAAAGCCCAACTACAGGGAATGGCGAAGAGCTTCT	120
Db	1833	CAGCTGGAGTACCAGGAGAACTGAGGTCCCACTACAAGACATGCTCAGCGAACTCTCC	1892
QY	121	GAATTCATGCATGAGCAGATCTGCC	145
Db	1893	ACTATCATGAATGAGCAGCTCTGTC	1917

RESULT 14  
AK001253

LOCUS	AK001253	2036 bp	mRNA	linear	PRI 01-AUG-2002
DEFINITION	Homo sapiens CDNA FLJ10391 fis, clone NT2RM4000139, moderately similar to R.norvegicus trg mRNA.				

ACCESSION	AK001253
VERSION	AK001253.1
KEYWORDS	oligo capping; fis (full insert sequence).
SOURCE	Homo sapiens teratocarcinoma cell_line:NT2 CDNA to mRNA,

## ORGANISM

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Craniata; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS

Sugawara, M., Takahashi, M., Chiba, Y., Ishida, S., Murakawa, K., Ono, Y., Takiguchi, S., Watanabe, S., Kimura, K., Murakami, K., Ishii, S., Kawai, Y., Saito, K., Yamamoto, J., Wakamatsu, A., Nakamura, Y., Nagahari, K., Masuho, Y., Ninomiya, K. and Iwayanagi, T. NEDO human cDNA sequencing project

JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 2036)  
AUTHORS Isogai,T. and Otsuki,T.  
TITLE Direct Submission  
JOURNAL Submitted (16-FEB-2000) Takao Isogai, Helix Research Institute,  
Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan  
(E-mail:genomics@rhl.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
NEDO human cDNA sequencing project supported by Ministry of  
International Trade and Industry of Japan; cDNA full insert  
sequencing: Research Association for Biotechnology; cDNA library  
construction, 5'- & 3'-end one pass sequencing and clone selection:  
Helix Research Institute (supported by Japan Key Technology Center  
etc.) and Department of Virology, Institute of Medical Science,  
University of Tokyo.

FEATURES  
source location/Qualifiers  
1..2036  
/organism="Homo sapiens"  
/db\_xref="taxon:9606"  
/clone="NT2RM4000139"  
/cell\_line="NT2"  
/cell\_type="teratocarcinoma"  
/clone\_1lb="NT2RM4"  
/note="cloning vector: pME18SFL3-mRNA from uninduced NT2  
neuronal precursor cells."  
153..1400  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="BAA91583.1"  
/db\_xref="GI:7022394"  
/translation="MFSMGWPAFLSTIPNIKEGAMKEDSGMODTPYNNILVEQLYM  
CVELFWKSERYELIADVDPKIAYFEKQRDFKLSDLYDIHRSYLKAQEVNSEKRLL  
FGRYYRVAIFYGGGFEEEEEKEYIKPEPLTGSEISQRLKLYADKFGADNVKITIQD  
SNKNVPKDLDPRKYAIVTYVTPTFFEEKIEERKTDFEMHHNINRFVETPILLSKKKK  
HGGAEOCKRRITLTSHLEPYVKRIQVISOSTELNPIEVAIDMSKVSELNOLOC  
TMEVDVMIRLOLKLOGSVSKVNAGPMAYARAFLEEETNAKKYPDNQVKLKETFRQFA  
DACGQALDVNERLIKEDOLEYOELRSHYKMDLSLVMNEQITGRDL SKRGVDQT  
CTRVISKATPALPTVSISSSAEV"

CDS

BASE COUNT 634 a 390 c 460 g 552 t  
ORIGIN

Query Match 15.6%; Score 78.2; DB 9; Length 2036;  
Best Local Similarity 67.5%; Pred. No. 2.1e-11;  
Matches 110; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

Oy 1 CAATTGTGAGACTTCGCCGTCAAGCCCTTAGCGGTAACGACGCTCTGATTAAAGAAGAC 60  
||||| |||| | | | | | | | | | | | | | |  
Db 1146 CAA TT TGC AG ATG CAT GTGG CAG GCC CT TG AC GT GA ATG AG CG CC TC CAT C AA A GA G AC 1205  
  
Oy 61 CAG CTC GAG TA TCAG GA A GA A ATG A A GC CA ACT ACA GGA A AT GG CG A AG AG ACT TTC T 120  
||||| |||| | | | | | | | | | | | | | |  
Db 1206 CAG CTG AGT ACC AGA GA A C TGA GGT CC CAC TACA A GA G AC ATG CT CAG C GA ACT CTC C 1265  
  
Oy 121 GAA ATCATGCATGAGCAGACATCTGCC CCC CTG AGG AGA GAGA CAGA 163  
| ||||| | ||||| | ||||| | ||||| | |||||  
Db 1266 ACA GTCATGATGAGCAGACATTTACGGG CAG GAG CAG CACTGTCAA 1308

RESULT 15  
BC015018 BC015018 2413 bp mRNA linear PRI 04-OCT-2001  
DEFINITION Homo sapiens, clone MGC:8871 IMAGE:3922744, mRNA, complete cds.  
ACCESSION BC015018  
VERSION BC015018.1 GI:15929124  
KEYWORDS MGC.  
SOURCE Homo sapiens.  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 2413)  
Strausberg,R.  
Direct Submission  
Submitted (01-OCT-2001) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer

```

REMARK      NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT     Contact: MGC help desk
            Email: cgapbs-remail.nih.gov
            Tissue Procurement: ATCC/DCTD/DTF
            CDNA Library Preparation: Life Technologies, Inc.
            CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
            DNA Sequencing by: Genome Sequence Centre,
            BC Cancer Agency, Vancouver, BC, Canada
            info@bcgsc.bc.ca
Steven Jones, Jennifer Asano, Ian Bosdet, Yaron Butterfield,
Susanna Chan, Readman Chiu, Chris Fjell, Erin Garland, Ran Guin,
Letlicia Hsiao, Martin Krzywinski, Reta Kutsche, Oliver Lee, Soo
Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven
Ness, Pawan Pandoh, Anna-Lissa Prabhu, Parvaneh Saeedi, Jacqueline
Schein, Duane Smalios, Michael Smith, Lorraine Spence, Jeff Stoltz,
Michael Thorne, Miranada Tsai, Natasja van den Bosch, Jill Vardy,
George Yang, Scott Zuyderduyn, Marco Marra.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LNL at: http://image.lnl.gov
Series: IRAC Plate: 15 Row: P Column: 18
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gl: 8923209.

FEATURES
source
    1..2413
        /organism="Homo sapiens"
        /db_xref="taxon:9606"
        /clone="MGC:8871 IMAGE:3922744"
        /tissue_type="Skin, melanotic melanoma."
        /clone_lib="NIH_MGC_72"
        /lab_host="DH10B"
        /note="Vector: pCMV-SPORT6"
        /codon_start=1
        /product="unknown (protein for MGC:8871)"
        /protein_id="AAH15018.1"
        /db_xref="GI:15929125"
        /translation="MKNSNPFAVEKDLTKRITVLMTAQMKEHEKDPEMLVDLYSL
ANSYASTPELRRTWLLESMARKNDLSEAMCYIHIALIAEYLKRKYWKVEIK
TASLSIEDTHPCDSNSLTTPSGGSWMFGWPAFLSTPNIKEGAKEDSGMODTPY
NENLIVEQLYMCEFLMKSERELIADVNKPILAVFEKQRFKKLSLDLYDIHSRYLK
VAEVNSEKRLNGFRYRVAFYGGGFEEEGKEYIIKEPKLTGLSEISQLKLKYADK
FGADNVKLIQDSKNVPKDLDPKRAYIQVTYVTFEFEEKTEIDRKTDPEMHNNIRFV
FETPFTLSGKHGVAEQCKRRILTTSHLFYPVKRIQVISOSTELNPIEVAIDEM
SKKVSELNQICTMEVDMIRQLKLGSSVSXKVNAGPMAYARAFLEETNAKKYPDNQV
KLKEIFROFADACGOALDVNERLIKEDOLEYOELRSHYKMDLSELSTVMNEQITGR
DDLKRGVDQTCTRVISKATPALPTVSISSSAEV"

BASE COUNT   761 a   477 c   549 g   626 t
ORIGIN
Query Match          15.6%; Score 78.2; DB 9; Length 2413;
Best Local Similarity 67.5%; Pred. No. 2.le-11;
Matches 110; Conservative 0; Mismatches 53; Indels 0; Gaps 0;

OY       1 CAATTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAACGTCGTGATTAAAGAAGAC 60
         ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       1513 CAATTTCAGATGCATGTGGCGAGGCCCTTGACGTGATGAGCGCCTCATCAAGAAGAGAC 1572

OY       61 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACACTACAGGGAATGGCGAAGAGAGCTTTCT 120
         ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       1573 CAGCTGGAATACCAGGAAGAACTGAGGTCCCACTACAAGGACATGCTCAGCGAAGCTCTCC 1632

OY       121 GAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGA 163
         - ||||| | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db       1633 ACAGTCATGATGAGCACAGATTACGGCGCAGGAGCAGACCTGTCAA 1675

```



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 05:36:04 ; Search time 128.085 Seconds  
(without alignments)  
8808.598 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_3800\_4300  
Perfect score: 501  
Sequence: 1 caattgtggaagcttcg...ttgtgtcttaacaaagtgt 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N\_Geneseq\_101002:\*  
1: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:\*  
2: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:\*  
3: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:\*  
4: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:\*  
5: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:\*  
6: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:\*  
7: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:\*  
8: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:\*  
9: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:\*  
10: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:\*  
11: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:\*  
12: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:\*  
13: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:\*  
14: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:\*  
15: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:\*  
16: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:\*  
17: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:\*  
18: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:\*  
19: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:\*  
20: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:\*  
21: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:\*  
22: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:\*  
23: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:\*  
24: /SIDS2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	501	100.0	1493	22	AA186535 Human polynucleoti
2	501	100.0	3614	24	ABK84967 DNA encoding cadhe
3	501	100.0	4806	24	ABK84964 DNA encoding cadhe
4	501	100.0	4807	21	AAC87972 Human CLASP-2 nucl
5	501	100.0	4807	21	AAC87973 Human CLASP-2A nuc
6	501	100.0	4807	24	ABK84966 DNA encoding cadhe
7	501	100.0	4807	24	ABK84973 DNA encoding cadhe
8	501	100.0	4898	21	AAC87974 Preliminary CLASP-
9	501	100.0	4898	21	AAC87975 Preliminary CLASP-

10	501	100.0	4898	21	AAC87976 Preliminary CLASP-
11	501	100.0	4898	21	AAC87977 Preliminary CLASP-
12	501	100.0	4898	21	AAC87978 Preliminary CLASP-
13	501	100.0	4898	21	AAC87979 Preliminary CLASP-
14	501	100.0	4898	21	AAC87980 Preliminary CLASP-
15	501	100.0	4898	21	AAC87981 Preliminary CLASP-
16	501	100.0	4898	24	ABK84992 DNA encoding cadhe
17	501	100.0	4898	24	ABK84993 DNA encoding cadhe
18	501	100.0	4898	24	ABK84994 DNA encoding cadhe
19	501	100.0	4898	24	ABK84995 DNA encoding cadhe
20	501	100.0	4898	24	ABK84996 DNA encoding cadhe
21	501	100.0	4898	24	ABK84997 DNA encoding cadhe
22	501	100.0	4898	24	ABK84998 DNA encoding cadhe
23	501	100.0	4898	24	ABK84999 DNA encoding cadhe
24	501	100.0	6791	24	ABK85003 DNA encoding cadhe
25	501	100.0	6816	21	AAC74524 Human ORFX ORF79 p
26	501	100.0	7506	22	AAD19118 Angiogenesis assoc
27	490	97.8	3899	22	AAF32675 Human cDNA encodin
28	483	96.4	5048	24	ABK84965 DNA encoding cadhe
29	471	94.0	5862	24	ABK84970 DNA encoding cadhe
30	261	52.1	1250	24	ABK84969 DNA encoding cadhe
31	261	52.1	3642	24	ABK84971 DNA encoding cadhe
32	261	52.1	3705	24	ABK84968 DNA encoding cadhe
33	79.4	15.8	2165	21	AAC76949 Human cDNA sequenc
34	78.2	15.6	2036	22	AAH14086 Human cDNA encodin
35	78.2	15.6	5214	21	ABK87968 Mouse CLASP-1 nucl
36	78.2	15.6	5214	21	AAAI4824 DNA encoding a mur
37	78.2	15.6	5688	21	AAC87969 Human CLASP relate
38	78.2	15.6	5688	21	AAAI4825 DNA encoding a hum
39	78.2	15.6	7277	24	AAS18951 Human cDNA encodin
40	78	15.6	662	21	AAC87999 Human CLASP-2 geno
C 41	78	15.6	662	24	ABK84991 DNA encoding cadhe
C 42	67.4	13.5	2610	22	AAF32647 Human cDNA encodin
43	67.4	13.5	3472	22	AAS08358 Human cDNA encodin
44	67.4	13.5	4393	22	AAS08357 Human cDNA encodin
45	67.4	13.5	6454	22	AAS08334 Human cDNA encodin

ALIGNMENTS

RESULT 1	AA186535/c	
ID	AA186535	standard; cDNA; 1493 BP.
XX	AA186535;	
AC	AA186535;	
XX		
DT	06-NOV-2001	(first entry)
XX		
DE	Human polynucleotide SEQ ID NO 6595.	
XX		
KW	Human; cytokine; cell proliferation; cell differentiation; gene therapy;	
KW	vaccine; peptide therapy; stem cell growth factor; haematopoiesis;	
KW	tissue growth factor; immunomodulatory; cancer; leukaemia;	
KW	nervous system disorders; arthritis; inflammation; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	W0200164835-A2.	
XX		
PD	07-SEP-2001.	
XX		
PF	26-FEB-2001; 2001WO-US04927.	
XX		
PR	28-FEB-2000; 2000US-0515126.	
PR	18-MAY-2000; 2000US-0577409.	
XX		
PA	(HYSE-) HYSEQ INC.	
XX		
PI	Tang YT, Liu C, Drmanac RT;	
XX		
DR	WPI; 2001-514838/56.	
DR	P-PSDB; AAO06604.	

XX Isolated nucleic acids and polypeptides, useful for preventing  
PT diagnosing and treating e.g. leukaemia, inflammation and immune  
PT disorders -  
XX  
XX Claim 1; SEQ ID NO 6595; 1399pp + Sequence Listing; English.  
PS  
CC The invention relates to human polynucleotides (AA179941-AA193841) and  
CC the encoded proteins (AA000010-AA013910) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
XX Sequence 1493 BP; 466 A; 314 C; 249 G; 464 T; 0 other;  
SQ  
  
Query Match 100.0%; Score 501; DB 22; Length 1493;  
Best Local Similarity 100.0%; Pred. No. 2.1e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1 CAATTGTGGAAGCTTGGCTCAAGCCCTTAGCGGTAAAGCAAGCTGTGATTAAGAAGAC 60  
DB 1404 CAATTGTGGAAGCTTGGCTCAAGCCCTTAGCGGTAAAGCAAGCTGTGATTAAGAAGAC 1345  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGGAGCTTTCT 120  
DB 1344 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGGAGCTTTCT 1285  
QY 121 GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAAAGACGAGCTTTACCGAATTCC 180  
DB 1284 GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAAAGACGAGCTTTACCGAATTCC 1225  
QY 181 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGACAATGGTTCACGGGATGACC 240  
DB 1224 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGACAATGGTTCACGGGATGACC 1165  
QY 241 AGCTCGTCTTCGGTGTGTGATTACATCTCATGGCCCCGTGTGTGGGACTTGCTTTGTCA 300  
DB 1164 AGCTCGTCTTCGGTGTGTGATTACATCTCATGGCCCCGTGTGTGGGACTTGCTTTGTCA 1105  
QY 301 TTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGACCGAGACAGGAGGAC 360  
DB 1104 TTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGACCGAGACAGGAGGAC 1045  
QY 361 CAAGGGGAAGGGAGAGAAAGAAATAAAGAACACAGTATTATTCTTAACAGACTTTCTAT 420  
DB 1044 CAAGGGGAAGGGAGAGAAAGAAATAAAGAACACAGTATTATTCTTAACAGACTTTCTAT 985  
QY 421 AGGAGTGTGAAGAGGTGCACATATTTTAAATCTCACGTGGCAATATTCAAGATTTC 480  
DB 984 AGGAGTGTGAAGAGGTGCACATATTTTAAATCTCACGTGGCAATATTCAAGATTTC 925  
QY 481 ATTGTGCTTAACAAGGTGT 501  
DB 924 ATTGTGCTTAACAAGGTGT 904  
  
RESULT 2  
ABK84967  
ID ABK84967 standard; cDNA; 3614 BP.  
XX  
AC ABK84967;  
XX  
DT 13-AUG-2002 (first entry)  
XX

DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #2.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO20023117-A2.  
XX  
PD 18-APR-2002.  
XX  
PE 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARM/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX  
DR WPI; 2002-416861/44.  
DR P-PSDB; ABG61673.  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis -  
XX  
PS Disclosure; Figure 3A; 245pp; English.  
XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists.  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digesorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or

CC hypersensitivity to an antigenic molecules, organ rejection or graft-versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and PCR primers of the invention.

XX SQ Sequence 3614 BP; 1009 A; 834 C; 874 G; 897 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 3614;  
Best Local Similarity 100.0%; Pred. No. 3.3e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTGTGGAAGCTTGGGTCAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAAGAC 60  
DB 2607 CAATTGTGGAAGCTTGGGTCAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAAGAC 2666  
QY 61 CAGCTCGAGTATCAGAGAAATGAAGCCAACTACAGGAAATGGCGAAGGAGCTTCT 120  
DB 2667 CAGCTCGAGTATCAGAGAAATGAAGCCAACTACAGGAAATGGCGAAGGAGCTTCT 2726  
QY 121 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGACGAGCGTCTTACCGAATTCC 180  
DB 2727 GAAATCATGCATGAGCAGATCTGCCCTTGAGAGAGACGAGCGTCTTACCGAATTCC 2786  
QY 181 CTTACATCTTCAACGCCATCAGTGGGACTCCAACACAGCACAATGTTACGCGGATGACC 240  
DB 2787 CTTACATCTTCAACGCCATCAGTGGGACTCCAACACAGCACAATGTTACGCGGATGACC 2846  
QY 241 AGCTCGTCTTCGGTGTGTGATTCATCTCATGCCCCGTGTGGGACTTGTGTGCA 300  
DB 2847 AGCTCGTCTTCGGTGTGTGATTCATCTCATGCCCCGTGTGGGACTTGTGTGCA 2906  
QY 301 TTTCGAAACTCAGGATGCTTTCGAAAGCCAACTCAGTGGGAGACCGAGCACAGGAGAGC 360  
DB 2907 TTTCGAAACTCAGGATGCTTTCGAAAGCCAACTCAGTGGGAGACCGAGCACAGGAGAGC 2966  
QY 361 CAAGGGGAGGAGAGAAAGAAATAAGACAACTTATTCTTAACAGACTTCTAT 420  
DB 2967 CAAGGGGAGGAGAGAAAGAAATAAGACAACTTATTCTTAACAGACTTCTAT 3026  
QY 421 AGCAGTTGTAGAAGGTGCACATATTTTAAATCTCAGTGGCAATATTTCAAGTTTTC 480  
DB 3027 AGCAGTTGTAGAAGGTGCACATATTTTAAATCTCAGTGGCAATATTTCAAGTTTTC 3086  
QY 481 ATTGTGCTTACCAAGGTGT 501  
DB 3087 ATTGTGCTTACCAAGGTGT 3107

RESULT 3  
ABK84964 ID ABR84964 standard; cDNA; 4806 BP.  
XX AC ABR84964;  
XX DT 13-AUG-2002 (first entry)  
XX DE DNA encoding cadherin-like asymmetry protein (CLASP).

KW Human; autoimmune disease; haematopoietic disorder; DiGeorge syndrome; blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia; ataxia telangiectasia; common variable immunodeficiency; lymphopenia; thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease; haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus; endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity; autoimmune pulmonary inflammation; organ rejection; inflammation; CLASP; gene; ss.

OS Homo sapiens.  
XX XX  
PN WO200231117-A2.  
XX XX  
PD 18-APR-2002.  
XX XX

PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.

XX Lu PS;  
PI WPI; 2002-416861/44.  
XX P-PSDB; ABG61670.  
DR

PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating an immune response, and for treating multiple sclerosis, rheumatoid arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock, and sepsis

PS Disclosure; Figure 1; 245pp; English.

CC The invention relates to an isolated polypeptide (I) comprising an amino acid sequence that has 90 % sequence identity to one of the human cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E) sequences (PS). (I) is useful for identifying a compound or agent that binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for detecting a CLASP-2 polypeptide in a sample. (II) is useful for inhibiting a immune response in a subject. A pharmaceutical composition comprising a nucleic acid encoding (I), or (II) is useful for preventing or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where the autoimmune disease is caused or exacerbated by increased activity of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for detection or inhibition of CLASP-2 expression (e.g., antisense or ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2 polynucleotides can express CLASP-2 polypeptides, produce anti-CLASP-antibodies or are used as therapeutic polypeptides. The CLASP-2 polynucleotide or fragments can be used in diagnostics (e.g., as probes for CLASP-2 expression), as a lymphocyte marker and for therapeutic purposes. CLASP-2 polynucleotides can construct transgenic and knockout animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2 polynucleotides can screen for CLASP-2 agonists and antagonists. CLASP-2 polypeptides or polynucleotides can treat deficiencies or disorders of the immune system, by activating or inhibiting the activation, differentiation of immune cells and can treat or detect deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides or polynucleotides can increase differentiation and proliferation of haematopoietic cells, including the pluripotent stem cells to treat those disorders associated with a decrease in certain (or many) types of haematopoietic cells e.g., immunologic deficiency syndromes including blood protein disorders (e.g., agammaglobulinaemia, dysgammaglobulinaemia, ataxia telangiectasia, common variable immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia, Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus, endometriosis, autoimmune thyroiditis, and autoimmune pulmonary inflammation. CLASP-2 can be used to treat anaphylaxis or hypersensitivity to an antigenic molecules, organ rejection or graft-versus-host disease (GVHD) and inflammation. ABK84922-ABK85018 represent cadherin-like asymmetry protein (CLASP) coding sequences and PCR primers of the invention.

XX SQ Sequence 4806 BP; 1352 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 4806;  
Best Local Similarity 100.0%; Pred. No. 3.8e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTGTGGAAGCTTGGGTCAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAAGAC 60  
DB 3799 CAATTGTGGAAGCTTGGGTCAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAAGAC 3858  
QY 61 CAGCTCGAGTATCAGAGAAATGAAGCCAACTACAGGAAATGGCGAAGGAGCTTCT 120  
|||||



Db 3859 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 3918

QY 121 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAGACGAGCGTCTTACCGAATTCC 180

Db 3919 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAGACGAGCGTCTTACCGAATTCC 3978

QY 181 CTTGACATCTTCAACGCCATCAGTGGGACTCCAAACAAGCACAATGGTTCACGGGATGACC 240

Db 3979 CTTGACATCTTCAACGCCATCAGTGGGACTCCAAACAAGCACAATGGTTCACGGGATGACC 4038

QY 241 AGCTCGTCTTCGCTCGTGTGATTTACATCTCATGGCCCGTGTGGGACTTGCTTTGTCA 300

Db 4039 AGCTCGTCTTCGCTCGTGTGATTTACATCTCATGGCCCGTGTGGGACTTGCTTTGTCA 4098

QY 301 TTTGCAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACCGAGCACAGGAGGAC 360

Db 4099 TTTGCAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACCGAGCACAGGAGGAC 4158

QY 361 CAAGGGAGAGGGGAGAGAAGGAATAAGACAACAGCTTATTTCTTAACAGACTTTCTAT 420

Db 4159 CAAGGGAGAGGGGAGAGAAGGAATAAGACAACAGCTTATTTCTTAACAGACTTTCTAT 4218

QY 421 AGGAGTTGTAGAAGGTGCACATATTTTTTAATCTCAGTGGCAATATTCAAAGTTTC 480

Db 4219 AGGAGTTGTAGAAGGTGCACATATTTTTTAATCTCAGTGGCAATATTCAAAGTTTC 4278

QY 481 ATTGTGCTTAAACAAGGTGT 501

Db 4279 ATTGTGCTTAAACAAGGTGT 4299

RESULT 4

AAC87972

ID AAC87972 standard; cDNA; 4807 BP.

XX AAC87972;

AC AAC87972;

XX 07-MAR-2001 (first entry)

DT 07-MAR-2001 (first entry)

XX Human CLASP-2 nucleotide sequence.

DE Human CLASP-2 nucleotide sequence.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;

KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;

KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;

KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;

KW hypersensitivity; transplantation rejection response; immunodeficiency;

KW proliferation; differentiation; inflammatory response; arthritis;

KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;

KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;

KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO200061747-A2.

PN WO200061747-A2.

XX 19-OCT-2000.

PD 19-OCT-2000.

XX 13-APR-2000; 2000WO-US10158.

PF 13-APR-2000; 2000WO-US10158.

XX 14-APR-1999; 99US-0129171.

XX 14-MAY-1999; 99US-0134114.

PR 14-MAY-1999; 99US-0134117.

PR 14-MAY-1999; 99US-0134118.

PR 21-OCT-1999; 99US-0160860.

PR 29-OCT-1999; 99US-0162498.

PR 13-DEC-1999; 99US-0170453.

PR 14-JAN-2000; 2000US-0176195.

PR 14-FEB-2000; 2000US-0182296.

XX (ARBO-) ARBOR VITA CORP.

PA (ARBO-) ARBOR VITA CORP.

XX Lu PS;

PI Lu PS;

XX Lu PS;

DR MPI: 2000-619230/59.

DR P-PSDB; AAB36527.

XX Isolated cadherin-like asymmetry protein-2 polynucleotide and

PT polypeptide used to diagnose, treat and prevent autoimmune diseases and

PT inflammatory responses -

XX Example 1; Fig 1; 286pp; English.

PS The present invention describes cadherin-like asymmetry protein-2

XX (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,

CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,

CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be

CC used to inhibit an immune response in a subject by interfering with the

CC ability of a CLASP-2 protein to bind to another T cell or B cell. An

CC immune response in a subject may also be inhibited by administering an

CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,

CC proteins and antibodies can be used to prevent or treat a CLASP-2

CC mediated disease, such as an autoimmune disease caused or exacerbated

CC by increased activity of TH1 cells. They can also be used to treat

CC hypersensitivities, prevent transplantation rejection responses and

CC augment immune responsiveness in immunodeficiency states, inhibit

CC proliferation and differentiation of cells involved in an inflammatory

CC response e.g, arthritis, inflammatory bowel disease and increase

CC differentiation and proliferation of haematopoietic cells e.g. to treat

CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders

CC treated by disrupting CLASP-2 function include multiple sclerosis,

CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.

CC The present sequence encodes human CLASP-2, which is used in the

CC exemplification of the present invention.

XX Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

SQ

Query Match 100.0%; Score 501; DB 21; Length 4807;

Best Local Similarity 100.0%; Pred. No. 3.8e-143;

Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAAGAACGACGTCTGATTAAAGAGAC 60

Db 3800 CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAAGAACGACGTCTGATTAAAGAGAC 3859

QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGAGCTTTCT 120

Db 3860 CAGCTCGAGTATCAGGAAGAAATGAAGGCCAACTACAGGGAATGGCGAAGAGCTTTCT 3919

QY 121 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAAGACGAGCGTCTTACCGAATTCC 180

Db 3920 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAAGACGAGCGTCTTACCGAATTCC 3979

QY 181 CTTGACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGGTTCACGGGATGACC 240

Db 3980 CTTGACATCTTCAACGCCATCAGTGGGACTCCAACAAGCACAATGGTTCACGGGATGACC 4039

QY 241 AGCTCGTCTTCGGTCTGTGATTACATCTCATGGCCCGTGTGGGAGCTTCTTGTC A 300

Db 4040 AGCTCGTCTTCGGTCTGTGATTACATCTCATGGCCCGTGTGGGAGCTTCTTGTC A 4099

QY 301 TTTGCAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACCGAGCACAGGAGGAC 360

Db 4100 TTTGCAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACCGAGCACAGGAGGAC 4159

QY 361 CAAGGGAGAGGGGAGAGAAGGAATAAGAACCAACGTTATTCTTAACAGACTTTCTAT 420

Db 4160 CAAGGGAGAGGGGAGAGAAGGAATAAGAACCAACGTTATTCTTAACAGACTTTCTAT 4219

QY 421 AGGAGTTGTAGAAGGTGCACATATTTTTTAATCTCAGTGGCAATATTCAAAGTTTC 480

Db 4220 AGGAGTTGTAGAAGGTGCACATATTTTTTAATCTCAGTGGCAATATTCAAAGTTTC 4279

QY 481 ATTGTGCTTAAACAAGGTGT 501

Db 4280 ATTGTGCTTAAACAAGGTGT 4300



RESULT 5  
AAC87973  
ID AAC87973 standard; cDNA; 4807 BP.  
XX  
AC AAC87973;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Human CLASP-2A nucleotide sequence.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
b1 Lu PS;  
XX  
DR WPI; 2000-619230/59.  
DR P-PSDB; AAB36528.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Example 1; Fig 2B; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence encodes human CLASP-2A, which is used in the  
CC exemplification of the present invention.

XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;  
Query Match 100.0%; Score 501; DB 21; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.8e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAATTGCTGGAAGCTTGGCTCAAGCCTTAAGCGGTAAACGAACGTCGATTAAAGAACAC 60  
DB 3800 CAATTGCTGGAAGCTTGGCTCAAGCCTTAAGCGGTAAACGAACGTCGATTAAAGAACAC 3859  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGCTTTCT 120  
DB 3860 CAGCTCGAGTATCAGGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGCTTTCT 3919  
QY 121 GAAATCATGATGAGCAGATCTGCCCTTGAGAGGAAGACGAGCGTCTTACCGAATTC 180  
DB 3920 GAAATCATGATGAGCAGATCTGCCCTTGAGAGGAAGACGAGCGTCTTACCGAATTC 3979  
QY 181 CTTACATCTTCAACGCCCATCAGTGGGACTCCACAAACACATGGTTCACGGGATGACC 240  
DB 3980 CTTACATCTTCAACGCCCATCAGTGGGACTCCACAAACACATGGTTCACGGGATGACC 4039  
QY 241 AGCTCGTCTTCGGTCTGTGATTACATCTCATGGCCCGTGTGTGGGACTTGCTTTGTCA 300  
DB 4040 AGCTCGTCTTCGGTCTGTGATTACATCTCATGGCCCGTGTGTGGGACTTGCTTTGTCA 4099  
QY 301 TTGCAAACTCAGATGCTTCCAAAGCCCAATCAGTGGGGAGACCAGACACAGGAGGAC 360  
DB 4100 TTGCAAACTCAGATGCTTCCAAAGCCCAATCAGTGGGGAGACCAGACACAGGAGGAC 4159  
QY 361 CAAGGGGAAGGGGAGAGAAAGAAATAAAGACACAGCTTATTCTTAACAGACTTCTAT 420  
DB 4160 CAAGGGGAAGGGGAGAGAAAGAAATAAAGACACAGCTTATTCTTAACAGACTTCTAT 4219  
QY 421 AGGAGTTGTAAGAAGGTGCACATATTTTAAATCTCACTGGCAATATCAAGTTTTC 480  
DB 4220 AGGAGTTGTAAGAAGGTGCACATATTTTAAATCTCACTGGCAATATCAAGTTTTC 4279  
QY 481 ATTGTGCTTTAACAAAGGTGT 501  
DB 4280 ATTGTGCTTTAACAAAGGTGT 4300  
RESULT 6  
ABK84966  
ID ABK84966 standard; cDNA; 4807 BP.  
XX  
AC ABK84966;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform #1.  
XX  
KW Human; autoimmune disease; haematopoietic disorder; Digesorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PF 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX

PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
PI Lu PS;  
XX WPI: 2002-416861/44.  
DR P-PSDB; ABG61672.  
DR  
XX  
PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Disclosure; Figure 3A; 245pp; English.

XX  
CC The invention relates to an isolated polypeptide (I) comprising an amino  
CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, Digeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences and  
CC PCR primers of the invention.

XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.8e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAAACGTCGTGATTAAGAAGAC 60  
DB 3800 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAAACGTCGTGATTAAGAAGAC 3859  
QY 61 CAGCTCGAGTATCAGAGAATAAGAAAGCAACTACAGGAAATGGCGAAGAGACTTTCT 120  
DB 3860 CAGCTCGAGTATCAGAGAATAAGAAAGCAACTACAGGAAATGGCGAAGAGACTTTCT 3919  
QY 121 GAAATCATGCATGAGCAGATCTGCCCTGAGAGAGAAGACGAGCGTCTTACCGAATTCC 180  
|||||

DB 3920 GAAATCATGCATGAGCAGATCTGCCCTGAGAGAGAAGACGAGCGTCTTACCGAATTCC 3979  
QY 181 CTTACACATCTTCAACGCCATCAGTGGAGCTCCAACACAGCAATGGTTACGGGATGACC 240  
DB 3980 CTTACACATCTTCAACGCCATCAGTGGAGCTCCAACACAGCAATGGTTACGGGATGACC 4039  
QY 241 AGCTCGTCTTCGCTCGTGTGATTAATCTCATGTGGCCCGTGTGTGGGACTTGGCTTCTCA 300  
DB 4040 AGCTCGTCTTCGCTCGTGTGATTAATCTCATGTGGCCCGTGTGTGGGACTTGGCTTCTCA 4099  
QY 301 TTGCAAACTCAGGATGCTTTCCAAGCCCAATCCTACTGGGAGACCGAGCAGGAGGAGAC 360  
DB 4100 TTGCAAACTCAGGATGCTTTCCAAGCCCAATCCTACTGGGAGACCGAGCAGGAGGAGAC 4159  
QY 361 CAAGGGGAGGGGAGAGAAAGCAATTAAGACACAGCTTATTCTTAACAGACTTTCTAT 420  
DB 4160 CAAGGGGAGGGGAGAGAAAGCAATTAAGACACAGCTTATTCTTAACAGACTTTCTAT 4219  
QY 421 AGGAGTTGTAGAAAGGTGCACATATTTTAAATCTCAGTGGCAATATTCAAAGTTTC 480  
DB 4220 AGGAGTTGTAGAAAGGTGCACATATTTTAAATCTCAGTGGCAATATTCAAAGTTTC 4279  
QY 481 ATTGTGCTTAACAAAGGTGT 501  
DB 4280 ATTGTGCTTAACAAAGGTGT 4300  
|||||

RESULT 7  
ABK84973  
ID ABK84973 standard; DNA: 4807 BP.  
XX  
AC ABK84973;  
XX  
DT 13-AUG-2002 (first entry)  
XX  
DE DNA encoding cadherin-like asymmetry protein (CLASP) isoform.

XX Human; autoimmune disease; haematopoietic disorder; Digeorge syndrome;  
KW blood protein disorder; agammaglobulinaemia; dysgammaglobulinaemia;  
KW ataxia telangiectasia; common variable immunodeficiency; lymphopenia;  
KW thrombocytopenia; haemoglobinuria; Addison's disease; Grave's disease;  
KW haemolytic anaemia; multiple sclerosis; rheumatoid arthritis; lupus;  
KW endometriosis; autoimmune thyroiditis; anaphylaxis; hypersensitivity;  
KW autoimmune pulmonary inflammation; organ rejection; inflammation;  
KW CLASP; gene; ds.  
KW  
XX  
OS Homo sapiens.  
XX  
PN WO200231117-A2.  
XX  
PD 18-APR-2002.  
XX  
PE 15-OCT-2001; 2001WO-US32202.  
XX  
PR 13-OCT-2000; 2000US-0687837.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PA (GARW/) GARMAN J D.  
PA (CAND/) CANDIA A F.  
XX  
XX  
PI Lu PS;  
XX  
DR WPI: 2002-416861/44.  
DR P-PSDB; ABG61686.

PT New human cadherin-like asymmetry protein(s) (CLASP)-2 for modulating  
PT an immune response, and for treating multiple sclerosis, rheumatoid  
PT arthritis, endometriosis, lupus, autoimmune thyroiditis, septic shock,  
PT and sepsis  
XX  
PS Example 4; Figure 6A; 245pp; English.

CC The invention relates to an isolated polypeptide (I) comprising an amino

CC acid sequence that has 90 % sequence identity to one of the human  
CC cadherin-like asymmetry protein(s) (CLASP)-2 (hCLASP-2A, 2B, 2C, 2E)  
CC sequences (PS). (I) is useful for identifying a compound or agent that  
CC binds CLASP-2 polypeptide. An antibody (II) to (I) is useful for  
CC detecting a CLASP-2 polypeptide in a sample. (II) is useful for  
CC inhibiting a immune response in a subject. A pharmaceutical composition  
CC comprising a nucleic acid encoding (I), or (II) is useful for preventing  
CC or treating a CLASP-2 mediated disease e.g. an autoimmune disease, where  
CC the autoimmune disease is caused or exacerbated by increased activity  
CC of TH1 cells. CLASP-2 polynucleotides are useful as probes or primers for  
CC detection or inhibition of CLASP-2 expression (e.g., antisense or  
CC ribozyme-mediated inhibition), for gene knockout, etc. The CLASP-2  
CC polynucleotides can express CLASP-2 polypeptides, produce anti- CLASP-  
CC antibodies or are used as therapeutic polypeptides. The CLASP-2  
CC polynucleotide or fragments can be used in diagnostics (e.g., as probes  
CC for CLASP-2 expression), as a lymphocyte marker and for therapeutic  
CC purposes. CLASP-2 polynucleotides can construct transgenic and knockout  
CC animals, e.g., for screening of CLASP-2 agonists and antagonists. CLASP-2  
CC polynucleotides can screen for CLASP-2 agonists and antagonists.  
CC CLASP-2 polypeptides or polynucleotides can treat deficiencies or  
CC disorders of the immune system, by activating or inhibiting the  
CC activation, differentiation of immune cells and can treat or detect  
CC deficiencies or disorders of haematopoietic cells. CLASP-2 polypeptides  
CC or polynucleotides can increase differentiation and proliferation of  
CC haematopoietic cells, including the pluripotent stem cells to treat those  
CC disorders associated with a decrease in certain (or many) types of  
CC haematopoietic cells e.g., immunologic deficiency syndromes including  
CC blood protein disorders (e.g., agammaglobulinaemia,  
CC dysgammaglobulinaemia, ataxia telangiectasia, common variable  
CC immunodeficiency, DiGeorge syndrome, lymphopenia, thrombocytopenia, or  
CC haemoglobinuria). CLASP-2 polynucleotides or polypeptides can treat or  
CC detect autoimmune diseases, e.g., Addison's disease, haemolytic anaemia,  
CC Grave's disease, multiple sclerosis, rheumatoid arthritis, lupus,  
CC endometriosis, autoimmune thyroiditis, and autoimmune pulmonary  
CC inflammation. CLASP-2 can be used to treat anaphylaxis or  
CC hypersensitivity to an antigenic molecules, organ rejection or graft-  
CC versus-host disease (GVHD) and inflammation. ABK84922-ABK85018  
CC represent cadherin-like asymmetry protein (CLASP) coding sequences  
CC and PCR primers of the invention.

XX  
SQ Sequence 4807 BP; 1353 A; 1117 C; 1136 G; 1201 T; 0 other;

Query Match 100.0%; Score 501; DB 24; Length 4807;  
Best Local Similarity 100.0%; Pred. No. 3.8e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAGAC 60  
Db 3800 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAAACGAACGCTCTGATTAAAGAGAC 3859  
QY 61 CAGCTCGAGTATCAGAGAAATGAAGCCCACTACAGGAAATGGCGAAGAGAGCTTTCT 120  
Db 3860 CAGCTCGAGTATCAGAGAAATGAAGCCCACTACAGGAAATGGCGAAGAGAGCTTTCT 3919  
QY 121 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGCTCTTACCGGAATTCC 180  
Db 3920 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGCTCTTACCGGAATTCC 3979  
QY 181 CTTGACATCTTCAAGCCCATCAGTGGGACTCCAACACAGACACAATGTTCCACGGGATGACC 240  
Db 3980 CTTGACATCTTCAAGCCCATCAGTGGGACTCCAACACAGACACAATGTTCCACGGGATGACC 4039  
QY 241 AGCTCGTCTTCGGTGTGATTACATCAGTGGCCCGTGTGGGGACTGCTTTGCA 300  
Db 4040 AGCTCGTCTTCGGTGTGATTACATCAGTGGCCCGTGTGGGGACTGCTTTGCA 4099  
QY 301 TTGCAAACTCAGGATGCTTCCAAAGCCATCACTGGGAGACCGACAGGAGAGAC 360  
Db 4100 TTGCAAACTCAGGATGCTTCCAAAGCCATCACTGGGAGACCGACAGGAGAGAC 4159  
QY 361 CAAGGGGAAGGGAGAAAGAAATAAAGACAACGTTATTTCTTAACAGACTTCTAT 420  
Db 4160 CAAGGGGAAGGGAGAAAGAAATAAAGACAACGTTATTTCTTAACAGACTTCTAT 4219

QY 421 AGGACTGTAGAGAGTGACATATTTTAAATCTCAGTGGCAATATTCAAGTTTC 480  
Db 4220 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCAGTGGCAATATTCAAGTTTC 4279  
QY 481 ATTGTGCTTTAACAAGGTGT 501  
Db 4280 ATTGTGCTTTAACAAGGTGT 4300

RESULT 8  
AAC87974  
ID AAC87974 standard; cDNA; 4898 BP.  
XX  
AC AAC87974;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #1.

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.  
XX WO200061747-A2.  
PN  
XX 19-OCT-2000.  
PD  
XX

PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.

XX (ARBO-) ARBOR VITA CORP.

PA  
XX  
PI  
XX  
PI  
XX  
DR  
XX  
DR  
XX  
DR  
XX  
PT  
XX  
PT  
XX  
PT  
XX  
PS  
XX  
PS

WIPI; 2000-619230/59.  
P-PSDB; AAB36529.

Isolated cadherin-like asymmetry protein-2 polynucleotide and  
polypeptide used to diagnose, treat and prevent autoimmune diseases and  
inflammatory responses -

Disclosure; Fig 10A; 286pp; English.

CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and



CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 3.9e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGGAAGCTTGGGTCAGCGCTTAGCGGTAAACGACGTCTGATTAAGAGAC 60  
Db 3891 CAATTTGTGGAAGCTTGGGTCAGCGCTTAGCGGTAAACGACGTCTGATTAAGAGAC 3950  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAAATGGCGAAGAGCTTCT 120  
Db 3951 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAAATGGCGAAGAGCTTCT 4010  
QY 121 GAAATCATGATGAGCAGATCTGCCCTGGAGGAGAAGACGCGCTTTACCGAATTCC 180  
Db 4011 GAAATCATGATGAGCAGATCTGCCCTGGAGGAGAAGACGCGCTTTACCGAATTCC 4070  
QY 181 CTTACATCTTCAAGCCCATCAGTGGGACTCCAACAGCACAAATGTTACGGGATGACC 240  
Db 4071 CTTACATCTTCAAGCCCATCAGTGGGACTCCAACAGCACAAATGTTACGGGATGACC 4130  
QY 241 AGCTCGTCTTGGTGGTGTGATTACATCTATGCCCCGTGTGGGGAAGCTTGTGTTCA 300  
Db 4131 AGCTCGTCTTGGTGGTGTGATTACATCTATGCCCCGTGTGGGGAAGCTTGTGTTCA 4190  
QY 301 TTTGCAAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACGACACAGGAGAC 360  
Db 4191 TTTGCAAACTCAGGATGCTTTCCAAAGCCAATCACTGGGAGACGACACAGGAGAC 4250  
QY 361 CAAGGGAGAGGGAGAGAAAGAAATAAGACACACGTTATTTCTTAACAGACTTTCTAT 420  
Db 4251 CAAGGGAGAGGGAGAGAAAGAAATAAGACACACGTTATTTCTTAACAGACTTTCTAT 4310  
QY 421 AGGAGTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTC 480  
Db 4311 AGGAGTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTC 4370  
QY 481 ATGTGTCTTAACAAAGGTGT 501  
Db 4371 ATGTGTCTTAACAAAGGTGT 4391

RESULT 9  
AAC87975  
ID AAC87975 standard; cDNA; 4898 BP.

XX AAC87975;  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #2.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
XX cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
XX immunomodulatory; antiinflammatory; antiarthritic; cytosolic;  
XX hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
XX hypersensitivity; transplantation rejection response; immunodeficiency;  
XX proliferation; differentiation; inflammatory response; arthritis;  
XX inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
XX anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
XX endometriosis; pregnancy induced hypertension; ss.

OS Homo sapiens.

XX  
PN W0200061747-A2.

XX  
PD 19-OCT-2000.

XX  
PF 13-APR-2000; 2000WO-US10158.

XX  
PR 14-APR-1999; 99US-0129171.

PR 14-MAY-1999; 99US-0134114.

PR 14-MAY-1999; 99US-0134117.

PR 14-MAY-1999; 99US-0134118.

PR 21-OCT-1999; 99US-0160860.

PR 29-OCT-1999; 99US-0162498.

PR 13-DEC-1999; 99US-0170453.

PR 14-JAN-2000; 2000US-0176195.

PR 14-FEB-2000; 2000US-0182296.

XX  
PA (ARBO-) ARBOR VITA CORP.

XX  
PI Lu PS;

XX  
DR WPI: 2000-619230/59.

XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and

PT polypeptide used to diagnose, treat and prevent autoimmune diseases and

PT inflammatory responses

XX  
PS Disclosure; Fig 10B; 286pp; English.

XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytosolic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 3.9e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGGAAGCTTGGGTCAGCGCTTAGCGGTAAACGACGCTGATTAAGAGAC 60  
Db 3891 CAATTTGTGGAAGCTTGGGTCAGCGCTTAGCGGTAAACGACGCTGATTAAGAGAC 3950  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAAATGGCGAAGAGCTTCT 120  
Db 3951 CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAAATGGCGAAGAGCTTCT 4010  
QY 121 GAAATCATGATGAGCAGATCTGCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCC 180  
Db 4011 GAAATCATGATGAGCAGATCTGCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCC 4070  
QY 181 CTTACATCTTCAAGCCCATCAGTGGGACTCCAACAGCACAAATGTTACGGGATGACC 240  
Db 4071 CTTACATCTTCAAGCCCATCAGTGGGACTCCAACAGCACAAATGTTACGGGATGACC 4130



QY 241 AGCTGCTTCGCTCGTGTGATTACATCTCATGCGCCCGTGTGGGACTTGCTTTGTCA 300  
|||||  
Db 4131 AGCTCGTCTTCGGTCTGTGATTACATCTCATGCGCCCGTGTGGGACTTGCTTTGTCA 4190  
QY 301 TTGCAAACTCAGCATGCTTTCCAAAGCCAAATCAGTGGGAGACCGACACAGGAGGAC 360  
|||||  
Db 4191 TTGCAAACTCAGCATGCTTTCCAAAGCCAAATCAGTGGGAGACCGACACAGGAGGAC 4250  
QY 361 CAAGGGGAGGGAGAGAAAGAAATTAAGACACACGTTATTCTTAACAGACTTCTAT 420  
|||||  
Db 4251 CAAGGGGAGGGAGAGAAAGAAATTAAGACACACGTTATTCTTAACAGACTTCTAT 4310  
QY 421 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 480  
|||||  
Db 4311 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 4370  
QY 481 ATTGTGCTTTAACAAAGGTGT 501  
|||||  
Db 4371 ATTGTGCTTTAACAAAGGTGT 4391

RESULT 10  
AAC87976  
ID AAC87976 standard; cDNA; 4898 BP.  
XX  
AC AAC87976;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #3.  
XX

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
Kw cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
Kw immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
Kw hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
Kw hypersensitivity; transplantation rejection response; immunodeficiency;  
Kw proliferation; differentiation; inflammatory response; arthritis;  
Kw inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
Kw anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
Kw endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.  
OS  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000MO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX  
DR WPI; 2000-619230/59.  
XX

PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10C; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2

CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 3.9e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCCTTAGCGGTAACGAAAGCTGTGTTAAAGAAAGAC 60  
|||||  
Db 3891 CAATTTGTGAAGCTTGCGGTCAAGCCCTTAGCGGTAACGAAAGCTGTGTTAAAGAAAGAC 3950  
QY 61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGCTTCT 120  
|||||  
Db 3951 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGCTTCT 4010  
QY 121 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCC 180  
|||||  
Db 4011 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATTCC 4070  
QY 181 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAAGCACAATGGTTACCGGATGACC 240  
|||||  
Db 4071 CTTACATCTTCAACGCCATCAGTGGGACTCCACAAAGCACAATGGTTACCGGATGACC 4130  
QY 241 AGCTGCTCTTGGTCTGTGATTACATCTCATGCGCCCGTGTGGGACTTGCTTTGTCA 300  
|||||  
Db 4131 AGCTGCTCTTGGTCTGTGATTACATCTCATGCGCCCGTGTGGGACTTGCTTTGTCA 4190  
QY 301 TTGCAAACTCAGGATGCTTTCCAAAGCCAAATCAGTGGGAGACCGACACAGGAGGAC 360  
|||||  
Db 4191 TTGCAAACTCAGGATGCTTTCCAAAGCCAAATCAGTGGGAGACCGACACAGGAGGAC 4250  
QY 361 CAAGGGGAGGGAGAGAAAGAAATTAAGAACACGTTATTCTTAAACAGACTTCTAT 420  
|||||  
Db 4251 CAAGGGGAGGGAGAGAAAGAAATTAAGAACACGTTATTCTTAAACAGACTTCTAT 4310  
QY 421 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 480  
|||||  
Db 4311 AGGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 4370  
QY 481 ATTGTGCTTTAACAAAGGTGT 501  
|||||  
Db 4371 ATTGTGCTTTAACAAAGGTGT 4391

RESULT 11  
AAC87977  
ID AAC87977 standard; cDNA; 4898 BP.  
XX  
AC AAC87977;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #4.

XX CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosiis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
PI Lu PS;  
XX  
XX WPI; 2000-619230/59.  
DR  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10D; 286pp; English.  
XX  
XX The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosiis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX  
SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 3.9e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTGTGGAAGCTTGCGGTCAAGCCTTAGCGGTAACGACGTCGTGATTAAGAAGAC 60  
|||||  
Db 3891 CAATTGTGGAAGCTTGCGGTCAAGCCTTAGCGGTAACGACGTCGTGATTAAGAAGAC 3950

QY 61 CAGTCGAGTATCAGGAAGAAATGAAGCCCAACTACAGGGAATGGCGAAGACCTTCT 120  
|||||  
Db 3951 CAGTCGAGTATCAGGAAGAAATGAAGCCCAACTACAGGGAATGGCGAAGACCTTCT 4010  
QY 121 GAAATCATGCATGAGCAGATGCCCCCTGGAGAGAGACGAGCGTCTTACGAATTCC 180  
|||||  
Db 4011 GAAATCATGCATGAGCAGATGCCCCCTGGAGAGAGACGAGCGTCTTACGAATTCC 4070  
QY 181 CTTCAATCTTCAACGCCATFAGTGGGACTCCAACAAGCACATATGTTACGGGATGACC 240  
|||||  
Db 4071 CTTCAATCTTCAACGCCATFAGTGGGACTCCAACAAGCACATATGTTACGGGATGACC 4130  
QY 241 AGCTGCTCTTGGTGGTGTGTATTCATCTCATGCGCCCGTGTGGGACTTGTGTTCA 300  
|||||  
Db 4131 AGCTGCTCTTGGTGGTGTGTATTCATCTCATGCGCCCGTGTGGGACTTGTGTTCA 4190  
QY 301 TTTGCAAACTCAGGATGCTTTCCAAAGCCAATCAGTGGGAGACCGACAGGAGGAC 360  
|||||  
Db 4191 TTTGCAAACTCAGGATGCTTTCCAAAGCCAATCAGTGGGAGACCGACAGGAGGAC 4250  
QY 361 CAAGGGGAAGGGGAGAGAGAAAGAAATAAGAACACGTTATTTCTTAACAGACTTCTAT 420  
|||||  
Db 4251 CAAGGGGAAGGGGAGAGAGAAAGAAATAAGAACACGTTATTTCTTAACAGACTTCTAT 4310  
QY 421 AGGAGTTGTAAGAGGTGCACATATTTTAAATCTCACGTGGCAATATTCAAAGTTTC 480  
|||||  
Db 4311 AGGAGTTGTAAGAGGTGCACATATTTTAAATCTCACGTGGCAATATTCAAAGTTTC 4370  
QY 481 ATGTGCTTTAACAAAGGTGT 501  
|||||  
Db 4371 ATGTGCTTTAACAAAGGTGT 4391

RESULT 12

AAC87978  
ID AAC87978 standard; cDNA: 4898 BP.  
XX  
AC AAC87978;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #5.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cyostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosiis; pregnancy induced hypertension; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX

PI Lu PS;  
XX WPI; 2000-619230/59.  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10E; 286pp; English.

XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.

SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match Best Local Similarity 100.0%; Score 501; DB 21; Length 4898;

Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTGTGGAAGCTTGGGTCAAGCCTTAGCGGTAACGACGCTGTGATTAAGAGAGAC 60  
Db 3891 CAATTGTGGAAGCTTGGGTCAAGCCTTAGCGGTAACGACGCTGTGATTAAGAGAGAC 3950  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAAGCCAACTACAGGAAATGGCGAAGAGCTTCT 120  
Db 3951 CAGCTCGAGTATCAGGAAGAAATGAAAGCCAACTACAGGAAATGGCGAAGAGCTTCT 4010  
QY 121 GAAATCATGCATGAGCAGATCTGCCCGCTGGAGGAGAGACGCGCTTTACCGAATTCC 180  
Db 4011 GAAATCATGCATGAGCAGATCTGCCCGCTGGAGGAGAGACGCGCTTTACCGAATTCC 4070  
QY 181 CTTACATCTTCAACGCCCATCAGTGGGACTCCACAAGACAAATGTTTCACGGGATGACC 240  
Db 4071 CTTACATCTTCAACGCCCATCAGTGGGACTCCACAAGACAAATGTTTCACGGGATGACC 4130  
QY 241 AGCTCGTCTTGGTGTGATTTACATCTCATGGCCCGTGTGTGGGACTTGGCTTGTCA 300  
Db 4131 AGCTCGTCTTGGTGTGATTTACATCTCATGGCCCGTGTGTGGGACTTGGCTTGTCA 4190  
QY 301 TTTCGAAACTCAGGATGCTTTCCAAAGCCAAATCAGTGGGGAGAGCCGAGCACAGGGAGGAC 360  
Db 4191 TTTCGAAACTCAGGATGCTTTCCAAAGCCAAATCAGTGGGGAGAGCCGAGCACAGGGAGGAC 4250  
QY 361 CAAGGGGAAGGGAGAGAAAGGAAATTAAGAACCAACGTTATTTCTTACAGACTTTCTAT 420  
Db 4251 CAAGGGGAAGGGAGAGAAAGGAAATTAAGAACCAACGTTATTTCTTACAGACTTTCTAT 4310  
QY 421 AGGAGTTGTAAGAGCTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 480  
Db 4311 AGGAGTTGTAAGAGCTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTTTTC 4370  
QY 481 ATTGTGTCTTAACAAGGTGT 501  
Db 4371 ATTGTGTCTTAACAAGGTGT 4391

RESULT 13  
AAC87979  
ID AAC87979 standard; cDNA; 4898 BP.  
XX  
AC AAC87979;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #6.  
XX  
KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
KW cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
KW immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
KW hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
KW hypersensitivity; transplantation rejection response; immunodeficiency;  
KW proliferation; differentiation; inflammatory response; arthritis;  
KW inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
KW anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
KW endometriosis; pregnancy induced hypertension; ss.  
OS Homo sapiens.  
XX  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PF 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX  
PA (ARBO-) ARBOR VITA CORP.  
XX  
PI Lu PS;  
XX WPI; 2000-619230/59.  
DR  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10F; 286pp; English.  
XX  
CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated  
CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.



XX	Sequence	4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;
SQL	Query Match	100.0%; Score 501; DB 21; Length 4898;
	Best Local Similarity	100.0%; Pred. No. 3.9e-143;
	Matches 501; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1	CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTCTGATTTAAGAAGAC 60
Db	3891	CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTCTGATTTAAGAAGAC 3950
QY	61	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTTCT 120
Db	3951	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTTCT 4010
QY	121	GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 180
Db	4011	GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 4070
QY	181	CTTCACATCTTCAACGCCATCAGTGGGACTCCAACAGCACAAATGGTTACGGGATGACC 240
Db	4071	CTTCACATCTTCAACGCCATCAGTGGGACTCCAACAGCACAAATGGTTACGGGATGACC 4130
QY	241	AGCTCGTCTTCGGTCTGTGATTAATCTCATGTGCCCCGTGTGTGGGACTTGGTTGTCA 300
Db	4131	AGCTCGTCTTCGGTCTGTGATTAATCTCATGTGCCCCGTGTGTGGGACTTGGTTGTCA 4190
QY	301	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGAGACCGACACAGGAGGAC 360
Db	4191	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGAGACCGACACAGGAGGAC 4250
QY	361	CAAGGGGAAGGGGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGACTTTCTAT 420
Db	4251	CAAGGGGAAGGGGAGAGAAAGAAATAAGACACACGTTATTCTTAACAGACTTTCTAT 4310
QY	421	AGGAGTTGTAAGAAGGTGCACATATTTTTTAAATCTCACTGGCAATATTTCAAGTTTTC 480
Db	4311	AGGAGTTGTAAGAAGGTGCACATATTTTTTAAATCTCACTGGCAATATTTCAAGTTTTC 4370
QY	481	ATTGTGCTTTAACAAAGGTGT 501
Db	4371	ATTGTGCTTTAACAAAGGTGT 4391
RESULT 14		
AAC87980		
ID	AAC87980 standard; cDNA; 4898 BP.	
XX	AAC87980;	
AC	AAC87980;	
XX	AAC87980;	
DT	07-MAR-2001 (first entry)	
XX	07-MAR-2001 (first entry)	
DE	Preliminary CLASP-2 nucleotide sequence #7.	
XX	Preliminary CLASP-2 nucleotide sequence #7.	
XX	Preliminary CLASP-2 nucleotide sequence #7.	
KW	CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;	
KW	cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;	
KW	immunomodulatory; antiinflammatory; antiarthritic; cytostatic;	
KW	hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;	
KW	hypersensitivity; transplantation rejection response; immunodeficiency;	
KW	proliferation; differentiation; inflammatory response; arthritis;	
KW	inflammatory bowel disease; haematopoietic cell; blood protein disorder;	
KW	anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;	
KW	endometriosis; pregnancy induced hypertension; ss.	
OS	Homo sapiens.	
XX	Homo sapiens.	
PN	WO200061747-A2.	
XX	WO200061747-A2.	
PD	19-OCT-2000.	
XX	19-OCT-2000.	
PF	13-APR-2000; 2000WO-US10158.	
XX	13-APR-2000; 2000WO-US10158.	
PR	14-APR-1999; 99US-0129171.	
PR	14-APR-1999; 99US-0129171.	

PR	14-MAY-1999;	99US-0134114.
PR	14-MAY-1999;	99US-0134117.
PR	14-MAY-1999;	99US-0134118.
PR	21-OCT-1999;	99US-0160860.
PR	29-OCT-1999;	99US-0162498.
PR	13-DEC-1999;	99US-0170453.
PR	14-JAN-2000;	2000US-0176195.
PR	14-FEB-2000;	2000US-0182296.
XX	(ARBO-) ARBOR VITA CORP.	
PA	Lu PS;	
PI	WPI; 2000-619230/59.	
DR	Isolated cadherin-like asymmetry protein-2 polynucleotide and	
XX	polypeptide used to diagnose, treat and prevent autoimmune diseases and	
PT	inflammatory responses -	
PT	Disclosure; Fig 10G; 286pp; English.	
XX	The present invention describes cadherin-like asymmetry protein-2	
CC	(CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,	
CC	antiinflammatory, antiarthritic, cyostatic, hypotensive, antirheumatic,	
CC	antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be	
CC	used to inhibit an immune response in a subject by interfering with the	
CC	ability of a CLASP-2 protein to bind to another T cell or B cell. An	
CC	immune response in a subject may also be inhibited by administering an	
CC	antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,	
CC	proteins and antibodies can be used to prevent or treat a CLASP-2	
CC	mediated disease, such as an autoimmune disease caused or exacerbated	
CC	by increased activity of TH1 cells. They can also be used to treat	
CC	hypersensitivities, prevent transplantation rejection responses and	
CC	augment immune responsiveness in immunodeficiency states, inhibit	
CC	proliferation and differentiation of cells involved in an inflammatory	
CC	response e,g, arthritis, inflammatory bowel disease and increase	
CC	differentiation and proliferation of haematopoietic cells e.g. to treat	
CC	anaemia, thrombocytopaenia and other blood protein disorders. Disorders	
CC	treated by disrupting CLASP-2 function include multiple sclerosis,	
CC	rheumatoid arthritis, endometriosis and pregnancy induced hypertension.	
CC	The present sequence represents a preliminary CLASP-2 nucleotide	
CC	sequence, from the present invention.	
XX	Sequence 4898 BP; 1379 A; 1134 C; 1166 G; 1219 T; 0 other;	
SQL	Query Match	100.0%; Score 501; DB 21; Length 4898;
	Best Local Similarity	100.0%; Pred. No. 3.9e-143;
	Matches 501; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1	CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTCTGATTTAAGAAGAC 60
Db	3891	CAATTTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTCTGATTTAAGAAGAC 3950
QY	61	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTTCT 120
Db	3951	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTTCT 4010
QY	121	GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 180
Db	4011	GAATCATGCATGAGCAGATCTGCCCCCTGGAGAGAGAAGACGAGCGTCTTACCGAATTCC 4070
QY	181	CTTCACATCTTCAACGCCATCAGTGGGACTCCAACAGCACAAATGGTTACGGGATGACC 240
Db	4071	CTTCACATCTTCAACGCCATCAGTGGGACTCCAACAGCACAAATGGTTACGGGATGACC 4130
QY	241	AGCTCGTCTTCGGTCTGTGATTAATCTCATGTGCCCCGTGTGTGGGACTTGGTTGTCA 300
Db	4131	AGCTCGTCTTCGGTCTGTGATTAATCTCATGTGCCCCGTGTGTGGGACTTGGTTGTCA 4190
QY	301	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGAGACCGACACAGGAGGAC 360
Db	4191	TTTGCAAACTCAGGATGCTTTCCAAAGCCCAATCAGTGGGAGAGACCGACACAGGAGGAC 4250



QY 361 CAAGGGAGGGAGAGAAAGGAATAAGACACACGTTATTCTTAAACAGACTTTCTAT 420  
|||||  
Db 4251 CAAGGGAGGGAGAGAGAAAGGAATAAGACACACGTTATTCTTAAACAGACTTTCTAT 4310  
QY 421 AGGAGTTGTAAAGAGGTGCACATATTTTAAATCTCAGTGCATATTTCAAGTTTTC 480  
|||||  
Db 4311 AGGAGTTGTAAAGAGGTGCACATATTTTAAATCTCAGTGCATATTTCAAGTTTTC 4370  
QY 481 ATTGTGCTTTAACAAAGGTGT 501  
|||||  
Db 4371 ATTGTGCTTTAACAAAGGTGT 4391

RESULT 15  
AAC87981  
ID AAC87981 standard; cDNA; 4898 BP.  
XX  
AC AAC87981;  
XX  
DT 07-MAR-2001 (first entry)  
XX  
DE Preliminary CLASP-2 nucleotide sequence #8.  
XX

KW CLASP-1; CLASP-2; transmembrane protein; immune response; inflammatory;  
Kw cadherin-like asymmetry protein; autoimmune disease; immunosuppressive;  
Kw immunomodulatory; antiinflammatory; antiarthritic; cytostatic;  
Kw hypotensive; antirheumatic; antianaemic; haemostatic; neuroprotective;  
Kw hypersensitivity; transplantation rejection response; immunodeficiency;  
Kw proliferation; differentiation; inflammatory response; arthritis;  
Kw inflammatory bowel disease; haematopoietic cell; blood protein disorder;  
Kw anaemia; thrombocytopaenia; multiple sclerosis; rheumatoid arthritis;  
Kw endometriosis; pregnancy induced hypertension; ss.

XX Homo sapiens.  
OS  
PN WO200061747-A2.  
XX  
PD 19-OCT-2000.  
XX  
PE 13-APR-2000; 2000WO-US10158.  
XX  
PR 14-APR-1999; 99US-0129171.  
PR 14-MAY-1999; 99US-0134114.  
PR 14-MAY-1999; 99US-0134117.  
PR 14-MAY-1999; 99US-0134118.  
PR 21-OCT-1999; 99US-0160860.  
PR 29-OCT-1999; 99US-0162498.  
PR 13-DEC-1999; 99US-0170453.  
PR 14-JAN-2000; 2000US-0176195.  
PR 14-FEB-2000; 2000US-0182296.  
XX

PA (ARBO-) ARBOR VITA CORP.  
XX  
XX Lu PS;  
PI  
XX  
DR WPI; 2000-619230/59.  
XX  
XX  
PT Isolated cadherin-like asymmetry protein-2 polynucleotide and  
PT polypeptide used to diagnose, treat and prevent autoimmune diseases and  
PT inflammatory responses -  
XX  
PS Disclosure; Fig 10H; 286pp; English.  
XX

CC The present invention describes cadherin-like asymmetry protein-2  
CC (CLASP-2). CLASP-2 can have immunosuppressive, immunomodulatory,  
CC antiinflammatory, antiarthritic, cytostatic, hypotensive, antirheumatic,  
CC antianaemic, haemostatic and neuroprotective activities. CLASP-2 can be  
CC used to inhibit an immune response in a subject by interfering with the  
CC ability of a CLASP-2 protein to bind to another T cell or B cell. An  
CC immune response in a subject may also be inhibited by administering an  
CC antibody which specifically binds to CLASP-2. CLASP-2 polynucleotides,  
CC proteins and antibodies can be used to prevent or treat a CLASP-2  
CC mediated disease, such as an autoimmune disease caused or exacerbated

CC by increased activity of TH1 cells. They can also be used to treat  
CC hypersensitivities, prevent transplantation rejection responses and  
CC augment immune responsiveness in immunodeficiency states, inhibit  
CC proliferation and differentiation of cells involved in an inflammatory  
CC response e.g, arthritis, inflammatory bowel disease and increase  
CC differentiation and proliferation of haematopoietic cells e.g. to treat  
CC anaemia, thrombocytopaenia and other blood protein disorders. Disorders  
CC treated by disrupting CLASP-2 function include multiple sclerosis,  
CC rheumatoid arthritis, endometriosis and pregnancy induced hypertension.  
CC The present sequence represents a preliminary CLASP-2 nucleotide  
CC sequence, from the present invention.  
XX

SQ Sequence 4898 BP; 1376 A; 1140 C; 1162 G; 1220 T; 0 other;

Query Match 100.0%; Score 501; DB 21; Length 4898;  
Best Local Similarity 100.0%; Pred. No. 3.9e-143;  
Matches 501; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAACGAAACGTCGTGATTAAGAAGAC 60  
|||||  
Db 3891 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAACGAAACGTCGTGATTAAGAAGAC 3950  
QY 61 CAGCTCGAGTATCAGGAAGAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 120  
|||||  
Db 3951 CAGCTCGAGTATCAGGAAGAATGAAGCCAACTACAGGGAATGGCGAAGAGCTTCT 4010  
QY 121 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATGCC 180  
|||||  
Db 4011 GAAATCATGCATGAGCAGATCTGCCCCCTGGAGGAGAAGACGAGCGTCTTACCGAATGCC 4070  
QY 181 CTTACATCTTCAACGCCATCAGTGGACTCCAAACAAGCACAAATGGTTACGGGATGACC 240  
|||||  
Db 4071 CTTACATCTTCAACGCCATCAGTGGACTCCAAACAAGCACAAATGGTTACGGGATGACC 4130  
QY 241 AGCTGCTTCGCGTGTGTGATTTACATCTCATGCCCCGTGTGGGACTTGCTTGCA 300  
|||||  
Db 4131 AGCTGCTTCGCGTGTGTGATTTACATCTCATGCCCCGTGTGTGGGACTTGCTTGCA 4190  
QY 301 TTGCAAACTCAGGATGCTTTCCAAAGCCAATCAGTGGGAGACCGAGCACAGGAGAC 360  
|||||  
Db 4191 TTGCAAACTCAGGATGCTTTCCAAAGCCAATCAGTGGGAGACCGAGCACAGGAGAC 4250  
QY 361 CAAGGGAGGGAGAGAGAAAGGAATAAGACACACGTTATTCTTAAACAGACTTTCTAT 420  
|||||  
Db 4251 CAAGGGAGGGAGAGAGAAAGGAATAAGACACACGTTATTCTTAAACAGACTTTCTAT 4310  
QY 421 AGGAGTTGTAAAGAGGTGCACATATTTTAAATCTCAGTGCATATTTCAAGTTTTC 480  
|||||  
Db 4311 AGGAGTTGTAAAGAGGTGCACATATTTTAAATCTCAGTGCATATTTCAAGTTTTC 4370  
QY 481 ATTGTGCTTTAACAAAGGTGT 501  
|||||  
Db 4371 ATTGTGCTTTAACAAAGGTGT 4391

Search completed: February 7, 2003, 07:08:42  
Job time : 163.085 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:00:34 ; Search time 28.6858 Seconds  
(without alignments)  
5356.145 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_3800\_4300  
Perfect score: 501  
Sequence: 1 caattgtggaagctgcgg.....ttgtgtcttaacaaagtgt 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents\_NA:\*  
1: /cgn2\_6/ptodata/1/ina/5A\_COMB.seq:\*  
2: /cgn2\_6/ptodata/1/ina/5B\_COMB.seq:\*  
3: /cgn2\_6/ptodata/1/ina/6A\_COMB.seq:\*  
4: /cgn2\_6/ptodata/1/ina/6B\_COMB.seq:\*  
5: /cgn2\_6/ptodata/1/ina/PCTUS\_COMB.seq:\*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	139	27.7	1031	4	US-09-397-787-157	Sequence 157, Appl
2	41.8	8.3	2225	4	US-09-484-970B-33	Sequence 33, Appl
3	40.8	8.1	7218	1	US-08-232-463-14	Sequence 14, Appl
4	33	6.6	36519	3	US-08-923-137-2	Sequence 2, Appli
5	32.8	6.5	2570	2	US-09-056-075-2	Sequence 2, Appli
6	32.8	6.5	2613	4	US-09-255-829-7	Sequence 7, Appli
7	32.8	6.5	3891	1	US-08-480-604A-27	Sequence 27, Appl
8	32.8	6.5	3891	2	US-08-405-496A-27	Sequence 27, Appl
9	32.8	6.5	3891	4	US-08-915-136-27	Sequence 17, Appl
10	32.4	6.5	289	4	US-09-007-005-17	Sequence 17, Appl
11	32.4	6.5	289	4	US-09-244-796-17	Sequence 17, Appl
12	32.4	6.5	6559	4	US-09-234-186-1	Sequence 1, Appli
13	32.4	6.5	6559	4	US-09-233-527-1	Sequence 1, Appli
14	32.4	6.5	6560	5	PCT-US93-05651-1	Sequence 1, Appli
15	32	6.4	1241	1	US-08-471-033-39	Sequence 39, Appl
16	32	6.4	1241	1	US-08-471-033-42	Sequence 42, Appl
17	32	6.4	1241	2	US-08-471-044-39	Sequence 39, Appl
18	32	6.4	1241	2	US-08-471-044-42	Sequence 42, Appl
19	32	6.4	1241	2	US-08-463-483A-39	Sequence 39, Appl
20	32	6.4	1241	2	US-08-463-483A-42	Sequence 42, Appl
21	32	6.4	1241	2	US-08-471-046A-39	Sequence 39, Appl
22	32	6.4	1241	2	US-08-471-046A-42	Sequence 42, Appl
23	32	6.4	1241	2	US-08-470-566B-39	Sequence 39, Appl
24	32	6.4	1241	2	US-08-470-566B-42	Sequence 42, Appl
25	32	6.4	1241	2	US-08-469-334-39	Sequence 39, Appl
26	32	6.4	1241	2	US-08-469-334-42	Sequence 42, Appl
27	32	6.4	1241	3	US-09-300-529-39	Sequence 39, Appl

28	32	6.4	1241	3	US-09-300-529-42	Sequence 42, Appl
29	32	6.4	1358	1	US-08-471-033-45	Sequence 45, Appl
30	32	6.4	1358	2	US-08-471-044-45	Sequence 45, Appl
31	32	6.4	1358	2	US-08-463-483A-45	Sequence 45, Appl
32	32	6.4	1358	2	US-08-471-046A-45	Sequence 45, Appl
33	32	6.4	1358	2	US-08-470-566B-45	Sequence 45, Appl
34	32	6.4	1358	2	US-08-469-334-45	Sequence 45, Appl
35	32	6.4	1358	3	US-09-300-529-45	Sequence 45, Appl
36	32	6.4	1389	1	US-08-471-033-27	Sequence 27, Appl
37	32	6.4	1389	2	US-08-471-044-27	Sequence 27, Appl
38	32	6.4	1389	2	US-08-463-483A-27	Sequence 27, Appl
39	32	6.4	1389	2	US-08-471-046A-27	Sequence 27, Appl
40	32	6.4	1389	2	US-08-470-566B-27	Sequence 27, Appl
41	32	6.4	1389	2	US-08-469-334-27	Sequence 27, Appl
42	32	6.4	1389	3	US-09-300-529-27	Sequence 27, Appl
43	32	6.4	1399	1	US-08-471-033-24	Sequence 24, Appl
44	32	6.4	1399	2	US-08-471-044-24	Sequence 24, Appl
45	32	6.4	1399	2	US-08-463-483A-24	Sequence 24, Appl

ALIGNMENTS

RESULT 1  
US-09-397-787-157  
; Sequence 157, Application US/09397787  
; Patent No. 6468758  
; GENERAL INFORMATION:  
; APPLICANT: Benson, Darin R.  
; APPLICANT: Lodes, Michael J.  
; APPLICANT: Mitcham, Jennifer L.  
; APPLICANT: King, Gordon E.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR OVARIAN  
; TITLE OF INVENTION: CANCER THERAPY AND DIAGNOSIS  
; FILE REFERENCE: 210121.466C2  
; CURRENT APPLICATION NUMBER: US/09/397,787  
; CURRENT FILING DATE: 1999-09-16  
; NUMBER OF SEQ ID NOS: 334  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 157  
; LENGTH: 1031  
; TYPE: DNA  
; ORGANISM: Homo sapien  
; US-09-397-787-157

Query Match 27.7%; Score 139; DB 4; Length 1031;  
Best Local Similarity 96.6%; Pred. No. 4.3e-33;  
Matches 142; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 CAATTGTGGAAGCTTGGGTCAGACCTTAGCGGTAACGAACGCTGTGATTAAGAAGAC 60  
DB 511 CAATTGTGGAAGCTTGGGTCAGACCTTAGCGGTAACGAACGCTGTGATTAAGAAGAC 570  
QY 61 CAGCTCGAGTATCAGGAAGAAATGAAGCCCAACTACAGGGAATGGCGAGAGAGCTTCT 120  
DB 571 CAGCTCGAGTATCAGGAAGAAATGAAGCCCAACTACAGGGAATGGCGAGAGAGCTTCT 630  
QY 121 GAATCATGCATGAGCAGATCTGCCCC 147  
DB 631 GAATCATGCATGAGCAGATCTGCCCC 657

RESULT 2  
US-09-484-970B-33  
; Sequence 33, Application US/09484970B  
; Patent No. 6426186  
; GENERAL INFORMATION:  
; APPLICANT: Jones, Karen A.  
; APPLICANT: Volkmuth, Wayne  
; APPLICANT: Walker, Michael G.  
; TITLE OF INVENTION: BONE REMODELING GENES  
; FILE REFERENCE: PB-0014 US  
; CURRENT APPLICATION NUMBER: US/09/484,970B

```

; CURRENT FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 172
; SOFTWARE: PERL Program
; SEQ ID NO 33
; LENGTH: 2225
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Incyte ID No. 6426186 238544.2CB1
US-09-484-970B-33

```

Query Match	8.38;	Score 41.8;	DB 4;	Length 2225;
Best Local Similarity	56.08;	Pred. No. 0.0035;		
Matches 79; Conservative	0;	Mismatches 62;	Indels 0;	Gaps 0;

OY	16	TGCGGTCAAGCCTTAGCCGGTAAACCAACGTC	TGATTAAAGAACACCAGCTCGAGTATCAG	75
Db	721	TGTGTTGAAGCTGTAGAGAAAAACAAGCTGTCATC	CAGGCAGACCCAGAGGGAATATTCAG	780
OY	76	GAAGAATGAAGCCCACTACAGGGAATGCGAAGGAGCTT	TCTGAATCATGCATGAG	135
Db	781	CAGGAACCTCAAAGAAGACTATAACACAGCTAAAAGAGA	AACCTCAGGCCAATGATCGAGCGG	840
OY	136	CAGATCTGCCCCCTGGAAGAG		156
Db	841	AAAATTCCAGAACTGTACCAAG		861

RESULT 3  
US-08-232-463-14/c  
; Sequence 14, Application US/08232463

GENERAL INFORMATION:  
APPLICANT: DORNER, F.  
APPLICANT: SCHEFFELINGER, F.  
APPLICANT: FALKNER, F. G.  
TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS  
NUMBER OF SEQUENCES: 52  
CORRESPONDENCE ADDRESS:

```

: ADDRESS: Foley & Lardner
: STREET: 1800 Diagonal Road, Suite 500
: CITY: Alexandria
: STATE: VA
: COUNTRY: USA
: ZIP: 22313-0299
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: PatentIn Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/232,463
:

```

CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/07/935,313  
FILING DATE:  
APPLICATION NUMBER: EP 91 114 300.6  
FILING DATE: 26-AUG-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: BENT, Stephen A.  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 30472/114 IMMU  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (703)836-9300  
TELEFAX: (703)683-4109  
TELEX: 899149  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 7218 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single

```

;          TOPOLOGY: linear
;          IMMEDIATE SOURCE:
;          CLONE: PTZgpt-F1S
US-08-232-463-14

```

Query Match	8.1%;	Score 40.8;	DB 1;	Length 7218;
Best Local Similarity	6.8%;	Pred. No. 0.012;		
Matches	30;	Conservative 213;	Mismatches 195;	Indels 0;
				Gaps 0;

[illegible]

RESULT 4  
US-08-923-137-2/c  
Sequence 2, Application US/08923137

GENERAL INFORMATION:  
APPLICANT: Wilson, James M.  
APPLICANT: Farina, Steven F.  
APPLICANT: Fisher, Krishna J.  
TITLE OF INVENTION: Chimpanzee Adenovirus Vectors  
NUMBER OF SEQUENCES: 5  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Howson and Howson  
STREET: Spring House Corporate Cntr., P.O. Box 457  
CITY: Spring House  
STATE: Pennsylvania  
COUNTRY: United States of America  
ZIP: 19477  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/923,137  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/024,700  
FILING DATE: 06-SEP-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Bak, Mary E.



```

;      REGISTRATION NUMBER: 31,215
;      REFERENCE/DOCKET NUMBER: GNPVN.021CIP1USA
;      TELECOMMUNICATION INFORMATION:
;      TELEPHONE: 215-540-9200
;      TELEFAX: 215-540-5818
;      INFORMATION FOR SEQ ID NO: 2:
;      SEQUENCE CHARACTERISTICS:
;      LENGTH: 36519 base pairs
;      TYPE: nucleic acid
;      STRANDEDNESS: double
;      TOPOLOGY: unknown
;      MOLECULE TYPE: CDNA
US-08-923-137-2

```

Query Match	6.6%;	Score 33;	DB 3;	Length 36519;
Best Local Similarity	53.5%;	Pred. No. 6;		
Matches 69;	Conservative 0;	Mismatches 60;	Indels 0;	Gaps 0;
QY 67	GAGTATCAGAGAGAATGAAGCCCACTACAGGGAATGGCCGAGAGACTTTCTGAATC	126		
Db 9252	GAGGAAGAAGAGAGAAAGTGAGAGAACTCCCCGGGGCCCTTCGAGCGGAGAGGTGCGGCCACC	9193		
QY 127	ATGCATGAGCAGATCTGCCCCCTGGAGGAGAGAGACGAGCGTCTTACCGAATTCCCTTCAC	186		
Db 9192	ATGCGCCGAGCTCATCCGTCCTTCTGGAGGAGAGAGTGTGACCCGTCCTCGCGCGCACTCCAC	9133		
QY 187	ATCTTCAAC	195		
Db 9132	TTTTTCAAC	9124		

RESULT 5  
 US-09-056-075-2/c  
 ; Sequence 2, Application US/09056075  
 ; Patent No. 595368  
 ;  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Johnson, Eric A.  
 ; APPLICANT: Bradshaw, Marite  
 ; APPLICANT: Rood, Julian  
 ; TITLE OF INVENTION: Expression System for Clostridium  
 ; TITLE OF INVENTION: Species  
 ; NUMBER OF SEQUENCES: 2  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Quarles & Brady  
 ; STREET: 1 South Pinckney Street  
 ; CITY: Madison  
 ; STATE: WI  
 ; COUNTRY: US  
 ; ZIP: 53701-2113  
 ;  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/056,075  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Seay, Nicholas J.  
 ; REGISTRATION NUMBER: 27386  
 ; REFERENCE/DOCKET NUMBER: 960296.95238  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 608-251-5000  
 ; TELEFAX: 608-251-9166  
 ; INFORMATION FOR SEQ ID NO: 2:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 2570 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: double  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 ; US-09-056-075-2

Query Match	6.5%	Score 32.8;	DB 2;	length 2570;
Best Local Similarity	58.0%;	Pred. No. 2.1;		
Matches	58;	Conservative	0;	Mismatches 42;
				Indels 0;
				Gaps 0;

QY	402	TTCCTAACAGACTTTCATAGGAGTTGTAAAGAAGTGCAATATTTTTTAANAATCACT	461
Db	1539	TTAACAACATTCTCCAGAATCAGTTGAATAAAATTCCTCAATAATATTTTGTAACTCCT	1480
QY	462	GGAATATTTCAAAGTTTTCATTGTGCTTAACAAGAAGTGT	501
Db	1479	TTAATAATATTATCTTTTCATTATCTGTACTTAATAATGT	1440

```

RESULT 6
US-09-255-829-7/c
; Sequence 7, Application US/09255829
; Patent No. 6461617
; GENERAL INFORMATION:
; APPLICANT: Shone, Clifford Charles
; APPLICANT: Quinn, Conrad Padraig
; APPLICANT: Foster, Keith Alan
; TITLE OF INVENTION: Recombinant Toxin Fragments
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN, & FOX P.L.L.C.
; STREET: 1100 NEW YORK AVENUE, NW, SUITE 600
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: USA
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/255,829
; FILING DATE: 23-FEB-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB97/02273
; FILING DATE: 22-AUG-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/782,893
; FILING DATE: 27-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: ESMOND, ROBERT W.
; REGISTRATION NUMBER: 32,893
; REFERENCE/DOCKET NUMBER: 1581.0130002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-371-2600
; TELEFAX: 202-371-2540
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2613 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..2613
US-09-255-829-7

Query Match          6.5%; Score 32.8; DB 4; Length 2613;
Best Local Similarity 58.0%; Pred. No. 2.1;
Matches   58; Conservative    0; Mismatches   42; Indels     0; Gaps      0;

QY    402 TTCTTAACAGACTTTCATATAGAGGTGTAAGAAGTGCACATATTTTTAAATCTCACT 461
        || |||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db    325 TTAACAACATCTCCTCCAGATCACAGTGAATAAATCTCTCAAATATTCTGTAACCTCCCT 266

QY    462 GGCAATATTCGAAGTTTTTCATTTGTGTCTTAACAAGTGCT 501

```

Db 265 TTAATAATATCTTTTTCATATCTGTACTTAATAATGT 226

## RESULT 7

US-08-480-604A-27/c

; Sequence 27, Application US/08480604A  
; Patent No. 5736139

## GENERAL INFORMATION:

APPLICANT: KINK, JOHN A.  
APPLICANT: THALLEY, BRUCE S.  
APPLICANT: PADHYE, NISHA V.  
APPLICANT: FIRCA, JOSEPH R.  
APPLICANT: STAFFORD, DOUGLAS C.  
TITLE OF INVENTION: VACCINE AND ANTITOXIN FOR TREATMENT AND  
PREVENTION OF C. DIFFICILE DISEASE  
NUMBER OF SEQUENCES: 32  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MEDLEN & CARROLL, LLP  
STREET: 220 MONTGOMERY STREET, SUITE 2200  
CITY: SAN FRANCISCO  
STATE: CALIFORNIA  
COUNTRY: UNITED STATES OF AMERICA  
ZIP: 94104

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/480,604A  
FILING DATE: 07-JUN-1995  
CLASSIFICATION: 424

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/422,711  
FILING DATE: 14-APR-1995  
APPLICATION DATA:  
APPLICATION NUMBER: US 08/405,496  
FILING DATE: 16-MAR-1995

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/329,154  
FILING DATE: 25-OCT-1994  
APPLICATION DATA:  
APPLICATION NUMBER: US 08/161,907  
FILING DATE: 02-DEC-1993

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/985,321  
FILING DATE: 04-DEC-1992  
APPLICATION DATA:  
APPLICATION NUMBER: US 07/429,791  
FILING DATE: 31-OCT-1989

## ATTORNEY/AGENT INFORMATION:

NAME: INGOLIA, DIANE E.  
REGISTRATION NUMBER: 40,027  
REFERENCE/DOCKET NUMBER: OPHD-01763  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 705-8410  
TELEFAX: (415) 397-8338

## INFORMATION FOR SEQ ID NO: 27:

SEQUENCE CHARACTERISTICS:  
LENGTH: 3891 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:

NAME/KEY: CDS

LOCATION: 1..3888

US-08-480-604A-27

Query Match 6.5%; Score 32.8; DB 1; Length 3891;  
Best Local Similarity 58.0%; Pred. No. 2.6;  
Matches 58; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 402 TTCTTAACAGACTTCTATAGAGCTGTGAAGGTCACATATTTTAAATCTCACT 461  
|| ||| ||| | | | |||| | | | ||| | ||| ||  
Db 325 TTAACAACATCTCTCCAGATCAGTTGAATAAATTCCTCAATAATTTTGTAACTCCCT 266

QY 462 GGCAATATTCGAAGTTTTCATGTGTCTTAACAAGGTGT 501  
||| | | ||||| | | | ||| |||

Db 265 TTAATAATATCTTTTTCATATCTGTACTTAATAATATGT 226

## RESULT 8

US-08-405-496A-27/c

; Sequence 27, Application US/08405496A  
; Patent No. 5919665

## GENERAL INFORMATION:

APPLICANT: WILLIAMS, JAMES A.  
TITLE OF INVENTION: VACCINE FOR CLOSTRIDIUM BOFULINUM  
TITLE OF INVENTION: NEUROTOXIN  
NUMBER OF SEQUENCES: 30  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: MEDLEN & CARROLL, LLP  
STREET: 220 MONTGOMERY STREET, SUITE 2200  
CITY: SAN FRANCISCO  
STATE: CALIFORNIA  
COUNTRY: USA  
ZIP: 94104

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/405,496A  
FILING DATE: 16-MAR-1995  
CLASSIFICATION: 424

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/329,154  
FILING DATE: 25-OCT-1994  
APPLICATION DATA:  
APPLICATION NUMBER: US 08/161,907  
FILING DATE: 02-DEC-1993

## PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/985,321  
FILING DATE: 04-DEC-1992  
APPLICATION DATA:  
APPLICATION NUMBER: US 07/429,791  
FILING DATE: 31-OCT-1989

## ATTORNEY/AGENT INFORMATION:

NAME: INGOLIA, DIANE E.  
REGISTRATION NUMBER: 40,027  
REFERENCE/DOCKET NUMBER: OPHD-01308  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 397-8338  
TELEFAX: (415) 705-8410

## INFORMATION FOR SEQ ID NO: 27:

SEQUENCE CHARACTERISTICS:  
LENGTH: 3891 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:

NAME/KEY: CDS

LOCATION: 1..3888

US-08-405-496A-27

Query Match 6.5%; Score 32.8; DB 2; Length 3891;  
Best Local Similarity 58.0%; Pred. No. 2.6;  
Matches 58; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 402 TTCTTAACAGACTTCTATAGAGCTGTGAAGGTCACATATTTTAAATCTCACT 461  
|| ||| ||| | | | |||| | | | ||| | ||| ||  
Db 325 TTAACAACATCTCTCCAGATCAGTTGAATAAATTCCTCAATAATTTTGTAACTCCCT 266

QY 462 GGCAATATTCAAAGTTTTCATGTGCTTACAAAGGTGT 501  
||||| | | | | | | | | | | | | | | | | |  
Db 265 TTAATAATATATCTTTTTCATATCTGTACTTAATATGT 226

RESULT 9

US-08-915-136-27/c

; Sequence 27, Application US/08915136

; Patent No. 6290960

; GENERAL INFORMATION:

; APPLICANT: KINK, JOHN A.

; APPLICANT: THALLEY, BRUCE S.

; APPLICANT: PADHAYE, NISHA V.

; APPLICANT: FIRCA, JOSEPH R.

; APPLICANT: STAFFORD, DOUGLAS C.

; TITLE OF INVENTION: VACCINE AND ANTITOXIN FOR TREATMENT AND

; PREVENTION OF C. DIFFICILE DISEASE

; NUMBER OF SEQUENCES: 32

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: MEDLEN & CARROLL, LLP

; STREET: 220 MONTGOMERY STREET, SUITE 2200

; CITY: SAN FRANCISCO

; STATE: CALIFORNIA

; COUNTRY: UNITED STATES OF AMERICA

; ZIP: 94104

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/915,136

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/480,604

; FILING DATE:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/405,496

; FILING DATE: 16-MAR-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/329,154

; FILING DATE: 25-OCT-1994

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/161,907

; FILING DATE: 02-DEC-1993

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/985,321

; FILING DATE: 04-DEC-1992

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/429,791

; FILING DATE: 31-OCT-1989

; ATTORNEY/AGENT INFORMATION:

; NAME: INGOLIA, DIANE E.

; REGISTRATION NUMBER: 40,027

; REFERENCE/DOCKET NUMBER: OPHD-01763

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 705-8410

; TELEFAX: (415) 397-8338

; INFORMATION FOR SEQ ID NO: 27:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 3891 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 1..3888

; US-08-915-136-27

Query Match

6.5%; Score 32.8; DB 4; Length 3891;

Best Local Similarity 58.0%; Pred. No. 2.6;  
Matches 58; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 402 TTCTTAACAGACTTTCTATAGAGTTGTAAGAAGTGACACATATTTTAAATCTGACT 461

Db 325 TTACACACATTTCTCCAGATCAGTTGATAAATTTCTCAATAATTTTGTAACTCCCT 266

QY 462 GGCAATATTCAAAGTTTTCATGTGCTTACAAAGGTGT 501

Db 265 TTAATAATATATCTTTTTCATATCTGTACTTAATATGT 226

RESULT 10

US-09-007-005-17

; Sequence 17, Application US/09007005B

; Patent No. 6258558

; GENERAL INFORMATION:

; APPLICANT: Szostak, Jack W.

; APPLICANT: Roberts, Richard W.

; APPLICANT: Liu, Rihe

; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN

; TITLE OF INVENTION: FUSIONS

; FILE REFERENCE: 00786/350003

; CURRENT APPLICATION NUMBER: US/09/007,005B

; CURRENT FILING DATE: 1998-01-14

; EARLIER APPLICATION NUMBER: 60/035,963

; EARLIER FILING DATE: 1997-01-27

; EARLIER APPLICATION NUMBER: 60/064,491

; EARLIER FILING DATE: 1997-11-06

; NUMBER OF SEQ ID NOS: 33

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 17

; LENGTH: 289

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Translation template

; FEATURE:

; NAME/KEY: misc\_feature

; LOCATION: (1)...(289)

; OTHER INFORMATION: n = A,T,C or G

US-09-007-005-17

Query Match 6.5%; Score 32.4; DB 4; Length 289;

Best Local Similarity 5.4%; Pred. No. 1.1;

Matches 11; Conservative 87; Mismatches 106; Indels 0; Gaps 0;

QY 191 TCAAGCCATCAGTGGACGTCACAAAGACACACATGTTACGGGATGACCGACTGCTT 250

Db 44 URARCRARARURGRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNR 103

QY 251 CGTCTGTGATTACATCTCATGCCCCGTGTGGGACTTGCTTGTCAATTTGCAAACT 310

Db 104 SRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNR 163

QY 311 CAGGATGCTTCCAAAGCCCAATCACTGGGAGAGACCGACACAGGAGGACCAAGGGAAG 370

Db 164 SRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNRNRSRNR 223

QY 371 GGGAGAGAAAGGAATAAGACA 394

Db 224 GRCRURGRCGRURARARCRURCR 247

RESULT 11

US-09-244-796-17

; Sequence 17, Application US/09244796

; Patent No. 6281344

; GENERAL INFORMATION:

; APPLICANT: Szostak, Jack W.

; APPLICANT: Roberts, Richard W.

; APPLICANT: Liu, Rihe

; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN

```
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350007
; CURRENT APPLICATION NUMBER: US/09/244,796
; CURRENT FILING DATE: 1999-02-05
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-27
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 289
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Translation template
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(289)
; OTHER INFORMATION: n = A,T,C or G
US-09-244-796-17
```

```
Query Match          6.5%; Score 32.4; DB 4; Length 289;
Best Local Similarity 5.4%; Pred. No. 1.1;
Matches 11; Conservative 87; Mismatches 106; Indels 0; Gaps 0;
```

```
QY 191 TCACGCCATCAGTGGGACTCCACAGACACATGTTCCAGGATGACCAGCTGCTTT 250
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 44 URARCRRARURGRNRRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRR 103

QY 251 CGGTCGTGTGATTACATCTCATGCGCCGCTGTGTGGGACTTGTTCATTTGCAACT 310
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 104 SRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRN 163

QY 311 CAGATGCTTTCCAAAGCCATCACTGGGAGACCGAGACAGAGAGACCAAGGGAAG 370
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 164 SRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSRNRRSR 223

QY 371 GGGAGAGAAAGAAATAAGACA 394
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 224 GRCRURGRCRURARARCRURCR 247
```

```
RESULT 12
US-09-234-186-1/c
; Sequence 1, Application US/09234186
; Patent No. 6312947
; GENERAL INFORMATION:
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Hengartner, Michael
; TITLE OF INVENTION: IDENTIFICATION AND CHARACTERIZATION OF A
; TITLE OF INVENTION: GENE WHICH PROTECTS CELLS FROM PROGRAMMED CELL DEATH AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 01997/201005
; CURRENT APPLICATION NUMBER: US/09/234,186
; CURRENT FILING DATE: 1999-01-20
; EARLIER APPLICATION NUMBER: 07/898,933
; EARLIER FILING DATE: 1992-06-12
; EARLIER APPLICATION NUMBER: 07/927,681
; EARLIER FILING DATE: 1992-08-10
; EARLIER APPLICATION NUMBER: 08/288,295
; EARLIER FILING DATE: 1994-08-10
; EARLIER APPLICATION NUMBER: 08/801,248
; EARLIER FILING DATE: 1997-02-19
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 6559
; TYPE: DNA
; ORGANISM: Caenorhabditis elegans
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: (1)...(6559)
; OTHER INFORMATION: n = A,T,C or G
US-09-234-186-1
```

```
Query Match          6.5%; Score 32.4; DB 4; Length 6559;
Best Local Similarity 52.2%; Pred. No. 4.3;
Matches 72; Conservative 0; Mismatches 66; Indels 0; Gaps 0;
```

```
QY 358 GACCAAGGGAGGGAGAGAAAGAAATAAGACACAGTTATTTCTTAACAGACTTTC 417
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6430 GTCGACTGAAAAGGACAGCCTAGACTGCTAGCCACAAATTTTATACCTACATACTTAA 6371

QY 418 TATAGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTT 477
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6370 AAATGATTTGTTTAAAGAACACAGTAGTTTCTGAGTGGGTCTTGCCACGATCACAGTTC 6311

QY 478 TTCATTGTGCTTAACAA 495
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6310 ATAGTGTGCTGCAGAA 6293
```

```
RESULT 13
US-09-233-527-1/c
; Sequence 1, Application US/09233527
; Patent No. 6465617
; GENERAL INFORMATION:
; APPLICANT: Horvitz, H. Robert
; APPLICANT: Hengartner, Michael
; TITLE OF INVENTION: IDENTIFICATION AND CHARACTERIZATION OF A
; TITLE OF INVENTION: GENE WHICH PROTECTS CELLS FROM PROGRAMMED CELL DEATH AND
; TITLE OF INVENTION: USES THEREOF
; FILE REFERENCE: 01997/201004
; CURRENT APPLICATION NUMBER: US/09/233,527
; CURRENT FILING DATE: 1999-01-20
; EARLIER APPLICATION NUMBER: 07/898,933
; EARLIER FILING DATE: 1992-06-12
; EARLIER APPLICATION NUMBER: 07/927,681
; EARLIER FILING DATE: 1992-08-10
; EARLIER APPLICATION NUMBER: 08/288,295
; EARLIER FILING DATE: 1994-08-10
; EARLIER APPLICATION NUMBER: 08/801,248
; EARLIER FILING DATE: 1997-02-19
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 6559
; TYPE: DNA
; ORGANISM: Caenorhabditis elegans
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(6559)
; OTHER INFORMATION: n = A,T,C or G
US-09-233-527-1
```

```
Query Match          6.5%; Score 32.4; DB 4; Length 6559;
Best Local Similarity 52.2%; Pred. No. 4.3;
Matches 72; Conservative 0; Mismatches 66; Indels 0; Gaps 0;
```

```
QY 358 GACCAAGGGAGGGAGAGAAAGAAATAAGACACAGTTATTTCTTAACAGACTTTC 417
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6430 GTCGACTGAAAAGGACAGCCTAGACTGCTAGCCACAAATTTTATACCTACATACTTAA 6371

QY 418 TATAGAGTTGTAGAAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAAGTT 477
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6370 AAATGATTTGTTTAAAGAACACAGTAGTTTCTGAGTGGGTCTTGCCACGATCACAGTTC 6311

QY 478 TTCATTGTGCTTAACAA 495
   :|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 6310 ATAGTGTGCTGCAGAA 6293
```

```
RESULT 14
```



```

PCT-US93-05651-1/c
; Sequence 1, Application PC/7US9305651
; GENERAL INFORMATION:
; TITLE OF INVENTION: A Gene Which Prevents Programmed Cell Death
; NUMBER OF SEQUENCES: 5
; COMPUTER READABLE FORM:
; MEDIUM TYPE: diskette
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/05651
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 6560 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-05651-1

Query Match 6.5%; Score 32.4; DB 5; Length 6560;
Best Local Similarity 52.2%; Pred. No. 4.3;
Matches 72; Conservative 0; Mismatches 66; Indels 0; Gaps 0;

QY 358 GACCAAGGGGAGGCGGAGAGAAAGAAATTAAGAACACGTTATTTCTTAACAGACTTTC 417
Db 6431 GTCGACTGAAAAAGGCGAGCCTAGACTGCTAGCCACACAATTTTATACCTACATACTTAA 6372

QY 418 TATAGAGTTGTGAAGAGTGACACATATTTTAAATCTCAGCTGGCAATATTCAAAGTT 477
Db 6371 AAATGTATTTGTTTAAAGAACACGCTAGTTTCTGAGTGGGTCCTTGCCACGATCACAGTC 6312

QY 478 TTCATTGTGCTTTAACAA 495
Db 6311 ATAGTGTGCTGCTGCAGAA 6294

RESULT 15
US-08-471-033-39
; Sequence 39, Application US/08471033
; Patent No. 5770696
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5770696el Pesticidal Proteins and Strains
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,033
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/314,594
; FILING DATE: 09-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/218,018
; FILING DATE: 23-MAR-1994

```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/037,057
; FILING DATE: 25-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Pace, Gary M.
; REGISTRATION NUMBER: P-40,403
; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3/DIV7 - SOLV3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8582
; TELEFAX: 919-541-8689
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1241 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Synthetic DNA"
; HYPOTHETICAL: NO
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 9..1238
; OTHER INFORMATION:
; OTHER INFORMATION: /note= "Maize optimized DNA
; OTHER INFORMATION: sequence encoding VIP2A(a) with the Bacillus secretion sig
; US-08-471-033-39 removed as contained in PCIB5527"

Query Match          6.4%; Score 32; DB 1; Length 1241;
Best Local Similarity 51.4%; Pred. No. 2.7;
Matches    74; Conservative      0; Mismatches   70; Indels     0; Gaps     0;

QY 59 ACCAGCTCGGATATCAGGAAGAATAAGCCCAACTACAGGGAAATGGCGAGAGCTTT 118
    ||||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 139 ACTTCCTGGACACAAGAAGCACATCAAGACCACCACTACAAGAGATCACCCTTCAGCATAG 198

QY 119 CTGAATCATGCATGAGCAGATGTCCCCCTGGAGAGAGAAGACGAGCGCTTACCGAATT 178
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 199 CCGGACGCTTCGAGGACGAGATCAAGGACCCTGAAGGAGATCGACAAGATGTTGACAAGA 258

QY 179 CCCTTCACATCTTCAACGCCATCA 202
    || | | | | | | | | | | | |
Db 259 CCAACCTGAGCAACAGCATCATCA 282
```

Search completed: February 7, 2003, 09:06:22  
Job time : 63.6858 secs



GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 7, 2003, 07:01:14 ; Search time 32.3549 Seconds  
(without alignments)  
7339.716 Million cell updates/sec

Title: US-09-687-837-1\_COPY\_3800\_4300  
Perfect score: 501  
Sequence: 1 caattgtggaagcttgcgg.....ttgtgtcttaacaaagtgt 501

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 1.0

Searched: 408267 seqs, 237001491 residues

Total number of hits satisfying chosen parameters: 816534

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Published\_Applications\_NA:\*

1: /cgn2\_6/ptodata/2/pubpna/US07\_PUBCOMB.seq:\*  
2: /cgn2\_6/ptodata/2/pubpna/PCT\_NEW\_PUB.seq:\*  
3: /cgn2\_6/ptodata/2/pubpna/US06\_NEW\_PUB.seq:\*  
4: /cgn2\_6/ptodata/2/pubpna/US06\_PUBCOMB.seq:\*  
5: /cgn2\_6/ptodata/2/pubpna/US07\_NEW\_PUB.seq:\*  
6: /cgn2\_6/ptodata/2/pubpna/PCTUS\_PUBCOMB.seq:\*  
7: /cgn2\_6/ptodata/2/pubpna/US08\_NEW\_PUB.seq:\*  
8: /cgn2\_6/ptodata/2/pubpna/US08\_PUBCOMB.seq:\*  
9: /cgn2\_6/ptodata/2/pubpna/US09\_NEW\_PUB.seq:\*  
10: /cgn2\_6/ptodata/2/pubpna/US09\_PUBCOMB.seq:\*  
11: /cgn2\_6/ptodata/2/pubpna/US10\_NEW\_PUB.seq:\*  
12: /cgn2\_6/ptodata/2/pubpna/US10\_PUBCOMB.seq:\*  
13: /cgn2\_6/ptodata/2/pubpna/US60\_NEW\_PUB.seq:\*  
14: /cgn2\_6/ptodata/2/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	336	67.1	487	10	US-09-998-598-1612
2	139	27.7	1031	10	US-09-876-889-157
3	71	14.2	423	10	US-09-960-352-3043
4	67.4	13.5	4391	10	US-09-736-969A-7
5	67.4	13.5	6454	10	US-09-736-969A-1
6	50	10.0	434	9	US-09-796-692-4813
7	44	8.8	505	9	US-09-796-692-5039
8	44	8.8	505	9	US-09-796-692-5223
9	41.8	8.3	244	10	US-09-736-960-84
10	41.8	8.3	4026	10	US-09-736-960-3
11	41.8	8.3	7215	10	US-09-736-960-1
12	41.8	8.3	6686	10	US-09-736-960-86
13	37.2	7.4	521	10	US-09-964-824A-1
14	37.2	7.4	521	10	US-09-954-456-1193
15	36.6	7.3	696	10	US-09-815-242-7900
16	36.4	7.3	143068	10	US-09-967-768A-316
17	35.2	7.0	126512	10	US-09-804-474A-3
18	35	7.0	23626	10	US-09-764-878-261
19	35	7.0	23626	10	US-09-764-860-940

20	35	7.0	23632	10	US-09-764-878-262	Sequence 262, App
21	35	7.0	23632	10	US-09-764-860-941	Sequence 941, App
22	34.8	6.9	429	10	US-09-800-729-160	Sequence 160, App
23	34.8	6.9	690	10	US-09-815-242-7864	Sequence 7864, Ap
24	34.8	6.9	368004	10	US-09-949-654-3	Sequence 3, Appli
25	32.8	6.5	1461	10	US-09-880-192-42	Sequence 42, Appli
26	32.8	6.5	3891	12	US-10-051-952-1	Sequence 1, Appli
27	32.8	6.5	4835	10	US-09-288-326-10	Sequence 10, Appli
28	32.6	6.5	245	10	US-09-864-761-23212	Sequence 23212, A
29	32.6	6.5	469	10	US-09-864-761-6499	Sequence 6499, Ap
30	32.6	6.5	563	10	US-09-833-381-542	Sequence 542, App
31	32.6	6.5	4753	9	US-10-098-841-18	Sequence 18, Appli
32	32.4	6.5	695	9	US-10-016-157A-69	Sequence 69, Appli
33	32	6.4	1767	10	US-09-864-761-30592	Sequence 30592, A
34	32	6.4	2604	10	US-09-529-063-9	Sequence 9, Appli
35	31.8	6.3	384	10	US-09-983-965-198	Sequence 198, App
36	31.8	6.3	1750	10	US-09-925-300-633	Sequence 633, App
37	31.6	6.3	337	10	US-09-864-761-22871	Sequence 22871, A
38	31.4	6.3	740	10	US-09-735-705-6	Sequence 6, Appli
39	31.4	6.3	740	10	US-09-850-716A-6	Sequence 6, Appli
40	31.4	6.3	740	10	US-09-897-778-6	Sequence 6, Appli
41	31.4	6.3	1249	10	US-09-925-301-501	Sequence 501, App
42	31.4	6.3	4218	10	US-09-752-639-8	Sequence 8, Appli
43	31.4	6.3	4218	10	US-09-984-198-8	Sequence 8, Appli
44	31.4	6.3	202001	10	US-09-734-674-3	Sequence 3, Appli
45	31.2	6.2	2000	9	US-09-938-842A-4943	Sequence 4943, Ap

ALIGNMENTS

RESULT 1  
US-09-998-598-1612  
; Sequence 1612, Application US/09998598  
; Patent NO. US20020150922A1  
; GENERAL INFORMATION:  
; APPLICANT: Stolk, John A.  
; APPLICANT: Xu, Jiangchun  
; APPLICANT: Chenault, Ruth A.  
; APPLICANT: Meagher, Madelein Joy  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND  
; TITLE OF INVENTION: DIAGNOSIS OF COLON CANCER  
; FILE REFERENCE: 210121.561  
; CURRENT APPLICATION NUMBER: US/09/998, 598  
; CURRENT FILING DATE: 2001-11-16  
; NUMBER OF SEQ ID NOS: 2606  
; SOFTWARE: Corixa Invention Disclosure Database  
; SEQ ID NO 1612  
; LENGTH: 487  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; US-09-998-598-1612

Query Match	67.1%;	Score 336;	DB 10;	Length 487;
Best Local Similarity	100.0%;	Pred. No. 2e-91;		
Matches 336;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CAATTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTGTGATTAAAGAAGAC	60	
Db	152	CAATTGTGGAAGCTTGGCGTCAAGCCTTAGCGGTAACGAACGCTGTGATTAAAGAAGAC	211	
QY	61	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTCT	120	
Db	212	CAGCTCGAGTATCAGGAAGAAATGAAGCCCACTACAGGGAATGGCGAAGAGCTTCT	271	
QY	121	GAAATCATGATGAGCAGATCTGCCCCCTGGAGGAGAGACGAGCGTCTTACCGAATTCC	180	
Db	272	GAAATCATGATGAGCAGATCTGCCCCCTGGAGGAGAGACGAGCGTCTTACCGAATTCC	331	
QY	181	CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGCACATGTTTACGGGATGACC	240	
Db	332	CTTACATCTTCAACGCCATCAGTGGGACTCCACAAGCACATGTTTACGGGATGACC	391	

QY 241 AGCTGCTCTTCGGTCTGTGATTCATCTCATGCCCCGTGTGTGGGACTTGCCTTTGTCA 300  
|||||  
Db 392 AGCTGCTCTTCGGTCTGTGATTCATCTCATGCCCCGTGTGTGGGACTTGCCTTTGTCA 451  
QY 301 TTGCAACTCAGGATGCTTCCAAAGCCAATCACT 336  
|||||  
Db 452 TTGCAACTCAGGATGCTTCCAAAGCCAATCACT 487

RESULT 2

US-09-876-889-157  
; Sequence 157, Application US/09876889  
; Patent No. US20020076715A1  
; GENERAL INFORMATION:  
; APPLICANT: Benson, Darin R.  
; APPLICANT: Lodes, Michael J.  
; APPLICANT: Mitcham, Jennifer L.  
; APPLICANT: King, Gordon E.  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR OVARIAN  
; TITLE OF INVENTION: CANCER THERAPY AND DIAGNOSIS  
; FILE REFERENCE: 210121.466C3  
; CURRENT APPLICATION NUMBER: US/09/876, 889  
; CURRENT FILING DATE: 2001-06-06  
; NUMBER OF SEQ ID NOS: 353  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 157  
; LENGTH: 1031  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-09-876-889-157

Query Match 27.7%; Score 139; DB 10; Length 1031;  
Best Local Similarity 96.6%; Pred. No. 5.1e-32;  
Matches 142; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAACGAACTGTGATTAAGAAGAC 60  
|||||  
Db 511 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAACGAACTGTGATTAAGAAGAC 570  
QY 61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGAGGAAATGGCGAAGAGCTTTCT 120  
|||||  
Db 571 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGAGGAAATGGCGAAGAGCTTTCT 630  
QY 121 GAAATCATGCATGAGCAGATCTGCCCC 147  
|||||  
Db 631 GAAATCATGCATGAGCAGATCTGCCCC 657

RESULT 3

US-09-960-352-3043  
; Sequence 3043, Application US/09960352  
; Patent No. US20020137139A1  
; GENERAL INFORMATION:  
; APPLICANT: Warren, Wesley C.  
; APPLICANT: Tao, Nengbing  
; APPLICANT: Byatt, John C.  
; APPLICANT: Mathialagan, Nagappan  
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND  
; TITLE OF INVENTION: MUSCLE AND FAT DEPOSITION  
; FILE REFERENCE: 16511.006/37-21(10298)C  
; CURRENT APPLICATION NUMBER: US/09/960,352  
; CURRENT FILING DATE: 2001-09-24  
; NUMBER OF SEQ ID NOS: 15112  
; SEQ ID NO 3043  
; LENGTH: 423  
; TYPE: DNA  
; ORGANISM: Bos taurus  
; OTHER INFORMATION: Clone ID: 14-BOVMS1-017-Q1-E1-D5  
US-09-960-352-3043

Query Match 14.2%; Score 71; DB 10; Length 423;  
Best Local Similarity 70.4%; Pred. No. 8.9e-12;  
Matches 95; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1 CAATTTGTGAAGCTTGCGGTCAAGCCTTAGCGGTAACGAACGCTGTGATTAAGAAGAC 60  
|||||  
Db 289 CAATTTGCAGATGCGTGTGGCCAGGCCCTTGATGTGAATGAGCGCCTCATCAAGGAGAT 348  
QY 61 CAGCTCGAGTATCAGAGAAGAAATGAAGCCAACTACAGGAAATGGCGAAGAGCTTTCT 120  
|||||  
Db 349 CAGCTGAGTACAGAGAAGAACTGAGTCCATTACAAAGACATGCTCAGCAGACTCTCG 408  
QY 121 GAAATCATGCATGAG 135  
|||||  
Db 409 GAAATCATGAATGAG 423

RESULT 4

US-09-736-969A-7  
; Sequence 7, Application US/09736969A  
; Patent No. US20020068302A1  
; GENERAL INFORMATION:  
; APPLICANT: Lu, Peter  
; APPLICANT: Garman, Jonathan David  
; APPLICANT: Candia IT, Albert Frederick  
; APPLICANT: Arbor Vita Corporation  
; TITLE OF INVENTION: CLASP-4 Transmembrane Protein  
; FILE REFERENCE: 020054-000411US  
; CURRENT APPLICATION NUMBER: US/09/736, 969A  
; CURRENT FILING DATE: 2000-12-13  
; PRIOR APPLICATION NUMBER: US 60/160,860  
; PRIOR FILING DATE: 1999-10-21  
; PRIOR APPLICATION NUMBER: US 60/162,498  
; PRIOR FILING DATE: 1999-10-29  
; PRIOR APPLICATION NUMBER: US 60/170,453  
; PRIOR FILING DATE: 1999-12-13  
; PRIOR APPLICATION NUMBER: US 60/176,195  
; PRIOR FILING DATE: 2000-01-14  
; PRIOR APPLICATION NUMBER: US 60/182,296  
; PRIOR FILING DATE: 2000-02-14  
; PRIOR APPLICATION NUMBER: US 09/547,276  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,267  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,460  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,527  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 60/196,528  
; PRIOR FILING DATE: 2000-04-11  
; PRIOR APPLICATION NUMBER: US 09/687,837  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,503  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,508  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,539  
; PRIOR FILING DATE: 2000-10-13  
; PRIOR APPLICATION NUMBER: US 60/240,543  
; PRIOR FILING DATE: 2000-10-13  
; NUMBER OF SEQ ID NOS: 153  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 4391  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: human CLASP-4 cDNA  
; NAME/KEY: CDS  
; LOCATION: (414)..(4058)  
; OTHER INFORMATION: human CLASP-4  
US-09-736-969A-7

Query Match 13.5%; Score 67.4; DB 10; Length 4391;  
Best Local Similarity 67.4%; Pred. No. 3.5e-10;



	Matches	95;	Conservative	0;	Mismatches	46;	Indels	0;	Gaps	0;
QY	2	AATTGTGGAAGCTTGGCGGTACGCCGTAACGAACGCTCTGATTAAAGAACACC	61							
Db	3802	AATTATTACAAAGCATGACAGATTGCACTTGAACCTAAATGAGCGCGCTAATTAAAGAAAGATC	3861							
QY	62	AGCTCGAGTATCAGGAAGAATGAAAGCCCACTACAGGGAATGGCGAAGGAGCTTCTG	121							
Db	3862	AAGTTGAGTACCATTGAAGGGCTTAAAGTCMAATTTCAGAGACATGGTAAAAGCAATTATCTG	3921							
QY	122	AAATCATGTCATGAGCAGATCT	142							
Db	3922	ACATTATTCATGAGCAGATAT	3942							

RESULT 5  
US-09-736-969A-1

```

; Sequence 1, Application US/09736969A
; Patent No. US20020068302A1
; GENERAL INFORMATION:

```

```

1  APPLICANT: Lu, Peter
2  APPLICANT: Garman, Jonathan David
3  APPLICANT: Candia III, Albert Frederick
4  APPLICANT: Arbor Vita Corporation
5  TITLE OF INVENTION: CLASP-4 Transmembrane Protein
6  FILE REFERENCE: 020054-000411US
7  CURRENT APPLICATION NUMBER: US/09/736,969A
8  CURRENT FILING DATE: 2000-12-13
9  PRIOR APPLICATION NUMBER: US 60/160,860
10 PRIOR FILING DATE: 1999-10-21
11 PRIOR APPLICATION NUMBER: US 60/162,498
12 PRIOR FILING DATE: 1999-10-29
13 PRIOR APPLICATION NUMBER: US 60/170,453
14 PRIOR FILING DATE: 1999-12-13
15 PRIOR APPLICATION NUMBER: US 60/176,195
16 PRIOR FILING DATE: 2000-01-14
17 PRIOR APPLICATION NUMBER: US 60/182,296
18 PRIOR FILING DATE: 2000-02-14
19 PRIOR APPLICATION NUMBER: US 09/547,276
20 PRIOR FILING DATE: 2000-04-11
21 PRIOR APPLICATION NUMBER: US 60/196,267
22 PRIOR FILING DATE: 2000-04-11
23 PRIOR APPLICATION NUMBER: US 60/196,460
24 PRIOR FILING DATE: 2000-04-11
25 PRIOR APPLICATION NUMBER: US 60/196,527
26 PRIOR FILING DATE: 2000-04-11
27 PRIOR APPLICATION NUMBER: US 60/196,528
28 PRIOR FILING DATE: 2000-04-11
29 PRIOR APPLICATION NUMBER: US 09/687,837
30 PRIOR FILING DATE: 2000-10-13
31 PRIOR APPLICATION NUMBER: US 60/240,503
32 PRIOR FILING DATE: 2000-10-13
33 PRIOR APPLICATION NUMBER: US 60/240,508
34 PRIOR FILING DATE: 2000-10-13
35 PRIOR APPLICATION NUMBER: US 60/240,539
36 PRIOR FILING DATE: 2000-10-13
37 PRIOR APPLICATION NUMBER: US 60/240,543
38 PRIOR FILING DATE: 2000-10-13
39 NUMBER OF SEQ ID NOS: 153
40 SOFTWARE: PatentIn Ver. 2.1
41 SEQ ID NO 1
42 LENGTH: 6454
43 TYPE: DNA
44 ORGANISM: Homo sapiens
45 FEATURE:
46 OTHER INFORMATION: full length human CLASP-4 CDNA
47 NAME/KEY: CDS
48 LOCATION: (95)..(6121)
49 OTHER INFORMATION: human CLASP-4
50 US-09-736-969A-1

```

Query Match 13.58; Score 67.4; DB 10; Length 6454;

Best Local Similarity	67.48;	Pred. No. 4.3e-10;
Matches	95; Conservative	0; Mismatches 46; Indels 0; Gaps 0;

Accession	Sequence	Position
QY	2 AATTGTGGAAGCTTGGCGGTCAAGCCCTTAGCGGTTAAACGAACGTCGTGATTTAAGAAGAAC	61
Db	5865 AATTATACAAAGCATGCAGCAATTGCACCTTGAACCTAAATGAGCGGCTAAATTAAAGAAGATC	5924
QY	62 AGCTCGAGTATCAGGAAGAAATGAAAGCCAACTACAGGGAAATGGCGAAGGAGCTTCTG	121
Db	5925 AAGTTGAGTACCATGAAGGGCTTAAAGCTCAATTTTCAGAGACATGGTTAAAGAATTATCTG	5984
QY	122 AAATCATGCATGAGCAGATCT	142
Db	5985 ACATTATCCATGAGCAGATAT	6005

## RESULT 6

US-09-796-692-4813

; Sequence 4813, Application US/097966692A  
; Publication No. US20020198362A1

; GENERAL INFORMATION:

; APPLICANT: Gaiger, Alexander  
; APPLICANT: Algate, Paul A.

; APPLICANT: Mannion, Jane

```

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THER
; TITLE OF INVENTION: HEMATOLOGICAL MALIGNANCIES

```

; FILE REFERENCE: 2077.001200

```

; CURRENT APPLICATION NUMBER: US/09/796,692
; CURRENT FILING DATE: 2001-03-01

```

; PRIOR APPLICATION NUMBER: 60/186,126

;  
PRIOR FILING DATE: 2000-03-01  
;  
PRIOR APPLICATION NUMBER: 60/190,479  
;

PRIOR FILING DATE: 2000-03-17

;; PRIOR APPLICATION NUMBER: 60/200,545  
;; PRIOR FILING DATE: 2000-04-27

PRIOR APPLICATION NUMBER: 60/200,303

;; PRIOR FILING DATE: 2000-04-28  
;; PRIOR APPLICATION NUMBER: 60/200,779

PRIOR FILING DATE: 2000-04-28

;; PRIOR APPLICATION NUMBER: 60/200,999  
; PRIOR FILING DATE: 2000-05-01

PRIOR APPLICATION NUMBER: 60/202,084

; PRIOR FILING DATE: 2000-05-04  
 ; PRIOR APPLICATION NUMBER: 60/206,201  
 ; PRIOR FILING DATE: 2000-05-03

PRIOR FILING DATE: 2000-05-22

; PRIOR APPLICATION NUMBER: 60/218,950  
 ; PRIOR FILING DATE: 2000-07-14  
 ; PRIOR APPLICATION NUMBER: 60/223,003

PRIOR APPLICATION NUMBER: 60/222,903  
 PRIOR FILING DATE: 2000-09-03

; PRIOR FILING DATE: 2000-08-03  
 ; PRIOR APPLICATION NUMBER: 60/223,416  
 ; PRIOR FILING DATE: 2000-08-04

PRIOR FILING DATE: 2000-08-04  
PRIORITY ADDITION NUMBER: 60/4333 379

; PRIOR APPLICATION NUMBER: 80/223,318  
 ; PRIOR FILING DATE: 2000-08-07  
 ; NUMBER OF SEQ. NOS.: 9507

```

; NUMBER OF SEQ ID NOS: 999 /
SOFTWARE: FastSeq for Windows version 3.0

```

SOFTWARE: FDS  
: SEO ID NO 4813

```

      SEQ ID NO 4
      ; LENGTH: 4
      ; TYPE: DNA

```

ORGANISM: Homo sapiens

ORIGINALLY: 10/10/13  
TIS-09-796-692-4813

query match	10.0%;	Score 50;	DB 9;	Length 434;
-------------	--------	-----------	-------	-------------

Best Local Similarity 100.0%; Pred. No. 1.8e-05;

```
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 452 A A A T C T A C T G G C A A T A T T C A A A G T T T T C A T T G T G T C T T A A C A A A G G T G T 501  
|||||  
|||  
Db 1 A A A T C T A C T G G C A A T A T T C A A A G T T T C A T T G T G T C T T A A C A A A G G T G T 50  
|||||

Db 1 AAATCTCACTGGCAATATTCAAAGTTTTCATTGTGTCTTAACCAAGGTGT 50

## RESULT 7

US-09-796-692-5039

; Sequence 5039, Application US/097966692

```
; Publication No. US20020198362A1
; GENERAL INFORMATION:
; APPLICANT: Gaiger, Alexander
; APPLICANT: Algate, Paul A.
; APPLICANT: Mannion, Jane
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY
; TITLE OF INVENTION: HEMATOLOGICAL MALIGNANCIES
; FILE REFERENCE: 2077.001200
; CURRENT APPLICATION NUMBER: US/09/796,692
; CURRENT FILING DATE: 2001-03-01
; PRIOR APPLICATION NUMBER: 60/186,126
; PRIOR FILING DATE: 2000-03-01
; PRIOR APPLICATION NUMBER: 60/190,479
; PRIOR FILING DATE: 2000-03-17
; PRIOR APPLICATION NUMBER: 60/200,545
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 60/200,303
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,779
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,999
; PRIOR FILING DATE: 2000-05-01
; PRIOR APPLICATION NUMBER: 60/202,084
; PRIOR FILING DATE: 2000-05-04
; PRIOR APPLICATION NUMBER: 60/206,201
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: 60/218,950
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/222,903
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 60/223,416
; PRIOR FILING DATE: 2000-08-04
; PRIOR APPLICATION NUMBER: 60/223,378
; PRIOR FILING DATE: 2000-08-07
; NUMBER OF SEQ ID NOS: 9597
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5039
; LENGTH: 505
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (341)
; OTHER INFORMATION: n=A,T,C or G
US-09-796-692-5039

Query Match      8.8%; Score 44; DB 9; Length 505;
Best Local Similarity 65.0%; Pred. No. 0.0013;
Matches 65; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 64 CTCGAGTATCAGGAGAAGATGAAGCCAACTACAGGGAATGGCGAAGAGAGCTTTCTGAA 123
    ||||| ||||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1 CTGAGTACCGAGAGAACTGAGGTCCCACTACAAGGACATGCTCAGCAACTCTCCACA 60

QY 124 ATCATGCATGACGAGATCTGCCCTGAGGAGAGAGACGA 163
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 61 GTCATGAATGACGAGATTACGGGCGAGGACGACCTGTCAA 100

RESULT 8
US-09-796-692-5223
; Sequence 5223, Application US/09796692
; Publication No. US20020198362A1
; GENERAL INFORMATION:
; APPLICANT: Gaiger, Alexander
; APPLICANT: Algate, Paul A.
; APPLICANT: Mannion, Jane
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DETECTION, DIAGNOSIS AND THERAPY
; TITLE OF INVENTION: HEMATOLOGICAL MALIGNANCIES
; FILE REFERENCE: 2077.001200
; CURRENT APPLICATION NUMBER: US/09/796,692
; CURRENT FILING DATE: 2001-03-01
; PRIOR APPLICATION NUMBER: 60/186,126
```

```
; PRIOR FILING DATE: 2000-03-01
; PRIOR APPLICATION NUMBER: 60/190,479
; PRIOR FILING DATE: 2000-03-17
; PRIOR APPLICATION NUMBER: 60/200,545
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 60/200,303
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,779
; PRIOR FILING DATE: 2000-04-28
; PRIOR APPLICATION NUMBER: 60/200,999
; PRIOR FILING DATE: 2000-05-01
; PRIOR APPLICATION NUMBER: 60/202,084
; PRIOR FILING DATE: 2000-05-04
; PRIOR APPLICATION NUMBER: 60/206,201
; PRIOR FILING DATE: 2000-05-22
; PRIOR APPLICATION NUMBER: 60/218,950
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/222,903
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 60/223,416
; PRIOR FILING DATE: 2000-08-04
; PRIOR APPLICATION NUMBER: 60/223,378
; PRIOR FILING DATE: 2000-08-07
; NUMBER OF SEQ ID NOS: 9597
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 5223
; LENGTH: 505
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-796-692-5223

Query Match      8.8%; Score 44; DB 9; Length 505;
Best Local Similarity 65.0%; Pred. No. 0.0013;
Matches 65; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 64 CTCGAGTATCAGGAGAAGATGAAGCCAACTACAGGGAATGGCGAAGAGAGCTTTCTGAA 123
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 1 CTGAGTACCGAGAGAACTGAGGTCCCACTACAAGGACATGCTCAGCAACTCTCCACA 60

QY 124 ATCATGCATGACGAGATCTGCCCTGAGGAGAGACGA 163
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
DB 61 GTCATGAATGACGAGATTACGGGCGAGGACGACCTGTCAA 100

RESULT 9
US-09-736-960-84
; Sequence 84, Application US/09736960
; Patent No. US20020102267A1
; GENERAL INFORMATION:
; APPLICANT: Lu, Peter
; APPLICANT: Garman, Jonathan David
; APPLICANT: Candia III, Albert Frederick
; APPLICANT: Arbor Vita Corporation
; TITLE OF INVENTION: CLASP-5 Transmembrane Protein
; FILE REFERENCE: 020054-000511US
; CURRENT APPLICATION NUMBER: US/09/736,960
; CURRENT FILING DATE: 2001-09-20
; PRIOR APPLICATION NUMBER: 60/160,860
; PRIOR FILING DATE: 1999-10-21
; PRIOR APPLICATION NUMBER: 60/162,498
; PRIOR FILING DATE: 1999-10-29
; PRIOR APPLICATION NUMBER: 60/170,453
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: 60/176,195
; PRIOR FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: 60/182,296
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: US 09/547,276
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,267
; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 60/196,460
; PRIOR FILING DATE: 2000-04-11
```



```

; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 7215
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: full length human CLASP-5 cDNA
; NAME/KEY: CDS
; LOCATION: (112)..(6159)
; OTHER INFORMATION: human CLASP-5
US-09-736-960-1

```

Query Match	8.38;	Score 41.8;	DB 10;	Length 7215;
Best Local Similarity	56.08;	Pred. No. 0.022;		
Matches	79;	Conservative	0;	Mismatches 62;
			Indels	0;
			Gaps	0;

QY	16	TGGGGTCAAGCC	TTAGCGG	TAAACGAAC	GTCTGAT	TAAAGAAG	ACCAGCTCGAG	TATCAG	75
Db	5929	TGTGTTGAAGCT	GTAGAGAAA	AAACAAGCGT	CTCATC	ACGGCAGAC	CGAGAGGAAT	TATCAG	5988
QY	76	GAAGAAATGAA	AGCCAACTAC	AGGGAATGCG	GAAGAGCTT	TCTGAAT	CATGCATGAG	135	
Db	5989	CAGGAAC	TCAAAAAAG	AACTATTAACA	GAGCTAA	AAAGAGAAC	CTCAGGCCAATGATCG	ACGG	6048
QY	136	CAGATCTGCCC	CTGGAGGAG	156					
Db	6049	AAAAATTCAGA	ACTGTACAAG	6069					

RESULT 12  
US-09-736-960-86  
: Sequence 86, Application US/09736960  
: Patent No. US20020102267A1  
: GENERAL INFORMATION:  
: APPLICANT: Lu, Peter  
: APPLICANT: Gorman, Jonathan David  
: APPLICANT: Candia III, Albert Frederick  
: APPLICANT: Arbor Vita Corporation  
: TITLE OF INVENTION: CLASP-5 Transmembrane  
: FILE REFERENCE: 020054-00051IUS  
: CURRENT APPLICATION NUMBER: US/09/736,960  
: CURRENT FILING DATE: 2001-09-20  
: PRIOR APPLICATION NUMBER: US 60/160,860  
: PRIOR FILING DATE: 1999-10-21  
: PRIOR APPLICATION NUMBER: US 60/162,498  
: PRIOR FILING DATE: 1999-10-29  
: PRIOR APPLICATION NUMBER: US 60/170,453  
: PRIOR FILING DATE: 1999-12-13  
: PRIOR APPLICATION NUMBER: US 60/176,195  
: PRIOR FILING DATE: 2000-01-14  
: PRIOR APPLICATION NUMBER: US 60/182,296  
: PRIOR FILING DATE: 2000-02-14  
: PRIOR APPLICATION NUMBER: US 09/547,276  
: PRIOR FILING DATE: 2000-04-11  
: PRIOR APPLICATION NUMBER: US 60/196,267  
: PRIOR FILING DATE: 2000-04-11  
: PRIOR APPLICATION NUMBER: US 60/196,460  
: PRIOR FILING DATE: 2000-04-11  
: PRIOR APPLICATION NUMBER: US 60/196,527  
: PRIOR FILING DATE: 2000-04-11  
: PRIOR APPLICATION NUMBER: US 60/196,528

```

; PRIOR FILING DATE: 2000-04-11
; PRIOR APPLICATION NUMBER: US 09/687,837
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,503
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,508
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,539
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: US 60/240,543
; PRIOR FILING DATE: 2000-10-13
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 86
; LENGTH: 66686
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: ordered human genomic DNA at CLASP-5 locus
US-09-736-960-86

```

Query Match	8.38;	Score 41.8;	DB 10;	Length 66686;
Best Local Similarity	56.08;	Pred. No. 0.068;		
Matches 79; Conservative	0;	Mismatches 62;	Indels 0;	Gaps 0;

QY 16 TCGGGTCAAGCCCTTAGCCGTAACGAAACGCTGTGATTTAAGAGAGACCAGCTCGAGTATCAG 75  
 || ||| |||| | | | | | | | | | | | | | | | |  
 Db 62399 TGTGTTGAAGCTGTAGAGAAAAACAAGCGTCTCATCAGCGCAGACCAGAGGGAATATCAG 62458  
 QY 76 GAAGAAATGAAAGCCCACTACAGGGAATGGCGAAGGAGCGTTTCTGAATCATGTCATGAG 135  
 | ||| | ||| ||||| | | | | | | | | | | |  
 Db 62459 CAGGAACCTCAAAAAGAACTATTAACAAGCTAAAGAAGAACCTCAGGCCAATGATCGAGCGG 62518  
 QY 136 CAGATCTGCCCCCTGGAGGAG 156  
 | || | ||| | |||  
 Db 62519 AAAATTCCAGAACTGTACAAG 62539

```

RESULT 13
US-09-964-824A-1
; Sequence 1, Application US/09964824A
; Patent No. US20020102531A1
; GENERAL INFORMATION:
; APPLICANT: Horrigan, Stephen
; TITLE OF INVENTION: Cancer Gene Determination and Therapeutic Screening Using Sign
; TITLE OF INVENTION: Sets
; FILE REFERENCE: 689290-73
; CURRENT APPLICATION NUMBER: US/09/964,824A
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: US/60/236,033
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236,032
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US/60/236,028
; PRIOR FILING DATE: 2000-09-28
; NUMBER OF SEQ ID NOS: 583
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 521
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(521)
; OTHER INFORMATION: n=a,t,g or c
US-09-964-824A-1

```

	Query Match	7.48;	Score 37.2;	DB 10;	Length 521;
	Best Local Similarity	57.4%;	Pred. No. 0.14;		
	Matches 66; Conservative	0;	Mismatches 49;	Indels 0;	Gaps
QY	360 CCAAGGGGAAGGCGAGAGAAGAATAAACAACGTTATTTCTTAACAGACTTCTA	419			



Db 245 CCTGGGGCTTGGGAGGGGAGTGGATTAAATAAAGCTTTAGAAGGCCCATAGNATAATA 304

QY 420 TAGGAGTTGTAGAGAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAA 474

Db 305 TCGAAATAGTATGAATTTTAATATATACTTTTAAAGGGGTTAGGCAATGATGAAA 359

RESULT 14

US-09-954-456-1193

; Sequence 1193, Application US/09954456

; Patent No. US20020115057A1

; GENERAL INFORMATION:

; APPLICANT: Young, Paul

; TITLE OF INVENTION: Process for Identifying Anti-Cancer Therapeutic Agents Using Canc

; TITLE OF INVENTION: Sets

; FILE REFERENCE: 689290-76

; CURRENT APPLICATION NUMBER: US/09/954,456

; CURRENT FILING DATE: 2001-09-18

; PRIOR APPLICATION NUMBER: US/60/233,617

; PRIOR FILING DATE: 2000-09-18

; PRIOR APPLICATION NUMBER: US/60/234,052

; PRIOR FILING DATE: 2000-09-20

; PRIOR APPLICATION NUMBER: US/60/234,923

; PRIOR FILING DATE: 2000-09-25

; PRIOR APPLICATION NUMBER: US/60/235,134

; PRIOR FILING DATE: 2000-09-25

; PRIOR APPLICATION NUMBER: US/60/235,637

; PRIOR FILING DATE: 2000-09-26

; PRIOR APPLICATION NUMBER: US/60/235,638

; PRIOR FILING DATE: 2000-09-26

; PRIOR APPLICATION NUMBER: US/60/235,711

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: US/60/235,720

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: US/60/235,840

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: US/60/235,863

; PRIOR FILING DATE: 2000-09-27

; NUMBER OF SEQ ID NOS: 2276

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1193

; LENGTH: 521

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: misc\_feature

; OTHER INFORMATION: n=a,t,g or c

US-09-954-456-1193

Query Match 7.4%; Score 37.2; DB 10; Length 521;

Best Local Similarity 57.4%; Pred. No. 0.14;

Matches 66; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 360 CCAAGGGGAGGAGAGAAAGAAATAAGAACACGTTATTTCTTAACAGACTTTCTA 419

Db 245 CCTGGGGTTGGGAGGGGAGTGAATTAATAAAAAAGTTTGAAGGCCCATAGNATAATA 304

QY 420 TAGGAGTTGTAGAGAGGTGCACATATTTTAAATCTCACTGGCAATATTCAAA 474

Db 305 TCGAAATAGTATGAATTTTAATATATACTTTTAAAGGGGTTAGGCAATGATGAAA 359

RESULT 15

US-09-815-242-7900

; Sequence 7900, Application US/09815242

; Patent No. US20020061569A1

; GENERAL INFORMATION:

; APPLICANT: Haselbeck, Robert

; APPLICANT: Ohlsen, Kari L.

; APPLICANT: Zyskind, Judith W.

; APPLICANT: Wall, Daniel

; APPLICANT: Trawick, John D.

; APPLICANT: Carr, Grant J.

; APPLICANT: Yamamoto, Robert T.

; APPLICANT: Xu, H. Howard

; TITLE OF INVENTION: Identification of Essential Genes in

; TITLE OF INVENTION: Prokaryotes

; FILE REFERENCE: ELITRA.011A

; CURRENT APPLICATION NUMBER: US/09/815,242

; CURRENT FILING DATE: 2001-03-21

; PRIOR APPLICATION NUMBER: 60/191,078

; PRIOR FILING DATE: 2000-03-21

; PRIOR APPLICATION NUMBER: 60/206,848

; PRIOR FILING DATE: 2000-05-23

; PRIOR APPLICATION NUMBER: 60/207,727

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: 60/242,578

; PRIOR FILING DATE: 2000-10-23

; PRIOR APPLICATION NUMBER: 60/253,625

; PRIOR FILING DATE: 2000-11-27

; PRIOR APPLICATION NUMBER: 60/257,931

; PRIOR FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 60/269,308

; PRIOR FILING DATE: 2001-02-16

; NUMBER OF SEQ ID NOS: 14110

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 7900

; LENGTH: 696

; TYPE: DNA

; ORGANISM: Pseudomonas aeruginosa

; FEATURE:

; NAME/KEY: CDS

; LOCATION: (1)...(696)

US-09-815-242-7900

Query Match 7.3%; Score 36.6; DB 10; Length 696;

Best Local Similarity 52.3%; Pred. No. 0.25;

Matches 81; Conservative 0; Mismatches 74; Indels 0; Gaps 0;

QY 128 TGCATGACGAGATCTGCCCTGGAGGAGAGACGAGCGTCTTACCGAATTCCTTCACA 187

Db 249 TGCCGAAGCCGCTGTGGCTGCCGCGCCGACACAAGGTGGTATGACGAGCGTGGCCGA 308

QY 188 TCTTCAAGCCATCAGTGGGACTCCACAAGCACAAATGGTTCACGGGATGACCACTCGT 247

Db 309 AATGAAGGCGGCGACCTGAACCTACGACGTCGTCAATCGCTTCCCGGATGCCATGCCGTGT 368

QY 248 CTTGCGTGTGTGATTACATCTCATGGCCCGTGTG 282

Db 369 CGTCGTCAGCTGGGCCAGATCTCGGCCCGCGGTG 403

Search completed: February 7, 2003, 09:15:32

Job time : 83.3549 secs

